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Abstract 
Id iopathic pulmonary f ibrosis (IPF) is a fatal condit ion with l imited 
treatment options. The diagnosis is usually made radiolog ically but a 
careful history to  exclude identif iable causes of interst it ia l lung disease is  
required. A lthough the median surv ival is poor, there is considerable 
variabil i ty in d isease progression. Th is thesis investigates the diagnostic 
accuracy of IPF, a novel treatment option for IPF and biomarkers 
predictive of disease progression. 
An audit project determined a confident d iagnosis of IPF in  only 9% of  
patients due to lack of aetio log ical factors assessment. In a do uble-bl ind,  
mult i-centre study, 181 patients with  f ibrot ic id iopathic interstit ia l  
pneumonia was randomised to receive co -tr imoxazole or placebo for 12 
months in  addit ion to  usual care. Measurements were made of forced v ital 
capacity (FVC), and quality adjusted l ife years (QALYs). A ll -cause 
mortal i ty,  costs, and adverse events were recorded. Co -trimoxazole had no 
effect on measures of lung function. However in those adhering to  
treatment, co-tr imoxazole showed a signif icant reduction in al l -cause 
mortal i ty associated with reduction in respiratory tract infections and 
improvements in QALYs gained. Treatment with co -tr imoxazole was cost-
effective at UK thresholds.  
The role of c l in ica l-physio log ical parameters, exhaled alveolar nit r ic oxide 
concentration (CaNO) and plasma vascular endothelia l growth factor 
(VGEF) in predict ing disease behav iour were assessed in two studies. 
Prednisolone therapy was predict ive of death at 12 months and 10% 
decline in FVC at 6 months, St George’s Respiratory Questionnaire  score 
was predict ive of death at 12 months. A prospective pi lot  study of 27 
patients with IPF showed that CaNO has a strong predictive value for 
subsequent s ignif icant decline in diffusing capacity of carbon monoxide 
and that VGEF level is a strong predictive factor of subsequent s ignif icant 
FVC decline.  
Structured proforma could aid  diagnostic process in  IPF while  b iomarkers 
could be used in prediction  models. Surv ival of IPF is improved by 
prophylactic treatment with antib io t ics .  
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Abbrev iations 
AE Adverse event 
ATS  American Thoracic Society 
BAL Broncho-alveolar lavage 
BTS British Thoracic Society  
CaNO Alveolar concentration of nitric oxide 
CFA Cryptogenic fibrosing alveolitis 
COPD Chronic obstructive airways disease 
CPET Cardiopulmonary Exercise Testing  
CXR Chest radiograph 
DLCO Diffusing capacity of carbon monoxide 
DPLD  Diffuse parenchymal lung diseases 
eNO Exhaled Nitric Oxide 
EQ-5D EuroQol Questionnaire 
ERS European Respiratory Society 
FeNO Fraction of exhaled NO  
FF  Fibroblastic foci 
FVC Forced vital capacity 
HRCT High Resolution Computed Tomography 
HRQL Health-related quality of life  
ICER Incremental cost-effectiveness ratio 
IIP  Idiopathic Interstitial Pneumonias 
ILD  Interstitial Lung Disease 
IPF  Idiopathic Pulmonary Fibrosis 
ITT analysis Intention to treat analysis  
JawNO Total flux of nitric oxide 
MID Minimum important difference  
MDT  Multi-disciplinary team meeting 
MRC Medical Research Council  
NAC N-acetylcysteine  
NSIP  Nonspecific interstitial pneumonia 
PFT Pulmonary function tests 
PP analysis Per protocol analysis 
RTI Respiratory tract infection 
QALYs Quality Adjust Life Years  
SAE Serious adverse event  
SGRQ Saint George Respiratory Questionnaire 
SLB Surgical lung biopsy 
TBB Transbronchial lung biopsy  
VATs Video-assisted thoracoscopic biopsy  
VC Vital capacity 
VEGF Vascular endothelial growth factor 
UIP  Usual interstitial pneumonia 
6MWT 6 minute walk test 
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Chapter 1  
Introduction 
 
1.1. Intersti tial Lung Disease  
Id iopathic Pulmonary Fibrosis (IPF) is the commonest of the Interstit ia l 
Lung Diseases (ILD), which comprise over 200 condit ions. Interstit ia l Lung 
Disease describes a heterogeneous group of disorders involv ing the 
pulmonary parenchyma, that are characterised by inf lammation and/or 
f ibrosis of varying extent and 
severity.  Interst it ia l lung disease and 
Dif fuse Parenchymal Lung Disease 
(DPLD) are inter-changeable terms.  
 
Figure 1.1 A diagram demonstrat ing 
the components of the pulmonary 
parenchyma 
 
The pulmonary parenchyma cons ists  
of the alveolar epithelium, the alveolar -capil lary inter face and air -spaces 
at the level of the alveolar sacs, ducts and respiratory bronchioles (Figure 
1.1) [1]. The alveolar epithelium consists of two cell types: type I and type 
II. The majority of the alveolar surface that comes in contact with inspired 
air is covered by f lat type 1 alveolar epithelia l cel ls, wh ich act principally 
as a physical barr ier to regulate ion and f lu id balance v ia t ight junctions.   
Whereas the cuboidal type II epithelia l cel ls cover 5% of the alveolar 
surface area and have three essential funct ions: surfactant synthesis, 
alveolar epithelia l repair , and ion and f lu id transport. Surfactant consists 
predominantly of l ip ids (90%) and proteins, in part icular surfactant protein  
A (SP-A), SP-B, SP-C and SP-D. The hydrophil ic  proteins SP-A and SP-D 
play a ro le in innate immunity, wh ilst the hydrophobic surfactant pr oteins B 
and C maintain the biophysical properties of the lung. Furthermore, SP -A 
and SP-C mutations have been reported with ILD [2]. Following injury, type 
II a lveolar epithelia l cel ls undergo hyperplasia and differentiat ion into type 
I cel ls as part of the normal repair process.  
 
The alveolar epithelia l cel ls are supported and separated from the capil lary 
network by a basement membrane.  Capil lary endothelia l cel ls are  jo ined 
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by t ight or semi-t ight junctions that al low molecules to traverse the 
capil lary wa ll and contribute to its high permeabil ity.  Other components of 
the alveolar wa ll inc lude the extracellu lar m atr ix constituents collagen, 
elastin and proteoglycans, as well as nerve endings, mast cells, f ibroblasts 
and small numbers of lymphocytes.  Alveolar macrophages can engulf  
ingested partic les by migrat ing into the interst it ium.  Thus the interstit ium 
not only prov ides structure to the lung, but is important for regulat ing 
al lergen exposure, f lu id and gas exchange.  It  is  not surpris ing that 
diseases that target the interstit ium can affect all these components, in  
particular the epithelia l cel ls and f ibroblasts. 
 
1.2 Classification of ILDs 
 
1.2.1 First c lassif icat ion by Leibow and Carrington in 1969 and Katzenstein 
c lassif icat ion in 1998 with new ent it ies  
Hamman and Rich f irst described the histopathologic features in 4 pat ients 
with I IP in 1944 [3]. As a result  of an increased use of surgical lung 
biopsies, Leibow and Carrington published a classif icat ion of IIPs in 1969 
consisting of the fo l lowing f ive patterns: usual interst it ia l pneumonia (UIP),  
bronchiol i t is  obliterans with interstit ia l pneumonia, desquamative 
interst it ia l pneumonia (DIP), lymphoid interst it ia l p neumonia (LIP), and 
giant cell interst it ia l pneumonia.  It  was not unti l the classif ication of  
Kazenstein and Myers in 1998 that the importance of quantify ing the 
presence of f ibrosis and inf lammat ion as well as its distr ibut ion, intensity 
and nature [4]  was highlighted.  This c lassif icat ion not only described a 
new entity - nonspecif ic interst it ia l pneumonia (NSIP) but also emphasized 
the importance of separat ing the histological ent it ies to help predict  
prognosis for indiv idual pat ients.  Furthermore, Kazenstein and Myers  
identif ied specif ic histolog ical characterist ics, inc luding temporal 
heterogeneity of the f ibros is, accumulat ion of intra -alveolar macrophages, 
and grade of cellu lar ity and f ibrosis, to aid with the diagnosis making 
process.  They concluded that the term idiopathic pulmonary f ibrosis (IPF) 
should be reserved only for cases of UIP histo logy [4].  
In order to prov ide a unify ing approach and set an international standard 
for the diagnosis of IPF the American Thoracic Society (ATS) and 
European Respiratory Society (ERS) published a jo int Internat ional 
Consensus Statement Idiopathic Pulmonary Fibrosis: Diagnosis and 
Treatment. Some of its key conclusions are as follows:  
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1. Usual interst it ia l pneumonia (UIP) is the histopathological pattern 
that ident if ies patients with IPF, whilst the patterns of desquamativ e 
interst it ia l pneumonia (DIP), respiratory bronchiol it is -associated 
interst it ia l lung disease (RBILD), nonspecif ic interst it ia l pneumonia 
(NSIP), lymphoid interst it ia l pneumonia (LIP), acute interstit ia l 
pneumonia (AIP), and id iopathic bronchiol i t is  oblit erans organising 
pneumonia (BOOP) are considered separate entit ies.  
2. Surgical lung biopsy is recommended in most patients, particular ly 
those with atyp ical features of IPF [5].  
3. The IPF consensus also for the f irst t ime suggested major and minor 
criter ia for the diagnosis of IPF in an immunocompetent adult in the  
absence of lung biopsy.  
Generally ILDs are classif ied according to whether a known associated 
factor can be identif ied such as occupational, env ironmental, or drug 
exposures, and collagen vascular diseases. In the absence of an 
identif iable cause, the ILDs are grouped as id iopathic interstit ia l 
pneumonias (IIP) (Figure 1.2) [6]. Clin ical and radiolog ical features of IIP  
are not always diagnostic, hence a surgical lung biopsy is ofte n required 
for a histo lopathological d iagnosis.   
12 
 
 
Figure 1.2  Diffuse parenchymal lung diseases (DPLDs) or ILDs consist of disorders of 
known causes (collagen vascular disease, environmental or drug related) as well as 
disorders of unknown cause. The latter include idiopathic interstitial pneumonias (IIP), 
granulomatous lung disorders (e.g. sarcoidosis), and other forms of interstitial lung 
disease including lymphangioleiomyomatosis (LAM), pulmonary Langerhans' cell 
histiocytosis/histiocytosis X (HX), and eosinophilic pneumonia. (Reproduced from 
American Thoracic Society/European Respiratory Society International Multidisciplinary 
Consensus Classification of the Idiopathic Interstitial Pneumonias (2)). 
 
Based upon the Kazenstein and Myers c lassif icat ion system, the American 
Thoracic Society and European Respiratory Society established a uniform 
set of defin it ions and criter ia for the diagnosis of IIP(2). Th is c lassif ied IIP 
into seven cl in ical- radio logic-pathologic entit ies. The consensus 
recommended the use of the term “pattern” when describ ing the 
histopathology in order to distinguish it from the clin ica l -rad iologic-
pathologic diagnosis (Table 1.1, [6 ]).  
Histopathological pattern Clinical-radiologic-pathologic pattern 
Usual interstitial pneumonia  
Nonspecific interstitial pneumonia 
Organising pneumonia  
Diffuse alveolar damage 
Respiratory bronchiolitis 
Desquamative interstitial pneumonia  
Lymphoid interstitial pneumonia 
Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis 
Nonspecific interstitial pneumonia  
Cryptogenic organising pneumonia  
Acute Interstitial Pneumonia  
Respiratory bronchiolitis interstitial lung disease 
Desquamative interstitial pneumonia 
Lymphoid interstitial pneumonia 
Table 1.1 Histopathologic and cl in ica l c lassif icat ion of the id iopathic 
interst it ia l pneumonias [6] 
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1.2.2 Advantages and l imitat ions of the histo logical c lassif icat ion system  
Clin ical and radiologica l features cannot always dist inguish between the 
various IIP and histopathology may be required for establishing a c l in ical -
pathologic diagnosis. This al lows the patient and clin ic ian to make a more 
informed decis ion about prognosis and therapy. This l imits unnecessar y 
r isks and side effects of treatment in the presence of diagnostic 
uncertainty [6]. I t  may also identify specif ic, often occupational, exposures 
as the cause of the underly ing ILD that may be compensatable [6].  
Nevertheless this approach has a number of l imitat ions. The most 
important being the low level of inter -observer agreement in some 
histolog ic scores [7]. Secondly, the presence of histopathologic  
heterogeneity with discordant UIP ( i.e. UIP and NSIP present in specimens 
from different lobes) may potential ly lead to an erroneous diagnosis when 
only a s ingle lobe biopsy is performed [8]. Thirdly, sampling error may 
result in a specimen of “end stage f ibrosis” being obtained which would not 
enable accurate diagnosis. Finally, the histopathologic pattern should not 
be interpreted without appropriate c l in ical and radio logical information.   
This is particu lar ly important for UIP as it can be associated with  
connective t issue disease, occupational exposures, famil ia l f ibrosis, 
chronic hypersensit iv ity pneumonit is as well as IPF (F igure 1.3).  
 
Figure 1.3  Interstit ia l Lung Diseases are associated with  UIP 
histopathology.  
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IPF is the commonest of the IIPs, accounting for 47 to 62% of cases [6, 9],  
whereas NSIP occurs in 14 to 36% of cases [10-12].  
 
1.3 What is IPF? 
1.3.1 Definit ion 
Histor ical ly d if ferent terms have been used for IPF, inc luding cryptogenic 
f ibrosing alveolit is  or  CFA. This term encompassed a group of condit ions  
cl in ically typ ical of IPF but also present in other IIPs and hypersensit iv ity 
pneumonit is. At th is t ime, the clin ical relevance of distinguish ing between 
different IIPs had not been established  [13, 14]. It  was not unti l the 
ATS/ERS consensus classif icat ion of IIP, which considered the importance 
of histolopathological c lassif icat ion for predicting cl in ical outcome, that led 
to worldwide adoption of the term IPF. Based upon this, IPF is a chronic,  
progressive and fatal f ibrosing interstit ia l pneumonia, characterised by the 
radio logical and/or histopathological pattern of UIP [5].  
  
1.3.2 Histopathological features of IPF  
Microscopically IPF has the histopathological pattern of UIP. UIP is  
characterised by spatial heterogeneity i.e. an abrupt transit ion between 
areas of remodelled lung parenchyma, consist ing of intersti t ia l 
inf lammation, f ibros is and honeycomb change, with normal lung t issue 
(Figure 1.4a). This transit ion occurs through patchy areas of lung injury 
with lymphocytes and plasma cells inf i lt rat ing the alveolar septa, 
hyperplasia of type II a lveolar epithelia l ce l ls and f ibrob last prol ife ration  
[6]. The remodelled lung is present predominantly in a subpleural and 
peri lobular d istr ibut ion. A lthough inf lammation is not a major feature of 
UIP, chronic inf lammatory cells, lymphoid aggregates with germinal 
centres, and occasionally acute inflammation may be prominent in and 
around honeycomb areas [15]. 
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Figure 1.4  Microscopic appearance of UIP. Surgical lung biopsy 
specimens demonstrating UIP pattern. (A) Scanning power microscopy 
showing a patchy process with honeycomb spaces (thick arrow),  some 
preserved lung t issue regions (thin arrow), and f ibros is extending into the 
lung from the subpleural regions. (B) Adjacent to the regions of more 
chronic f ibrosis (th ick arrow) is a f ibrob last focus (asterisk), recognized by 
its convex shape and composit ion of oedematous f ibroblast ic t issue, 
suggestive of recent lung injury [16].  
 
The areas of f ibrosis are at  various stages of maturity,  from f ibroblast ic 
foci to dense collagen, which is referred to as temporal heterogeneity.   
Fibroblast ic foci (F igure 1.4) represent a collect ion of prol i ferat ing spind le -
shaped fibroblasts and myofibroblasts with in mixo id stroma.  They 
synthesise and secrete collagen and extracellu lar matrix constituents.  
Although fibroblast ic foci are not pathognomonic of UIP their presence i s 
supportive of th is diagnosis.  In addit ion, the number of f ibrob lastic foc i 
has been shown to be predictive of a poorer outcome in IPF [17], but th is 
has been disputed by others [18]. 
The areas of pleural f ibrosis may contain proli ferat ing smooth muscle cells  
and microscopic honeycombing. These cysts are lined by ci l iated columnar 
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epithelium and typically are f i l led with mucus and inflammatory debris [15].  
Exactly how these honeycomb cysts form is unclear. One possibi l i ty is that 
they arise from centri lobular a irways that are trapped in the f ibrous 
remodell ing, becoming pulled to the periphery of the lobule. In support of 
th is concept, a v is ible central airway is often absent in lobules with  
microscopic honeycombing. With more advanced disease, gross 
honeycomb cysts form giv ing the macroscopic appearance of “honeycomb 
lung” as  seen with end-stage UIP (Figure 1.5)  
 
 
Figure 1.5 Macroscopic 
appearance of IPF lung. End-
stage UIP is characterised by 
honeycomb cysts, containing 
mucus and inflammatory cell 
debris. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main histopathologic criter ia for UIP are summaris ed in Table 1.2 [19]. 
Along with key histo logic cr iter ia helping to confirm the diagnosis of UIP 
ATS/ERS consensus specif ies pert inent negative f indings the presence of 
wh ich would suggest against the diagnosis of UIP as in Table 1.2 [6].  
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Histopathological diagnostic criteria 
for UIP 
Pertinent negative findings 
Patchwork pattern of parenchymal 
involvement  
(nonuniformity, spatial heterogeneity) 
 
Architectural distortion  
(honeycomb change and/or scars) 
 
Temporal heterogeneity  
(fibroblast foci and collagen deposition) 
Lack of active lesions of other interstitial diseases 
(i.e. sarcoidosis or Langerhans’ cell histiocytosis) 
 
Lack of marked interstitial chronic inflammation 
 
Granulomas: inconspicuous or absent 
 
Lack of substantial inorganic dust deposits, i.e. 
asbestos bodies (except for carbon black pigment) 
Lack of marked eosinophilia 
Table 1.2 Histopathological diagnostic criteria for UIP and pertinent negative findings 
 
In the presence of an acute exacerbation or an accelerated phase of IPF, 
there may also be histological features of diffuse alveolar damage (DAD), 
organising pneumonia and capil lar it is  [6]. Areas of DAD are characterised 
by areas of interst it ia l f ib roblast prol i ferat ion that are larger and more 
confluent than the small and discrete f ibroblast ic foci of UIP hyaline  
membranes are present; squamous metaplasia in bronchial epithelium 
l in ing honeycomb areas and small arter ia l thrombi; organising pneumonia 
is recognised by prominent c lusters of f ibroblast plugs within a irspaces of 
otherwise typ ical UIP [15]. DAD may obscure the histological f ind ings of 
UIP. 
 
1.3.3 Clin ical s ignif icance of histological c lassif icat ion/diagnosis  
Following publication of the ATS/ERS consensus statement for IIP, a  
number of studies have assessed how the histopathological d iagnosis 
effects surv ival, d isease progression and response to therapy. Flaherty et  
al. undertook a prospective study of 168 patients who had a diagnostic 
surgical lung biopsy (SLB) and determined that the most important 
predictor of surv ival was the absence of UIP [20]. Th is study also 
demonstrated that amongst patients with NSIP there were more responders 
to treatment compared to those with UIP. Th is was one of the earl iest  
studies to confirm the importance of UIP histopathological  d iagnosis fo r  
predicting mortal ity.  
Two studies have addressed if specif ic h istopathological features of UIP 
are predictive of poor outcome. In a study by King et al. four experienced 
pathologists independently graded single lung biopsies from 87 patients  
with UIP for the extent and sever ity of specif ic histopathologic features, 
inc luding the stages of f ibrosis (ongoing and established). Their  
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mult ivariate age-, sex-, and smoking adjusted surv ival analys is identif ied  
that only the granulation /connective t issue score (compris ing the alveolar 
space granulat ion t issue and f ibrotic/reparative changes in immature 
extracellu lar matrix) was a signif icant predictor of surv ival in patients with 
IPF, with a one unit increase in i t  being associated with a 1.74 -fold greater 
r isk of death [17]. This study was the f irst to demonstrate that immature 
f ibrosis was associated with  a better outcome and supported the 
hypothesis of epithelia l in jury and persistent f ibroblast ic prol iferat ion as 
key to the pathogenesis of IPF. These f ind ings were supported by the 
study of 53 patients with IPF and a histolog ical d iagnosis of UIP by 
Nicholson et al. (83 separate biopsies). Mortal i ty was independently l inked 
to an increas ing f ibrob lastic foc i (FF) score (p=0.006) and a decreasing 
DLCO% predicted (p=0.01) and was not influenced by  age and sex; 
increasing FF scores were independently associated with greater declines 
in FVC and DLCO at both 6 and 12 months [10]. 
Flaherty et a l. and Monaghan et al.  determined if mult ip le biopsy 
specimens from the same patient with IIP would show the same 
histolog ical pattern and assessed if h isto logical variabil i ty (or d iscordance) 
would affect the prognosis. The study by Flaherty et al [8] confirmed the 
presence of histolog ic heterogeneity as it  demonstrated the coexistence of 
histolog ic patterns of UIP and NSIP in the same patient with 28 out of 109 
patients hav ing discordant UIP (UIP in at least one lobe and NSIP in at  
least one lobe) [8]. Histo logica l diagnosis and heterogeneity af fected 
surv ival and patients with NSIP had a better surv ival: r isk of mortal ity was 
24.3 greater (95% CI: 3.3 to 177; p<0.0001) for patients concordant for  
UIP and 16.8 t imes greater (95% CI: 2.8 to 98.9, p<0.0001) for patients 
with discordant UIP compared with NSIP patients. This study had  the 
fol lowing major implicat ions: patients who have a combination of UIP and 
NSIP patterns should be classif ied as hav ing UIP as it is  associated with a  
poor prognosis and that more than one lobe should be biopsied, with  
sampling from areas of relat ively preserved lung. These results were 
supported by the f indings of Monaghan et al wh ich showed that among 64 
patients with UIP and NSIP histology patterns, 75% of concordant NSIP 
group were al ive 5 years after biopsy while on ly 17% in the concordant and 
37% in the discordant UIP group were al ive [21].  
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1.3.4 Importance of distinguishing from NSIP 
NSIP is the second commonest pattern of the IIP. Unti l the late 1990s, 
NSIP was considered a similar  disease to UIP and was frequently 
misdiagnosed as UIP. Subsequently, NSIP has been recognised as a 
dist inct c l in ical ent ity with characterist ic c l in ica l, rad io logic, and pathologic  
features that differ from other IIPs [22]. Though radiolog ically and 
histolog ically it  might be diff icult to dist inguish from UIP, there are 
features that would favour a diagnosis of NSIP: radiolog ical features would  
inc lude bilatera l symmetrical predominantly lower lung reticu lar opacit ies  
with tract ion bronchiectasis and lower lobe volume loss that is usually 
diffuse or subpleural in the absence of honeycomb change [22]; 
h istolog ical features would dif fer from UIP by a uniform and diffuse type of 
change [15, 22]. The populat ion of NSIP is not homogeneous as it can be 
div ided histopathologically in to f ibrotic NSIP (the majority of cases) and 
cellu lar NSIP. Pat ients with f ibrot ic NSIP have a worse prognosis than 
those with ce llu lar NSIP [22]. Overall  the 5-year mortal ity rate for NSIP is  
18% [22]. Different iat ing UIP from NSIP remains an important issue as it 
helps to predict prognosis and to target appropriate treatment as 
recommended by the BTS ILD guidelines, which recommends that all  
suitable patients with IPF should be considered for a c lin ical t r ia l i f  
availab le.  On the other hand, the presence of severe funct ional 
impairment in patients with f ibrot ic NSIP renders a prognosis s imilar to  
that for UIP [23]. 
 
1.4 The epidemiology of IPF  
 
1.4.1 Incidence and prevalence of IPF  
The recently reported incidence and prevalence rates for IPF are 
calculated from data obtained from general practice databases, disease 
registr ies, c l in ic attendances and healthcare claims databases as well as  
death certif icates in both the UK and USA.  The annual incidence is 
reported to be 7.44/100000 in the UK and 6.8/100000 in the USA with an 
11% increase between 1991 and 2003[24, 25].  Gr ibbin et  al. [26] observed 
a higher incidence in men (5.69 (95% CI 5.24 to 6.18) than women (3.44 
(95% CI 3.10 to 3.82)) and in older people.  In addit ion, between 1991 and 
2003 the incidence of IPF signif icantly increased, even after taking into  
account confounding factors such as age and male sex.  After control l ing  
for these variables, Gribb in et al. estimated the annua l increase in the 
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inc idence of IPF to be 11%.  This could not be explained by aging of the 
UK populat ion or accrual of milder cases as the prognosis was unchanged 
over this t ime interval.  Hence, it  is  antic ipated that 5000 new cases of IPF 
wil l be diagnosed in the UK annually[24].  Similar ly in the US Raghu 
analysed the healthcare claims processing system database to calculate 
the incidence and prevalence of IPF to be 6.8 and 14.0 per 100 000 
person-years respectively [25].  
 
1.4.2 Risk factors for IPF 
Epidemio logical studies have identif ied several r isk factors that affect 
inc idence as well as the mortal ity associated with IPF.  These include 
gender, advancing age, race and ethnic ity, area of l iv ing, season, 
exposures to c igarette smoke, occupational expo sures, height,  
comorbidit ies.  
 
Race and ethnic ity  
The data on race and ethnic ity and surv ival are confl ict ing. In a 
retrospective analys is of 2635 patients with IPF, l is ted for lung 
transplantation between 1994 and 2003 in 94 transplant centres in the 
USA, Lederer et al identif ied that black and Hispanic patients had a higher 
mortal ity rate than non-Hispanic wh ites, wh ich was independent of age, 
gender, comorbidit ies, insurance status, transplantation and socio -
economic status. This may be attr ibutable to p oorer lung function at the 
t ime of lis t ing for a transplant, reflect ing the barriers faced by minor ity 
patients to obtain high-quality health care and consequent later referral for  
transplantation [27]. In contrast, Olson et al. in the ir US Mult ip le Cause -of-
Death mortal ity database study showed that overall age-adjusted mortal i ty 
rates increased between 1992 and 2003, but that the increase in mortal i ty 
was lower in Hispanics compared to wh ite, non -Hispanics 1992 and 2003 
[28].  However their recent study has shown that Hispanics were more 
l ike ly to die of IPF than non-Hispanic whites [29].  This suggests that there 
are genetic dif ferences between racia l groups.  
 
Geographical Location 
The incidence of IPF varies s ignif icantly between areas in the UK, with the 
highest rates reported in Scotland and the North, whilst the lowest rates 
are in the South East [30]. In addit ion, a study of IPF in the USA observed 
that mortali ty rates differed with the lowest values (34.3 -35.5 per 
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1,000,000) in New Jersey, New York and Nevada, and the highest levels 
(69.3-69.5 per 1,000,000) in Vermont and New Mexico [28].  Th is implies 
that local env ironmental factors may play a ro le in pathogenesis of IPF.  
 
Smoking and occupational exposures 
A number of epidemiologica l and observational studies have identif ied that 
certain env ironmental and occupat ional exposures are associated with an 
increased risk of IPF. A meta-analys is of 23 case-control studies 
demonstrated that c igarette smoking and exposures to agriculture and 
farming, l ivestock, wood and metal dust, stone and sil ica s ign if icantly 
increased the risk of IPF[31]. The highest population-attr ibutable risk 
percentages were for smoking (Odds ratio (OR)=2.5),  and agricultural and 
farming exposures (OR=2.8), suggesting that 49 and 21% of IPF could be 
prevented by el iminat ing these exposures, respectively [31]. 
There has been much debate about smoking and IPF as some studies 
suggested a protective smoking effect [17, 20, 32]. It  was Antoniou et al.  
who emphasized the importance of adjustment for baseline disease 
severity in mortal ity stud ies, part icular ly in s ituat ions where a “healthy 
smoker” effect is possible, i.e.  patients with milder d isease and fewer 
symptoms are less l ikely to g ive up smoking, hence smoking cessation 
may be a surrogate marker of more advanced disease. The group used the 
composite physiolog ic index (CPI) to adjust for the confounding functional 
effects of concurrent emphysema (higher FVC and lower DLCO) to  
evaluate 240 patients with IPF (63  non-smokers, 166 former smokers, 20 
current smokers). They observed that overall mortal ity was higher in 
former than current smokers, however severity adjusted surv ival assessed 
with the use of CPI did not diffe r s ign if icantly between the two groups. 
non-smokers had better surv ival than the combined group of current and 
former smokers (HR=0.63; 95% CI = 0.45, 0.90; p,0.01) and this changed 
l i t t le with adjustment for the extent  of d isease on CT (HR = 0.68; 95% CI = 
0.47, 1.00; p<0.05) and DLCO levels (HR = 0.59; 95% CI = 0.40, 0.87; 
p<0.01) but increased with adjustment for CPI level (HR = 0.49; 95% CI = 
0.33, 0.73; p<0.0005) [33].  
 
Comorbidit ies  
Two studies have identif ied an association between IPF and diabetes 
mell itus (DM). A case-control study from Japan of 52 untreated IPF 
patients and 184 controls noted that the prevalence of DM was higher in  
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the IPF group (32.7%) compared to the controls (11.4%), with an adjusted 
odds ratio of 4.04 (95% CI 1.8 -9.15) [34]. A similar  associat ion between 
type II d iabetes mell itus and IPF (11.3% in IPF vs 2.9% in chronic 
respiratory d isease control group) was observed in a study f rom 
Mexico[35]. It  remains to be determined why DM increases the risk of IPF.  
A number of studies have suggested that abnormal acid gastroesophageal 
reflux (GER), is a risk factor for IPF due to its possible association with  
microaspirat ion[16]. Abnormal reflux is a common condit ion in patients 
with IPF but is often asymptomatic [36]. The use of GER medications is 
associated with decreased radiolog ic f ibrosis  and is an independent 
predictor of longer surv ival t ime in patients with IPF [37].  
As shown in patients on transplant l is t who underwent left  heart 
catheterizat ion there is ev idence of a higher prevalence of coronary artery 
disease in IPF patients (66%) compared to matched COPD group (46%) 
and this association is independent of usual coronary artery disease risk 
factors; IPF patients with s ignif icant CAD had a worse outcome[38]. It  was 
also demonstrated that HRCT is a useful screening tool for the detection of 
s ignif icant CAD in pat ients with IPF and should be used routinely [39] . 
 
1.5 Clinical presentation 
 
1.5.1 Symptoms/history  
IPF typica lly presents in patients over 50 years of age with gradual onset 
exertional dyspnoea and a dry cough for more than 3 months, although 
symptoms may have been present for a few years. It is  more common in 
males. Constitut ional symptoms are unusual. W ith advanced disease, 
patients may experience weight loss due to respiratory fa i lure and an 
increased work of breathing. As the disease progresses, features of r ight  
heart fa i lure may become apparent with per ipheral oedema, abdomina l 
discomfort and increase in abdominal girth due to hepatomegaly and 
ascites.  
1.5.2 Clin ical examinat ion  
Dig ita l c lubbing is present in 25-50% of patients with IPF [6]. Ve lcro-type, 
f ine end-inspiratory crackles in it ia l ly confined to the basal areas are found 
on auscultat ion of the chest in  80% of cases [5]. As the disease 
progresses, cyanosis and signs of r ight heart fa i lure, including 
accentuated pulmonary second heart sound, right ventricular heave and 
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peripheral oedema, become apparent. Extrapulmonary involvement does 
not usually occur.  
 
1.5.3 Exclusion of other causes  
It is  important to establish a history of occupational, env ironmental, drug 
and smoking exposures as discussed in section 1.4.2. Symptoms and signs  
of connective t issue disease, such as arthralgia or synov it is, myalg ia and 
weakness, fever, fatigue, photosensit iv ity, Raynaud’s phenom enon, s icca 
and reflux symptoms, should be excluded. Sometime these features are 
subtle and can occur after the onset of the interstit ia l lung disease. It is  
important to consider the possibi l i ty of a connective t issue disease (CTD) 
even in patients with radio logical ev idence of UIP as they have a better 
prognosis and require different treatment to patients with IPF. Park et al.  
in a study of 269 cases of IPF-UIP and 93 CTD-UIP showed that those 
patients in the CTD-UIP group surv ived longer (mean 125.5 ± 16 .0 months) 
than those in IPF-UIP group (mean 66.9 ± 6.5 months), p=0.001. Both the 
3-year surv ival rate (81.6 vs 57.4%) and 5 -year surv ival rate (81.6 vs 
44.8%) were better in the CTD-UIP group compared to the IPF-UIP group, 
respectively (p=0.001) [40]. 
Up to 20% of patients with IPF have a family h istory of pulmonary 
f ibrosis [41]. Famil ia l pu lmonary f ibrosis affects at least two members of 
primary bio log ical family (parent, chi ld, s ib l ing) and presents in a s imilar  
manner to IPF, except it  has an ear l ier age of onset [42]. A number of 
studies support an autosomal dominant inher itance with variab le 
penetrance[43]. At present, no genetic testing is available in the UK to 
identify famil ia l forms of PF and  clin ical screening is crucia l [43]. The study 
by Steele et al. suggests that near ly 8% of self -reported unaffected family 
members have a preclin ical form of PF as assessed by HRCT or 
histopathological f ind ings [43], wh ich justif ies the need for surveil lance of 
family members of affected indiv iduals.  
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1.6 Radiological Evaluation  
1.6.1 Role of CXR 
  
Figure 1.6 Chest radiograph in IPF 
 
Typ ical chest radiograph (CXR) abnormalit ies in IPF include peripheral 
reticu lat ion with a basal predominance, honeycombing and lower lobe 
volume loss. These changes may be the f irst c lue to a possible intersti t ia l 
lung disease. On rev iew of prev ious CXRs it may become apparent that 
subtle changes have been present for a few years. Nevertheless a norm al 
CXR in a symptomatic patient with a characterist ic h istory and restr ict ive 
pulmonary function tests should not exclude the diagnosis. This 
demonstrates the insensit iv ity of CXR for d iagnosing limited or early stage 
IPF. In th is sett ing High Resolution Computed Tomography (HRCT) should 
be performed, as it is  more sensit ive for identify ing and characteris ing 
parenchymal abnormalit ies. CXR remains a useful too l for monitor ing 
disease progression and complications such as pneumothora x and lung 
cancer. 
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1.6.2 Role of HRCT 
  
Figure 1.7  HRCT scan in IPF 
 
HRCT has revolut ionised the management of patients with ILD and is 
ind icated for all pat ients with a suspected IIP [6]. I t  is  an essential 
d iagnostic tool for assessing the pattern and extent of the interstit ia l lung 
disease, progression as determined by seria l scans, and associated  
emphysema and potential complications, inc luding acute exacerbations, 
pneumothorax, lung cancer.  and PE when complemented by a pulmonary 
angiogram.  
The primary ro le of  HRCT is to identify typ ical, often d iagnostic patterns of 
ILD and to different iate pat ients with typical f ind ings of IPF from those with  
the less specif ic f indings associated with other id iopathic IIP [6].  
 
1.6.3 HRCT features supporting IPF  
Thin-section CT images typical and not typical for UIP pattern are 
described in Tab le 1.3.  
HRCT features typical for UIP[6] HRCT features not typical for UIP[44] 
reticular opacities  
traction bronchiectasis  
architectural distortion 
honeycombing  
lobar volume loss  
basal and peripheral distribution (often patchy)  
ground glass opacities if present are less 
extensive than reticular abnormality 
extensive ground glass opacification 
consolidation 
micronodules 
air trapping 
nonhoneycomb cysts 
predominantly peribronchovascular distribution 
Table 1.3 Typical and atyp ical HRCT features for UIP pattern  
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CT-pathologic correlation has been described with ret iculat ion correlat ing  
with f ibrosis and radiologica l honeycombing with histopathologica l 
honeycombing. When ground glass attenuation is associated with  
reticu lat ion and traction bronchiectasis or bronchioloectasis, i t  usually 
ind icates histologic f ibrosis.  However, the issue arises with isolated 
ground glass attenuation as this may indicate interstit ia l inf lammation,  
airspace f i l l ing by macrophages or f lu id, and/or f ibros is [6].  
 
1.6.4 Sensit iv ity and specif ic ity of HRCT 
Since HRCT has became a diagnostic tool for IIP, a number of studies 
have addressed whether particular HRCT features would enable a 
confident diagnosis of IPF and obviate the need for a lung biopsy, whether 
some HRCT features aid prognostic information obtained by the biopsy and 
could serve as predictors of mortal i ty, and how the experience of the 
radio logists inf luences interpretation of the HRCT findings.  
Studies have shown that a posit ive predict ive value of a CT diagnosis of 
IPF is 70-100% and that in more than 50% of cases with possible IPF the 
biopsy is not required due to a presence of typ ical HRCT features when 
they are interpreted by expert radiologists [45, 46].  
The f irst study to prospectively determine pretest probabil i ty of the cl in ica l 
diagnosis of ILD including IPF was a tert iary un iversity centre study by 
Raghu et al. published in 1999 of patients with a new onset ILD  referred 
by community physic ian for further evaluation when cl in ical and 
radio logical (HRCT) d iagnosis was made within a month prior to surgica l 
lung biopsy. In 29 patients with an eventual histo logical d iagnosis o f IPF 
(out of total 59) the sensit iv ity and specif ic ity of the radiolog ical d iagnosis 
was 78.5 and 90% respectively (the sensit iv ity and specif ic ity of c l in ical  
diagnosis were 62 and 97% respectively), th is showing that SLB is not 
required in al l  patients but that in a quarter of patients the diagnosis would  
be missed is based on assessment of HRCT features without SLB [46].  
These f indings are being supported by a later study of Hunninghake et al.  
[45] who in a prospective blinded study in 8 centres when the clin ical and 
radio logical f indings of 91 patients with IIP were assessed by physic ians 
and radiologists with subsequent prov is ion of the diagnosis (rating its  
certainty as diagnosis certain, uncertain or unlikely) before the surgical 
lung biopsy, showed that sensit iv ity specif ic ity, accuracy and posit ive 
predictive value for confident HRCT diagnosis of IPF were 87, 95, 90 and 
96% respectively; posit ive predictive value of a confident c l in ical d iagnosis 
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of IPF by the referring centres was 80%; as in prev ious study there was a 
substantial group of patients (50%) in who a confident CT diagnosis was 
not made and it would be a group of patients with uncertain or unlikely 
diagnosis of IPF who required lung biopsy as the probabil ity of agreeme nt 
as reflected by kappa score among pulmonologists and radiolog ists for that  
group was only fa ir (0.32 and 0.31 respectively). Of interest both Raghu et 
al and Hunninghake et al demonstrated that there were no patients with  
IPF who had normal HRCT [45, 46]. 
 
1.6.5 HRCT features that predict diagnosis and prognosis  
The next important question to answer would b e whether certain HRCT 
features predict diagnosis, add prognostic information and correlate with 
mortal ity.  
Flaherty et a l.  c lassif ied HRCT scans of 96 patients (73 of which showed 
histolog ical UIP and 23 histolog ical NSIP) as defin ite UIP, probable UIP 
(honeycombing being the feature different iat ing the two), indeterminate 
(equal probabil ity of UIP and NSIP), probable NSIP, or defin ite NSIP. 27 
patients were felt to have defin ite or probable HRCT diagnosis of UIP with  
al l of them showing histo logica l pictu re of UIP ( in contrast to 18 of 44 
patients with HRCT suggestive of probable or defin ite NSIP showing 
histolog ical diagnosis of NSIP).  As in prev iously mentioned studies 
radio logists demonstrated high specif ic ity for the diagnosis of IPF (100%) 
but lower than prev iously reported sensit iv ity (37%). Patients with a 
histolog ical d iagnosis of UIP had worse surv ival than those with the 
histolog ical d iagnosis of NSIP (HR=7.24, 95% CI 1.74 to 30.2, log rank 
p=0.0015); more importantly there was no difference in su rv ival when 
comparing patients with HRCT diagnoses of probable or defin ite UIP 
(HR=1.67, 95% CI 0.6 to 4.64, log rank p=0.32), or comparing patients with  
HRCT diagnoses of defin ite or  probable NSIP (HR=1.31, 95% CI 0.38 to 
4.54, log rank p=0.67) [47]. As evidenced by Figure 1.7 patients with UIP 
histology could have both defin ite/ probable HRCT diagnosis and 
indeterminate diagnosis and the f irst group of patients has the worst  
prognosis thus demonstrating that HRCT features do indeed add 
prognostic information to the histo logical d iagnosis of UIP.  
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Figure 1.8 Kaplan-Meier 
survival curves for (A) patients 
with an HRCT diagnosis of 
NSIP (n=44, dotted line), 
indeterminate (n=25, dashed 
line), and UIP (n=27, solid 
line), p=0.01; (B) patients with 
a histopathological diagnosis 
of NSIP (n=23, dotted line) 
and UIP (n=73, solid line), 
p=0.0006; and (C) patients 
grouped by combining HRCT 
and histopathological features 
as follows: histopathological 
pattern showing NSIP and 
HRCT was interpreted as 
indeterminate or NSIP (n=23, 
dotted line), histopathological 
pattern showing UIP and 
HRCT was interpreted as 
indeterminate or NSIP (n=46, 
dashed line), and 
histopathological pattern 
showing UIP and HRCT was 
interpreted as UIP (n=27, solid 
line), p=0.001. + = last follow 
up visit; ø = death. [47] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A number of studies showed that out of all HRCT features typical for UIP 
only the extent of t raction bronchiectasis and quantity of f ibrosis are  
signif icant predictors of mortal ity.  Hav ing assessed the extent of intersti t ia l 
opacity (CTf ib) on a scale of 0-5 in 106 patients with histo logically 
confirmed UIP Flaherty et al demonstrated that a mean CTfib score of ≥2 
in any lobe (representing the presence of honeycomb change) or mean 
CTfib score of ≥2 for all lobes was highly predict ive for the presence of 
UIP and that the RR for dying with a mean CTfib score of ≥2 for entire lung 
was 2.51 (95% CI 1.39-4.54; p=0.002) and 3.72 (95% CI 1.83-7.56; 
p=0.0003) for those with at least one lobe with a CTf ib score of ≥2 
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(dif ference probably ref lect ing the disease heterogeneity)  [20]. A posit ive 
predictive value of 92% suggested that these patients do not need to 
undergo a lung biopsy. A l imited negative predictive value (47% for al l  
lobes and 69% for at least one lobe) reflected the absence of 
honeycombing on HRCT of many patients with UIP.  CT f ib  score <2 is not  
rel iab ly predict ive of absence of UIP therefore these patient should 
undergo a biopsy [20]. 
Lynch et al in a large cohort of patients (315) recruited into the study 
evaluating IFN-γ1b showed that DLCO was the only physio logic  
characterist ic most highly correlated with HRCT f indings and that a higher 
overall extent of f ibrosis on HRCT was associated with a 2.7-fold increase 
r isk of mortali ty in the mult ivariate analys is [44]. Th is f inding agreed with  
the prev ious f indings of Mogulkoc et al with percent predicted DLCO and 
the HRCT fibrosis score being the sole two predictors of mortali ty of 2 year 
surv ival in 115 patients with UIP [48]. 
 
1.6.6 Inter-observer differences 
The majority of c l in ica l tr ia ls performed in IPF originate from large 
academic centres and this should be taken into account as the expertise 
and experienced in IIP of tert iary centres radiolog ists and radiologists from 
community hospitals might differ wh ich wil l lead to different radio logical 
interpretat ion of the same scans. Agreement between expert radiologists is  
good as demonstrated by Hunninghake et al. in his study of 91 patients 
HRCT of which were independently assessed by 4 radiologists.  The 
probabil ity of agreement for presence or absence of IPF was 0.77 (kappa 
0.54) while posit ive predict ive value of UIP d iagnosis was 85%, th is 
improved to 96% for cases of confident UIP diagnosis [45]. An 
interobserver agreement fo r the combination of probable and definite UIP 
was similar (64%, kappa 0.52) in 2 other studies of 73 and 69 patients  
respectively [47, 49]. In a large study involv ing 315 patients where core 
radio logists were not blinded to the radiologica l and histolog ical diagnosis 
of the patients their interpretation of HRCT confirmed the diagnosis in 90% 
of cases originally rev iewed by radio logists of 58 sites, 19 of which were 
community based. This could partly be a result of the use of predefined 
criter ia for HRCT interpretat ion by study-site radio log ists [44]. 
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1.6.7 Definite vs probable IPF vs atyp ical  
Thus several studies demonstrated  that even radiolog ists with s ignif icant 
expertise in I IP can f ind diagnostic diff icu lty between UIP and NSIP 
patterns on HRCT [46, 47, 49]. Not al l patients with IPF exhib it a l l typ ical 
features of HRCT as a result of which to enable accurate diagnosis of IPF 
on radiologica l grounds and ident ify patients who d o not require a lung 
biopsy a set of criter ia for “defin ite” and “probable” diagnosis of IPF has 
been determined. A radiographic diagnosis of “defin ite IPF” required all  
three of the fol lowing cr iter ia: (1) presence of reticu lar abnormality and/or 
traction bronchiectasis with basal and peripheral predominance; (2)  
presence of honeycombing with basal and peripheral predominance; (3) 
absence of atypical features, such as micronodules, peribronchovascular 
nodules, consolidat ion, isolated (nonhoneycomb) cysts, extensive ground 
glass attenuation, or extensive mediastinal lymphadenopathy [44]. The 
presence of the f irst and third criter ia (honeycombing not present) only 
qualif ies as “probable IPF”. The presence of atypical rad io logical features 
(as in (3)) and/or atypica l c l in ical features (young age, inconclus ive 
exposure history, lack of dyspnoea, absence of restrict ive lung defect on 
pulmonary function tests) is an ind ication for a b iopsy to c lar ify the  
diagnosis [6].  
 
1.6.8 Novel imaging modalit ies  
Though HRCT is an imaging standard in IIP it is  only a structural 
technique, hence Groves and Screaton decided to use Positron Emission 
Tomography (PET) which offers an abil ity to noninvasively invest igate 
cellu lar mechanisms in v ivo in combination with CT; this combination 
al lows direct comparison of 18F-f luorodeoxyglucose (18F-FDG) uptake 
with the structura l appearance of the lung parenchyma. The maximal 
pulmonary 18F-FDG metabolism is measured as standardised uptake value 
(SUVmax). As antic ipated raised pulmonary 18F -FDG was associated with  
ground glass opacity on HRCT of 18 patients with IPF (mean SUVmax 2 .9  
± 1.1) and 18 patients with other ILD (mean SUVmax 2.7 ± 0.9); but the 
site of maximal metabolism was corresponding to the ground glass  
changes in 7 out of 36 patients only, wh ile ret iculat ion and honeycombing 
encountered for 26 of 36 patients. The authors hypothesized that the area 
of HRCT ret iculat ion and honeycombing might not represent burnt -out inert  
disease but be an area of metabolica l ly act ive f ibrotic process and hence 
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even patients with extensive f ibrotic change on HRCT may st i l l be 
amenable to  pharmacologic manipulat ion [50]. 
This method is not routinely used in IPF and other form of IIP but adds to 
understanding of pathological mechanisms.  
 
1.7 Role of BAL and TBB 
Broncho-alveolar lavage (BAL) is a method used as an addit ional 
investigat ional tool during bronchoscopy. It is  used in the f irst place to 
detect bronchia l and alveolar cells metaplasia  or to identify infectious 
pathogens. It could also be used for assessment of differentia l cel l counts 
wh ich might point towards a particular diagnosis. Normal BAL values from 
non-smoking subjects show the fol lowing: a lveolar macrophages 80 -90%, 
lymphocytes 5-15%, neutrophils 1-3%, eosinophils <1%, mast cells <1%.  
Though there are no pathognomonic BAL features for UIP a f inding of 
raised neutrophils (>4%) and raised eosinophils (>2%) is charac terist ic of 
UIP and is distinct from differential cel l count in sarcoidosis and 
hypersensit iv ity pneumonit is.  
Problem with obtain ing a good size specimen that would represent both 
abnormal and normal lung parenchyma in UIP as well as lack of 
architectural preservation due to mechanical crash makes TBB unhelpfu l in  
IPF. This has been confirmed by an 85% rate of nondiagnostic TBB in 59 
patients with ILD (29 of them IPF) [46]. 
BAL alone is used for the purpose of exclusion of infection and other 
diagnoses as well as to assess prognosis in IPF. To answer the question if  
baseline BAL cell  count would predict h igher mortali ty among persons with  
IPF Kinder et al. performed a prospective study of 156 patients with biopsy 
proven IPF. 67% of the cohort had an elevated BAL neutrophil count of 
>3%; the surv ival analysis demonstrated a l inear relat ionship between 
increased neutrophil percentage and the risk of mortali ty, each doubling o f  
neutrophil percentage was associated with a nearly 30% increased r isk of 
death or transplantation in adjusted analys is (HR 1.28; 95% CI 1.01 to 
1.62, adjusted p=0.04) (this was not affected by smoking or treatment 
status). The median surv ival t ime for those with neutrophil count >11% was 
1.9 years, for those with a count of 3 -10% was 2.3 years and those with a  
count of <3% - 3.7 years [51]. Therefore an increased BAL neutrophil 
percentage is an independent predictor of early mortal ity in IPF and could 
help to identify pat ients who require treatment at an earl ier stage.  
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As mentioned prev iously NSIP particu lar ly its ce llu lar form can exhib it  
h igher levels of BAL lymphocytosis. It  had therefore been explored if BAL 
cell count differences in UIP and NSIP could help to different iate between 
the two condit ions. Veeraraghavan et al. retrospectively evaluated BAL 
f indings in 54 patients with h istological d iagnosis of UIP (35 patients) and 
NSIP (19 patients). It  was the f irst s tudy where the diagnosis was 
confirmed surgically and was defined based on ATS/ERS criter ia of IIP.  
There were no signif icant or marginal d if ferences found in BAL data 
between UIP and NSIP patients and BAL cell counts did not predict  
changes in lung function; none of the constituents of BAL cell count 
predicted surv ival [52]. 
A more recent large retrospective study of 87 UIP and 35 NSIP pat ients 
demonstrated that UIP was characterised by a highe r neutrophil count of 
7% vs 3% in NSIP and a lower lymphocyte count of 5% vs 29% in NSIP 
[53]. In summary the diagnostic usefulness of BAL in IPF is l imited but is 
helpful in  identify ing a group of patients who have worse prognosis  
although admittedly there is no evidence that an earl ier commencement of 
treatment improves surv ival.  
 
1.8 Surgical Lung biopsy 
1.8.1 Who to biopsy  
HRCT features of defin ite IPF obviate the need for lung biopsy in around 
50% of IPF cases. The remaining 50% include cases of c lin icall y or  
radio logically probable ( lack of honeycombing) or atyp ical IPF when a 
surgical lung biopsy (SLB) is required as this could demonstrate UIP even 
in the absence of typical HRCT p icture or an alternat ive diagnosis. 
Histor ical ly only about 10-15% of these cases are being referred for a SLB 
due to the fact that physic ians are often reluctant to refer patients to a 
potential ly r isky procedure on one hand and to a limited availab il i ty of  
effective treatment options no matter what the f ina l d iagnosis is on the  
other hand. Nevertheless development of thoracoscopic v ideo -assisted 
thoracoscopic (VATs) biopsy and of new treatment options (for example  
antif ibrot ic drugs) emphasizes the importance of accurate diagnose to 
enable prediction of surv ival in an indiv idual  case and correct use of new 
drugs in correct c ircumstances. 
If b iopsy is considered it should be taken early in the course of the 
disease and include both areas of  end stage lung as well as less f ibrosed 
areas, which could be targeted with the guidance from a radiologist.   
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1.8.2 Safety of lung biopsy.  
A retrospective study of Utz et al. of 60 SLB (14 VATs biopsies and 46 
open lung biopsies (OLB) of pat ients with atyp ical for UIP h istory or  
examination demonstrated a high early 30 day mortal ity rate of near ly 17% 
(10 patients of 60). A lower DLCO was predictive of mortal ity at 30 days 
(34.7% vs 52.1%) which might make one consider that patients who died 
had a more severe disease. Also 4 of 10 patients who died had ev idence of 
DAD on biopsy meaning they had an accelerated course of the disease. 7 
of 10 cases had OLB rather than VATs [54]. 
Lett ier i [55] and Hunninghake [45] demonstrated that the early mortal i ty  
rate after surgical lung biopsy was low (1.1% and 1.5% respectively)  
among patients who were not receiv ing immunosuppression or 
mechanically venti lated; the last  two factors were the onl y ones that 
different iated surv ivors from nonsurv ivors in Lett ier i study. At the same 
t ime gender, pulmonary function indices, oxygen use and age did not 
affect surv ival [55] .  
 
1.8.3 Mult ip le biopsies  
Returning back to the studies of Flaherty et al. [8]  and Monaghan et al.  
[21] discussed in section 1.3.3 it  is  important to remember another 
implicat ion toward SLB: patients who have a combination of UIP and NSIP 
patterns should be classif ied as hav ing UIP as it is  associat ed with a poor 
prognosis; biopsy technique should be such that mult ip le lobe biopsies 
should be considered from areas of relat ively preserved lung. Patients with 
biopsies taken from only one lobe could be mistakenly c lassif ies as NSIP 
due to possible co-existence of UIP and NSIP patterns in the same patient.  
Therefore biopsies should be taken from more than one lobe.  
 
1.8.4 Does biopsy accelerate disease? 
Case reports have described acute exacerbation of IPF after surgical lung 
biopsy, the majority of th is cases died with in 30 days of the b iopsy [56,  
57]. Kondoh et al hypothesized intraoperative respiratory management is  
contributing to the exacerbation: hyperoxia, prolonged anaesthesia during 
the procedure, excessive mechanical stretch/in jury, th is could contribute to 
free radical oxidat ive damage to the non -biopsied lung where most of the 
in jury usually occurs [57]. 
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1.8.5 Role of MDT 
ATS/ERS consensus statement on IIP emphasizes that achiev ing a correct 
diagnosis is a dynamic process, it  requires close communication between 
cl in ic ian, radio log ist, and pathologist and that the diagnosis might need to 
be rev ised once more cl in ica l, radiolog ical and histo logica l  information 
becomes available [6]. Th is addit ional information is to mutual benefit to  
al l three diagnostic parties. For example, pathologist suggest ing a 
diagnosis of NSIP on histological grounds alone might reconsider the 
diagnosis in favour of UIP if an information about a presence of s ignif icant 
honeycombing on HRCT is prov ided by radio logist or when suggest ing a 
diagnosis of UIP in favour of connective t issue disease related ILD if an  
information about jo ints involvement and posit ive autoimmune screen is  
prov ided by cl in ic ian. In turn a c l in ic ian might reconsider a diagnosis o f 
IPF in favour of Hypersensit iv ity Pneumonit is i f  prov ided with information 
by a radiolog ist about air trapping and upper zone involvement on HRCT or 
on noncaseating granulomas in pathological lung specimens.  
The most practical way of arranging a jo int c ase discussion is at  
mult id iscip l inary meetings involv ing clin ic ians, radiologist, pathologist and 
surgeon.  
Role of mult id iscip l inary approach to the diagnosis of IIP including IPF was 
looked at by Flaherty et al. in h is 2 studies, one in academic sett ing s and 
one comparing community sett ings with academic sett ing. In a prospective 
study of 58 cases of IIP including 28 cases of f inal consensus diagnosis of 
IPF in academic sett ings, when the information to partic ipant was given in 
a stepwise fashion (HRCT f irst, then clin ical information, then pathology 
data) it  was shown that the level of agreement between observers and 
diagnostic confidence was improv ing as more cl in ical, rad iographic and 
pathological data was prov ided and that the greatest improvement for  the 
cl in ic ians interobserver variat ion occurred after the discussion of cl in ica l 
and radiolog ical features with radiologists, thus underl in ing the importance 
of rev iewing the actual scans jointly rather than rely ing on a report. In  
paralle l i t  is  importan t to note that a diagnosis of IPF by each of two 
cl in ic ians and by each of three radio logists fol lowing the rev iew of c l in ical 
and radiographic data (before pathology data) coincided in al l but 2 cases 
which confirms that patients with c l in ica l and radiogr aphic picture 
consistent with confident diagnosis of IPF do not require surgical lung 
biopsy [58]. 
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A retrospective study of 39 cases of DPLD (13 cases of IPF whe n 
diagnosis could not be based on radiolog ical cr iter ia only) looked at a 
diagnostic agreement between academic and community based physic ians. 
It showed that c l in ica lly s ign if icant disagreement exists regarding the 
diagnosis of IIP among two groups of c lin ic ians, with community -based 
cl in ic ians more like ly to make the diagnosis of IPF (with some cases 
subsequently be ing reconsidered by the academic cl in ic ians as hav ing 
secondary/ident if iable causes); f inal diagnostic agreement was higher 
between academic physic ians (k=0.71 vs 0.44 for community based 
physic ians) and most diagnostic agreement occurred for cases of IPF [59]. 
In summary dynamic mult id iscip l inary approach to the diagnosis of IPF 
improves interobserver agreement among both community and academic 
cl in ic ians (to a greater extent between the latter) and that patients without 
the cl in ical and radio log ical data suggesting confident diagnosis of IPF 
should be referred to special ist centres for c lar if icat ion of diagnosis.  
 
1.9 Physiological Assessment and Assessment of Disease Progression  
Physiolog ical assessment of the disease severity and progression could be 
made based on data obtained dur ing pulmonary function tests, exercise 
testing and when using mathematical scoring system which take into 
account a number of c lin ical, physio logica l and radiolog ical parameters at 
the same time. Though diagnosis of IPF carries a poor prognosis there is a  
s ignif icant variabil ity in d isease progression between patients and in their  
surv ival. Therefore it is  important to c larify baseline parameters that would  
help to identify pat ients with more advanced disease at the t ime of 
diagnosis that would enable more proactive therapeutic approach includ ing 
consideration of referra l for a lung transplant assessment. At the same 
t ime for patients with milder disease at b aseline it is  important to c lar ify 
parameters that would help to identify those with progressive disease over 
t ime.  
Characterist ic f ind ings of pulmonary function tests (PFT) in IPF include 
restrict ive pattern on spirometry as reflected by reduced Forced V ita l 
Capacity (FVC), normal or increased Forced Expiratory Volume in f irst  
second (FEV1) and normal or increased FEV1 to FVC ratio.  Spirometry 
values might be normal in early d isease and the only abnormality apparent 
could be reduced gas transfer (DLCO) c orrected for haemoglobin level as 
a result of ventilat ion and perfusion mismatch and a reduction in a lveolar 
and capil la ry bed. Lung volumes including Total Lung Capacity (TLC) and 
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Residual Volume (RV) are reduced as the disease progresses. In case of 
coexisting emphysema lung volumes could be increased and DLCO could 
be more signif icantly reduced.  
PFTs are easily accessible in  the majority of Chest c l in ics, are 
standardised and when assisted by a trained staff according to 
internat ional guide lines are relat ively easy to perform and are 
reproducible.  
Exercise tests used for the assessment of severity and progression of IPF 
inc lude six minute walk (6MW) and Cardiopulmonary Exercise Testing 
(CPET). The 6MW test is a s imple, safe and inexpensive assessment of 
self-paced exercise capacity [6]. I ts with in subject reproducibi l i ty is good 
and it has a good prognostic value [60]. CPET assesses maximal oxygen 
uptake which is an integrated measure of cardiovascular, respiratory and 
neuromuscular function.  
 
1.9.1 Role of FVC and DLCO 
Four large studies of well def ined populat ion of biopsy proven IPF and 
NSIP from tert iary centres demonstrated the role of these physiolog ical 
parameters both at baseline and over t ime. King et a l. in  h is prospective 
study of 238 patients with  IPF showed that the severity of impairment of 
spirometry and DLCO at baseline are signif icant (p<0.05) predictors of 
surv ival [61]. The other three studies looked at change in PFT over t ime.  
Latsi et a l in a retrospective study of 61 patients with UIP and 41 pat ients 
with NSIP along with once again confirming that the former diagnosis  
carries worse prognosis (the median surv ival of 33 months versus 56 
months respectively), showed that reduction in FVC, FEV1 and DLCO at 6 
months is an independent determinant of surv ival and that the predict ive 
power of these changes is equivalent to the  histopathologic diagnosis in 
predicting surv ival. Changes in these parameters at 12 months were also 
substantial ly more predictive of outcome than the histopathologic  
diagnosis. Importantly the study also showed that in patients with DLCO < 
35% predicted biopsy evaluation ( IPF or NSIP) prov ided no prognost ically 
useful information as the surv ival did not differ between the two groups 
[23]. 
Collard et al. in a prospective study of 81 patients with IPF demonstrated 
that changes in both FVC % p redicted and DLCO % predicted at both 6 
and 12 months are predictive of surv ival t ime and importantly th is remains 
unchanged after adjustment for the variables baseline measurements, 
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suggesting that the rate of progression is independent of the in it ia l deg ree 
of disabil i ty.  Patients who did not demonstrate a 10% decline in their PFT 
had improved surv ival compared to those with th is c l in ically relevant 
decline [62].  
While a variety of thresholds for change in FVC had been previous ly 
suggested (ranging from 10 to 15%) Flaherty et al. in a retrospective study 
of 80 patients with IPF documented that a 10% decrease in FVC over 6 
months period from the t ime of the surgical lung biopsy exhib ited strong 
predictive abil ity in defin ing long  term surv ival; th is remained unchanged 
on mult ivariate analys is, wh ile changes in TLC and DLCO did not 
contribute further information once these factors were included in the 
mult ivariate model [63].  
 
1.9.2 Exercise Testing  
6 MW test and CPET are both used in IPF as gas exchange deteriorates on 
exercise in th is condit ion.  
6 MW test prov ides information on distance walked at submaximal exertion  
and on a degree of desaturation during exercise and has been used in  
studies to assess the signif icance of values at the t ime of diagnosis 
inc luding in a separate group of patients on a wait ing l is t for  a lung 
transplant, to assess the signif icance of changes over a period of 6 and 12 
months after diagnosis; it  is  a lso used for assessment of effect of 
treatment. Exertional desaturation is a result of venti lat ion/perfusion 
mismatch, l imitat ion in oxygen perfusion and low mixed venous pO2 [64]. 
A consensus statement on IPF [5] suggests that a 4% decrease in oxygen 
saturation (SaO2) during 6 MW is an adverse prognostic s ign. Lama et al.  
supported this statement in their study of 83 patients with biopsy proven 
UIP by showing a 14-fold increase in mortali ty for such a  degree of 
desaturation; they also showed that desaturation is common (44 out of 83 
patients) and that patients desaturating below 88% have a fourfold 
increased risk of death (HR 4.2; 95% CI 1.4 -12.56; p=0.01) after adjusting 
for age, sex, smoking, baseline DLCO, FVC and resting saturation. The 4 
year surv ival rate of those who desaturated below 88% was 34.5% 
compared to 69.1% in patients who did not desaturate [64].  
In a subsequent study Flaherty et  al.  looked at the prognostic value of a 
baseline and seria l changes in 6 MW in relat ion to changes in FVC and 
DLCO in 197 patients with IPF. It was demonstrated that subtle 
desaturation defined by increased desaturation area during a baseline 6 
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MW increases the risk of subsequent mortali ty even if saturation remains 
greater than 88%; 15% decline in DLCO % at 6 months t ime is a sole 
predictor of increased risk of mortal i ty in those patients who desaturate 
below 88% at baseline while in those who do no not desaturate declines in 
DLCO, FVC, walk distance and worsening desaturation at 6 months wil l  
need to be used [65]. 
In order to identify a baseline cut off for 6 MW distance in IPF patients 
l is ted for a lung transplant Lederer et a l. in  a retrospective cohort study of 
454 patients used receiver operating characterist ic (ROC) curves for 6 MW 
distance, 6 MW distance % predicted and FVC % predicted for predict ion 
of mortality at 6 months (for those who did not undergo transplant). It  was 
shown that patients with a walk distance of less than 207 m had more than 
fourfold greater mortali ty than those with a walk distance of more than 207 
m, despite adjustment for demographics, antropomorphics, FVC % 
predicted, pulmonary hypertension and medical comorbidit ies (adjusted 
rate ration 4.7; 95% CI 2.5 -8.9; p<0.0001); in these patients 6 MW 
distance was a signif icantly better predic tor of 6 months mortality than 
FVC % predicted [66]. 
Unti l recently it  was not c lear what distance would constitute a minimum 
important difference (MID) when assessing changes over t ime. Two recent 
studies made attempts to c lar ify this. Swigr is et al. assessed changes in 6 
MW distance in 123 patients with IPF over 6 and 12 months by two 
statist ical methods. Though the study confirmed prev iously exist ing data 
that there was no statist ical ly s ign if icant difference in mean 6 MW distance 
between any t ime point (378.1 m at baseline vs 376.8 a t 6 months vs 361.3 
m at 12 months, p=0.5), the mean MID was 28 m (10.8 -58.5 m) [67] ). 
Similar MID of 24-45 m was found to be cl in ica lly important in a study of 
822 patients of du Bois; it  a lso showed that a 24 -week decline of greater 
than 50 m was associated with a fourfold increase in risk of death at 1 
year (hazard ratio, 4.27; 95% conf idence interval, 2.57 - 7.10; P < 0.001); 
6MWD was weakly correlated with measures of physiologic funct ion and 
health-related quality of l i fe; however, values were consistently and 
signif icant ly lower for patients with the poorest functional status, 
suggesting good construct valid ity [68]. 
Maximal oxygen uptake during CPET is an integrated measure of 
cardiovascular, respiratory and neuromuscular function which more 
accurately than measures of lung volume reflects derangements in 
haemodynamics and venti lat ion dur ing exercise [69]. In a study by Fell et  
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al. of 117 patients with IPF and longitudina l CPET assessed 
retrospectively it  was shown that baseline maximal oxygen uptake of less 
than 8.3 ml/kg/min had an increased risk of death (HR 3.24; 95% CI 1.1 -
9.56; p=0.03) after adjusting for  age, gender, smoking status, baseli ne 
FVC and DLCO; it appeared it was a more robust measure of surv ival than 
desaturation below 88% on 6 MW and resting pO2. The study team was 
unable to define a unit change in maximal oxygen uptake that would  
predict surv ival [69]. 
 
1.10 Prognosis  
1.10.1 Surv ival in IPF  
While the course of IPF is typ ically described as one of relentless decline 
in respiratory function, the course of indiv idual patients is highly var iable  
[70]. As prev iously described by Bjoraker [11] and Hubbard [71] in the  
studies that were performed prior to new c lassif icat ion of IIP the median 
surv ival in IPF is l imited to 2.8 years from the t ime of diagnosis; the 
median surv ival in most studies performed after the development i f  new 
classif icat ion is between 2 and 4 years from the t ime of diagnosis and 5 
year surv ival is between 20 and 40% [10, 12, 17, 63]. Nevertheless both 
Collard [62] and Flaherty [63] demonstrated that along with pat ients with  
ev idence of decline in PFT over 6 -12 months there is a group of pat ients 
who have either improvement or no signif icant change in their parameters 
over this period of t ime. Collard showed that only 27% of pat ients had 
decline in the ir FVC % predicted at 6 month s while 61% had no change in 
their FVC % predicted and 12 % had improvement; Flaherty demonstrated 
that 49% of patients remained within 10% of baseline at 6 months, though 
by 12 months this reduced to 21% only. There are known cases of biopsy 
proven UIP who surv ive up to 10 years and more. Surv ival in prevalent 
cases is higher due to selection bias as some incident cases died earl ier  
due to more aggressive disease [71]. 
Morta l ity rate have been shown to be high and to increase in a number of 
studies recently both in the UK and USA. Hubbard et al. was the f i rst one 
to demonstrate the importance of using inc ident rather than prevalent 
cases in assessing incidence due to prevalent cases demonstrating  
surv ival bias by excluding those who die from aggressive disease while  
inc ident cases would represent the ful l s pectrum; median surv ival for  
inc ident cases was 2.9 years and for prevalent cases 9 years compared to 
expected values of 10 and 13 years respectively; the expected li fe span 
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was therefore estimated to be reduced by approximately 7 years [71]. In 
the study of Gribbin et al. in the UK the 3 and 5 year surv iv al percentage 
for patients with IPF were 57 and 43% respectively as opposed to 88 and 
81% in a comparison cohort of non -IPF population; median surv ival t ime 
was 3.9 years [30]. Olson et al.  on the grounds of analys is of the US 
Mult ip le Cause-of-Death mortal i ty database in 1992 and 2003 
demonstrated an increase in mortal i ty rate of 27.5% in men (from 48.1 
deaths per 1,000,000 in 1992 to 61.2 deaths per 1,000,000 in 2003) and of 
40.8% in women (from 38.7 deaths per 1,000,000 in 1992 to 54.5 deaths 
per 1,000,000 in 2003) [28]. 
Pulmonary f ibrosis itself was reported to be an underly ing cause of death 
in 60 ± 2.2% of deaths, with ischaemic heart disease being a case in 8.5 ± 
0.6%, lung cancer in 2.9 ± 0.4%, pneumonia in 2.4 ± 0.5%, 
cerebrovascular disease in 1.3 ± 0.2%,  congestive heart fa i lure in 1.3 ± 
0.3%, pulmonary embolism in 0.37 ± 0.05% and other causes in 23.4 
±1.3% [28]. 
Male gender and increasing age are both important determinants of 
surv ival (28,29,30,31) with HR of  1.4 (95% CI 1.15 to 1.7, p=0.001) for 
male gender and 8.75 (95% CI 4.98 to 15.36, p<0.0002) for the age >85 
[30]. A statist ica l ly s ign if icant advantage for females was demonstrated not 
to be related to the severity of  the disease in a mult ivariate analys is 
evaluating gender differences  adjusted for age, smoking history, DLco % 
predicted and desaturation on 6 minute walk [72].Seasonal varia t ion in  
mortal ity, with an increased winter  inc idence of pneumonia and in chronic 
obstructive airway d isease, is well documented. On the basis of analysis of 
the underly ing cause of death in pulmonary f ibrosis from National Centre 
for Health Statist ics between 1992 and 2003 Olson et al. observed the 
same seasonal variation with mortal i ty rates in patients dying from PF 
being 15.9% higher in winter (p<0.0001), 12.7% higher in the spring 
(p<0.0001) and 5.1% higher in autumn (p=0.0008) than in the summer. It is  
hypothesised that the winter increase is related to an infectious 
tr igger[73]. 
 
1.10.2 Disease Progression  
A number of recent c l in ica l tr ia ls demonstrated that a rate of annua l 
decline of PFT is not that high. A randomised placebo control led tr ia l of  
Interferon-1γb showed that patients who surv ived t i l l week 72 had a 
decrease in mean % FVC predicted from 64.5% to 61%, and a decrease in  
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mean DLCO predicted from 37.8 to 37%. In a  randomised placebo 
controlled tr ia l of N-acetylcyste ine during 12 months in placebo arm a 
mean reduction in V ita l Capacity was 190ml (7.5 % from baseline) and 
mean decline in DLCO of 0.7 mmol/min/kPa (13.3% from baseline).  
The discordance between the rate  of decline in PFT and mortal ity suggests 
that the clin ical course of IPF may be less a gradual decline and more a 
step like process, with periods of relat ive stabil ity punctuated by periods of 
acute decompensation that may be associated with high mortal it y, Figure 
1.8 [70].  
Figure 1.9 Schematic drawing of 
the potential clinical course of 
patients with IPF. The majority 
show a relatively slow decline in 
functional status after the 
diagnosis. Others appear to have 
episodes of acute clinical 
deterioration (acute exacerbation) 
that precede and possibly initiate 
the terminal phase of their illness. 
A minority of patient appear to 
have a short duration of illness with 
a more rapidly progressive course. 
Jagged mark = acute 
exacerbations[70]. 
 
 
 
1.10.3 Accelerated Decline  
Accelerated decline is characterised by unexpected worsening of the 
underly ing d isease over a short period of t ime which leads to death in the 
vast majority of cases. While at t imes the cause of it  could be identif ied  
( infection, pulmonary embolism, pneumothorax and heart fa i lure) and 
therefore treated, quite often there is no id entif iable cause and this 
episodes are called acute exacerbations. In order to call an episode an 
acute exacerbation it is  important to exc lude any identif iable cause as 
above. 
 
42 
 
1.11 Assessment of disease severity  
Assessment of disease severity is required at in it ia l presentation and at 
subsequent fol low up of each patient with IPF. This wil l  help to decide on 
the t ime and appropriateness of commencement of medical treatment as 
well as on the need for referral for  a transplant assessment and to support 
serv ices including breathlessness cl in ic and Macmil lan nurse, and could be 
done using a combination of parameters including the results of PFT, 
exercise testing, HRCT a long with taking into account presence or absence 
of complicat ions.  
It was demonstrated recently that the disease severity could be defined as 
advanced and l imited on the grounds of pulmonary function tests. 
Mogulkoc et al. studied PFT of 115 patients referred for a lung transplant 
assessment in a tert iary centre and related it to two year surv ival. A 
mult ivariate stepwise regression analysis identif ied that only DLCO % 
predicted and HRCT fibros is score are independent predictors of 2 year 
surv ival. Receiver operator characterist ic analys is showed that a DLCO of 
39% predicted and HRCT fibros is score of 2.25 have an 80% sensit iv ity 
and specif ic ity for predicting death with in 2 years [48]. DLCO of 39% could 
be used as a discriminator between advanced and limited disease and 
tr igger a referral for a transplant assessment accordingly. In tune with the 
above study Latsi et al showed that patients with reduction in DLCO to 
<35% had a surv ival t ime of less than 2 years irrespectively of whether 
they had a histological diagnosis of UIP or NSIP [23]. 
As described above a number of parameters have been shown to predict 
surv ival in IPF, th is is summarized in Table 1.4.  
Parameters associated 
with  
more severe disease 
Degree of impairment reflecting  
more severe disease 
Demographic  Male gender 
Age above 75 years old 
Current or former smoking 
Physiologic DLCO < 39% predicted  
6 minute walk distance < 207 m in patients referred for 
transplant assessment 
24-45 m decline in 6 minute walk distance over 6 months 
Desaturation below 88% on 6 minute walk 
Radiographic (HRCT) UIP pattern 
Fibrosis score of > 2 
Histological UIP pattern 
Fibroblastic foci 
Clinical Evidence of respiratory failure at rest  
Pulmonary Hypertension 
Emphysema 
Table 1.4 Parameters associated with severe IPF  
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1.12 Who to treat? 
  
Current jo int committees IPF guidelines suggest selected features 
commonly observed in c l in ical practice that are associated with increased 
r isk of mortal ity with in 2 years in an attempt of identify ing patients who 
should be considered for lung transplantation (Tab le 1.5)[16]. 
 
 
Baseline factors 
Level of dyspnoea* 
DLCO < 40% predicted 
Desaturation ≤ 88% during 6MWT 
Extent of honeycombing on HRCT* 
Pulmonary hypertension 
Longitudinal factors 
Increase in level of dyspnoea* 
Decrease in forced vital capacity by ≥ 10% absolute value 
Decrease in DLCO by ≥ 15% absolute value 
Worsening of fibrosis on HRCT* 
 
Table 1.5 Selected features associated with increased risk of mortality in IPF[16]. 
*Currently, there is no uniformity in approach to quantification. 
 
Presence of a number of parameters developed based on data from cl in ica l 
tr ia ls is consis tent with progressive disease in the absence of another 
identif iable cause and helps to guide appropriate treatment interventions 
inc luding consideration of lung transplant [16].  
 Progressive dyspnoea (objectively assessed) 
 Progressive sustained decrease decline from baseline in absolute FVC 
 Progressive sustained decrease decline from baseline in absolute DLCO 
(corrected for hemoglobin) 
 Progression of fibrosis form baseline on HRCT 
 Acute exacerbation 
 Death from respiratory failure 
 
I t  is  suggested that a combination of FVC and DLCO is useful in assessing 
disease progression rather than each of th is measures indiv idually as the 
presence of s ignif icant emphysema impacts FVC results [16]. 
It  is  recommended that on average progression of disease is monitored 
over periods of 3 to 6 months but sustained changes in symptoms, 
physiology, and radiology over shorter periods of t ime may also identify 
disease progression in which case fol low up measurement should be done 
earl ier[16].  
The fol lowing schematic pathway is currently recommended for c l in ica l 
management of IPF patients  (Figure 1.9)[16]: 
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Figure 1.10 Schematic pathway for clinical management of patients with IPF. Clinicians 
are required to spend adequate time with patients to discuss patients' values, preferences, 
and prognosis. All patients should be made aware of available clinical trials for possible 
enrollment. Patient at increased risk of mortality should be considered for lung 
transplantation. Pharmacologic treatment should be limited to a carefully selected minority 
of patients who are willing to accept possible adverse consequences even if expected 
benefits are small. See text for specific recommendations of pharmacological therapies. 
Oxygen supplementation (if hypoxemic) and pulmonary rehabilitation are recommended 
treatments (strong yes and weak yes, respectively). All patients should be monitored for 
disease progression and identification of complications at 4 to 6 months or sooner as 
clinically indicated. Corticosteroids are an appropriate treatment option for acute 
exacerbation. Mechanical ventilation is not recommended for the majority of patients with 
respiratory failure due to progression of their disease. Symptom control (palliative care) 
focuses on reducing symptoms (e.g., cough and dyspnoea) and providing comfort to 
patients, rather than treating patients' disease. Advanced directives must be discussed in 
the ambulatory setting.[16] 
 
1.13 Quality of life in patients with IPF  
Though slowing of the disease progression and improvement in surv ival 
are crucial targets in IPF optimis ing the quality of l ife  is judged by some 
patients with IPF to be as much or more important than their length of 
surv ival[74] .  Quality of l i fe is defined as a person’s “holist ic”  evaluation of  
satisfaction with his own l i fe in areas (domains)  that he considers to be 
important[75]. Health-related quality of l i fe (HRQL) incorporates t he 
subjectively perceived impact of one’s health –  including aspects of well -
being (or lack of thereof) in the physical, mental, emotional, social, and 
spir itua l facets of l ife –  on l ife domains of perceived importance [76]. HRQL 
is being measured by generic instruments or condit ion -specif ic  instruments 
with the lat ter ones being tai lored to patients with the d isease of interest 
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which makes them more sensit ive to underly ing change than generic 
instruments [77].  
Studies assessing HRQL in IPF as well as interventional tr ia ls in IPF 
assessing HRQL as secondary endpoints used generic or non-IPF 
respiratory specif ic instruments as there was no IPF -specif ic instruments 
availab le. Respiratory specif ic instruments included obstructive lung 
disease specif ic HRQL questionnaires: Chronic Respiratory Questionnaire, 
CRQ (assessing domains of dyspnoea, fatigue, emotional function and 
mastery) and Saint George Respiratory Questionnaire, SGRQ (assessing 
symptoms, activ ity and impact domains). Impairment in HRQL was 
demonstrated in many l ife domains of IPF patients but physical he alth was 
most negatively impacted; other domains were rated consistently lower 
compared to healthy controls or large sample of the general populat ion  
inc luding those that assess respiratory symptoms, energy levels, and 
degrees of independence[78].  
Patients’ v iews on how IPF affects their l ives have been assessed  in two 
studies. In a study the primary aim of which was assessment of the 
relevance of two instruments  (SGRQ and WHOQOL -100) in IPF De Vries 
et al in three focus groups asked 10 patients with IPF (no defin it ion of IPF 
cases given) directly of the ir v iews  on how IPF affects their l ives [79]. 
Swigr is et al through focus groups and interv iews performed a study in 20 
patients of varying age with IPF with broad range of disease duration (from 
a short t ime prior to enrolment into the study to those l isted for 
transplantation or those in hospice care) with a l l pat ients but one taking at  
least one medication specif ical ly for IPF and 50% patient s using 
continuous supplemental oxygen. The study specif ical ly aimed at gain ing 
further ins ight into the effects of IPF on patients’ l ives from their own 
prospective and at organising those effects into a structured conceptual 
framework along with assessing if the exist ing instruments adequately 
covered the elements of th is framework and if they inc luded items that 
might be irrelevant to patients with IPF. The results of both studies were 
consistent but due to possibly a larger number and more systematic an d 
detailed analys is used by Swigr is et al the addit ional effects of IPF were 
identif ied that were not prev iously reported. Patients noted that symptoms 
of breathlessness and cough were extremely bothersome and l imited 
physical activ ity, social partic ipation, travel, and sexual relat ions. Most 
patients had to rearrange their l ives extensively because of the effects of 
IPF and were taking more t ime to prepare for the day, used a lot of mental 
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energy examining tasks to determine if they could complete them and  were 
fearful of the impending need to depend on other people [76].  
 
SGRQ 
SGRQ is a self  administered respiratory specif ic instruments designed for 
obstructive lung disease. It has 50 items which are used to calculate Total 
and three domain scores including Symptoms (distress caused by 
respiratory symptoms), Activ ity (physical act iv it ies that are caused or 
l imited by breathlessness) and Impact (social and psychological effects of 
the disease). It  is  scored from 0 to 100 with 0 ind icating the best health 
and 100 indicating the worst health; an increase in score over t ime shows 
worsening of health status. In 750 healthy adult control populat ion the 
fol lowing scores were shown to be normal (mean ± SD): Tota l 7±7, 
Symptom 12±15, Activ ity 11±13, Impact 3±5 [80]. A change in score of four 
units was shown to be consistent with c l in ically s ignif icant change in 
patient’s health.  
SGRQ has been used in a number of studies assessing HRQL and 
interventional tr ia ls in IPF. Chang et al in the ir study of 50 patients with  
ILD (24 patients with IPF) showed that SGRQ scores were particularly 
impaired in symptoms and activ ity domains (median 50.5 and 54. 4 
respectively ref lect ing a moderate rate of impairment) and that total score 
had a strong correlat ion (Pearson correlation coeff ic ient of 0.45 to 0.66, 
p<0.01) with physio logica l parameters (in particu lar FEV1, FVC, DLCO, 
6MWD and dyspnoea score) [81]. The degree of impairment was similar in  
10 IPF patients in the study of De Vries et al and 41 IPF patients in the 
study of Nishiyama (Symptoms domain 47 and 40 respectively, Activ ity 
domain 55 and 45 respectively) [79, 82]. In the latter study TLC, DLCO, 
arteria l part ia l pressure of oxygen at rest, the lowest oxygen saturation 
during exercise test, and the baseline dyspnoea index (BDI) score were 
signif icant ly correlated with the total SGRQ score with a s imilar tendency 
being observed in each component. Nevertheless in stepwise mult ip le  
regression analys is, the BDI score was selected as the only factor 
s ignif icant ly contribut ing to the total SGRQ score [82]. This is not 
unexpected as clin ical observations show that patients with object ively 
equal physiolog ical parameters can have different quality of l i fe [78]. Of 
four HRQL questionnaires (SGRQ, CRQ, QWB and SF -36) SGRQ total 
score showed the strongest correlat ion with al l  objective parameters of 
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disease progression used in routine clin ical pract ice –  FVC % predicted 
(r=-0.45), DLCO % predicted (r=-0.55), 6 MWD (r=-0.66)[74]. 
Recently the f irst systematic examinat ion of the longitudina l performances 
(over 6 months) of SGRQ in 129 patients with IPF (recruited into BUILD -1 
study) was performed to establish if the scores are  responsive to the 
change in the condit ion over t ime and if they can discriminate between 
patients whose status improves, deteriorates or remains unchanged over 
t ime. The authors found that subjects whose clin ical status changed most 
(FVC ≥ 12%) had the greatest changes in SGRQ scores, subjects whose 
cl in ical status did  not change (FVC change with in 7%) had no change in 
the scores and those whose clin ical status changed minimally (FVC 
change between 7 and 12%) had minimal changes in scores. This results 
support the valid ity of SGRQ for longitudinal use in IPF and allow to apply 
meaning to the changes in the scores [83]. 
It  has also been assessed if SGRQ score could predict mortal ity in IPF. In 
a study of 87 IPF patients over an observation period of 44 ± 30 months 
univariate regression analysis showed that FVC % predicted, DLCO% 
predicted, baseline pO2 and the activ ity score of SGRQ (HR1.016, 1.004 -
1.029, 0.01) were signif icant ly predictive of mortal ity; in mult ivariate 
analysis however only FVC % predicted was a signif i cant predictor of 
surv ival therefore mortal ity can not be predicted from the SGRQ score 
(data in an abstract form only) [84].   
Compared to IPF 736 patients with COPD were sho wn to have more 
signif icant ly impaired Symptoms (67 units) and Activ ity (62 units) scores 
(the total score was 50) [80]. This is as opposed to the results in 28 
patients with Scleroderma associated ILD (in the absence of pulmonary 
vascular disease) who showed total SGRQ score of 35 with Symptoms 
domain score of 27 and Activ ity of 51 [85]. The latter study confirmed the 
valid ity of SGRQ in assessing the HRQL in pat ients with Sc leroderma 
associated ILD and its good correlation with the 6MWD, HRCT scores and 
MRC though not PFT[85]. The use of SGRQ has been validated in 
asthma[86] and it has been shown that patients with asthma have a better 
QOL as indicated by a lower tota l SGRQ score of 37 [87]. 
It  is  accepted that HRQL instruments prov ide information about IPF 
patients that is unique from that generated by the other measures of 
disease severity (both physiologica l and radiolog ical) [74]. As a result  
investigators see HRQL as an important outcome to use when assessing 
the effectiveness of a particular  intervention [83]. 
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1.14 Treatments 
 
Current best medical pract ice approach is suggested to be rely ing on 
cl in ical guidelines which are supported by ev idence based 
recommendations. The best ev idence comes from well designed 
prospective placebo control led bl inded cl in ica l t r ia ls. Current ev idence of 
treatment of IPF is diff icu lt to interpret particular ly when it refers to earl ier  
studies prior to a new classif icat ion of IIP when a group of patients with  
the diagnosis of IPF was heterogeneous as included patients with  other 
condit ions which could be more responsive to treatment than true IPF with  
UIP histology. The interpretat ion was also hampered by methodolog i cal 
issues including study design problems: uncontrol led, not blinded type, 
inadequately powered, use of small number of patients, varying pr imary 
and secondary end points which are poorly reproducible or not 
standardised. Another issue is a selection b ias  which along with security of  
diagnosis at recruitment mentioned prev iously includes disease severity 
(mild/moderate versus severe) and its duration (recruitment of patients  
with disease duration of more than 3 years means representing a prevalent 
rather than incident group considering median surv ival of 3 years only)  
[88, 89]. The next problem was  understanding of pathophysiological 
mechanisms involved in IPF and its transit ion from a hypothesis 
associated with inf lammatory alveolit is  to a hypothesis of f ibroproli ferat ion 
disorder. As a result most of conventional therapy approaches do not have 
suff ic ient ev idence under it  and in fact at present there is no therapy 
proven to improve surv ival or otherwise s ignif icant ly modify the cl in ica l 
course of IPF [14].  
The above issues are being addressed in more recent studies designed 
and conducted in the last 10 years which are also more stringent in 
diagnostic inc lusion cr iter ia requi r ing either ev idence of confident c l in ical -
radio logical d iagnosis of IPF based on ATS/ERS consensus criter ia [6] or  
in case of probable IPF –  surgical lung biopsy compatible with UIP pattern. 
An important question here is t iming of a central HRCT and histology 
rev iew as it can divert diagnosis away f rom IPF in ≤25% of cases 
suggesting that ideally the rev iew should occur before the enrolment into a 
tr ia l [89].  
I t  is  now appreciated that the appropriateness of outcome measure should 
be judged according to its c l in ical relevance in its abil ity to ide ntify either 
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improvement or a progression of the disease [89] and the like l ihood that it  
could be used to detect statist ical ly s ignif icant effects [90]. The 
importance of identify ing the primary and secondary outcome measures in 
advance of tr ia l commencement is emphasized to avoid misinterpretation  
of results.  
Outcome measures include physiolog ical measures, measures of mortal i ty  
(defined as t ime unti l  death; progression– free surv ival defined as t ime unti l  
a prespecif ied decline in a prespecif ied parameter, though does not 
measure mortal ity uses surv ival analysis methodology), measures of 
morbidity (acute exacerbations which have been shown to precede death 
and therefore are cl in ically relevant; hospita l isations; adverse events 
inc luding pulmonary embolism, pneumonia and respiratory fa i lure  with  
changes in oxygen requirements; degree of dyspnoea), changes in 
radio logical scores, measures of quality of l i fe, composite measures which 
combine two or more measures [90]. Outcome measures that are able to  
demonstrate c lear benefit to pat ient wel l-being should be given pr imary 
importance in later stage defin it ive tr ia ls (phase III tr ia ls) and while  
surv ival benefit would be clin ically relevant and benefic ial to patient well -
being, achiev ing such a result would require we ll -designed, long-term 
studies with a large number of we ll -defined IPF patients [90].  
Physiolog ical measures are based on validated and reproducible  
pulmonary function testing the procedu res for which are well defined and 
standardised in relevant guidelines. These measures in IPF include FVC, 
TLC, DLCO, measures of oxygenation (oxygen saturation measured by 
pulse oximetry, arteria l b lood gases, 6 minute walk distance and 
desaturation. 
Lack of effective and proven treatment options in IPF leads to a constant 
search for new treatment options. This involves either search among 
already exist ing medication or a dedicated development of new agents. 
According to most recent ILD guidelines of the B rit ish Thoracic Society 
Interstit ia l Lung Disease Guideline Group form 2008 it is  now 
recommended that all pat ients be considered for recruitment to high 
quality c l in ical tr ia ls of therapy and/or for lung transplantation if  
appropriate [14].  
Overall current treatment strategies involve the fol lowing areas: 
conventional therapy (ant i- inf lammatory therapy with cort icosteroids or i ts 
combination with immunosuppressive drugs), antif ibrot ic drugs, novel 
therapies, pulmonary rehabil itat ion, lung transplant, best supportive care 
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and symptomatic treatment (of cough, breathlessness, gastro -oesophageal 
reflux).  
 
1.14.1 Conventional –  Histor ica l Treatments 
Corticosteroids suppress neutrophil and lymphocyte migration into the 
lungs, decrease the level of immune complexes, and alter alveolar 
macrophage function [88]. The hypothesis of inflammatory alveolit is  as a 
main pathophysiologica l mechanism in IPF led to use of prednisolone as 
f irst l ine treatment fol lowing its re lease for c l in ical use in 1948. This was 
also supported by tr ia ls data showing that up to 30% patients showed 
physiolog ical and radiographic response with prednisolone in older 
studies. Nevertheless it was subsequently acknowledged that those tr ia ls  
involved heterogeneous group of patients inc luding those who did not have 
IPF but a more inf lammatory condit ions with a higher degree of cellu lar ity 
on biopsy. A Cochrane rev iew of the role of cort icost eroids alone in IPF 
identif ied no suitable randomised controlled or case -controlled tr ia ls and 
therefore there was no data availab le for inclusion in meta -analys is (a l l  
studies had inadequate methodologies); it  concluded that there was no 
ev idence that steroids prolonged surv ival or improved quality of l i fe in  
patient with IPF [91]. Main adverse events with the use of cort icosteroids 
inc lude weight gain, hyperg lycaemia, osteoporosis.  
Corticosteroids have been assessed in combination with another 
immunosuppression drug with the greatest c l in ica l impact being produced 
by its combination with Azathioprine. Azathiopr ine is a purine analogue 
converted into mercaptopurine which inhib its adenine deaminase which 
leads to impairment of prol iferation of cells especial ly lymphocytes. 
Cochrane analysis identif ied only 2 case -controlled and 1 randomised 
controlled studies assessing the role of Azathiopr ine [92]. A randomised 
controlled study of Raghu which compared the addit ion of Azath ioprine (3  
mg/kg) to high dose prednisolone showed that there was no differ ence on 
lung function at 1 year of treatment but there was a statist ical ly s ignif icant 
improvement in surv ival in the  Azathiopr ine/Prednisolone group (14 
patients) when adjusted for age (57% vs 23%, p<0.05) but only after 9 
years of fo l low up and the surv ival curves did not diverge until  4 years 
[93]. Nevertheless the changes in lung function tests were not s ignif icant 
between the two groups and a longer than median surv ival could reflect  
patients with milder d isease. Main  adverse events of Azathioprine include 
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gastrointestinal s ide effects, myelosuppression, hepatotoxic ity, increased 
r isk of infect ion and skin cancer.  
Cyclophosphamide is another immunosuppression drug that has been 
tested as an add on therapy to corticosteroid. It is  an alkylat ing agent 
wh ich suppresses lymphocyte function. There are no prospective 
randomised placebo control led tr ia ls using Cyclophosphamide in a we ll 
defined IPF population. The most recent retrospective study of 82 patients  
with IPF by Collard et al showed no surv ival differenc e between pat ients 
treated with a combination of prednisolone and cyclophosphamide 
compared to untreated patients (median surv ival 1,431 days in treated 
group vs 1,665 days in untreated group (p = 0.58). Subgroup analysis in  
patients with presumed milder d isease (FVC ≥ 60% predicted) or in 
patients with biopsy proven diagnosis showed no difference in mortal ity 
[94]. Main adverse events include myelosuppression, hepatotoxic ity,  
increased risk of infection and of several cancers, haemorrhagic cystit is .  
Colchic ine inhib its f ibroblast collagen formation and possibly increases 
collagen degradation. Though some in v itro and animal model studies 
suggested that it  may slow fibrot ic process several c l in ical studies fai led to 
show signif icant difference in the rate of decline of lung function or 
improvement in surv ival. In the most recent randomised open -label paralle l 
group eff icacy study comparing a group of 32 patients treated with  
interferon gamma-1b and a groups of 18 patients with colchic ine over 2 
years no surv ival benefit  was found with colchic ine, with s ignif icant 
difference in FVC %predicted detected  after 24 months treatment in favour 
of interferon gamma-1b (though not at 6 and 12 months of treatment) [95]. 
The main adverse events include gastrointestinal upset.  
The l i terature on cyclospor in, methotrexate, chlorambucil,  and D-
penici l lamine  contains only case reports or small case series.  
In summary there is no ev idence to support the use of high dose 
corticosteroids, cyclophosphamide and colchic ine in IPF as it does not 
improve surv ival or modify the cl in ical course of the disease. BTS ILD 
guidelines from 2008 suggest that prednisolone and azathioprine without  
N-acetylcysteine (see further) are  not recommended; lower dose steroids 
(20 mg or less) or omission of azathiopr ine are very l ikely to be better 
to lerated but are entire ly without ev idence base [14]. 
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1.14.2 Novel therapies  
Current pathophysiological hypothesis suggests that IPF is a result of  
continuing patchy alveolar epithelia l in jury due to unknown agent followed 
by an abnormal wound healing. Therefore new treatment strategies have 
inc luded agents that inh ib it,  the proinf lammatory and profibrotic effects of 
oxidants and endothelins, blood coagulation and chemokines, tumour 
necrosis factor-alpha, transforming growth factor -ß, connective t issue 
growth, plate let-der ived growth factor, tyrosine kinases. Phase I, I I  and  III 
have util ised the following novel groups of treatment: antioxidant (N -
acetylcysteine), immunomodulators (interferon -γ -1b), antif ibrot ic agents 
(pir fenidone), endothelin receptor 1 antagonists (bosentan), anticoagulants 
(Warfarin), tumour necrosis factor-alpha antagonist (etanercept), 
transforming growth factor-ß antibody, tyrosine kinase inhib itor ( imatin ib)  
(Table 1.6).  
Trial, drug 
used 
Drug action Study design 
 
Number 
of 
patients 
Primary endpoint Results (primary and 
secondary endpoints) 
Refer
ence 
IFIGENIA 
N-
acetylcystei
ne 600 mg 
tds 
Antioxidant Multinational, double-
blind, randomised, 
placebo-controlled trial, 
12 months, 
 
182 Absolute change in 
VC and DLco at 12 
months of treatment  
Reduction in the rate of 
decline of both VC and 
DLco with the use of NAC. 
No difference in CRP 
score, dyspnoea, HRCT 
and SGRQ score. 
[96] 
Interferon-γ-
1b 
Cytokine with 
antifibrotic, 
antiproliferative, 
immunomodulat
ory effect 
Multicentre double-blind, 
randomised, placebo-
controlled trial, median 
58 weeks 
 
INSPIRE multinational 
double-blind, placebo-
controlled trial, 96 weeks  
330 
 
 
 
 
826 
(ratio 2:1 
IFG to 
placebo) 
Progression free 
survival 
 
 
 
Survival time 
No significant difference in 
the duration of progression 
free survival. 
 
 
No significant difference in 
survival at 64 weeks 
treatment. 
No effect on FVC, DLco, 
survival without lung 
transplantation, dyspnoea, 
QOL. NO significant 
difference in deaths 
[97] 
 
 
 
[98] 
Bosentan Dual endothelin 
receptor 
antagonist (Eta 
and ETb) which 
reduces collagen 
deposition in the 
lungs 
BUILD-1 
multinational double-
blind, placebo-controlled 
trial, 12 months 
 
 
 
 
BUILD-3 
mean duration 19.9 
months (event driven 
study) 
158 
 
 
 
 
 
 
 
616 
6 minute walk 
distance 
 
 
 
 
 
 
Time to IPF 
worsening/acute 
exacerbation or 
death 
No significant difference in 
6 minute walk distance. 
A trend in favour of 
Bosentan in time to death 
or disease progression  
and in dyspnoea and QOL 
 
 
No effect 
[99] 
 
 
 
 
 
 
 
[100] 
Pirfenidone Anfibrotic, 
antiinflammatory 
and antioxidant 
properties 
Multicentre double-blind, 
randomised, placebo-
controlled trial (Japan), 9 
months 
 
 
 
 
 
 
 
 
Multicentre, double-blind, 
placebo-controlled, 
randomised phase III 
clinical trial (Japan), 52 
weeks 
 
107 
 
 
 
 
 
 
 
 
 
 
 
275 
 
 
 
 
 
Change in the lowest 
oxygen saturation 
(SaO2) during 6 
minute walk  
 
 
 
 
 
 
 
change in VC at 52 
weeks 
 
 
 
 
Change in FVC % 
No significant difference in 
change from baseline of 
the lowest SaO2.  
Statistically significant 
difference in VC at 9 
months and in frequency of 
acute exacerbations; no 
difference in TLC. DLco, 
resting PaO2. No 
difference in dyspnoea or 
QOL. 
 
Significant differences 
were observed in VC 
decline and in PFS (the 
secondary end-point) 
 
 
[101] 
 
 
 
 
 
 
 
 
[102] 
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CAPACITY 2 if published 
by then, 72 weeks 
779 predicted  Significant difference in  
percent predicted FVC 
change 
Treatment effect favouring 
Progression free survival, 
categorical FVC change 
and 6 minute walk 
distance. 
 
[103] 
Etanercept  Recombinant 
soluble human 
tumour necrosis 
factor-alpha 
receptor 
Multinational double-
blind, exploratory trial, 48 
weeks 
87 Change in FVC 
%predicted, DLCO 
%predicted, P(A-
a)O2 
No significant difference in 
change from baseline of 
FVC %predicted, DLco 
%predicted, P(A-a)O2. 
No difference in dyspnoea, 
HRCT scores, QOL, 
SGRQ scores 
[104] 
Imatinib Tyrosine kinase 
inhibitor 
Multinational double-
blind, randomised, 
placebo-controlled trial, 
96 weeks, 
 
119 Time to disease 
progression or time 
to death 
 
No significant difference in 
time to disease 
progression or time to 
death. 
No effect on change in 
FVC or DLco 
[105] 
Warfarin Anticoagulant  Multicentre nonblinded 
randomised placebo 
controlled trial, median 
follow up 347 days 
56 Overall survival time 
to death and 
hospitalisation free 
period 
Survival to death was 
significantly better in an 
active group; no difference 
in hospitalisation free 
period 
[106] 
Sildenafil Phosphodiestera
se-5 inhibitor 
Multicentre double-blind, 
randomised, placebo-
controlled trial in patients 
with advanced IPF, 3 
months 
180 20% improvement in 
6 minute walk 
distance at 3 months 
No significant difference in 
a number of patients with 
20% improvement in 6 
minute walk distance. 
Significant improvement in 
degree of dyspnoea and 
quality of life, arterial 
oxygenation and DLCO. 
NO significant difference in 
deaths or rate of acute 
exacerbations.  
[107] 
Everolimus A macrocyclic 
proliferation 
signal inhibitor 
with anti-
fibroproliferative 
activity 
Placebo-controlled, 
double-blinded, 
multicentre study, 3 
years 
89 Disease progression 
or death 
more rapid disease 
progression in a 
everolimus group 
[108] 
BIBF1120 Tyrosine kinase 
inhibitor 
Multicentre double-blind, 
randomised, placebo-
controlled trial 
432 Annual rate of 
decline of FVC 
Trend towards a reduction 
in decline in FVC (p=0.06). 
Reduction in a number of 
acute exacerbations and 
improvement in quality of 
life (SGRQ), no change in 
TLC, DLCO and 6MWD 
(as secondary endpoints). 
NO significant difference in 
deaths. 
[109] 
Table 1.6 Recently conducted clinical trials in IPF 
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Antioxidant (N-acetylcyste ine)  
The rational for the use of N-acetylcysteine (NAC) in IPF is based on the 
ev idence that patients with IPF have depleted levels of glutathion in the 
BAL flu id and in the epithelia l f lu id l in ing and that  the depletion could be 
corrected by treating patients with oral NAC, this being associated with  
improvement in PFT [110]. Activated inf lammatory cells release increase 
amount of reactive oxygen species which could contribute to parenchymal 
in jury and interst it ia l f ibrosis [111]. Glutathion is an important antioxidant 
in al l t issues and is v ita l for cell metabolism and surv ival and t issues 
depleted of it  are more susceptible to in jury. NAC is used to increase the 
production of glutathione as it is  capable of crossing cell membranes 
easily and can be converted to cysteine.  
In the IFIGENIA tr ia l (a mult inat ional, double -bl ind, randomised, placebo-
controlled tr ia l) 182 patients were randomised to receive NAC 600 mg tds 
or placebo in addit ion to prednisolone and azathioprine over 12 months, of 
these 155 qualif ied for  f inal analys is and 108 completed 12 months 
treatment. The primary end points were the absolute changes in v ita l 
capacity and DLco between baseline and month 12. The results showed 
that both parameters declined over t ime in both groups but NAC slowed 
the rate of loss of v ita l  capacity by 180 ml (or 9%, p=0.02) and of DLco by 
0.75 mmol/min/kPa (or 24%, p=0.003) [96]. Therefore it was a posit ive 
study in its pr imary end point, though there was no difference in the 
mortal ity between the two groups (though the study was not powered to 
detect a difference in mortal ity). NAC was well to lerated and the level of 
adverse events was similar in both groups. Th e study did not have a true 
placebo arm or an NAC alone arm but the study using these two addit ional 
arms is on the way at the USA at present.  
This study has generated a weak recommendation (grade C) for the BTS 
ILD guidelines from 2008: prednisolone (tapering from 0.5 mg/kg to 10-20 
mg/d) with azathiopr ine (2 mg/kg, maximum 150 mg/day) and NAC (600 mg 
three t imes a day) has been shown to have a signif icantly better t reatment 
effect than prednisolone and azathioprine a lone; prednisolone and 
azathioprine without NAC are not recommended [14]. 2011 Joint IPF 
guidelines recommend that the majority of patients should not be treated 
with th is combination though it might  be a reasonable choice in a minor ity 
[16] . 
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Immunomodulators ( interferon -γ -1b) 
Interferon-γ -1b is known to down-regulate the gene for transforming growth 
factor-ß (TGF-ß) and to inhib it p rol i ferat ion of f ibroblasts. As shown by 
Zeische et al in a preliminary study of long -term (1 year) treatment of 18 
patients with IFG, exogenous IFG administered subcutaneously leads to a 
marked reduction of the levels of transcript ion of the genes for TGF-ß and 
connective t issue growth factor; th is was associated with an increase in  
Total lung capacity and partia l pressure of oxygen [112]. Subsequent 
mult icentre double-bl ind, randomised, placebo-control led tr ia l of Raghu et 
al of 330 patients with IPF unresponsive to corticosteroid therapy alone 
showed a trend toward improved surv ival in the IFG group but the results 
did not reach statist ical s ignif icance (median t ime to death or disease 
progression  was 439 and 344 days in active and placebo group 
respectively, p=0.5). No treatment effect was observed on FVC( -0.2 li tre in  
active and -0.16 li tre in the p lacebo group), P(A -a)O2 (3.3 and 2.9 mm Hg 
respectively), DLco ( -1.0 and 0.7 ml/min/mmHg respectively). However 
among patients with less severe impairment of FVC (≥ 62 % predicted) 
there was signif icant difference in surv ival in act ive group compared to 
placebo (12 versus 4%, p=0.04) [97]. 
Subsequent large scale mult inat ional study by King et a l enrolled 826 
patients with moderate to mild IPF; patients were randomly assigned in a  
2:1 ratio to receive 200 μg interferon gamma -1b (n=551) or equivalent 
placebo (n=275) subcutaneously,  three t imes per week. The primary 
endpoint was overall surv ival t ime from randomisation measured at the 
second interim analys is; then the hazard ratio for mortali ty in patients on 
interferon gamma-1b showed absence of minimum benefit compared with 
placebo (1·15, 95% CI 0·77—1·71, p=0·497), that  indicated that the study 
should be stopped. In terms of s ide effect profi le constitutional symptoms 
occurred more frequently in an active group (6% versus 1%), none of them 
were graded as l ife threatening [98].  
 
Endothelin receptor 1 antagonists (bosentan)  
Endothelin-1 is an endogeneous vasoconstrictor with profibrot ic properties 
that can modulate matrix production and turnover result ing in increased  
collagen synthesis and decreased interst it ia l co l lagenase production [99]. 
BUILD-1 study recruited patients with mild -moderate disease with a 
disease duration of under 3 years who were able to produce a 6 min ute 
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walk distance of at least 150 m (and did not desaturate below 80%), and 
prescribed 158 patients with e ither 125 mg of Bosentan or placebo. 
Though the primary endpoint of 6 minute walk distance did not 
demonstrate s ignif icant difference (with median tre atment effect of -17 m, 
p=0.226), a trend in favour of Bosentan was shown in secondary end -point 
of t ime to death or disease progression up to 12 months (HR 0,613; 95% 
CI 0.328-1.144, p=0.119); in pat ients with b iopsy proven disease this 
reached statist ica l s ignif icance (HR 0.315; 95% CI 0.126 -0.789, p=0.009). 
In terms of to lerabil ity of  bosentan the main dif ference was in higher 
frequency of hepatic aminotransferase elevation with 12.2% of active arm 
group needing to discontinue treatment as a result (vers us none in placebo 
group) [99].  Subsequent event driven BUILD-3 study of 616 patients with  
IPF with mean duration of fo l low up of 19.9 months showed no effect on 
t ime to IPF worsening/acute exacerbation or de ath and no effect on quality 
of l i fe [100]. 
 
Antif ibrot ic agents (pirfen idone) 
A novel compound with combined anti - inf lammatory, antioxidant and anti -
f ibrotic propert ies which was previously tested in exper imental models of 
pulmonary f ibrosis has been a part of 2 studies one of which was 
conducted in Japan and another one was mult inational the f inal results of  
wh ich are awaited.  
The study conducted in Japan enrolled 107 patients with mild to moderate 
disease for 9 months. The study did not meet its pr imary end point of  
improvement of the lowest oxygen saturation during 6 minute walk (a mean 
increase from baseline of 0.47% in active group compared with a mean 
decrease of 0.94% in placebo arm, p=0.0722). However there was a 
signif icant d if ference in the change of v ita l capacity ( -0.03 l i tre in active 
versus -0.13 l itre in placebo group, p=0.0366) and a number of acute 
exacerbations (none in active group versus 5 in p lacebo group, p=0.0031) 
the latter leading to premature termination of th e tr ia l. A signif icant  
number of patients in act ive group had adverse events but only 15% 
discontinued treatment; a larger scale study was expected to c lar ify the 
safety aspect further. [101].  
In subsequent large mult inat ional study (CAPACITY programme consist ing  
of two studies) of pirfenidone which used a variety of dose regimens its 
part where patients were assigned in a 2:1:2 ratio to pirfenidone 2403 
mg/day (435 patients), p irfenidone 1197 mg/day (87 patients), or placebo 
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(174 patients) pirfenidone reduced decline in FVC (primary endpoint, (a  
mean 76 mls less decline than in p lacebo group)p=0.001). Mean FVC 
change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day 
group and -12.4% (18.5) in the placebo group (diffe rence 4.4%, 95% CI 0.7 
to 9.1); the drug was shown to be safe and well to lerated [103]. A 
subsequent Cochrane rev iew of the three studies using pirfenidone 
( including the CAPACITY study and study by Taniguchi [102]) suggested 
that pirefenidone reduced the risk of disease progression by 30% (HR 0.7, 
95% CI 0.56-0.88). 
 
Tumour necrosis factor-alpha antagonist (etanercept)  
Tumour necrosis factor-alpha (TNFα) is  a cytokine with proinf lammatory 
and profibrot ic properties the elevated levels of wh ich were detected in the 
lungs of patients with IPF; pulmonary f ibros is develops in a mice 
expressing high levels of TNFα ;  in animal models of pulmonary f ibrosis 
TNF antagonists inhibit pulmonary inf lammation and f ibrosis [104]. 
Etanercept, recombinant soluble  human tumour necrosis factor -alpha 
receptor wh ich binds to TNF and neutral ises its act iv ity,  was used in a  
mult icentre double-bl ind, exploratory tr ia l of 87 patients over 12 months 
where all other treatment for IPF was forbidden. No statist ica l ly s ignif icant  
difference was achieved for any of the primary end points (Change in FVC 
%predicted, DLCO %predicted, P(A-a)O2); nevertheless subjects in the 
etanercept group showed a tendency toward reduced disease progression 
in mult ip le physio logic and functional endpoints (FVC % predicted, DLCO 
% predicted, PA-a gradient, TLC % predicted, O2 saturation). Etanercept 
was well to lerated and the rate of adverse events were similar between the 
two groups [104]. 
 
Tyros ine kinase inhib itors  
Two tyrosine kinase inhibitors have been assessed in c lin ical practice. 
Imatinib is a tyrosine kinase inhibitor with activ ity against the platelet -
derived growth factors (PDGFR-α and –ß), discoidin domain receptors 
(DDR1 and DDR2), c -k it and c-Abl; i t  was defined as a potent inhibitor of 
lung f ibroblast-myofibroblast transformation and proliferat ion as well as  
extracellu lar matrix production through inhib it ion of PDFG and 
transforming growth factor-ß signall ing; i t  was also shown to inhib it lung 
f ibrosis in bleomycin models of lung f ibrosis [105]. BIBF 1120 is a potent 
intracellu lar  tyrosine k inase inhibitor and a lso targets platelet -derived 
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growth factors (PDGFR-α and –ß) as well as vascular endothelia l growth 
factor receptors and f ibrob last growth factors receptors. Since signal l ing  
pathways activated by these tyrosine kinase receptors were shown to be 
involved in lung f ibrosis i t  was suggested that inhib it ion of receptors might 
s low the progression of IPF.  
The tr ia l by Daniels et al was an investigator in it iated mult inat ional do uble-
bl ind, randomised, placebo-control led study of 119 patients with IPF for 
the duration of 96 weeks. No signif icant dif ference in pr imary endpoint 
wh ich was t ime to disease progression or t ime to death was identif ied.  
There was a dif ference in resting pO2 at 48 weeks but not at 96 weeks. 
There was also no effect on change in FVC or DLco, SGRQ score, overall  
mortal ity or CRP score. More imatin ib treated patients discont inued 
treatment because of perceived drug related adverse event [105]. A phase 
2 tr ia l by Richeldi of 432 patients randomised to receive one of three 
doses of BIBF1120 (50, 100 or 150 mg twice a day) or p lacebo for the 
duration of 12 months showed that the group receiv ing 150 mg twice a day 
demonstrated preservation in lung function compared to placebo group 
(0.06 l versus 0.19 l annual decline respectively (p=0.0 6 with the closed 
testing procedure for mult ip l ic ity correction; p=0.01 with the hierarchical 
testing procedure); th is was also associated with a lower incidence of 
acute exacerbations  (2.4 vs 15.7 per 100 patient -years, p=0.02) and a 
decrease in SGRQ symptoms and activ ity score. Thus from a group of 
tyrosine kinase inhib itors there is a potential c l in ica l benefit from BIBF 
1120 that warrants its assessment in phase 3 clin ical study.  
 
Phosphodiesterase inhib itor  
On the basis that patients with severe IPF have abnormalit ies in their  
pulmonary vasculature leading to decreased levels of resting and exercise 
induced production of nitr ic oxide and hence to pulmonary vasoconstr ict ion 
and impaired gas exchange it was hypothesized that treatment with  
s i ldenafi l (a  phosphodiesterase-5 inhib itor wh ich leads to vasodilatation) 
would improve walk distance, dyspnoea and quality of l i fe in pat ients with 
severe IPF (mean DLco 26% and 27% predicted in active and placebo 
arms respectively) . There was no sign if icant differen ce in a proport ion of 
patients with 20 or more % increase in 6 minute walk distance as a primary 
endpoint over 12 weeks of treatment. There was small but s ignif icant 
improvement in DLco, the degree of dyspnoea and total and symptoms 
domain score of SGRQ with the latter two being an important outcome for 
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a patient with advanced disease where no therapies are known to improve 
surv ival[107]. Th is study d id not assess involve right heart catheterisation 
to exclude severe pulmonary hyper tension. Symptomatic improvement in  
the absence of change in physiological parameters might sti l l be important 
for the patients.  
 
Anticoagulants (Warfarin)  
Pulmonary thromboembolic disease can cause progression of IPF and 
could be cl in ica lly subt le, therefore it should be excluded as a cause of 
disease progression by the means of addit ional imaging (CT pulmonary 
angiogram). It is  suggested that vascular in jury with subsequent increased 
profibrot ic state can contribute to the pathological process in IPF even  in 
the absence of c lassical pulmonary artery thrombi. Kubo et al conducted a 
nonblinded tria l comparing the effects of Warfarin and placebo in 56 
patients treated with prednisolone (patients were switched onto the low 
molecular weight heparin daltaparin dur ing hospital stay). The study 
showed signif icant improvement in surv ival in an active group (mortal ity 
hazard ration of 2.9, p=0.04) with a s ignif icant reduction in mortal it y 
associated with acute exacerbations (18 versus 71% respect ively, 
p=0.008), though the incidence of acute exacerbations was similar  [106]. 
Though this outcome is encouraging a number of methodological issues 
prevents the results of th is small s tudy being suggested f or the use routine 
cl in ical pract ice: nonblinded nature of the tr ia l, absence of the intent ion to 
treat analysis with a quarter of patients in placebo group withdrawing 
fol lowing randomisation but before treatment ( it  is  possible these pat ients 
had a more severe disease with potentia l ly h igher mortal ity).  
 
In summary only a few stud ies met their pr imary end -points, some of them 
demonstrated statist ica l ly s ign if icant results and trends in secondary end -
points. This suggests that either a treatment broadly la cks eff icacy but 
achieves a low average effect or, a lternatively, is very selective but 
achieves important eff icacy in selected subgroups [89]. Only the use of 
NAC (as an add on to prednisolone and azathioprine) and Pirfen idone led 
to statist ical ly s ignif icant change in pulmonary function tests over t ime.  
Current IPF guidelines based on rev iew of ev idence availab le by 30 May 
2010 demonstrate no suff ic ient ev idence to support the use of any specif ic  
pharmacologic therapy for  patients with IPF though tria ls of some agents 
60 
 
suggested a possible benefit [16] .The implication of the guidelines 
recommendation for the patient is l is ted in the Table 1.7[113]. 
 
Table 1.7 Evidence based treatment 
recommendation for patients with IPF. 
“Yes” is for the use of specific 
treatment, “No” is against the use of 
specific treatment[113]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.14.3 Current tr ia ls  
A number of high quality interventional studies are now recruit ing patients. 
Information about these studies could be obtained from a database located 
on a website called www.clinicalt r ials.gov  .   This involves the assessment 
of effectiveness of NAC in a four arm interventional study (also including 
prednisolone/azathioprine/NAC arm, NAC alone arm and placebo alone 
arm) including 390 patients; and the assessment of effectiveness of 
Warfarin in 256 patien ts over a period 48 weeks by assessing the t ime to 
disease progression. There is also a number of small phase I and II p i lot  
studies assessing the effects of already known drugs l ike Losartan, 
somatostatin analogue Octreotide, antif ibrot ic and anti - inf lammatory drug 
thalidomide, as well as of new compounds like BIBF 1120 (tr ip le 
angiokinase inhibitor that inhib its vascular endothelia l growth factor 
receptor, plate let der ived growth factor receptor and f ibroblast growth 
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factor receptor) , CNTO 888 (an experimental drug currently be ing studied 
in cancer patients with solid tumours), IW001 (a drug designed to treat 
anti-Co l (V)-mediated autoimmune diseases). Some studies are looking at  
the eff icacy of certain drugs in pat ients with IPF associated with pulmonary  
hypertension as its complications (ambrisentan  and treprostenil) .   
 
1.14.4. Lung transplantation  
None of the exist ing medical treatment has been proven to improve 
surv ival in IPF. Unlike lung transplantation which at the moment is the only 
treatment that offers surv ival benefit [114]. IPF is the most frequent 
ind ication for a lung transplant among all pat ients with ILD and since it has 
the worst prognosis among the rest of IIP it is  crucia l to d ifferent iate i t  
from the other forms. According to the Registry rep ort of the Internationa l 
Society for Heart and Lung Transplantation from 2008 [115] IPF was 
registered to be the second indication (20%) for transplantation between 
January 1995 and June 2007 after chronic obstructive pulmonary disea se, 
COPD, (36%) and before cystic f ibrosis (16%), α1 -antitr ipsin def ic iency 
emphysema (8%) and pulmonary hypertension (3.5%). At the same t ime 
with the introduction of the Lung allocation Score in 2005 a redistribution 
of indicat ions was observed in North America with IPF becoming a leading 
ind ication (38%) fol lowed by COPD (31%) according to the United Network  
for Organ Sharing [116]. 
Ideally, l is t ing for lung transplant should occur when l ife expectancy is  
greatly reduced but nonetheless greater than expected wait ing t ime for a 
suitable organ, and transplantat ion should be performed when l ife  
expectancy after transplantation exceeds l ife expectancy without the 
procedure [117]. Based on prev ious studies a range of prognostic factors 
for poor surv ival and indicating  the reason for earl ier referra l for a 
transplant assessment for patients with IPF has been identif ied.  Th is 
inc ludes histological, physio logical parameters at baseline and its 
subsequent change over t ime, radiolog ical ev idence of honeycombing. 
International guidelines for the selection of lung transplant candidates 
were updated in 2006 [117] and suggest the following guidelines for the 
referral and for t ransplantation:  
 
Guideline for Referra l  
•Histologic or radiographic evidence of UIP irrespective of vital capacity. 
•Histologic evidence of fibrotic NSIP. 
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Guideline for Transplantation  
•Histologic or radiographic evidence of UIP and any of the following:  
•A DLCO of less than 39% predicted 
•A 10% or greater decrement in FVC during 6 months of follow-up 
•A decrease in pulse oximetry below 88% during a 6-MWT 
•Honeycombing on HRCT (fibrosis score of > 2) 
•Histologic evidence of NSIP and any of the following:  
•A DLCO of less than 35% predicted 
•A 10% or greater decrement in FVC or 15% decrease in DLCO during 6 months 
of follow-up 
 
It is  now recognised that s ince current medical therapies do not offer  
surv ival benefit the referral for  transplant asses sment should not be 
delayed by wait ing for an assessment of response to tradit ionally used 
therapeutic tr ia ls.  
Risk-unadjusted surv ival after transplantation for IPF is 73%, 56%, 44% 
and 36% at 1, 3, 5 and 7 years respectively wh ich is s imilar to 81%, 61% , 
48% and 38% for the same intervals for non -IPF ind ications according to  
the analys is of 469 patients from Cleveland clin ic in a period between 
February 1990 and November 2005 [118].Nevertheless in propensity-
matched patients the risk -adjusted surv ival was worse [118] among 
patients with IPF which has been observed in a number of other  studies 
too.  
Procedure type in patients with IPF, in other words single - or b i lateral- lung 
transplant (SLT and BLT respectively) is a reason for a continuous 
discussion and institut ional pract ices are variable. S ince IPF patients often 
present acutely i l l i t  was histor ical ly felt that SLT as more limited operation  
with less cardiac manipulat ion would prov ide a better perioperative 
morbidity and mortal ity, but as surgical techniques have been refined BLT 
has been increasingly used in pat ients with nonsuppu rative lung disease 
with potentia l therapeutic benefits inc luding a reduction in a lveolar damage 
during reperfusion, improved pulmonary compliance and mechanics and 
avoidance of native lung pathology (with native lung demonstrating  
disease progression fol lowing SLT) [116] . There is a legit imate concern 
that BLT is not an optimal use of a l imited resource [116] though at the 
same time it is  suggested that the primary focus should be on an 
improvement of indiv idual patient outcome [118]. The results of some 
earl ier studies suggested that BLT was a risk factor for mortali ty in IPF 
patients (a study of Whelan et al of 830 patients transplanted between 
January 1995 and June 2002, [119]. More recent studies (s ince the BLT 
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started being used more frequently for IPF) have shown the  opposite  
trend[116, 118]. 
 
In summary lung transplantation offers surv ival benefit to those patients  
suitable for a transplant. Careful assessment of disease severity and 
comorbidit ies is crucial and in suitable candidates the referral should take 
into account a number of physiological and radiological factors rather than 
a diagnosis alone and not be delayed whi le wait ing for the effects of 
medical treatment.  
 
1.14.5 Best supportive care 
Best supportive care is a term or iginat ing from pall iat ive care approach 
adopted in oncology. In IPF it could be used either alone or along side with  
medical therapy and referra l for  a lung transplant. It  involves smoking 
cessation, treatment of breathlessness with and without resting or exercise 
induced hypoxia (with long term oxygen therapy in case of resting hypoxia  
or with nocturnal oxygen therapy in case of nocturnal desatur ation, or with  
ambulatory oxygen in mobile and active patients with exerc ise induced 
hypoxia; th is should be considered after an adequate formal assessment), 
treatment of cough (with opio ids), antiref lux therapy, withdrawal of  
treatment that does not prov ide benefit wh ile could potentia l ly cause harm, 
use of pulmonary rehabil itat ion . A recent Cochrane rev iew showed that 
pulmonary rehabil i tat ion in IPF is safe and that functional exercise 
capacity as measured by 6 minute walk distance improved signif icantly 
after a course with improvement in perception of dyspnoea and quality of  
l i fe though long term benefit of the  rehabil i tat ion is not c lear [120]. 
 
1.15 Complications/Associations 
1.15.1 Lung cancer  
There is an associat ion between IPF and lung cancer and current evidence 
suggests that th is might be independent of the effects of the cigarette 
smoking. Two large studies by Hubbard et al [121] and Le Jeune [122] both 
using GP databases and involv ing 890 and 1064 (incident cases) patients 
with IPF respectively (a long with 1:4 -6.6 control subjects) demonstrated an 
increased overall r isk of cancer in an IPF population compared to the 
general population which was a result of an increased risk of lung cancer. 
The results of most recently published BTS study of CFA and lung cancer 
[123] with the fol low up t ime of 11 years (between 1990 and 2001) 
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confirmed that the mortal ity rate from the lung cancer was much higher 
among IPF cohort compared to the number of expected deaths based on 
age-, sex- and period specif ic national lung cancer mortal ity rates with the 
standardised mortal ity rat io of 7.40 (95% CI 5.42 to 9.88), th is was similar  
to the results of the study by Hubbard et al. –  7.31 (95% CI 4.47 to 11.93) 
[121]. In BTS study stratif ied lung cancer mortal ity analys is ident if ied an 
increased risk among younger subjects, men, smokers (particular ly current 
smokers) and those who reported asbestos exposure [123]. In both studies 
the observed increase remained when the analys is was restricted to 
current smokers only (RR7.46 CI 1.54 to 35.19). Thus the mechanisms for 
increased risk of lung cancer in IPF are unclear but may be related to the 
presence of f ibrosis i tself or other exposures associated with IPF including 
immunosuppression. Although the risk of lung cancer in IPF populat ion 
seems to be independent of the smoking status smoking has b een 
identif ied as a potential r isk factor for IPF hence the implicat ion for the 
smoking cessation. It has been suggested that taking into account the 
higher risk of lung cancer in IPF patients this cohort might be suitable for 
lung cancer screening [122]. 
 
1.15.2 PE 
There is l imited clin ica l data on the role of coagulation cascade in patients 
with IPF. There are reports of pu lmonary embolism (PE) being a cause of 
death in patients with IPF in 0.37% [28] to 3.4% cases [124]. Danish 
nationwide study by Sode et al. showed that in the general population,  
ever-diagnosed venous thromboembolism was associated with id iopathic 
interst it ia l pneumonia, part icular ly among those never treated with 
anticoagulants: mult ivariate -adjusted hazard ratios for id iopathic intersti t ia l 
pneumonia were 1.8 (95% confidence interval [CI],  1.7 -1.9) in those ever 
diagnosed with venous thromboembolism, 2.4 (95% CI, 2.3 -2.6) in those 
ever diagnosed with pulmonary embolism, and 1.3 (95% CI, 1.2 -1.4) in 
those ever diagnosed with deep venous thrombosis only, compared with  
control subjects; corresponding hazard rat ios in those ever diagnosed with  
venous thromboembolism stratif ied in those ever and never treated with  
anticoagulants were 1.4 (95% CI, 1.2 -1.6) and 2.8 (95% CI, 2.4 -3.1) [125]. 
The study by [106]. Kubo assessing the role of anticoagulant therapy in  
IPF showed no cases of PE or deep vein thrombosis among 56 patients  
admitted with IPF [106]. There is a report of a higher rate of PE in IPF 
transplant recipients with PE occurring in 27% (6/23) of patient with IPF 
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compared to 0 among all other (49 patients) with no apparent d ifference in 
patients functional status not any predisposit ion to embolic events through 
lack of activ ity or pro longed hospital stay [126]. 
Pulmonary embolism needs to be excluded as a cause of IPF exacerbation 
the nature of which is not c lear s ince it is  a t reatable condit ion.  
 
1.15.3 Pulmonary hypertension  
Pulmonary Hypertension (PH) is diagnosed if the fol lowing haemodynamic 
parameters are present on right heart catheter: mean pulmonary artery 
pressure (mPAP) ≥ 25 mmHg at rest or ≥ 30 mmHg on exercise, pulmonary 
capil lary wedge pressure ≤ 15 mm Hg and pulmonary vascular resistance 
(PVR)  ≥ 3 Wood units/m2. [127]. 
The majority of studies of PH in IPF involve patients referred for lung 
transplantation, where the prevalence is reported to be between 31.6 and 
40.7% [128, 129]. Nevertheless even in this group of patients there is no 
correlat ion between the severity and extent of the underly ing lung disease 
(as ev idenced by the PFT measurements and composite physiological 
index) and the presence and severity of PH [128, 129]. In current 
c lassif icat ion of PH [127] PH associated with ILD is a part of the group 
called PH associated with lung disease and/or hypoxemia. Nevertheless 
there is a group of patients who have haemodynamic ev idence of PH in the 
presence of only mild to moderate disease and in the absence of 
hypoxia[130]. 
Presence of PH is a negative prognostic factor for patients with  IPF. 
Hamada et al. showed that 5 year surv ival in IPF patients with mPAP > 17 
mmHg is lower (16.7%) than in those with mPAP < 17 mmHg (62.2%) 
[131].  
There is a negative association between DLCO and the risk of PH as 
shown in studies by Lett ier i and Hamada [128, 131]. Transthoracic 
echocardiogram (TTE) when used in pat ients with IPF has been shown to 
overestimate systol ic PAP in patients with normal pressures and 
underestimate sPAP in patients with raised pressures [132], therefore the 
results should be interpreted with caution. Contrast enhanced computed 
tomography (combined with HRCT) is a convenient modality s ince it is  able 
to demonstrate both lung parenchima, the size of r ight ventric le and a ratio  
of pulmonary artery to ascending aorta diameter.  
Treatment of PH in IPF involves treatment of underly ing lung disease and 
correction of hypoxia as well as potential consideration of drugs used for 
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the treatment of id iopathic PH, but so far only small studies have been  
performed in patients with a combination of PH and IPF therefore larger 
studies are required before definite recommendations are prov ided.  
 
1.15.4 Respiratory Failure  
Respiratory fa i lure in IPF could be a consequence of a natural cause of 
the disease and its progression and be present only on exercise or on 
exercise and at rest (and in this  case contribute to the development of 
r ight heart fa i lure),  or be acute. Management of respiratory fa i lure depends 
upon the clin ical context. In patients with chronic respiratory fa i lure  there 
is no ev idence according to Cochrane rev iew that oxygen therapy improves 
quality of l i fe or long-term surv ival [133]. According to BTS guidelines [14] 
in the absence of suitable control led studies of long -term, short burst or 
ambulatory oxygen therapy in ILD recommendations are consistent with  
those published by the BTS Working Group and involve the following:  
patients with persist ing resting hypoxaemia PaO2 at or below 7.3 kPa (55 
mm Hg) or below 8 kPa with c l in ical ev idence of pulmonary hypertension 
and who are breathless should be considered for pall iat ive oxygen at home 
delivered by oxygen concentrator. Patients with exercise induced  hypoxia  
blow 90% who are mobile and breathless should be considered for 
ambulatory oxygen if improvement in exercise capacity and/or less 
breathlessness could be demonstrated by formal ambulatory oxygen 
assessment. Nocturnal hypoxaemia is common, its ro le  in development of 
pulmonary hypertension is not c lear and there is no ev idence that 
supplemental oxygen is useful.  
Patients with  IPF can present with acute respiratory fa i lure which could be 
due to respiratory infect ion, pulmonary embolism, pneumotorax or  
congestive cardiac failure, or could be a result of acute exacerbation. 
Current diagnostic criter ia of acute exacerbation inc lude prev ious or 
concurrent diagnosis of IPF, unexpla ined worsening or development of 
dyspnoea over 30 days or less, new bilateral  rad iographic opacit ies, no 
ev idence of pulmonary infect ion by endotracheal aspirate or 
bronchoalveolar lavage, exclusion of another identif iable aetiology.  
Irrespectively of the cause such patients are often considered for referral 
to the intensive care unit (ICU). Case series in IPF have demonstrated a 
nearly 100% hospital mortal ity rate in intubated patients in the short term 
even if  d ischarged from ICU ir respectively of  the cause of admission [14, 
134]. 
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1.17 Mechanisms of Pulmonary Fibrosis  
The pathogenesis of IPF is complex and three major hypotheses for the 
pathogenesis of IPF have emerged: dysregulated e pithelia l-mesenchymal 
interact ions, aberrant angiogenesis and the TH1/TH2 cytokine imbalance 
[135]. Phenotypic changes in alveolar epithelia l cel ls are  ear ly and 
consistent features of IPF, suggesting that a lveolar epithelia l cel l  in jury 
and apoptosis are key to the pathogenesis of IPF. Epithelia l -mesenchymal 
interact ions between altered epithelia l and mesenchymal phenotypes 
results in dysregulated interact ions between these cellu lar compartments. 
The cause(s) of alveolar epithelia l cel l in jury associated with IPF is 
unknown, and host responses to t issue injury are l ike ly to involve a 
combination of host-specif ic, genetic and env ironmental factors including 
latent v iral infections and cigarette smoke; genetic factors such as 
mutations in surfactant protein C and polymorphisms of tumour necrosis  
factor-alpha (TNF-α) are seen with increased frequency; polymorphisms in  
transforming growth factor-β1 (TGF -β1) are associated with more rapid 
progression of IPF. In response to an unknown stimulus, alveolar epithelia l 
cel ls in IPF develop a phenotype characterized by increased apoptosis, 
dysregulated proliferat ion, impaired regeneration/different iat ion and 
perhaps impaired migration. atyp ica l and apoptotic epithe lia l cel ls are 
f ibroblastic foci containing activated contracti le myofibroblasts. Alveolar  
epithelia l cel ls elaborate increased TGF-β1 and endothelin -1 along with  
decreased levels of PGE2. Mesenchymal cells in th is alveolar 
microenv ironment acquire a contracti le, synthetical ly active myofibroblast 
phenotype. Myof ibroblasts retain the capacity to prol i ferate and are 
resistant to apoptosis while secreting large amounts of extracellu lar matrix 
proteins, soluble growth factors/cytokines and extracellu lar oxidants, i ts  
different iat ion could be induced by such soluble factors as endothelin -1,  
thrombin, and thrombospondin -1. Soluble mediators and the insoluble  
matrix e laborated by these myofibroblasts may, in turn, lead to aberrant 
reepithelia l izat ion that perpetuates a feed-forward cycle. IPF 
f ibroblasts/myofibroblasts and alveolar epithelia l cel ls contribute to an 
imbalance in angiogenic chemokines that may promote neovascular izat ion 
and aberrant angiogenesis in IPF.  
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Figure 1.11 Though the leading theory is the one of fibroproliferation there is evidence of 
inflammatory cell involvement with an alveolar septal infiltrate of lymphocytes, plasma 
cells, and histiocytes associated with type II pneumocytes hyperplasia (ATS/ERS 
consensus Classification). One of the new hypotheses regarding the role of inflammation 
now focuses more on the balance between a “pro-inflammatory” TH1 cytokine profile 
(such as interferon gamma (IFN-γ) and interleukin (IL)-12  which tend to suppress fibrotic 
responses) and a “pro-fibrotic” TH2 cytokine profile (such as IL-4, IL-10, IL-13 that 
promote fibrotic response) suggesting an inappropriate shift in the TH1/TH2 cytokine 
balance, favoring the TH2 profile, results in the development of fibrotic disease in 
response to a chronic or persistent pathogen/antigen stimulation. It is thought that free 
radicals are involved in the role of fibrogenesis of human lungs in ILD and the activation of 
inflammatory cells leads to the production of reactive oxygen species: a strong expression 
of nitrotyrosine (a byproduct of protein nitration caused by a potent oxidant peroxinitrate) 
and nitric oxide synthase is seen in macrophages, neutrophils and alveolar epithelium of 
lungs of patients with early to intermediate stage of IPF compared to normal control 
subjects [135].  
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1.18 Biomarkers for IPF and the role of angiogenesis 
Diagnosis of IPF, monitor ing of disease activ ity and assessment of 
prognosis is based on the use of c l in ical, radio logica l, lung function and 
pathological data. Along with th is some soluble markers detected in serum 
have been studies including enzymes, cytokines, adhesion molecules, 
collagen-related products and products of type II epithelia l ce l ls. Type II 
epithelia l ce l ls are a major source of KL -6, surfactant protein -A (SP-A) and 
surfactant protein-D (SP-D). Studies showed that serum SP-A and SP-D 
were signif icantly elevated in patients with IPF and could dist inguish 
patients with IPF from patients with sarcoidosis, beryl l ium lung disease 
and healthy controls and that SP-D correlated with radiographic 
abnormalit ies in patients with IPF [2](Greene et al.). Stud ies by Yokoyama 
and Satoh demonstrated KL-6  to be a predictor of surv ival with  levels 
above 1000 u/ml at diagnosis to be a negative predictor; KL -6 levels 
inversely corre lated with DLCO and FVC [136, 137].  
Angiogenesis , defined as a process of new blood vessels growth [138], is  
an important part of wound healing process and is affected by the balance 
between various factors –  mainly chemokines that promote or inhibit  
angiogenesis [139]. The role of  angiogenesis in IPF is controversial . In lung 
t issue increased angiogenesis can aggravate pulmonary f ibr osis but 
prevent pulmonary hypertension [140]. On the other hand it is  not clear if  
angiogenesis is an essential part of f ibrogenesis or a necessary 
compensatory mechanism to prevent excessive f ibrosis [141]. In rodent 
models angiogenesis was shown to be a result of lung injury [142] and to 
contribute to f ibroproliferat ive and ext racellu lar matrix deposit ion observed 
in IPF[143]. Mice defic ient of angiogenic chemokine CXCL10 develop 
increased pulmonary f ibrosis fol lowing bleomycin -induced lung injury[144].  
An aberrant vascular remodell in g occurs in lungs affected by IPF but 
f ibrotic areas have fewer blood vessels, whereas adjacent nonf ibrotic  
t issue is highly vascularised [145]. Capil lar ies with in the f ibroblast ic foci 
are almost absent suggesting that the f ibrotic pro cess in IPF does not 
require neovascularisat ion [146]. The levels of potent angiostatic factors in  
patients with IPF are increased [147]. Therefore it  is  possible that an 
imbalance between angiogenic and angiostatic factors contributes  to the 
development of IPF[138].   
Angiogenesis as one of mult ip le pathways of pathogenesis of IPF was 
targeted in c lin ical t r ia ls using tyrosine kinase inhib itors  ( imatin ib[105] and 
BIBF 1120[109]) which affect pla telet-der ived growth factor receptors α 
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and β, vascular endothelia l growth factor receptors and f ibroblast growth 
factor receptors . Whilst t reatment with Imatin ib  over 96 weeks failed to 
demonstrate the effect on disease progression, treatment with BIBF 1120 in 
a dose of 150 mg twice a day for 12 months led to preservation in lung 
function compared to placebo group  (as described in section 1.14.2) . 
Vascular endothelia l growth factor  (VEGF) is a potent mediator of vascular 
regulation in angiogenesis and vascular permeabil ity [148]. Plasma 
concentrations of VEGF correlate with HRCT thoracic scan f ibrosis scores 
[149]. In support of its ro le in the development of pulmonary f ibrosis, a  
VEFG receptor antagonist attenuated bleomycin - induced lung f ibrosis in a  
murine model  [150]. Although its concentration is higher in pat ients with  
progressive disease (defined as those with a 10% change in FVC after 6 
months)[149], the usefulness of VEGF as a surv ival ind icator has not been 
evaluated. Along with the use for assessmen t of diagnosis and disease 
progression biomarkers have also been used as a marker of response to 
treatment when the levels of KL-6, SP-A and SP-D decrease slowly 
ind icating favourable response with regard to down regulation of lung 
inf lammation but not necessari ly a rel ief in  patient’s symptoms [151]. 
 
1.19 Health economics analysis 
During the past 30 years, health care expenditures have risen dramat ically 
throughout the world [152]. In the UK total expenditures as a percentage of 
gross domestic product have increased  from 4.6% in 1972 to 7.7% in 2003; 
during the same time period it increased in the USA from 7.4 to 15%, in  
France from 6.2 to 10.1% and in Germany from 7.1 to 11.1% [153, 154]. In 
response to these increases, countries around the world have been 
investigat ing methods to control health care cost. It  is  important to 
undertake analysis of the costs and sav ings of implementing a new 
medication or an exist ing medication for a new indicat ion; th is information 
could be obtained from clin ical tr ia ls that establish the eff icacy and 
effectiveness through the economic evaluation of medical therapies. The 
UK Medical Research Council and US National Institute of Health rout inely  
request the inclusion of economic assessments prior to funding large scal e 
mult icentre tr ia ls [152].  
Economic evaluation ( in other words eff ic iency evaluation) is defined as 
the comparative analys is of alternative courses of action in terms of both 
their costs (inputs) and consequences (outputs); therefore, the basic tasks 
of any economic evaluation are to identi fy, measure, value, and compare 
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the costs and consequences of the alternatives being considered [155]. The 
economic evaluation is considered to be ful l if  i t  includes each of the 
fol lowing three analyses: cost -effectiveness analys is (CEA), cost-uti l i ty 
analysis (CUA) and cost-benefit analys is (CBA).  
The resources consumed by health care programmes are considered to 
comprise four components – health care sector, patient/family sector, 
productiv ity losses, other sectors [155], the latter three could be looked at 
as societal costs. The health care sector would consist of the items l ike 
medications, equipment, hospital admissions, physic ian v is its . The 
patients and family resources would consis t of out-of-pocket expenses in 
travell ing to hospital, expenditures in the home (for example adapt ing a 
room to accommodate an oxygen concentrator), and t ime spent by a  
patient on receiv ing care or by a family member on prov iding care. This  
l inks with associated loss of productiv ity. The resources in other sectors 
depend upon the nature of the health care programme and an example 
could include nursing home care. 
CEA is of most use in s ituations where a decis ion maker, operating with a 
given budget, is considering a l imited range of options with in a given f ie ld;  
both costs and consequences of health programmes or treatments are 
examined[155]. The Panel of Cost Effectiveness in Health and Medic ine 
has recommended the use of quality-adjusted life years (QALYs) as the 
principa l measure of effect in CEA[156]. At the same time physiological 
outcomes could also be used as measure of effectiveness. There are two 
methods for developing point estimates for the difference in cost and effect 
–  the cost-effectiveness ratio and net monetary benefit.   
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The incremental cost-effectiveness rat io is defined as:  
 
ICER = CostA –  CostB / EffectA –  EffectB 
 
Where cost A and B are the arithmetic mean costs for treatment groups A 
and B, and Effect A and B are the arithmetic mean effect for treatment 
groups A and B[152]. Costs are usually described in monetary units wh ile  
benefits/effect in health status is measured in terms of quality-adjusted l ife  
years (QALYs) gained or lost. ICER prov ide policy makers with information 
on where resources should be allocated when they are l imited [155]. ICER 
is the most popular method of CEA but s ince it does not give the 
information on the size or scale of treatments an alternative summary 
measure has been prov ided in a form of net monetary benefit where the 
value is being estimated by comparing the result ing cost -effectiveness 
ratio to the wil l ingness to pay[152]. The therapies with a net benefit  of 
greater than 0, in other words therapies with ICERs that are less than the 
wil l ingness to pay, should be adopted [152] (Figure 1.11)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12  Threshold cost-effectiveness ratios on the cost -effectiveness 
plane[155]. Incremental cost-effectiveness ratio is a s lope of the l ine 
jo ining the point determined by costs and effects of the new programme.  
 
 
CUA is considered to be an especial ly useful technique as it a l lows for  
health-related quality of l i fe adjustments to a given set of treatment 
outcomes, and at  the same time prov ides a generic outcome measure 
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more effective 
New treatment 
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0 
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(usually expressed as QALYs) for comparison of costs and outcomes in 
different programmes. The term uti l i ty  is a synonym to preference; the 
more preferable the outcome, the more util i ty is associated with i t [155]. A 
widely used method of measuring preferences is the use of pre -scored 
mult i-at tr ibute health status classif icat ion systems. The most used are 
Quality of Well-being, Health Ut i l i t ies Index, EQ-5D, and Short Form 6D. 
EQ-5D questionnaire includes 5 attr ibutes (mobil ity, self -care, usual 
activ ity,  pain/d iscomfort, anxiety/depression. Each attr ibute has 3 levels: 
no problem, some problem, major problem; thus there are 243 possible 
health states and with addit ional “unconscious” and “dead” it  makes up a 
total of 245. Preferences for the scoring function were measured on a 
random sample of approximately 3000 adults in the UK [157]. The scoring 
system is between 0.0 (dead) and 1.0 (perfect health), th is represents 
quality we ights (that is  used in the vertical axis of F igure 1.12). The 
advantage of the QALY as a measure of health output is that it  can at the 
same time capture gains from reduced morbidity (quality gain) and reduced 
mortal ity (quantity gain),  and integrate this two into a s in gle measure[155]. 
Conventionally the quality adjustment weight for each health state is 
mult ip l ied by the t ime in each state and then summed to calculate the 
number of QALYs. As per an example in Figure 1.13 without the health 
intervention an indiv idual’s health -related quality of l i fe would deter iorate 
according to the lower curve and an indiv idual would d ie at t ime Death 1; 
with the health intervention the indiv idual wou ld deteriorate more slowly,  
l ive longer, and die at  t ime Death 2; the area between the two curves is 
the number of QALYs gained by the intervention with part A being the 
amount of QALY gained due to quality improvement  (that is the qualit y 
gain during the t ime that the person would have been alive anyhow)  and 
part B being the amount of QALY gained due to quantity improvement (that  
is, the amount of l ife extension, but adjusted by the quality of that l ife  
extension)[155]. 
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Figure 1.13 
QALYs gained 
from an 
intervention[155] 
 
 
 
 
 
Analysis that measures both costs and consequences of alternatives in  
monetary units is called cost -benefit analys is (CBA); CBA prov ides an 
estimate of the value of resources used up by each programm e compared 
to the value of resources the programme might save or create [155]. A 
comprehensive CBA of health care interventions would use wil l ingness -to-
pay for health benefits approach to value health benefits [155].  
In each of these components their quantit ies would be measures and the 
total cost calculated by mult ip ly ing the quantit ies by the re levant prices. If  
an economic study is being conducted alongside the clin ical tr ia l,  data on 
the resource quantit ies could be collected in case report forms by asking 
patients or by prov iding them with a diary [155]. The pragmatic approach to 
costing is to take exist ing market prices. In the UK the data on outpati ent  
v is it fees is prov ided in NHS Reference Costs [158] which give average 
costs and dispersion statist ics for the f irst and subsequent outpatient  
attendances by special i ty [152]. The drug prices are obtained from the 
national formulary l is ts [159].  
Economic evaluation can be performed by using either patient - level data 
(usually co llect ing data alongside randomised clin ical tr ia ls)  or decis ion 
analyt ic modell ing. Many countries have a formal requirement for prov is ion 
of safety and eff icacy data for health care interventions including 
administrat ion of drugs prior to product licensin g; the accepted standard 
for such data collection is the randomised control t r ia l [152]. It  is  an 
accepted practice to collect economic data alongside cl in ical data in a  
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clin ical tr ia l.  The advantages would be that hav ing patient -specif ic data on 
both costs and outcomes is potent ial ly att ract ive for analys is and internal 
valid ity, a lso the cost of collect ing the economic data is only modest 
compared to the cost of the main part of the tr ia l [152]. When economic 
analysis is a part of a c l in ica l study a number of limitat ions arise. The 
relevance of a placebo control led study depends upon whether the new 
drug is an adjunctive therapy or a substitute to exist ing therapy; tr ia ls  
comparing against placebo to no therapy would not be a relevant 
comparison for the economic question as they do not reveal the  
incremental impact of the new therapy on population health [152]. 
Inadequate fol low up data in patients who had to discontinue intervention 
prematurely with no record of longer term effect on health outcome and 
costs is another problem. Current statist ical methods with missing data 
imputation help to resolve this problem. Another way of assessing patient -
level data is designing a pragmatic tr ia l specif ica l ly for economic 
evaluation of treatment/programme under the real wor ld condit ions that 
would dominate once the intervent ion was in routine use; these tr ia ls st i l l  
use the concept of random allocation to treatment to minimise bias but 
patients and physic ians are not bl inded to treatment.  
Analyt ic modell ing offers a means of combining available ev idence from a 
range of sources (including interventional and epidemiologica l stu dies) 
rather than rely ing on a single study[155]. It  a lso helps to deal with  
another problem of patient - level data when a posit ive effect on an 
intermediate disease marker is not suff ic ient to show cost -effectiveness 
and impact on f inal health outcomes like morbidity and mortal ity have to be 
assessed indirect ly by using epidemiological data in a decis ion 
model[155]. The main elements of the analyt ic modell ing are probabil i t ies 
and expected values. A probabil i ty is a frequency of an event in a given 
sample of population and is a number showing if an event wil l or wil l not  
occur. As prior to treatment i t  is  not known which outcome 
( improvement/deterioration/no change) a specif ic patient is t o fo l low the 
concept of probabil i t ies is used to express the like l ihood of each 
occurring[155]. 
One of the methods for summariz ing information on uncertainty in cost -
effectiveness is cost-effectiveness acceptabil ity curve  (CEAC) which is  
produced from the combined distr ibut ion of incremental costs and 
incremental effects. A CEAC shows the probabil ity that an intervention is 
cost-effective compared with the alternat ive based on the observed data 
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for a range of maximum monetary values that a decis ion-maker might be 
wil l ing to pay for a part icular unit  change in outcome. Cost -effectiveness 
acceptabil ity curves were introduced as an alternative to producing 
confidence intervals around incremental cost -effectiveness ratios (ICERs), 
wh ich can be statist ical ly challenging; they are estimated by non -
parametric bootstrapping of the observed data [160]. 
Public decis ion-making bodies l ike National Institute for Clin ical 
Excellence (NICE) apply threshold cost -effectiveness ratios. NICE has 
generally enabled to keep the incremental cost per QALY below 
£30,000[155].  
The formal use of economic evaluation in health care decis ion making is  
sti l l  quite l imited though it has been used in a much wider range of 
s ituat ions both at a central level where a s ingle agency or an organisation 
make decis ions for the whole health care system or at a local level; the 
ev idence of use and usefulness of economic evaluation is currently 
stronger for the  local level[155]. It  is  shown that those responsible fo r  
formulating NICE guidance have to make judgements both about what is 
good and bad in the available science (scientif ic  value judgements) as well 
as what is good and bad for society (socia l value judgements) [161]. 
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1.20 Aims of the thesis 
 
The aim of th is thesis is to perform a number of studies to assess:  
  The accuracy of diagnosis of IPF in c lin ica l practice through an audit  
project 
  The eff icacy, safety and cost effectiveness of co -trimoxazole in  
patients with f ib rot ic interst it ia l pneumonia through interventional 
c l in ical tr ia l  
  The role of predictors of outcome in IPF (c l in ical, physio log ical and 
biomarkers) through an observational study analysing the role of 
exhaled nitr ic oxide and VEGF in IPF as well as through a study 
establishing pred ictors of death and FVC decline  
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Chapter 2  
Methods 
Study 1 –  Audit (Chapter 3) 
Study 2 –  Clin ical t r ia l of the investigational medicinal product (CTIMP) 
using Co-trimoxazole (TIPAC) (Chapter 4)   
Study 3 –  The role of exhaled nitr ic oxide and plasma vascular endothelia l 
growth factor in IPF study (Chapter 5)  
Study 4 –  Predictors of death or FVC decline study (Chapter 6) 
 
2.1. Subjects 
Study 1 was an audit project aimed at assessing the accuracy of the 
diagnosis of   Id iopathic Pulmonary Fibrosis. The rationale for the audit  
was the following: Idiopathic pulmonary f ibrosis (IPF) is a condit ion of 
unknown aetiology; ATS/ERS consensus statement on IPF includes the 
fol lowing statement as a major cr iter ion for the diagnosis: exclusion of 
other known causes of interstit ia l lung disease, such as drug toxic it ies,  
env ironmental exposures, and collagen vascular diseases. Therefore  a 
careful diagnosis is based on good history taking and exclusion of 
identif iable potentia l causes. Exclusion of occupational, drug induced lung 
disease is based on careful occupational history ( inc luding detai ls of 
employer, duration of exposure, protect ion used), spouse employment and 
drug history taking. Th is should be documented in case notes. Exclusion of 
collagen vascular disease is based on clin ica l assessment and is 
supported by testing blood samples for the presence of autoantibodies. 
Therefore every patient with  suspected IPF should have their  
autoantibodies checked to exclude collagen vascular disease as a cause of 
their pu lmonary abnormality even in the absence of its c l in ical features. It  
was aimed at rev iewing medical notes (the record of the in it ia l v is it  after  
the referral to the respiratory c l in ic) of  al l  pat ients with the d iagnosis of  
IPF registered under the respiratory c l in ic care on 1st March 2008 at the 
Norfolk and Norwich, Ipswich and James Paget Hospitals.  
 Patients with c l in ica l labelled d iagnosis of f ibrot ic id iopathic intersti t ia l 
pneumonia with HRCT scan features compatible with Usual Interstit ia l  
Pneumonia (UIP) or Fibrot ic Non-specif ic Interst it ia l Pneumonia (NSIP) 
were inv ited to partic ipate in studies 2 and 3. Assessment of el ig ib i l i ty of  
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diagnosis of IPF was based on the fol lowing criter ia adapted from the 
ATS/ERS consensus statement on IPF [5]:  
Major Criteria (All present): 
 Exclusion of other known causes of interstitial lung disease, such as drug 
toxicities, environmental exposures, and collagen vascular diseases 
 Abnormal pulmonary function studies that include evidence of restriction with or 
without impaired gas exchange 
 Bibasal reticular abnormalities with minimal ground glass opacities on HRCT 
Minor criteria (two out of three features): 
 Insidious onset of otherwise unexplained dyspnoea on exertion 
 Duration of illness 3 months 
 Bibasal inspiratory crackles (dry or ‘‘Velcro-’’ type in quality) 
All pat ients were recruited following prov is ion of patient information sheet 
and at least 24 hours to consider partic ipat ion.  
 
2.2 Ethical approval  
Study 1 was approved by each indiv idual s ite audit department.  
Study 2 REC reference 07/MRE05/45; The eff icacy and safety of co -
tr imoxazole therapy in patients with id iopathic interst it ia l pneumonia, 
orig inal approval 04/09/2007. 
Study 3 REC reference 09/H0310/78; Are alveolar nitr ic oxide and plasma 
VEGF  markers of disease severity and lung funct ion decline in patients  
with id iopathic pulmonary f ibros is; orig inal approval  07/12/2009.  
Study 4 was performed alongside the study 2  
 
For studies 2 and 3 an approval also was sought from the local Research 
Ethics committee and Research and Development d epartment of each 
Trust. For study 2 an approval was sought from the Medicines and 
Healthcare products Regulatory Agency (MHRA) (2007 -002324-15) and the 
study was registered on the International Standard Randomised Control led 
Tr ia l Number Register (ISRCTN22201583). All subsequent amendments to 
the protocols and patient information sheet were approved by the Ethics  
Committee and MHRA. Init ia l submission and submission of subsequent 
approvals and progress reports for study 3 was done by the MD student.  
Studies 2 and 3 were performed according to the principles of Good 
Clin ical Practice. In January 2011 co -trimoxazole study underwent a 
rev iew of the Medic ines and Healthcare products Regulatory Agency as a 
part of an inspection of its sponsor the University of East Anglia with no 
crit ica l issues identif ied.  
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2.3 Blinding  
In study 2, the double-bl ind placebo-control led cl in ical tr ia l of the  
investigat ional medicinal product (CTIMP), formulat ion and manufacture of 
the IMP p lacebo tablets to resemble Co -Tr imoxazole 400/80 mg according 
to the rules and guidance for Pharmaceutical manufacturers and 
Distr ibutors 2002 and the Medicines for Human Use (Clin ical Tr ia ls)  
regulations 2004 was a responsib i l ity of the Guys and St Thomas’ 
Pharmacy department. Blind ing of patients and investigators was prov ided 
by the use of tear off s l ips that were removed by pharmacy department at 
the stage of dispensing the IMP to a patient.  Emergency unblinding 
procedures were put in p lace.  
 
2.4 Instructions 
In studies 2 and 3 patients were prov ided with patient information sheet 
describ ing the rationale for conducting the study, advantages and 
disadvantages of taking part in i t  and a comprehensive lis t of s ide effects 
and interactions was included as well based on Summary of Product 
Characterist ics in CTIMP using Co-tr imoxazole. On recruitment into study 
2 (Co-trimoxazole study) patients were given a verbal instruction of how to 
take the study drug and instructed to discontinue it in case of experiencing 
sudden wheeziness, breathlessness; swell ing of the eyelids, face or l ips;  
or  b listers and a skin rash. All  patients were prov ided with a contact 
number for emergency situat ions. It was required from patients to exhib it  
at least 80% compliance with the study medication as assessed by the 
pharmacy drug returns in order for  the data to be included into per protocol 
analysis.  
 
2.5 Physiological outcomes 
2.5.1 Pulmonary function tests  
Change in FVC over 12 months treatment was a primary endpoints in the 
study 2 using Co-trimoxazole. Sp irometry was measured according to the 
Standardisation of spirometry guidance [162]. Method used to measure 
lung volumes was depending upon the equipment and procedure use d at 
ind iv idual study site and could involve body plethysmography, nitrogen 
washout or helium dilut ion. I t is  a standard approach to use the best out of  
three consistent measurements. Calibrat ion of equipment was done 
according to the indiv idual study s ite  policy.  
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In study 3 (exhaled NO) lung volumes were measured by body 
plethysmography using a pneumotachograph (Jaeger Master Screen Body, 
Germany). Single breath breath -holding test was used for the 
measurement of diffusion capacity. Patients were seated we aring nose cl ip 
during the test. The pneumotachograph was calibrated daily using a 3 li tre  
precis ion syr inge.  
 
2.5.2. 6 minute walk test  
Changes in 6 minute walk test distance and desaturation over 12 months 
treatment were secondary endpoints in the stud y 2 using Co-tr imoxazole   
and the test was performed according to the ATS Statement Guidelines for 
the Six-Minute Walk Test [163]. The test was self -paced and measured the 
distance that a patient could quickly wa lk on a f lat, hard surface in a  
period of 6 minutes (the 6MWD). Where possible (unless patients had 
progressive disease over 12 months of study drug intervention with  
progressively reducing physical capacity or  had interventions that 
prevented them from performing the test, for example hip rep lacement) i t  
was aimed at obtaining measurements at baseline, 6 months and 12 
months. It was aimed at preserving the oxygen supplementation status 
throughout the study for the consistency of the results unless it  was felt to  
be unsafe. 
 
2.6. MRC breathlessness score  
For study 2 and 3 Medical Research Council (MRC) dyspnoea scale was 
used for the estimation of impact of dyspnoea on daily activ it ies and could 
be used for the assessment of the severity of IPF and of effect of 
treatment. The scale ranges from level 1 (Not troubled by breathlessness 
except on strenuous exercise) to level 5 (too breathless to leave the house 
or breathless when dressing or undressing).  
 
2.7 Full blood count, Urea and Electrolytes and Liver function tests  
For study 2 venous  blood was taken for measurement of Full b lood count,  
Urea and Electrolytes and Liver function tests and was analysed at local 
pathology departments for safety indication.  
 
2.8 St Georges Respiratory Questionnaire (SGRQ) 
For study 2 SGRQ was used which was  a patient completed questionnaire 
consisting of two parts: part I produces the Symptoms score (the effect of 
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respiratory symptoms, their frequency and severity), and part 2 the Activ ity 
(activ it ies that cause or are l imited by breathlessness) and Impacts scores 
(social funct ioning and psychological disturbances). A Total score is also 
produced which summarises the impact of the disease on overall health 
status.  Scores were expressed as a percentage of overall impairment 
where 100 represented worst possib le health status and 0 indicated best 
possible health status. The threshold for a c l in ically s ignif icant d iffe rence 
between groups of patients and for changes with in groups of patients was 
four units.  
 
2.9 EuroQol (EQ-5D) Questionnaire 
For study 2 EQ-5D was a one page self administered simple questionnaire, 
taking only a few minutes to complete with instruct ions to respondents 
inc luded in the questionnaire. It used a descriptive system of health -
related quality of l i fe states consisting of f ive dimensions (mobil ity,  self -
care, usual activ it ies, pain/discomfort, anxiety/depression) each of wh ich 
can take one of three responses. The responses recorded three levels of  
severity (no problems/some or moderate problems/extreme problems) 
with in a particu lar EQ-5D dimension. Quality Adjust Life Years (QALYs) 
were calculated by converting the EQ-5D questionnaire results into ut i l it ies  
using UK health state valuations , then measuring the result ing area under 
the curve.  
 
2.10 A health and social care resource utilisation and costs 
questionnaire  
In study 2 a health and social care resource uti l isat ion and costs 
questionnaire was a 3 pages self administered simple questionnaire which 
reflected the use of primary (GP, nurse, other healthcare professionals), 
secondary and private healthcare resources, social serv ices,  personal 
expenditures for non-prescript ion medicat ions and days off work. Quality 
Adjust Life Years (QALYs) were calculated as well as costs and outcomes 
(point improvement in FVC and QALYs gained) of treating a patient with or  
without co-tr imoxazole. 
 
2.11 Radiology review 
For study 2 an independent retrospective radiological rev iew was 
undertaken by two special ist  respiratory rad io logists using published 
criter ia [164] where biopsy confirming usual interst it ia l pneumonia was not 
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availab le; study population included both patients with defin ite and 
probable UIP reflect ing the range of disease in c lin ica l practice. The HRCT 
scans of patients  without honeycombing were also scored according to the 
degree of interstit ia l changes and the algorithm described by Fell et 
al[165]was used to predict a biopsy confirmation of IPF.  
 
2.12 Review of causes of admission and death  
For study 2 the reason for admission  to hospita l and the cause of death 
was obtained from death certif icates and adverse event reporting forms. 
These were rev iewed by two blinded physic ians. Death was defined as 
respiratory re lated if resulted from respiratory fa i lure, acute exacerbation 
or progression of IPF, pneumonia or respiratory tract infection,   pulmonary 
empbolism, lung cancer,, pneumothorax or pulmonary embolism.  
 
2.13 Vascular endothelial growth factor  
In study 3 plasma samples were collected  for future assays for the 
assessment of levels of Vascular endothelia l growth factor by centrifuging 
EDTA blood sample for 10 minutes at 2500 revolut ions, subsequent 
separation of plasma and storage in a freezer at -80 degrees C. Levels of 
VEGF in plasma were assessed using a commercial ly avai lable validated 
VEGF ELISA kit.  
 
2.14 Exhaled Nitric Oxide 
In study 3 exhaled nitr ic oxide was measured using a NIOX 
hemilumin iscence nitr ic oxide gas analyzer (Aerocrine, Chicago, I l l inois  
USA), with an exp iratory f low ra te of 50ml/sec according to Americ an 
Thoracic Society guide lines [166]. In addit ion, measurements were taken 
at expiratory f low rates of 30, 100 and 200 ml/sec. The mean of three 
separate measures of nitr ic oxide were used in the analysis. The 
measurement technique was consistent with ATS/ERS guidelines (2005). 
Patient’s dead space was exhaled unrestricted without f low regulat ion to  
assure correct fraction of exhaled NO  (FeNO result).  V isual a id for the 
patient was used and the patient was sit t ing in a chair  for the durat ion of  
the measurement. Prior to measurement exhalation the patient was 
inhaling an NO-free air to total lung capacity to e l iminate any 
contamination from high ambient NO levels . The analyser was calibrated 
every 2 weeks using a cyl inder of nitr ic oxide at concentration of 205 ppb. 
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Alveolar concentration of nitr ic oxide  (CaNO) and total f lux of nitr ic  oxide  
(JawNO) were estimated by using the model by Tsoukias and George [167]. 
 
2.15 Statistical analysis  
Study 2 was powered as detailed.  Study 3 was a pilot study therefore no 
power calculat ion was used. A value of p<0.05  was considered to be 
signif icant and 95% confidence intervals for mean treatment d ifferences 
were calculated.  
In study 2 (co-trimoxazole) the comparison of continuous outcome 
measures between treatment arms was based on a mixed effects model 
with treatment centre as a random effect and treatment arm and status as 
f ixed effects. An adjus ted analys is was also carr ied out by includ ing the 
baseline value of the covariate as a f ixed effect in the above model. These 
were f it ted in Stata/SE 11.0 using the xtmixed command using restr icted 
maximum like l ihood treating centre and a random effect. A  cost-
effectiveness and cost-uti l ity analysis were performed to determine the 
costs and outcomes (point improvement in FVC and QALYs gained) of 
treating a patient with or without co -trimoxazole, measured from the 
v iewpoints of both the health serv ice and s ociety.  
In study 3 (Exhaled NO) alveolar NO was calculated using a l inear 
interpolat ion of the NO versus f low curve as described by George et al 
[167]. A T test was undertaken to compare the differences between 
baseline parameters in (1) pat ients with severe or mild/moderate IPF and 
(2) patients with or without a combined event defined as death, or a 10% 
decline in absolute FVC and/or 15% decline in absolute DLCO at 18 
months after recruitment. Mult ip le  l inear regression analys is was used to 
evaluate an abil i ty of alveolar NO as well as VEGF to predict a decline in 
absolute FVC, and a combined event as above.  
In study 4 (Predictors of death or FVC decline) log ist ic  regression analys is 
was used to identify independent predictors of all-cause mortal ity as wel l 
as of 5% and 10% decline in FVC at 6 and 12 months.  
The rest of the details of stat ist ical analysis are in re levant chapters.  
Statist ical analys is was performed by Allan Clark, stat ist ic ian at the 
University of East Anglia for  study 2 and 4, and by Ludmila Shulg ina for 
study 3.  
 
2.16 Investigational product 
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In study 2 using Co-trimoxazole pat ients were randomised to receive either 
of the fol lowing treatments for 12 months: Co -trimoxazole (non-proprietary)  
960mg twice daily as  2 tablets of 480mg twice daily or placebo tablets 
(manufactured from pharmacy at Guy’s and St Thomas’s Hospital –  to be 
identica l to Co-tr imoxazole 480mg) 2 tablets twice daily. Fo lic acid (non -
proprietary)  5mg once daily was used to prevent potential hae matological 
adverse events as a result of the use of Co -trimoxazole.  
 
2.17 Study visits  
Study v is its description is as detai led in a re levant chapter.  
 
2.18 Adverse events and adverse reactions 
The local investigator at the study site was responsible for t he detection 
and documentation of events meeting the criter ia and definit ion of adverse 
events or adverse reactions (as below) inc luding reporting to the sponsor.  
"Adverse event"  (AE) means any untoward medical occurrence in a subject 
to whom a medicinal product has been administered, inc luding occurrences 
which are not necessari ly caused by or re lated to that product.  
"Adverse reaction" (AR) means any untoward and unintended response in 
a subject to an investigational medic inal product, which is re lated t o any 
dose administered to that subject.  
“Serious adverse event” (SAE) or “serious adverse reaction” (SAR) or 
“unexpected serious adverse reaction” means an adverse event/reaction 
that fu lf i ls  at least one of the following criter ia:  
 Results in death 
 Is life-threatening 
 Requires hospitalisation or prolongation of existing hospitalisation  
 Results in persistent or significant disability or incapacity or 
 Consists of a congenital anomaly or birth defect 
 
“Unexpected adverse reaction” means any adverse reaction,  the nature or 
severity of wh ich is not consistent with the applicable product information 
(e.g. investigator’s brochure for an unapproved investigational product, or 
summary of product characterist ics [SMPC] for an authorised product).  
“Suspected Serious Adverse React ion (SSAR)” means an adverse reaction 
that is c lassed in nature as serious and which is consistent with the 
information about the medicinal product in question set out: in the case of 
a l icensed product, in the summary of product characterist i cs (SMPC) for 
that product; in the case of any other investigational medicinal product, in  
the Investigator’s brochure (IB) relating to the tr ia l in question.  
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“Suspected Unexpected Serious Adverse Reaction (SUSAR)”  
means an adverse reaction that is c lassed in nature as serious and which 
is not consistent with the information about the medicinal product in 
question set out: in the case of a l icensed product, in the summary of  
product characterist ics (SMPC) for that product; in the case of any other 
investigat ional medicinal product, in the Investigator’s brochure (IB) 
relat ing to the tr ia l in  question.  
 
Clin ical Laboratory Abnormalit ies and Other Abnormal Assessments  
Abnormal laboratory f indings (e.g., c l in ica l chemistry, haematology,  
urina lys is) or other abnormal assessments (e.g., ECGs, and v ita l s igns) 
that are judged by the investigator as cl in ica lly s ignif icant were recorded 
as AEs or ARs if they met the definit ion’s above. Clin ically s ignif icant 
abnormal laboratory f indings or other abnormal assessment s that are 
detected during the study or were present at baseline and signif icantly 
worsen fol lowing the start of  the study were reported as AEs or ARs. 
However, c l in ically s ignif icant abnormal laboratory f indings or other 
abnormal assessments that were associated with the d isease being 
studied, unless judged by the investigator as more severe than expected 
for the subject’s condit ion, or that are present or detected at the start of  
the study and do not worsen, were be reported as AEs or ARs. The 
investigator exercised his or her medical and scientif ic  judgment in  
deciding whether an abnormal laboratory f ind ing or other abnormal 
assessment was cl in ically s ignif icant.   
 
Time Period, and Frequency of Detecting AEs and ARs  
From the t ime a subject consents to pa rtic ipate in the study unti l he or she 
has completed the study (including any follow-up period), al l  SAEs 
assessed as related to study partic ipat ion (e.g., protocol -mandated 
procedures, invasive tests, or change in exist ing therapy) were reported 
promptly to the princip le investigator.  
 
Reporting of Adverse events  
In compliance with Art ic le 16 of the European Directive 2001/20/EC, the 
investigator was expected to report al l  SAEs promptly to the sponsor (Ms 
Sue Steel, RBS, UEA, Norwich Fax 01603 591550) wit h in 24 hours of 
being identif ied. The immediate report was expected to be fol lowed by 
detailed wr it ten reports. The immediate and fol low -up reports would  
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identify subjects by unique code numbers assigned to the latter. The 
investigator was expected to repo rt AE’s to the sponsor with in 3 months. 
For reported deaths of a subject, the investigator would supply the sponsor 
and the Ethics Committee with any addit ional in formation requested. The 
sponsor would keep detailed records of al l adverse events which were  
reported to him by the investigators. These records would be submitted to 
the Medicines and Healthcare Products Regulatory Agency, UK if they so 
request.  
 
Reporting of Ser ious adverse reactions  
In compliance with Art ic le 17 of the European Directive 2001/ 20/EC, the 
sponsor (Ms Sue Steel, RBS, UEA, Norwich) ensured that al l re levant 
information about SUSARs that were fatal or l ife -threatening would be 
recorded and reported as soon as possible to the Medic ines and 
Healthcare products Regulation Agency (MHRA) , the Data Monitor ing and 
Ethical Committee (DMEC) and to the Ethics Committee, and in any case 
no later than seven days after knowledge by the sponsor of such a case, 
and that relevant fol low-up information is subsequently communicated 
with in an addit iona l e ight days. 
All other suspected serious unexpected adverse reactions would be 
reported to MHRA, DMEC and Ethics Committee concerned as soon as 
possible but with in a maximum of f i f teen days of f irst knowledge by the 
sponsor (Ms Sue Steel, RBS, UEA, Norwich).  
Once a year throughout the cl in ical tr ia l,  the sponsor (Ms Sue Steel,  RBS, 
UEA, Norwich) was expected to prov ide the MHRA, DMEC and the Ethics 
Committee with a l is t ing of al l suspected serious adverse reactions which 
have occurred over this per iod and a report of the subjects'  safety.  
 
2.19 Quality control 
Study 2 was managed by the East Anglia Thoracic Society (EATS) cl in ica l 
fe l low. The EATS fel low was tra ined in Good Clin ical Pract ice. Prior to  
enrolment of a s ite, the EATS fel low contacted the site pr ior to the start of  
the study to rev iew with the site staff the protocol, study requirements, and 
their responsibi l i t ies to satisfy regulatory and ethical requirements. When 
rev iewing data collection procedures, the discussion included 
identif icat ion, agreement and documentation of data items for which the 
CRF served as the source document.  
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A monitor ing committee was formed and monitored that the study was 
consistent with the demands of the study and to verify that:  
• All outcomes and resource use data are authentic, accurate, and 
complete. 
• Safety and rights of subjects are being protected.  
• Study was conducted in accordance with the currently approved protocol 
and any other study agreements, GCP, and all applicable regulatory 
requirements. 
 
An independent tr ia l steer ing committee was formed. It was comprised of 
an Independent Chairman (no direct tr ia l involvement), two addit ional 
independent expert members, Chief Investigator and a patient/ lay 
representative 
A data monitor ing and ethical committee compr ised a statist ic ian and a 
researcher with special interest in interst it ia l lung disease. This committee 
monitored the serious adverse events and mortal ity.  
 
2.20 Data collection and validation 
A password protected web based database was used for the data 
collection from the source documents and for the interim and f inal study 
analysis. Data validat ion was performed prior to the database lock and 
unblind ing.  
Assessments and checks performed prior to database lock :  
 
1. Consort diagram collated  
2. System allocation of Adverse events: Drug Analysis Pr int (DAP) for  
active ingredients of Co-trimoxazole (sulphamethoxazole and 
tr imethoprim) from the  MHRA website was used for system  allocation of 
adverse events/reactions.  DAPs give complete l is t ings of al l  UK 
spontaneous adverse drug reactions (ADRs) reported through the Ye llow 
Card Scheme to the  MHRA and group together suspected  ADRs by 
medical terms, broken down by more specif ic condit ions. It uses 
terminology from so called  MedDRA - Medical D ict ionary for  Regulatory 
Activ it ies; its highest level grouping method is by System Organ 
Class which groups together reactions that affect s imilar systems/organs 
in the body. 
3. Escalat ion analysis together with the Chief Investigator: Assessment of  
the Escalation of therapy is being done using the number of disease 
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deteriorat ions with in 12 months, rather than a number of drug therapies 
being added. For example if  a patient was prescribed with  
Prednisolone, Azathioprine and N-acetylcyste ine this was approached 
as one escalat ion rather than 3 as was related to one disease 
deteriorat ion rather than 3 separate episodes. Therefore 
Prednisolone, Azathioprine and ant ioxidants were  grouped together and 
there was a separate assessment of the use of oxygen therapy due to a 
variety of  causes of  developing hypoxia in IPF.  
Overall change in treatment requirement (judged as escalation or not) 
was assessed and documented by two assessors prior to unblinding 
procedure; an agreement was achieved if there is a discrepancy in  
assessment.  
4. Source data val idation: Dedicated electronic database was used for the 
data analys is in the TIPAC study. The data was entered on a database 
from the source documents (the l is t of which is according to the 
protocol) wh ich wil l be stored at each site in indiv idual patient case 
report forms. Data entry for the sites within East Anglia was performed 
by the study co-ordinator unless there was a research nurse or data 
entry manager available to assist with th is in wh ich case the study co -
ordinator wou ld check on all  entries related to the pr imary end-point and 
one of secondary endpoints. 10% of data on primary end point and one 
of secondary endpoints in the sites where the data was prov ided sole ly 
by the study co-ordinator was validated by the Chief Investigator of the 
study. Entry error 0.9969%. 
Data entry for the sites outside East Anglia was performed by the study 
site team (usually a research nurse) and was validated by the study co -
ordinator during monitor ing and termination v is its unless a terminat ion 
v is it predated an exit  v is it for some patients. In that case the study co -
ordinator would validate al l pr imary end point data and some of  
secondary endpoints (pending on the results of the termination v is it data 
quality assessment).  
5. Protocol dev iation assessment by the Chief In vestigator with a per 
patient assessment of suitabil ity for per protocol analysis (spreadsheet 
with data available)  
6. Primary end point (FVC) predicted value check against ECSC spirometry 
equations (Th is check revealed the fol lowing errors that were correcte d: 
a. Wrong gender (2 patients)  
b. Wrong height (5 patients)  
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c. Dif ferent equipment used for dif ferent v is its with v ita lograph 
using different equations compared to Body box or other 
equipment, v ita lograph predicted values corrected  
d. Predicted in l it res rather than % predicted entered (2 cases)  
e. Obv ious error of calculation of % predicted (10 patients)  
Spreadsheet with or ig ina l and corrected data availab le.  
 
 
Audit checks on completeness of secondary and tert iary endpoint data, 
inc luding questionnaires as per eCRF.  
1. consent date should be put in for a l l  patients  
2. demographic section - al l  f ie lds should be f i l led in  
3. section Medical history other than  IPF if  any entr ies are put in there 
should be a Yes or a No for the next box "ongoing"  
4. in diagnosis section there should be there should be an entry for all  
4 top l ines and for the l ine saying Histo logical ev idence of diagnosis 
availab le  
5. there should be no blank  f ie lds for regular, a lternat ive and  prn 
medications (could say "uk" for unknown though)  
6. in Current Medicat ions  in immunosuppression section for each 
of Prednisolone and Azathiprin i f  the statement is Yes  there should 
be 4 items recorded: a dose, start date and last dose changed and 
how long on current dose inserted.  
a. there should be at least one f ie ld t icked for the  PFT method 
(Body plet ismography, helium or  nitrogen washout) for v is its  
1,3 and 5 where  the results are inserted 
7. dates for blood tests are inserted (prov ided there is a result  
there), ie there should not be a missed date.  
8. in b loods for all  v is its where at  least one result is  inserted WCC, Hb, 
Neutrophils, Lymphocytes, Platelets, Na, K, Creatinine, Bil irubin,  
ALT, ALP albumin should not blank (there wil l be an odd blank 
area but there would be a comment in addit ional info on that)  
9. in b loods for v is it 1  B12 and Folate should not be blank  
10. for al l  patients who had PFT or a blood test done for any of the 
v is its an MRC dyspnoea grade should be inserted.  
11. in section ECG both answers should not be b lank (should read Yes 
for both)  
12. there should be Yes or No for a l l Q for v is it  1  
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13. in  Lung function tests if  an absolute number is inserted there 
should be a % predicted  
14. in Randomisation and drug dispensing al l f ie lds should be f i l led  
15. For subsequent v is its:  
  adverse events should all have a close date or an "unresolved" 
box t icked; there should be grade,  severity and detai ls inserted 
for al l .  
  for escalat ions for regular or PRN medications top 5 l ines, bottom 
l ine and one of (prev ious or current does should be inserted)  
  for deaths al l f ie lds should inserted  
  a l l SAE entr ies  should have all f ie lds f i l led in and there should be 
no entries in "unresolved" box 
16. al l deaths should be al located to IPF and non -IPF, have the place 
of death recorded. 
17. Missing data in questionnaires should be checked to c larify if  an 
error of entry or a t rue missing value 
18. Ensure al location of patients to a type of analysis ( ITT, PP, Safety)  
performed 
 
2.21 Compliance assessment for study 2 
Adherence was assessed by a rev iew of returns from accountabil i ty logs 
for each patient and was considered to be acceptable if  each patient took 
at least 80% of their study medication doses.  
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Chapter 3 
Study 1 
 Assessing the accuracy of the diagnosis of Idiopathic 
Interstitial Pneumonia 
3.1 Introduction  
The commonest f ibrot ic Id iopathic Interstit ia l Pneumonias are Idiopathi c 
Pulmonary Fibrosis (IPF) and Nonspecif ic Interst it ia l Pneumonia (NSIP). 
These condit ions can be diff icu lt to d ifferent iate as they present with 
s imilar respiratory symptoms. Whilst h istolog ical confirmation of UIP was 
considered the “golden standard” for  the diagnosis of IPF, it  has now been 
recognised that specif ic H igh Resolution Computer Tomography (HRCT) 
features can be diagnostic for UIP and this obv iates the need for a surgical  
lung biopsy. Even in the presence of typ ical UIP rad iolog ical or  h istolo gical 
pattern, it  is  important to integrate this with the c l in ical symptoms, 
exposure history, examination f indings and pulmonary function tests to 
exclude other causes. This is because a histological or rad io logical pattern 
of UIP does not necessari ly equate with an idiopathic disease as it has 
been reported with asbestosis, chronic hypersensit iv ity pneumonit is, ILD 
associated with connective t issue disease particular ly rheumatoid arthrit is ,  
famil ia l pu lmonary f ibrosis, and sarcoidosis [168]. However, in cases where 
there is uncertainty due to either atypical rad io logical features  or c lin ical  
presentation, a surgical lung biopsy is required for h istopathological 
evaluation. Nevertheless a proportion of these patients may not be 
suitable for a surgica l lung biopsy either as a consequence of sever ity of  
their respiratory d isease or co-morbidit ies. In th is sett ing, the r isk of 
biopsy may outweigh any potential benefits and the diagnosis of IIP is 
based on the integration of c l in ica l and radiologica l information.  
Thus, in order to d ist inguish between NSIP and IPF, the American Thoracic 
Society/European Respiratory Society dev ised major and minor crite r ia for 
the diagnosis of IPF[5]. An important major diagnostic criter ion was the 
exclusion of o ther known causes of interst it ia l lung disease, such as drug 
toxic it ies, env ironmental exposures, and collagen vascular diseases [5]. 
Hence a careful and detailed  cl in ical assessment is essential in the in it ia l 
evaluation of a patient with  ILD as it  helps guide approaches to treatment 
and the information prov ided to pat ients regarding their disease and l ike ly 
prognosis.  
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The aim of th is audit was to assess the accu racy of data collect ion, in  
particular the aetio logical factors wh ich are associated with interst it ia l lung 
disease. The audit looks at the quality of predominantly h istory taking from 
patients with subsequent diagnosis of Fibrotic Id iopathic Intersti t ia l 
Pneumonia during their f irst v is it to the respiratory c l in ic fo l lowing an 
in it ia l referra l with or without respiratory symptoms (on some occasions 
the referral was tr iggered by an abnormal Chest XRay).   
The source of standard for the audit in  patients with  IPF was based on the 
internat ional consensus statement on idiopathic pulmonary f ibrosis [5] The 
standards included a 100% target compliance for the following data 
collection (Tab le 3.1).  
Assessment of data record of patients with id iopathic NSIP was based on 
the similar it ies in assessment of id iopathic nature of the disease between 
IPF and idiopathic NSIP (subsequently called NSIP) and on the report of 
the ATS project on NSIP[22]. 
Aspect of  care  Target % 
compliance 
Instructions/comments  
Patients  with IPF should have 
drug history assessed at  the t ime 
of  diagnosis  
100%  
Patients  with IPF should have  
occupational and environmental  
exposure history assessed at  the 
t ime of  diagnosis  
100%  
Patients  with IPF should have 
family  history of  ILD and CTD 
assessed at the t ime of  diagnosis  
100%  
Patients  with IPF should have a 
possibi l i ty  of  connective t issues  
disease assessed and 
autoantibod ies tested at  the t ime 
of  diagnosis  
100% This  should be performed dur ing 
init ial  cl in ical  assessment 
unless already done by another  
health care profess ional pr ior  to 
referral  to a respiratory team 
( the results  could be iden tif ied 
on the pathology system or  in 
the referral  letter )  
Table 3.1 .Standards of aspects of care and a target compliance  
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3.2 Methods  
 
Patients. 
Patients registered under the care of respiratory physic ians in respiratory 
c l in ic of three Trusts of East Anglia, on 1st March 2008 were included in 
the assessment. Patients were identif ied as a part of the patient  
identif icat ion process for the study 2 . 
 
Study design 
This was an audit project involv ing retrospective rev iew of medical notes 
of patients with the working d iagnosis of IPF in three trusts in East Anglia -  
the Norfolk and Norwich, Ipswich and James Paget Hospitals (approved by 
an audit department of each trust) with subsequent descriptive analysis of 
f indings. The adherence to the following standard s of care was assessed: 
al l pat ients with f inal working d iagnosis of IPF and NSIP (assumed to be 
id iopathic) should have had their occupational history, past medical history 
inc luding drug history checked at the t ime of diagnosis; al l patients should 
have had connective t issue disease excluded by the means of history 
taking and antibody profi le checking at the t ime of diagnosis. A data 
collection proforma was issued which became a basis for the web based 
database created by a data manager of the University of East Anglia, th is  
was used for electronic data collect ion and subsequent analys is.  
 
3.3 Results  
Patients with a  work ing diagnosis of  IPF or NSIP, recru ited for the  
interventional study assessing eff icacy of Co -trimoxazole in IPF (Chapter 
4), were ident if ied from Respiratory c l in ics from three hospitals (James 
Paget Hospital, Ipswich Hospital and Norfolk and Norwich University  
Hospita l) in East Anglia. Two of these hospitals are teaching hospitals and 
al l have an access to a thoracic surgery serv ice (1 hospital has a 
dedicated department of thoracic surgery and 2 hospitals have weekly 
input from a v is it ing thoracic surgeon). One hundred and forty cases of 
c l in ically d iagnosed IIP (IPF or NSIP) were identif ied and medical case 
notes were available for  108  patients (26/32 James Paget Hospital, 40/48 
Ipswich Hospital, and 42/60 Norfolk and Norwich University Hospita l) .  
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The baseline patient characterist ics are presented in table 3.2. The 
majority (65%) were prevalent cases; however of the 108 cases assessed, 
23 had been diagnosed with in 6 months and 15 with in 12 months of the 
date of the study. The mean time from diagnosis was 2.9 years (SD ±3 
years) and 83 (77%) were males. All  but one patient had a HRCT scan 
with in 3 months of diagnosis. For the case without  HRCT scan, the 
diagnosis of id iopathic pulmonary f ibrosis was based on clin ical and CXR 
data. In over 90%, integrat ion of c l in ical and radio logica l information was 
used to establish the f inal work ing diagnosis. Overall  7 patients (6.5%) had 
a histopatholo log ical diagnosis, wh ich included 2 out of the 11 patients 
with a working d iagnosis of NSIP.  
 
Table 3.2  Baseline demographic characterist ics  
 
A smoking history was obtained for 104 (96%) cases.  In contrast, less 
than 50% of patients had detailed occupational ( including asbestos and 
other dust or chemicals) and domestic exposures. The main f ind ings are 
summarized in tab le 3.3.  
 Number (%) 
Cases assessed 108 
Males 83 (77) 
Age at diagnosis, years  
(mean ±SD) 
74.5 ±8.6 
Time from diagnosis, years  
(mean ±SD) 
2.9 ±3 
NSIP 11 (10.2) 
IPF 97 (89.8) 
Surgical lung biopsy (VATS)  7 (6.5) 
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Audit Standard % of cases (number) with 
data enquired and 
documented 
Smoking History 
 
96% (104) 
Occupational history   
  Recorded 
  No record  
 
85.2% (92) 
14.8% (16) 
Asbestos exposure  
 
44% (48) 
Other exposures (inorganic dust, 
chemicals, drugs) 
 
20% (22) 
Spouse employment 
 
1.9% (2) 
Hobbies  
  Birds 
  Hobbies other than birds 
41% (44) 
0.9% (1) 
 
House dampness 
 
0.9% (1) 
Relevant past medical history and 
medication exposure 
 
  Malignancy and chemotherapy 
  Cardiovascular condit ions and its 
treatment 
  Use of Nitrofurantoin  
  DMARD 
 
14.8% (16) 
16.7% (18) 
9.3% (10) 
10.2% (11) 
Family history of ILD/CTD  
 
12% (13) 
CTD  
  Record of enquiry on symptom of 
CTD  
  Auto-antibody screen 
 
15.7% (17) 
61% (66) 
Table 3.3  Audit Standards  
 
Occupational history  
A detai led occupational history,  consisting of employer, duration of 
occupation and exposures, was present for 8 cases (7.4%), whilst 16  
patients (14.8%, 7 male) had no occupational data docum ented. For the 
remaining cases, l imited information, predominantly profession, was 
recorded in the medical notes. Overall  a record of employer detai ls was 
availab le for 19% (21) of the cases, and of these a descript ion of the job 
duties was recorded for 19  patients.  
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Asbestos exposure 
A history of  asbestos exposure was enquired from 44% (48) of the patients 
rev iewed in the audit.  N ineteen patients had no ev idence of exposure 
documented as “no history of asbestos exposure” and 9 cases had a 
record of “no occupational exposure/no known exposure/no occupational 
history” . Of the remaining cases with a posit ive history of asbestos 
exposure, 10 patients had no employment details (employer, duration ,  
protection), 2 had a record of their  employer only,  and 4 had 
documentation of duration of the exposure (4 -40 years) but no employer 
details.  The use of respiratory protection was enquired from one patient.  
Furthermore, out of 10 patients, who had professions with potential 
exposure to asbestos (plumber, electr ical/co nstruction engineer, seaman, 
builder), only 7 had ev idence of an enquiry of asbestos exposure. Twenty 
eight patients had occupations with low asbestos hazard (teacher, 
childminder, sales manager, police off icer, lorry dr iver) and only 7 of th is  
group had enquir ies about non-occupational asbestos exposure. Spouse 
employment, includ ing asbestos exposure, was recorded in 2 cases 
(1.9%).  
Other potential ly hazardous occupational exposures were identif ied in 22 
(20%) cases. These exposures had the most comprehen sive informat ion on 
employer, substances exposed to and duration of the exposure. These 
inc luded 2 leather workers, 2 bakers with f lour dust, 3 welders, 2 farmers, 
2 tobacco leaf factory workers, 1 each of poultry factory worker, cotton mil l  
worker, wood cabinet maker, polyester f ibre,  nickel su lphate and copper in  
an electrolys is laboratory, paper and print ing ink dust, organic solvents, 
abrasives in gr inder industry, Benzene chlor ine and acids in the 
pharmaceutical industry, organo-phosphates and pestic ides, and 
upholstery adhesives.   
 
Hobbies and domestic exposures 
Forty four (41%) patients were asked about exposure to birds. Twelve 
(27%) reported hav ing kept birds at some point in their l i fe, but only 3  
cases had a concise history including species of bi rds, duration of 
exposure and where the birds were housed. Av ian precipit ins were 
measured in f ive of the bird -keepers. One patient was reported to have a 
hobby other than bird keeping (dog breeder).  Enquiry on house mould 
exposure was reported in one pat ient only.  
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Relevant past medical history  
Out of the 16 patients asked about prev ious malignancy, radiotherapy and 
chemotherapy treatment, 6 cases were indentif ied: 1 case of groin 
lymphoma with local radiotherapy,  1 case of oesophageal adenocarcinoma 
treated with radiotherapy and chemotherapy prior to diagnosis of IPF, 3 
cases of breast carcinoma (one treated by mastectomy alone; one treated 
with chemotherapy and radiotherapy 18 years before a diagnosis of IPF, 
and one treated with radiotherapy with no do cumentation of the t ime 
interval for diagnosis of IPF), and 2 cases of transit ional cell carcinoma of 
bladder requir ing local excis ion only.  
Eighteen patients (16.7%) were questioned about cardiovascular 
condit ions, wh ich ident if ied prev ious use of amiodarone in 2 cases, In both 
instances, amiodarone was stopped due to the development of ILD. 
However it  was unclear if  symptoms were related to drug use in one 
patient with a history of pro longed use (10 years) of amiodarone.  
Of the 11 patients asked about exposure to methotrexate, 2 cases had a 
history of 9 and 40 years treatment for psoriasis respectively. In the case 
with a 9 year exposure, methotrexate had been discontinued 3 years prior 
to the occurrence of respiratory symptoms.  
 
Family and personal history of connective t issue disease 
A personal history of arthr it is , skin rash, Raynaud’s phenomenon or 
“history suggestive of connective t issue disease” was enquired in 17 
(15.7%) patients. One patient with a history in keeping with Raynaud's 
phenomenon, was noted to have ANA HEp 2 strong posit ive (analys is  
performed in 2001), but did not develop any other systemic features.  
Rheumatoid factor and/or auto -antibody screen (antinuclear antibodies 
(ANA), extractable nuclear antibodies (ENA), cryoglobulin, lupus 
anticoagulant, anticardiol ip in ant ibodies, anti -double-strandDNA (anti-
dsDNA)) were assessed in 66 (61%) patients. Ten out of 51 patients tested 
had elevated Rheumatoid factor t itres on one or more occasion. One 
patient, with a t i tre 10 t imes the upper l imit of  the normal reference range, 
was diagnosed with polymyalgia rheumatica/ inf lammatory polyarthr it is  in 
the same year as IPF. Posit ive ANA was identif ied in 15 out of the 59 
patients tested; 11 (9 weakly posit ive ANA) had no identif iable extractable 
nuclear antigen (ENA) although 2 cases had nucleolar and 2 cases had a 
homogeneous pattern. Two patients had anti -Ro antibodies and the 
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remaining 2 cases with a posit ive ENA had no detectable antigen. Lupus 
anti-coagulant was not assessed in any patient with ele vated ANA tit res. In 
the two pat ients that were tested, anti -card iol ip in ant ibodies were not 
present. Out of the 22 patients (20%) evaluated in this audit, 3 patients  
had a detectable anti-dsDNA (1 an isolated increase and 2 in combinat ion  
with posit ive ANA and ENA negative).  
A family h istory of connective t issue disease or pulmonary f ibros is was 
requested in 13 (12%) patients. Three patients had a history of pulmonary 
f ibrosis in a f irst degree relat ive (affected sister in two cases and father in  
another).  In one case, there was a history of scleroderma in f irst degree 
relat ive (mother), a lthough the patient had no systemic features or 
serology supportive of connective t issue disease at presentation for ILD.  
 
3.4 Discussion  
 
One of the earl iest studies to assess the approach to diagnosis and 
management of cryptogenic f ibrosing alveolit is  in three regions of the UK 
showed there was wide variat ions of practice, with the diagnosis based 
solely on cl in ical grounds in 60% of cases [169]. Subsequently,  the Brit ish  
Thoracic Society undertook a questionnaire based evaluation of new 
inc ident cases of cryptogenic f ibrosing alveolit is  over a 2 year period 
(1990-92). This included a detailed assessment of symptoms 
(breathlessness, cough, arthrit is) ,  structured occupational, smoking and 
past medical h istories, results of  blood tests including ESR, rheumatoid 
factor, ANA, av ian precip it ins as well as lung function and CXR 
appearances[170]. They observed that dust exposure, includ ing asbestos, 
was present in almost half of the cases and that 60% did not have a 
histolog ical d iagnostic procedure.  
 
A number of studies have evaluated the sensit iv ity and specif ic i ty of  
c l in ical d iagnostic criter ia for  IPF. One of the earl iest studies compared 
the accuracy of the clin ical d iagnosis with subsequent histological 
diagnosis in 59 patients with IPF in an academic centre with recognised 
expertise in management of ILD[46]. Th is was performed prior to the IPF 
consensus statement [5]. It  demonstrated that pre-defined cl in ical cr iter ia  
( including absence of c lin ical features suggestive of identif iable cause of 
ILD, insid ious onset of breathlessness of greater than six months duration,  
restrict ive PFT defect, b ibasilar ret icular abnormalit ies on CXR an d HRCT, 
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transbronchial b iopsy excluding specif ic diagnoses) had a high  specif ic ity 
(97%) but low sensit iv ity (62%) for IPF. But for ILD other than IPF the 
cl in ical assessment, including HRCT scan and bronchoscopic f ind ings, had 
low specif ic ity (88%) and sensit iv ity (40%). A mult icentre study by 
Hunninghake et al[45], using expert opinion rather than pre -defined clin ical 
criter ia, demonstrated that a confident c l in ical d iagnosis of IPF had a 
posit ive predictive value of 80% (referr ing centre physic ian),  wh ich 
increased to 87% (special ist pulmonologists) and 96% (specia l ist  
radio logists). These studies suggested that c lin ical and radio logical data 
supportive of a confident diagnosis of IPF may obv iate the need for a lung 
biopsy. In addit ion, a study of 26 patients by three board -cert if ied  
pulmonologists comparing the ATS/ERS clin ical cr iter ia for IPF [171] with  
subsequent lung biopsy results, showed that the sensit iv ity, specif ic ity, 
posit ive predictive value and negative predictive value of the cl in ica l 
criter ia were 71, 75, 77 and 69% respectively, wh ich means that 29% of 
cases would be missed if c l in ical criter ia a lone were applied . Hence, a 
lung biopsy is indicated when clin ical and radiolog ical data result  in an 
uncertain diagnosis. All of these studies used a set of diagnostic c l in ical 
criter ia and only those pa tients who qualif ied these criter ia were included 
into the studies; the accuracy of data record and the number of patients 
excluded from the study, either as a result of incomplete data or not 
qualify ing the inclusion cr iter ia, was not prov ided.  
 
L itt le is known about current practice for the diagnosis and management of 
IPF, in particular adherence to the ATS/ERS consensus recommendations 
for the diagnosis and treatment of IPF published in 2000. Two studies in 
the United States, using electronic questionna ires, assessed the level of 
acceptance of the ATS/ERS consensus statement and determined if the  
practice patterns were consistent with these recommendations. A survey of 
272 academic physic ians (33% response rate) by Collard et al. [172] and 
another of 814 academic and non -academic fellows of the American 
College of Chest Physic ians (13 % response rate) by Peikert et al. [173]  
demonstrated similar t rends regarding the use of HRCT for th e diagnosis 
of IPF (90 and 73% respectively) , surgical lung biopsy (< 30% of cases of 
IPF) and the lack of consensus regarding treatment of patients with IPF. 
The study by Peikert et al showed that 72% of the responders were 
famil iar with the ATS/ERS consensus statement and 63% found it c l in ically 
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useful, wh ilst 28% were not famil iar with the guidelines 7 years after their  
publicat ion[173].  
A benchmark exercise was performed among 370 consultant members of 
the Brit ish Thoracic Society (54% response rate) to compare the approach 
used for evaluating three clin ica l scenarios in ILD, two of wh ich were 
cases of IPF. Responders were asked to choose from a range of diagnostic 
and treatment options, the management decis ion was subsequently 
compared to the consensus statement [174]. This exercise clearly 
demonstrated that there was a lack of consensus in both the decis ion for a 
lung biopsy and selecting appropriate treatment options.  
 
L itt le is known about spontaneous record of the clin ical h istory and risk 
factors data in c lin ic env ironment for patients wi th ILD. This  audit 
evaluated the collect ion of aetio logical factors associated with ILD. The 
results were analysed using the assumption that 100% of patients should 
have data on aetio logical factors collected. It has demonstrated that there 
is considerable  variabil ity in the cl in ical assessment of patients with IIP 
across three hospitals in East Anglia. In th is cohort of patients assigned a 
cl in ical d iagnosis of IPF or NSIP, a smoking history was the only 
aetiolog ical factor that was consistently obta ined. Despite the ATS/ERS 
guidelines, occupational and domestic exposures, associated co -
morbidit ies, potential pneumotoxic therapies, and assessment for  
connective t issue disease was undertaken in less than half of the patients.  
Incomplete data sets, in conjunc tion with radio logy, were used to make a 
cl in ical d iagnosis of either IPF or NSIP in more than 90% of patients. A 
histolog ical diagnosis was only obtained in 7 cases, includ ing 2 patients 
with NSIP. Nine patients had a cl in ical d iagnosis of NSIP. However, in the 
absence of connective t issue disease radiology a lone is not sensit ive and 
a surgical lung biopsy should be performed . 
 
Whilst the data on employment and profession was collected in the 
majority of patients (77%), there was no systematic enquiry. A f ul l  
occupational history was only availab le for 8 cases (7.4%) and 16 patients 
(14.8%) had no detai ls prov ided, of these almost half were males and more 
l ike ly to be the income prov iders. Occupational exposures to hard metals,  
inorganic dusts (asbestos and  other f ibrous si l icates, mixed dust, kaolin,  
rare earths, cobalt, a lumin ium) are associated with an increased risk of 
IPF, and the radiolog ical and pathologica l appearance of UIP [151]. Hence 
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a detailed occupational history is essential to ensure that pneumoconios is  
is not misdiagnosed as IPF. Recognit ion of an occupational cause for the 
interst it ia l lung disease is important as it  helps to predict prognosis, 
guides treatment choice, and ident if ies potential industria l compensation .  
Occupational ILD accounted for a greater proportion of parenchymal lung 
disease in the European disease registr ies compared to connective tissue 
disease, drugs/radiation and vasculit is  combined [151]. Indiv idual 
susceptib i l ity fo r  pneumoconiosis is determined by both exposure -related 
(dose and duration) and host factors. For instance, host factors are key to 
the development of bioaerosol induced hypersensit iv ity pneumonit is,  
cobalt-re lated ILD and chronic beryl l ium disease, while dose and duration  
of exposure to asbestos, coal and si l ica play an important role in  
pneumoconiosis [151]. Accurate assessment of prev ious inhalationa l 
exposures should include a chronological l is t of al l jobs, the names of 
substances exposed to and dose ( if  applicable), the duration of exposure 
inc luding hours during the day and total number of years, any protective 
equipment used and a record of any respiratory symptoms associated with  
the exposure. As well as occupational contac t, exposures can occur in the 
domestic env ironment through hobbies or l iv ing condit ions. Contact with  
some of the substances, such as asbestos, metal and wood dust, text i le 
dust, stone and sand, l ivestock, may occur through both occupational and 
non-occupational routes; others predominantly ar ise through hobbies and 
non-occupational routes; i.e. caged birds, smoking, mould, wood fire. 
Although these exposures may lead to occupational lung disease or 
hypersensit iv ity pneumonit is, they also increase the risk of IPF. This was 
confirmed by a meta-analys is of 6 case control studies, wh ich identif ied  
that c igarette smoking (odds ratio  1.58), and exposures to agricultu re and 
farming, l ivestock, wood and metal dust (odds ratio 2.44), stone and si l ica 
are associated with an increased risk for IPF [31]. A minority of patients in 
this audit  were asked about exposures to these substances associated 
with IPF through either a non-occupational route or spouse’s employment.  
The presence of pleural th ickening is not suff ic ient ly sensit ive to 
discriminate between asbestos related lung disease and IPF, as the r isk of 
non-asbestos related f ibrot ic lung disease is the same in the general 
populat ion as in a patient prev iously exposed to asbestos [175]. In a 
comparative study of th in -section CT in 74 pat ients with asbestosis and 
212 patients with IPF, 2% of those with IPF had ev idence of diffuse pleura l 
th ickening but no pleural plaques, whereas the majority of patients with  
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asbestosis had ev idence of either pleural th ickening or pleural plaques and 
only 5% had no ev idence of pleura l d isease[176]. Thus rarely asbestosis 
presents in the absence of pleural disease. In this audit, only 44% of 
patients were asked about potential asbestos exposure.  
 
Chronic hypersensit iv ity pneumonit is (HP) is another ILD that may present 
with UIP radio logica l pattern s imil ar to IPF. Establishing if  a pat ient has 
had an exposure to potential a l lergens including caged birds, which is the 
commonest cause of HP in the UK and USA, and domestic mould. This  
audit ident if ied that only 41% of patients were directly asked about 
exposure to birds and only 1 patient was asked about damp or mould in the 
home.  
 
Furthermore, the differentia l of UIP pattern radiology also includes drug 
induced interstit ia l lung disease. A number of medications are potential  
pneumotoxins, however UIP histopathology is an uncommon manifestation  
of drug toxic ity[177]. Medicat ions recognised to cause a UIP radiolog ical 
pattern include chemotherapeutic agents (bleomycin, busulphan, 
chlorambucil, cyclophosphamide and nitrosureas), amiodarone, 
nitrofurantoin and less frequently gold, methotrexate and 
sulphasalazine[178]. There have been case reports of resolution of the 
f ibrotic radio logica l changes after cessation of n itrofurantoin 
treatment[179]. In contrast to IPF, drug induced ILD may be reversible  
upon cessation of the causative agent and is more l ikely to respond to 
immunosuppressive therapies. As the cl in ical and radiolog ical f indings of 
drug induced ILD may be diff icult  to distinguish from IPF, it  is  imperative 
that a careful history of prev ious medication use is obtained. The audit  
identif ied that less than a f if th of the patients were asked about the 
prev ious medications including radiotherapy, chemotherapy, 
cardiovascular condit ions and treatments, use of Nitrofurantoin,  and 
disease modify ing anti -rheumatic agents.  
 
Up to 20% of patients with IPF have a family h istory of pulmonary 
f ibrosis [41]. Famil ia l pu lmonary f ibrosis presents in a s imilar manner to 
IPF, except it  has an earl ier age of onset [42]. A number of studies support  
an autosomal dominant inheritance with variable penetrance [43]  . At 
present, no genetic testing is availab le in the UK to ident ify famil ia l forms 
of PF. Clin ical screening is crucia l as there is ev idence to support an 
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independent associat ion between cigarette smoking and phenotypic  
expression as the risk of developing pulmonary f ibrosis is increased in a 
genetically susceptible ind iv idual who smokes [43]. In addit ion, the study 
by Steele et al. suggests that near ly 8% of self -reported unaffected family 
members have a preclin ical form of PF as assessed by HRCT or 
histopathological f ind ings [43], wh ich justify ies the need for surveil lance of 
family members of affected indiv iduals. Our data show that a family history 
of pulmonary f ibrosis was obtained in 12 cases (11%) only and 3 of these 
patients had a f irst degree relative with PF.  
 
By defin it ion IPF is not a systemic disorder, but a disease confined to the 
lungs. Nevertheless the lung may be the f irst manifestation of a systemic 
disease such as the connective t issue disorders (CTD). NSIP is the most 
frequently occurring pattern of intersti t ia l lung involvement that occurs with  
CTD, except for rheumatoid arthrit is  which is associated with UIP. Less 
commonly, UIP has been reported with systemic lupus erythematosus 
(SLE), systemic sclerosis (SSc), Sjogren’s syndrome and 
polymyosit is /dermatomyosit is. There is ev idence that a large proportion of 
cases of id iopathic NSIP have or may develop features of undifferentiated 
connective t issue disease [180, 181]. Identify ing an underly ing CTD has 
important consequences for disease prognosis, treatment choice and l ike ly 
response to treatment. In keeping with th is, patients with UIP associated 
with CTD have a better outcome compared to those with IPF (mean 
surv ival 177 months versus 66.9 months respectively) [40]. Quite often 
patients may not be aware of systemic symptoms if they are not causing 
signif icant functional impairment or if  the respi ratory symptoms are more 
prominent. Systemic sclerosis is typica lly associated with skin thickening, 
the extent of which leads to c lassif ication into l im ited or d iffuse forms. 
There is a rare variant, characterised by v isceral involvement in the 
absence of skin thickening, called systemic sclerosis s ine scleroderma 
(ssSSc). A recent study of 6 pat ients with ssSSc, who were originally 
diagnosed with an idiopathic interstit ia l pneumonia, identif ied the cr iter ia  
of telangiectasia, Raynaud’s phenomenon with abn ormal capil laroscopy,  
gastro-esophageal ref lux, per icardial d isease (often asymptomatic) and the 
presence of a nucleolar-stain ing ANA, that may be of help to dif ferentiate  
these patients from those with IIP [182]. 
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Antinuclear antibodies (ANA) directed against a variety of  nuclear ant igens 
are detected in the serum of patients with rheumatic condit ions as well as 
a number of healthy controls, who were reported to have low t it res of th is  
antibody that increased with age especial ly in females: - 25-30% at 1:40, 
10-15% at 1:80 and 5% at 1:160 or greater [183]. ANA testing is performed 
either by enzyme-linked immunosorbent assay (ELISA) or indirect  
immunofluorescent staining of fresh frozen sections of r at l iver or k idney,  
or using the human epithelia l cel l tumour l ine (HEp -2 cell); the la tter of 
wh ich is most commonly used. ANA performed on HEp -2 cells are more 
frequently abnormal in patients with any ANA-associated disease, 
demonstrating increased sensi t iv ity, but th is is offset by a lower 
specif ic ity [183]. ANA staining demonstrates variable patterns including 
speckled (i.e. extractable nuclear antigen (ENA) antibodies such as antiRo 
(SS-A) antibodies characterist ic for SLE and Sjogren’s syndrome, antiLa 
(SS-B) ant ibodies characterist ic  for Sjogren’s syndrome, antiSmith 
antibodies characterist ic for SLE, antiU1 -RNP characterist ic for 
undifferentiated CTD, and antiScl70 an antitopoisomerase ant ibody 
characterist ic for SScl) , nucleolar (ANoA) (i.e.  antiTh/To,  antiAFA,  antiPM-
Scl and antiRNPI antibodies), anticentromere (ACA) and homogeneous  
antibodies. These antibodies are rarely found in healthy volunteers and 
are usually specif ic for  a particu lar type of CTD. Moreover the pattern of 
the ANA in SSc can predict not only the extent of the disease but also  
organ involvement:  antiScl70 antibodies are predictive of diffuse 
scleroderma associated with pulmonary f ibros is whereas anticentromere 
antibodies are predictive of l im ited cutaneous scleroderma associated with  
pulmonary hypertension[184]. Low ti tres of Rheumatoid factor and 
antinuclear antibodies can occur in  10 -20% of patients with IPF, wh ich may 
be a false posit ive result as a consequence of the ageing populat ion.  
Nevertheless in the sett ing of an ILD, h igher t itres may be of relevance 
and instigate a thorough evaluat ion for a CTD. The current BTS ILD 
guidelines[14] recommend that al l pat ients with suspected intersti t ia l 
pneumonia should have rheumatoid factor as well as ANA  and ENA 
tested, and lupus anticoagulant and anticardiol ip in ant ibodies measured in  
those with a ra ised ANA titre.  
  
Our audit identif ied that a record of enquiry of CTD associated symptoms 
was present in less than a f if th of patients, whilst serolog ical screening for 
Rheumatoid factor and ANA antibodies was performed in 61% of cases. 
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These results are much lower than two published studies, which found that 
these serological markers were uti l ised in the diagnostic evaluation of IPF  
by physic ians in up to 90-95% of patients [172, 173]. 
 
HRCT is an essentia l part of the assessment of a patient with IIP as it can 
different iate UIP from other forms of IIP. A survey of 272 academic 
physic ians (33% response rate) by Collard et a l. [172] reported that 90% of 
physic ians accept that HRCT should be obtained in al l pat ients suspected 
of hav ing IPF. Our results are in agreement as all but one patient had 
HRCT scan. A histolog ical conf irmation of the diagnosis was achieved in  
6.5% of our cases, which is compatib le with earl ie r studies by Johnston et 
al[169] and is s imilar with the survey of Fellows of the American College of 
Chest Physic ian where ≤30% of cl in ic ians uti l ised  surgical lung biopsy in 
the diagnosis of IPF[173].  
 
Our audit has a number of limitat ions.  We did not ensure the confidence 
of the HRCT diagnosis by performing an addit ional independent 
radio logical rev iew, but rel ied upon the reporting by the local hospital 
radio logists who have varying expertise in ILD. Although we rev iewed data 
on the patients who underwent a surgical lung biopsy, we did not collect 
the total number of patients referred for a diagnostic surgical lung biopsy 
who were deemed unsuitable fo r the procedure or who declined the 
investigat ion. None of the hospitals that part ic ipated in th is audit  had a 
dedicated ILD MDT, but al l the physic ians had an opportunity to discuss 
the cases with a respiratory radio log ist with in a general respiratory MDT;  
the number of cases when this discussion occu rred was not documented.  
 
In ILD the epidemiologica l studies are div ided into the fol lowing three 
categories: the quantif icat ion of the disease (assessing incidence, 
prevalence and mortal ity), the identif ication of aetio logica l factors (by 
surveying outbreaks of the disease and identify ing env ironmental and 
genetic associat ions using cohort or case -control studies), and cl in ica l 
epidemiolog ical studies (characteris ing disease behav iour includ ing 
patterns of c lin ica l presentation, natural history, t reated co urse, 
responsiveness to therapy and defin it ion of prognosis) [185]. Sources of 
data for these epidemiolog ical studies include routine national stat ist ics 
(national mortal ity stat ist ics, hospital episode data ), population based data 
(screening of “at r isk” professions of occupational lung diseases and 
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primary care data), and specif ic disease registr ies [185]. Registries of lung 
diseases such as the European database for cystic f ibrosis, the rare lung 
diseases including lymphangioleiomyomatosis, and the internationa l 
registry for organ transplantation, have been essentia l in develop ing 
standards of care, improv ing surv ival and understanding the disease 
pathogenesis. Although there are ILD registr ies in the United States 
(Bernali l lo County, New Mexico) and Europe (Belgium, Germany and Ita ly) ,  
there is no international registry fo r IPF [186]. The use of the ATS/ERS IPF 
guidelines would a id sett ing up such a registry,  wh ich would be invaluable  
for future epidemiolog ical studies, especial ly for assessing incidence, 
prevalence, mortali ty, d isease behav iour and response to treatment, and 
for recruit ing to c l in ical t r ia ls by identify ing potential ly suitable candidates 
based upon the inclusion and exclusion criter ia (age group, disease 
severity, prev ious treatment regimens). Electronic registries offer the 
possibi l i ty of being able to update the information on a patient’s progress 
and treatment.  
 
None of the three respiratory departments had a dedicated register or  
database of patients with interst it ia l lung diseases, nor used a proforma to 
collect the relevant c l in ica l information that is recommend ed by the 
ATS/ERS consensus statement for the assessment of interst it ia l lung 
disease[5, 6]We are aware that most of the patients in this audit had 
incomplete c l in ical detai ls to exclude other causes for their ILD, thus 
would not be suitable for ep idemiological studies.  
 
3.5 Conclusions 
 
This audit has identif ied that a confident diagnosis of IPF could only be  
made in 9.3% (10) patients. It  is  possible that the remaining 90.7% (98) 
patients may have had an underly ing cause for their  ILD e ither as a result 
of occupational exposures, drug induced or associated connective t issue 
disease. The accurate diagnosis of IPF is important for patient care, as 
this determines treatment choice and predicts prognosis. Since th is audit  
was undertaken, the ATS/ERS/JRS/ALAT have issued new guidance for 
the diagnosis and management of IPF [16]. Using these new criter ia, we 
propose that a proforma (appendix 4) should be used in the evaluat ion of 
al l pat ients with ILD to improve diagnostic certainty.   
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Chapter 4 
Study 2 
Treating Interstitial Pneumonia with the Addition of  
Co-Trimoxazole (TIPAC) Study 
 
4.1  Introduction 
Id iopathic pulmonary f ibrosis (IPF) is the most frequently occurring form of 
f ibrotic id iopathic interst it ia l pneumonia (IIP), wh ich has a poor prognosis  
result ing in progressive breathlessness, impaired quality of l ife and a 
marked reduction in l ife expectancy[25]. The annual inc idence is reported 
to be 7.44/100000 in the UK and 6.8/100000 in the U SA with an 11% 
increase between 1991 and 2003 [24]. The disease has a variable course in 
ind iv idual patients [70], however several studies performed using the 
current c lassif icat ion of IIP [6] have reported a median surv ival between 2 
and 4 years from the t ime of diagnosis and a 5 year surv ival between 20 
and 40%[63]. Furthermore, in a recent rev iew of a US Mult ip le Cause -of-
Death mortal ity database, Olson et al [28] reported that age-adjusted 
mortal ity for pulmonary f ibrosis increased by 27% in males and 40% in 
females between 1992 and 2003. 
Given the poor surv ival and lack of effective therapy for patients with IPF, 
there has been a renewed search for novel treatment options. A number of 
medications with anti -f ibrot ic , anti-oxidant, ant i-pro l iferat ive, and anti-
inf lammatory properties have been recently evaluated [96, 98, 100-102, 
105] but only a few of these studies achieved their primary endpoint. 
Though some had demonstrated statist ica l ly s ignif icant results and trends 
in secondary end-points[99, 187] this was not subsequently supported by 
larger studies[98, 100]. This suggests that current treatment options 
broadly lack eff icacy though some result in a low average effect or, 
a lternat ively, are very selective and achieve important eff icacy in selected 
patient subgroups[89]. 
A cl in ical observation that oral co -tr imoxazole could result  in c l in ical  
improvements in patients with advanced fibrot ic lung disease prompted a 
prev ious small double-bl ind randomised placebo-control led pilot study of 
20 patients with IIP. Pat ients, were prescribed co -trimoxazole at a dose of 
960 mg twice daily (1440 mg twice daily for patients over 70 kg) for 3 
months which was added to  the patients’ exist ing treatment. Active 
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treatment produced signif icant improvements in outcomes including shutt le  
wa lk distance, forced v ital capacity (FVC), Medical Research Council 
(MRC) dyspnoea score and St George’s Respiratory Questionnaire (SGRQ) 
symptoms score[188]. 
Based on these observations we conducted a randomised placebo-
controlled double-bl ind cl in ica l tr ia l to compare the eff icacy and safety of  
12 months therapy with oral co -tr imoxazole when added to standard 
treatment in patients with f ibrot ic id iopathic interst it ia l pneumonia. The 
secondary objective was to estimate the incremental cost effectiveness of 
co-trimoxazole p lus standard care compared with standard care alone.  
 
4.2  Methods 
Patients 
Patients with c l in ica l diagnosis of IPF or f ibrot ic NSIP were identif ied from 
the respiratory outpatient departments of 27 district general hospitals and 
one tert iary centre in England and Wales after being approached by the ir  
attending physic ian or a study coordinator (Dr Shulg ina).  
Patients with c l in ica l diagnosis of non -specif ic intersti t ia l pneumonia were  
entered if f ibrot ic features were predominant on HRCT. Histology was not 
required as an entry criter ion. No patients had exacerbation of their 
disease or respiratory t ract infect ion or changes in  their  
immunosuppression treatment with in 6 weeks of recruit ment. Patients were 
greater than 40 years old and were permitted to receive oral prednisolone, 
azathioprine or mycophenolate mofeti l at a stable dose and anti -oxidants. 
Patients had an MRC dyspnoea score of two or more and those who had 
not received immunosuppressive therapy had progressive disease with  
deteriorat ing lung function (>10% decline in FVC or >15% decline in  
diffus ing capacity of carbon monoxide (DLCO)  in the preceding 6-12 
months); female subjects were of non -childbearing potential, def ined as 
fol lows: postmenopausal females who have had at least 12 months of 
spontaneous amenorrhea or 6 months of spontaneous amenorrhoea with  
serum FSH>40mIU/ml; females who have had a hysterectomy or bilatera l 
oophorectomy with in 6 weeks. 
Patients were excluded f rom the study if a secondary cause for pulmonary 
f ibrosis was identif ied, if  they had a respiratory tract infection within two 
months prior to recruitment, a recognised signif icant co -exist ing  
respiratory disorder or if  they had a signif icant medical, surg ical or 
psychiatric d isease that would affect subject safety or inf luence the study 
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outcome, if  they were receiv ing immunosuppressant medication other than 
prednisolone, azathioprine or mycophenolate mofeti l ( includ ing 
cyclophosphamide, methotrexate, d -penici l lamine, colchic ines, gamma-
interferon), had co-trimoxazole al lergy or into lerance and untreated folate  
or B12 defic iency.  
The fol lowing concurrent therapy required caution or increased monitoring:  
digoxin, warfar in, phenytoin, sulphonylureas, procainamide hydrochlor ide.  
 
Study design  
Patients underwent 5 v is its within 12 months period of the study (Table  
4.1). At screening, all pat ients were given an opportunity to ask questions 
and were asked to s ign informed consent form, which was followed by 
collection of demographical data, history of past and current medical 
i l lnesses, current treatment including immunosuppression, physica l 
examination. Sp irometry or fu l l  pulmonary function test were performed in 
al l pat ients with in 1 months of recruitment.  In co-trimoxazole study 6 
minute walk test was performed where this serv ice prov is ion was available,  
screening for glucose-6-phosphate defic iency was performed in male 
subjects and an ECG was taken unless performed with in the prev ious 6 
months, a questionnaire  was admin istered to assess baseline health and 
social care resource uti l isat ion and costs, an addit ional questionnaire 
assessed baseline socioeconomic status.  
The fol lowing was performed at screening and 6 weeks, 6 months 9 months 
and 12 months after randomisation: 
  Spirometry  
  MRC Breathlessness score 
  Full b lood count, Urea and Electrolytes and Liver function tests (this 
is unlike ly to be addit ional to standard care)  
  The EuroQol EQ-5D  
  A health and social care resource uti l isat ion and costs questionnaire  
The fol lowing was performed at screening and 6 months and 12 months 
after randomisation:  
  Six minute walking test as described prev iously with assessment of 
desaturation during the test and distance walked –  in a subgroup of 
patients only  
  St George’s Respiratory Questionnaire  
  Total lung diffusing capacity of carbon monoxide  
  Static lung volumes including tota l lung capacity (TLC)  
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  Blood was stored for vascular endothelia l growth and KL -6 in a 
subgroup of patients only  
 
For the duration of the study an assessment was made of:  
  a l l cause mortali ty and mortal ity due to IPF 
  the requirement for escalation of therapy. This included an increase 
or decrease in the dose of prednisolone or azathioprine, addit ion of  
other treatments including acetylcyst ine and the commencement of 
oxygen therapy 
  adverse events 
  hospita l isations 
The 6 week assessment was undertaken between 4 and 8 weeks and the 6 
month assessment was conducted between 5 and 7 months, the 9 month 
assessment was between 8 and 10 months and the 12 month assess ment 
between 11-13 months to permit study v is its to coincide with routine 
medical fo l low-up. 
Patients on azathioprine or mycophenolate mofeti l required addit ional 
monitor ing of fu l l b lood count on two weekly basis due to potential r isk of  
neutropenia. Patients on mycophenolate mofeti l had their Urea and 
Electrolytes and Liver function tests checked two weeks after recruitment.  
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 
 0 6 weeks 6 months 9 months 1 year 
Consent X     
History & Examination X X X X X 
Drug dispensed X X X X  
Adverse events X X X X X 
Concomitant 
medication 
X X X X X 
Spirometry X X X X X 
MRC score X X X X X 
FBC, U&E, LFT X X X X X 
6 Min Walk X  X  X 
SGRQ X  X  X 
DLCO X  X  X 
TLC X  X  X 
EQ-5D X X X X X 
Socioeconomic status 
questionnaire 
X     
Cost questionnaire - 
baseline 
X     
Cost questionnaire – 
follow-up 
 X X X X 
Table 4.1  Time and events. Bold indicates measurements that are performed in all 
subjects. Other measurements are performed in a subgroup of patients. 
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Statistical analysis 
The primary endpoint was a change in FVC expressed in mil l i l i tres (ml)  
after 12 months of study drug. Patients were inc luded in the intent ion to 
treat (ITT) analys is irrespective of whether they remained in or withdrew 
from the study at any point and the v ita l status of all pat ients was 
determined at 12 months. A per -protocol (PP) analysis was also completed 
with patients being excluded if they did not adhere to study medication or 
withdrew from the tr ia l pr ior  to death. Assuming a residual SD of 400 ml 
(from data from ISOLDE and TRISTAN study courtesy of J. Anderson, 
GSK, Greenford), then with 63 patients in each group the study had an 
80% power to detect a mean difference of 200ml at a s ignif icance level of 
p = 0.05. Our sample size was higher in order to allow for drop-outs. The 
value of 200ml for the mean difference in FVC from baseline was used to 
power the study since this represents the minimum change required for a 
favourable or unfavourable response to treatment as proposed in the 
ATS/ERS International Consensus statement [5]. 
Quality Adjusted Life Years (QALYs) were calculated by converting the 
EQ-5D results at each t ime point into ut i l i t ies using UK h ealth state 
valuations[189], then measuring the result ing area under the curve. We 
analyzed the primary outcome by a l inear mixed model with s ite  as a 
random effect and the use of azathiopr ine as a f ixed effect. Site was 
inc luded as a random effect due to the inclusion of a number of hospitals  
entering with a small number of patients. We term this the “unadjusted” 
analysis. In addit ion an “adjus ted” analysis was performed by inc luding the 
baseline value of the outcome as a f ixed effect. A corresponding analys is 
was undertaken for each outcome, but for the b inary outcome measures a 
log ist ic mixed model was used and for t ime unti l death a Cox propo rt ional 
hazards model was used with robust variance by site.  
Data from patients were analyzed according to allocated group, with a l l  
patients with data available inc luded in the ITT analysis.  Addit ionally, a  
sensit iv ity analys is was conducted by mult ip le imputation from an 
imputation model wh ich contained randomisation group and all outcome 
measures; however if  40% or more of the data were missing the var iable  
was not imputed or used in the imputation model. The imputation model 
chosen was a mult ivariate no rmal distr ibut ion[190]; which has been shown 
to be robust against departures from mult ivariate normal distr ibution. A 
total of 5 imputed datasets were created and then combined using Rubin’s 
equations. No safety or per-protocol data was imputed.  
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Two subgroup analyses were prespecif ied, by disease severity (c lassif ied  
as severe if baseline FVC was 60% of predicted or less) and by whether 
the patient was taking medication or not at baseline. Subgroup analys is 
was undertaken by testing for an interaction between subgroup and 
treatment group in the mixed model specif ied above but also including the 
subgroup as a f ixed effect. Subgroup analyses were only completed on 
absolute FVC and death. 
The safety analysis consisted of al l pat ients who took at least one dose of 
study medication. The rate of adverse events was  compared using either 
Poisson or Negative binomial regression as required with  results presented 
as incidence rate ratios (IRR).  
A cost-effectiveness and cost-uti l i ty analys is estimated the incremental 
costs and outcomes (mls improvement in FVC and QALYs gained) of 
treating a patient with or without co -trimoxazole, measured from the 
v iewpoints of both the UK National Health Serv ice and society. Health 
serv ice costs were defined as drug costs, hospita l costs and GP practice 
costs. The societal analysis included NHS costs plus costs aris ing from 
social care prov iders, patient out of pocket costs and informal carer t ime. 
The price year of the analys is was 2009. Quantit ies of resource use were 
mult ip l ied by unit costs extracted from relevant UK [158, 159, 191]. 
Results are presented as point estimate incremental cost and outc omes 
and incremental cost-effectiveness ratios (ICERs) for both ITT and PP 
populat ions. A complete case analysis and imputed, adjusted (for baseline 
cost, FVC and QALY) analysis are reported. 95% confidence intervals 
around increments were calcula ted using  a non-parametric bootstrap 
approach. Uncertainty in the ICER is shown as the cost -effectiveness 
acceptabil ity curve (CEAC)[192].  
A subgroup analysis was performed for FVC and deaths to determine the 
effect of patients receiv ing concomitant immunosuppressive therapy at 
recruitment and two sensit iv ity analyses were undertaken for those 
patients with a def in ite/probable diagnosis of IPF (UIP biopsy or 
defin ite/probable UIP on HRCT[164] and UIP biopsy, honeycombing on 
HRCT or a score of more than 0.6 according to the algorithm described by 
Fell et a l l[165]).  
The reason for admission to hospital and the cause of death was obtained 
from death certif icates and adverse event reporting forms. These were 
rev iewed by two blinded physic ians.  
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Analyses were performed in a bl inded fashion by Allan Clark (stat ist ic ian) 
and Edward Wilson (health economist).  
 
Objective  
The primary objective is to compare the eff icacy and safety of 12 months 
therapy with co-tr imoxazole 960 mg twice daily to placebo in a double -
bl ind placebo-control led study of patients with f ibrot ic id iopathic interstit ia l 
pneumonia.  The secondary object ive is to es timate the incremental cost 
effectiveness of co-trimoxazole p lus standard care compared with standard 
care alone. 
 
Endpoints 
The primary endpoint of the study was change in forced v ital capacity after  
12 months of study drug.  
Secondary outcomes were  
  change in MRC breathlessness score 
  change in tota l lung capacity  
  change in tota l lung dif fusing capacity of carbon monoxide  
  change in St Georges Respiratory Questionnaire  
  change in 6 minute walking d istance and desaturation  
  change in EuroQol (EQ-5D) score 
Other endpoints were:  
  a l l cause mortali ty and mortal ity due to IPF 
  the requirement for escalation of therapy. This includes 
commencement of prednisolone or azathiopr ine (in pat ients who had 
not been on immunossupression pr ior to recruitment) or increase or 
decrease in the dose of prednisolone or azathioprine ( in those who 
had been on immunosuppression prior  to recruitment), addit ion of  
other treatments including acetylcystein and the commencement of 
oxygen therapy 
  the number of  hospita l isations  
Safety endpoints were:  
  Blood haematology and biochemistry  
  Drug related adverse event 
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4.3  Results  
4.3.1 Interim Analysis  
The inter im analys is of safety performed in a b l inded fashion in October 
2009 when 50% of patients completed six months of treatment. The 
baseline characterist ics showed no ev idence of imbalance, in particular, 
FVC was well balanced with a mean of 2.23 in Group A and 2.25 in Group 
B (Table 4.2).  
Characteristic Group A (n=35) Group B (n=32) 
Female 10/35 (28.6%) 9/32 (28.1%) 
MRC dyspnoea grade   
  1 0/35 (0.0%) 0/32 (0.0%) 
  2  2/35 (5.8%) 5/32 (15.6%) 
  3 14/35 (40.0%) 8/32 (25.0%) 
  4 14/35 (40.0%) 14/32 (43.8%) 
  5 5/35 (14.3%) 5/32 (15.6%) 
Smoking History   
 Ex-smoker 27/35 (77.1%) 23/32 (71.9%) 
 Never-smoker 8/35 (22.9%) 9/32 (28.1%) 
UIP 29/34 (85.3%) 26/32 (81.3%) 
NSIP 0/32 (0.0%) 3/25 (12.0%) 
Steriods (Prednisilone) 23/35 (65.7%) 27/32 (84.4%) 
Biopsy
* 
  
  Any 5 /35 10 /32 
  Open Lung 2 / 35 3 /32 
  TransBronchial 0 / 35 3 /32 
  VATS 3 /35 4 /32 
Age (years) 73.9 (8.6) 70.6 (9.2) 
FEV1   
   Absolute 1.83 (0.68) 1.86 (0.56) 
   % 70.25 (21.56) 73.94 (24.57) 
FVC   
   Absolute 2.23 (0.87) 2.25 (0.71) 
   % 66.96 (23.02) 69.49 (23.53) 
TLC   
   Absolute 3.79 (1.28) 4.07 (1.00) 
  % 60.64 (17.38) 64.86 (15.87) 
DLCO   
   Absolute 3.04 (0.88) 3.20 (1.22) 
  % 37.03 (9.11) 38.92 (12.99) 
KCO   
  Absolute 0.91 (0.23) 0.97 (0.33) 
  % 71.30 (17.36) 72.45 (25.71) 
Site   
  Addenbrookes 2 1 
  Basildon and Thurrock 1 1 
  Bedford 3 3 
  Colchester 3 1 
  Ipswich 5 5 
  JPH 2 1 
  Luton 1 1 
  NNUH 9 9 
  Papworth 4 3 
  QEH 3 6 
  Southend 0 1 
  Whipps Cross 1 0 
  Wythenshaw 1 0 
Table 4.2  Summary of baseline characteristics (Interim analysis).There was no 
imbalance in baseline characteristics between the two groups. 
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There was no difference in safety measures between the two treatment 
arms showing no signif icant dif ference in terms of the percentage dying 
(5.7% vs 15.6%, p=0.202), the average number of adverse events 
(p=0.656), and severe adverse events (p=0.681). However, in terms of th e 
average number of adverse reactions there was borderl ine ev idence of a 
difference (p=0.045) with an average of 0.34 adverse reactions per person 
in Group A compared with 0.09 in group B. No difference was observed in 
the rate of withdrawal (p=0.328), although this was high in both groups 
(Table 4.3).   
 
Measure Number 
Group A 
Number 
Group B 
Group A Group B IRR (95% CI)
+ 
p-value 
Adverse 
reaction 
12 3 0.34 (0.77) 0.09 (0.30) 0.27 
(0.08,0.97) 
0.045 
  ENT 0 2 0.00 (0.00) 0.06 (0.25) - 0.992 
  GI 2 0 0.06 (0.34) 0.00 (0.00) - 0.993 
  Renal 1 0 0.03 (0.17) 0.00 (0.00) - 0.993 
  Anorexia 2 0 0.06 (0.24) 0.00 (0.00) - 0.993 
  Nausea 6 1 0.17 (0.38) 0.03 (0.18) 0.18 
(0.02,1.51) 
0.115 
 Rash 1 0 0.03 (0.17) 0.00 (0.00) - 0.993 
AR (not 
nausea) 
6 2 0.17 (0.57) 0.06 (0.25) 0.36 
(0.07,1.81) 
0.217 
Adverse 
event (inc. 
Adverse 
reactions) 
55 46 1.57 (1.69) 1.44 (1.44) 0.91 
(0.62,1.35) 
0.656 
Serious 
Adverse 
event 
13 10 0.37 (1.03) 0.31 (0.54) 0.84  
(0.37,1.92) 
0.681 
SAE related  1 0 1/35 
(2.9%) 
0/32 
(0.0%) 
NA 0.335 
Deaths 2 5 2/35 (5.7%) 5/32 
(15.6%) 
3.06 
(0.55,17.01)
* 
0.202 
Withdrawn 15 10 15/35 
(42.8%) 
10/32 
(31.3%) 
0.61 
(0.22,1.65) 
0.328 
Table 4.3  Comparison safety measures between treatment arms (interim analysis).+ is 
the ratio of the mean in group A divided by the mean in  group B.* Odds ratio (95% CI). 
There was no difference in safety measures between the two groups. 
 
4.3.2 Final analysis  
4.3.2.1 Baseline characteristics 
582 patients with f ibrot ic id iopathic interst it ia l pneumonia  were screened 
between January 2008 and December 2009. The main reasons for not 
being included into the study were patient’s refusal to partic ipate, ongoing 
change in immunosuppression, a stable course of the disease and not 
meeting inclus ion criter ia due to a s ignif icant co -existing i l lness (for 
example recent myocardial infarct ion or s ignif icant renal impairment) or 
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fra i l ty. Of these patients 192 were enrolled, 10 of which were not 
randomized due to death (3 patients) or not meeting inclusion criter ia (for  
example identif iab le cause of pulmonary f ibrosis), and one was a 
postrandomisation withdrawal due to an inelig ib i l i ty of  the diagnosis 
(Figure 4.1) .  
 
Figure 4.1 Patient disposition. n= number of patients. Lung function data required for the 
primary endpoint was obtained from four patients in the placebo group and nine patients 
in the co-trimoxazole group from routine clinical data following withdrawal from the study 
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The intent ion to treat analysis included 181 randomised patients (Figure 
4.1). The mean age of the patients was 71 .6 ± 8.5 years, 28% were women 
and 75% were ex-smokers. The majority of pat ients had MRC dyspnoea 
score of 3 or 4. The mean FVC% predicted was 70.7 ± 21.2% and DLCO% 
predicted was 37.5 ± 11.5% consistent with moderate/severe disease. 
Seventy-f ive patients had definite  diagnosis of IPF (biopsy or diagnostic 
radio logical features) and 86 had probable IPF radiolog ically[ 15] and 87 
would be like ly to have UIP on biopsy according to Fell et al[16].  Sixty 
percent of patients were taking immunosuppressive treatment either with  
prednisolone alone or in combination with azathiopr ine or mycophenolate 
mofeti l,  28% were receiv ing antioxidants (Table 4.4). Pat ients who were 
not receiv ing immunosuppressive therapy showed ev idence of functiona l 
decline in preceding 6-12 months (>10% decline in FVC or >15% decline in  
diffus ing capacity of carbon monoxide (DLCO) ; those who were already on 
immunosuppression at the t ime of recruitment were not expected to 
demonstrate s imilar change in lung function over the preceding 6-12 
months as it was assumed that they had already developed progressive 
disease at an earl ier stage which led to prescribing of immunosuppression.  
The treatment groups were generally we ll matched (with the possible  
exception of MRC score), and hence no adjustment to the analys is was 
required to account for baseline imbalance.  
 Placebo 
(n=86) 
 Co-trimoxazole 
(n=95) 
 
Characteristic Mean / 
number 
Sd / % Mean/ number Sd / % 
Female 21  24.4% 29  30.5% 
Age (years) 70.65 8.56 72.38 8.45 
Body Mass Index (kg/m
2
) 28.61 5.54 28.86 8.03 
Smoking history     
   Current 1  1.2% 1  1.1% 
   Ex-smoker 65  75.6% 71  74.7% 
   Never 20  23.3% 23  24.2% 
Clinical diagnosis     
   Usual Interstitial Pneumonia 81 94.2% 89 93.7% 
   Non-Specific Interstitial Pneumonia 5 5.8% 6 6.3% 
Biopsy      
    Open lung 5 / 15 5.8% 3 / 14 3.2% 
    Video-assisted thoracic surgery 10 / 15 11.6% 11 / 14 11.6% 
Pathological/radiological diagnosis     
    Definite UIP (histologically confirmed UIP,     
honeycombing on HRCT or in report on 
destroyed HRCT)  
38  37  
    Probable UIP (all features consistent with 
UIP except honeycombing on HRCT or in 
report on destroyed HRCT) 
40  46  
Table 4.4  Summary of baseline characteristics for all ITT individuals. 
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    NSIP (histologically confirmed NSIP and 
HRCT features consistent with NSIP) 
7  11  
   HRCT report destroyed 1  1   
Fell Criteria     
    Definite UIP (histologically confirmed UIP, 
honeycombing on  HRCT or in report on 
destroyed HRCT)  
38  37  
   Probable UIP (Fell score ≥ 0.6) 41  46  
   Intermediate UIP/NSIP (Fell score < 0.6) 1  3  
   Absent honeycombing in report on 
destroyed HRCT 
4  6  
   Histological diagnosis of NSIP 1  2  
Table 4.4     
HRCT report destroyed 1  1   
Time from diagnosis to randomisation 
(months)*
 
31.1 56.8 25.5 37.1 
Diagnosis within 12 months 21  24.4% 25  26.3% 
Co-existing emphysema 9  10.5% 6  6.3% 
Medical Research Council (MRC) dyspnoea 
score 
    
      2 17  19.8% 12  12.6% 
      3 28  32.6% 42  44.2% 
      4 31  36.1% 31  32.6% 
      5 10  11.6% 10  10.5% 
FVC (ml) 2.4 0.8 2.3 0.9 
FVC percent predicted (%) 71.5 21.0 70.0 21.5 
TLC (ml) 4.2 1.6 3.8 1.1 
TLC percent predicted (%) 66.3 22.5 61.8 15.8 
DLCO (mmol/min/KPa)  3.5 1.9 3.2 1.6 
DLCO percent predicted (%) 39.1 12.8 36.0 10.0 
6 minute walk (6MW) distance (m) 331.2 117.6 285.6 96.1 
6MW desaturation of 4% or more  32 / 43 74.4% 31 / 38 81.6% 
St George Respiratory Questionnaire total 
(units) 59.3 17.5 55.7 17.9 
Treatment     
     Prednisolone 52  60.5% 54  56.8% 
     Azathioprine  26  30.2% 28  29.5% 
     Mycophenolate mofetil 3  3.5% 4  4.2% 
     Carbocysteine 2  2.3% 2  2.1% 
     Mecysteine 0  0.0% 1  1. 1% 
     N-acetylcysteine 20  23.3% 25  26.3% 
     Oxygen 10  11.6% 12  12.6% 
FVC% <= 60 26  30.2% 34  35.8% 
Table 4.4  Summary of baseline characteristics for all ITT individuals. Kg: kilogram, m: 
meters, MRC: Medical Research Council, FVC: forced vital capacity, ml: millilitres, TLC: 
total lung capacity, DLCO: diffusing capacity of carbon monoxide, 6MW: 6 minute walk. 
The number of patients undergoing the following measurements were: TLC: Placebo-67, 
co-trimoxazole-74; DLCO: Placebo-72, co-trimoxazole-77; 6 minute walk: Placebo-43, co-
trimoxazole-38; SGRQ: Placebo-81, co-trimoxazole-87. Units are number of patients 
unless indicated. *median and interquartile range 
 
A total of 71 patients did not complete 12 months treatment: 17 due to 
death and 52 (29%) discontinued the study medication prematurely, of  
these 17 due to withdrawal of consent and 3 5 due to adverse events (7 in  
placebo and 28 in co-tr imoxazole group). 56 patients in p lacebo group and 
54 in co-trimoxazole group completed 12 months treatment. The results of  
FVC at 12 months after randomizat ion were obtained in 60 pat ients in  
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placebo group and 63 in co-trimoxazole group irrespective of whether they 
completed 12 months treatment or withdrew prematurely.  
Overall adherence to the study medication was good with 96% of patients  
in the co-tr imoxazole group and 90% in the p lacebo group receiv ing more 
than 80% of the scheduled study drug doses.  
 
 
4.3.2.2 Efficacy 
Intention-to-treat population  
There was no signif icant difference between treatment groups for change 
in pulmonary function parameters in either the unadjusted or adjusted 
analyses (Table 4.5). Analysis of the other endpoints found signif icant 
differences in the symptom domain of the SGRQ ( -5.73, 95% CI -11.86 to 
0.40, p=0.009, above the threshold of 4 for a minimally important cl in ica l 
difference) and the percentage of patients requir in g an increase in oxygen 
therapy (OR=0.15, 95% CI 0.03 to 0.80, p=0.027) in favour of co -
tr imoxazole treatment.   
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 Placebo Co-trimoxazole Unadjusted Adjusted for baseline 
Outcome N Mean Sd N Mean Sd p-
value 
95 CI% p-
value 
95% CI 
FVC abs 
60 
-
195.67 288.82 63 
-
182.22 330.15 
0.781 15.50 
(-93.6,124.63) 
0.988 0.81 
 (-
107.44,109.07) 
FVC % 
60 -4.79 8.70 63 -4.65 9.96 
0.938 0.13  
(-3.14,3.40) 
0.978 0.05  
(-3.22,3.32) 
FEV abs 
60 
-
140.50 252.68 63 
-
126.19 245.89 
0.686 18.04 
(-
69.28,105.36) 
0.942 3.15 
(-82.34,88.64) 
FEV % 
60 -3.65 9.89 63 -3.71 9.47 
0.956 0.10  
(-3.26,3.45) 
0.992 0.02  
(-3.32,3.35) 
TLC abs 
45 
-
410.00 1328.39 44 
-
201.36 582.69 
0.127 307.98 
(-
87.42,703.38) 
0.943 11.29 
(-
298.59,321.16) 
TLC % 
45 -5.70 19.54 44 -3.58 9.87 
0.212 3.74  
(-2.14,9.62) 
0.972 -0.08  
(-4.73,4.57) 
DLCO abs 
50 -0.22 0.81 45 -0.30 0.68 
0.429 -0.12  
(-0.41,0.17) 
0.480 -0.11  
(-0.40,0.19) 
DLCO % 
50 -3.88 10.75 45 -3.67 8.10 
0.812 -0.44  
(-4.02,3.15) 
0.459 -1.34  
(-4.88,2.21) 
SGRQ 
symptoms 53 0.76 15.83 53 -4.82 16.37 
0.067 -5.73  
(-11.86,0.40) 
0.009 -6.88  
(-12.06,-1.70) 
SGRQ activity 
55 3.09 13.27 52 0.43 15.10 
0.339 -2.64  
(-8.05,2.77) 
0.484 -1.82  
(-6.91,3.27) 
SGRQ impact 
54 0.99 13.88 50 2.50 18.68 
0.643 1.50  
(-4.83,7.83) 
0.690 1.24  
(-4.86,7.34) 
SGRQ total 
52 1.78 11.59 49 0.71 13.96 
0.658 -1.13  
(-6.16,3.89) 
0.599 -1.30  
(-6.13,3.54) 
6MW distance 
31 -19.48 86.49 20 -18.70 75.39 
0.983 0.50  
(-45.98,46.97) 
0.835 -5.16  
(-53.55,43.24) 
EQ5D 
73 -0.18 0.31 71 -0.17 0.35 
0.801 0.01  
(-0.09,0.12) 
0.920 0.01 
(-0.10,0.11) 
MRC score 
56 0.21 0.82 54 0.07 0.72 
0.319 -0.15  
(-0.43,0.14) 
0.533 -0.09  
(-0.37,0.19) 
Hospital days 59 0.81 1.92 54 3.06 12.48 0.329 0.64 
(0.26,1.56) 
0.329 0.64 
(0.26,1.56) 
Any death  19/86 22.1  18/95 19.0 0.580 0.81 
(0.39,1.68) 
  
IPF death  4/82 4.9  3/80 3.8 0.703 0.74 
(0.16,3.44) 
  
Medicine 
increase 
 22/65 33.9  12/57 21.1 0.122 0.48 
(0.19,1.21) 
  
Medicine 
decrease 
 5/57 8.8  7/54 13.0 0.541 1.47 
(0.43,5.04) 
  
Oxygen 
increase 
 11/61 18.0  2/55 3.6 0.027 0.15 
(0.03,0.80) 
  
Oxygen 
decrease 
 0 / 56 0.0  0 /54 0.0 - -   
6 minute walk 
desaturation 
 31 / 35 88.6  16 / 20 80.0 0.396 0.52 
(0.11,2.36) 
0.634 0.64 
(0.10,4.07) 
Table 4.5  Change-from-baseline results of primary and secondary outcomes, ITT 
complete case analysis#. # The change from baseline (outcome – baseline) is presented 
with a negative value indicating a decrease from baseline and a positive value indicating 
an increase.  The unadjusted and unadjusted results refer to the effect of group 2 over 
group 1, i.e. a positive value indicates that group 2 is higher than group 1 and a negative 
value indicates that group 2 is lower than group 1. * median (iqr) and IRR rather than 
mean difference 
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For the number of hospita l n ights a negative binomial regression model 
was used as opposed to a Poisson regression model due to overdispersion 
in the data. There was no signif icant difference in the number of hospital 
n ights. There was no change in the risk of death one year after start ing the 
drug (OR 0.84, 0.39-1.68,p=0.580) or in the t ime unti l death with a  hazard 
ratio of 0.63 (95% CI 0.31-1.29, p=0.207). The Kaplan-Meier plot is  
presented in Figure 4.2.  
 
  
 
Figure 4.2 Kaplan-Meier p lot of t ime until death based on intention to treat 
populat ion.   
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Change over t ime analys is  
The results of the change over t ime analys is are given in Table 4.6. The 
change over t ime in the primary outcome is given in Figure 4.3, in SGRQ 
symptoms score, EQ5D and number of hospita l n ights is given in Figures 
4.4-4.6. 
  Unadjusted   Adjusted  
Outcome Overall mean  Treatment x 
time point 
interaction 
Overall mean  Treatment x 
time point 
interaction 
 95% CI p-value p-value 95% CI p-value p-value 
FVC abs 25.60 
(-
51.04,102.23) 
0.513 0.587 20.80 
(-55.42,97.02) 
0.593 0.595 
FVC % 1.37  
(-0.92,3.67) 
0.241 0.403 1.33  
(-0.96,.62) 
0.255 0.405 
FEV abs 21.49 
(-42.73,85.71) 
0.512 0.631 16.93 
(-46.13,79.99) 
0.599 0.631 
FEV % 0.11  
(-2.30,2.52) 
0.931 0.468 0.12  
(-2.27,2.50) 
0.922 0.478 
TLC abs 186.86  
(-
152.32,526.03) 
0.280 0.311 -5.72 
(-
258.52,247.09) 
0.956 0.403 
TLC % 2.36 
(-2.66,7.38) 
0.357 0.485 0.59 
(-3.34,4.52) 
0.769 0.640 
DLCO abs 0.20 
(-0.06,0.45) 
0.127 0.052 0.21  
(-0.04,0.47) 
0.106 0.054 
DLCO % 1.93 
(-1.13,4.98) 
0.217 0.273 1.46  
(-1.56,4.48) 
0.344 0.251 
SGRQ 
symptoms 
-2.68 (-
8.27,2.91) 
0.348 0.302 -4.02 (-
8.86,0.82) 
0.103 0.274 
SGRQ 
activity 
-1.89 (-
6.56,2.77) 
0.427 0.989 -1.64 (-
6.06,2.78) 
0.467 0.920 
SGRQ 
impact 
1.35 (-
4.14,6.84) 
0.630 0.661 0.52 (-
4.79,5.83) 
0.847 0.637 
SGRQ total -0.29 (-
4.65,4.07) 
0.895 0.976 -0.68 (-
4.91,3.54) 
0.752 0.994 
6MW 
distance 
-0.43 (-
43.26,42.4) 
0.984 0.723 -1.96 (-
45.31,41.40) 
0.930 0.703 
EQ5D 0.04  
(-0.05,0.13) 
0.363 0.647 0.04 
(-0.05,0.12) 
0.420 0.645 
MRC score 0.03 (-
0.17,0.22) 
0.803 0.323 0.03 (-
0.16,0.22) 
0.758 0.355 
Table 4.6 Results of change-over-time analysis 
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Group 1 – Placebo, Group 2 - Co-trimoxazole  
 
Figure 4.3 Change over the period of 12 months (visit 1 to visit 5) in FVC (absolute) 
since baseline visit 
 
 
 
 
Group 1 – Placebo, Group 2 - Co-trimoxazole 
 
 
 
Figure 4.4 Change over the period of 12 months (visit 1 to visit 5) in SGRQ 
symptoms since baseline visit 
FVC absolute 
FVC absolute versus visit number 
Visit 
 1  2 
1 5 
-27.0276 
2.82481 
Symptoms score 
Symptoms score versus visit 
Visit 
 1  2 
1 5 
-9.33298 
5.12207 
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Group 1 – Placebo, Group 2 - Co-trimoxazole 
 
 
 
Figure 4.5 Change over the period of 12 months (visit 1 to visit 5) in EQ5D score 
since baseline visit 
 
 
 
 
 
Group 1 – Placebo, Group 2 - Co-trimoxazole 
 
Figure 4.6 Cumulative number of nights in hospital over the period of 12 months 
(visit 1 to visit 5) 
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Subgroup analysis  
No ev idence of a subgroup effect for disease severity was observed on 
FVC (adjusted p=0.809) or deaths (p=0.816). Similar ly, no ev idence of a 
subgroup effect for medication was observed on FVC (adjusted p=0.816) or 
deaths (p=0.059) the OR for those not on medication was 3.50 (95% CI: 
0.62-19.96) compared to 0.54 (95% CI: 0.23 –  1.31) for those on 
medication.   
 
ITT imputed results  
Due to convergence problems with ICE it was decided to switch to mult ip le  
imputations assuming a mult ivariate normal distr ibut ion. The Markov chain 
Monte Carlo algor ithm was ran for 1,000 burn -in i terat ions subsequently 
imputing the data every 500 iterations to construct 5 imputed datasets. 
The results of the imputation sensit iv ity analys is revealed that the results 
were robust to missing data with the results not changing signif icantly 
(Table 4.7).  
 
 Unadjusted Adjusted for baseline 
Outcome p-value 95 CI% p-value 95% CI 
FVC abs 0.998 -0.19 
(-141.18,140.80) 
0.931 -5.99 
(-146.78,134.79) 
FVC % 0.807 -0.22 
(-2.00,1.56) 
0.745 -0.30 
(-2.08,1.48) 
FEV abs 0.808 -5.64 
(-51.29,40.00) 
0.586 -12.44 (-57.15,32.27) 
FEV % 0.629 -0.44 
(-2.24,1.35) 
0.582 -0.50 
(-2.29,1.29) 
EQ5D 0.557 0.02 
(-0.04,0.08) 
0.976 0.00 
(-0.05,0.05) 
Hospital days 0.295 0.47 
(0.66,3.82) 
0.098 0.69 
(0.88,4.53) 
Table 4.7 Change-from-baseline results of primary and secondary outcomes, ITT imputed 
analysis 
 
Per-protocol analys is  
The per-protocol sample consisted of 118 indiv iduals, 65 in placebo group 
and 53 in co-trimoxazole group. The results were in keeping with the ITT 
analys is with the exception of deaths. Co-trimoxazole resulted in a 
s ignif icant improvement in the symptom domain of SGRQ (mean difference 
-5.30 (-11.99, 1.40) units) and QALYs gained (mean difference 0.12 
(0.01,0.22) QALYs), and a reduction in the percentage of  patients 
requir ing an increase in oxygen therapy (OR=0.05 (0.00,0.61)) compared 
to placebo (Table 4.8).  
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 Placebo  Co-trimoxazole Unadjusted Adjusted for baseline 
Outcome N Mean Sd N Mean Sd p-
value 
95 CI% p-
value 
95% CI 
FVC abs 
51 -183.73 279.90 48 -175.21 359.30 
0.864 11.09  
(-115.47,137.64 
0.985 1.23 
(-125.9,128.37) 
FVC % 
51 -4.35 8.88 48 -4.80 10.88 
0.851 -0.37 
(-4.23,3.49) 
0.819 -0.45 
(-4.33,3.42) 
FEV abs 
51 -128.43 241.18 48 -124.79 273.11 
0.820 11.73 
(-89.48,112.94) 
0.987 0.81  
(-99.12,100.75) 
FEV % 
51 -3.19 10.06 48 -3.84 10.32 
0.866 -0.34 
(-4.32,3.64) 
0.822 -0.45 
(-4.41,3.50) 
TLC abs 
42 -427.14 1371.9 34 -167.35 635.41 
0.104 381.28 
(-78.36,840.92) 
0.811 44.10 
(-
317.16,405.37) 
TLC % 
42 -5.92 20.19 34 -3.11 10.49 
0.169 4.77 (-
2.03,11.57) 
0.881 0.41 
(-4.98,5.80) 
DLCO 
abs 43 -0.21 0.84 33 -0.39 0.70 
0.222 -0.22 
(-0.56,0.13) 
0.247 -0.20 
(-0.55,0.14) 
DLCO % 
43 -4.03 11.11 33 -4.66 7.91 
0.456 -1.63 
(-5.91,2.65) 
0.368 -1.94 
(-6.18,2.29) 
SGRQ 
symptoms 47 0.36 16.44 49 -4.63 16.75 
0.121 -5.30 
(-11.99,1.40) 
0.046 -5.73 
(-11.38,-0.10) 
SGRQ 
activity 49 2.99 13.97 48 1.56 14.91 
0.879 -0.52 
(-7.25,6.21) 
0.660 -1.23 
(-6.73,4.27) 
SGRQ 
impact 48 0.49 14.05 47 1.26 17.97 
0.811 -0.92 
(-8.48,6.64) 
0.839 0.66 
(-5.68,6.99) 
SGRQ 
total 46 1.40 11.93 46 0.36 14.07 
0.694 -1.08 
(-6.49,4.32) 
0.602 -1.38 
(-6.59,3.82) 
6MW 
distance 29 -13.34 85.10 19 -20.74 76.89 
0.768 -7.21 (-
55.15,40.72) 
0.546 -15.31 
(-64.97,34.36) 
EQ5D 
64 -0.16 0.30 53 -0.05 0.28 
0.025 0.12  
(0.01,0.22) 
0.024 0.11 
(0.01,0.21) 
MRC 
score 51 0.16 0.83 50 0.08 0.72 
0.643 -0.07 
(-0.38,0.23) 
0.841 -0.03  
(-0.33,0.27) 
Hospital 
days
*
 54 
0.89 
1.99 50 3.28 12.95 
0.181 0.53  
(0.21,1.34) 
0.182 0.53  
(0.21,1.35) 
Any death  14/65 21.5  3/53 5.7 0.018 0.20  
(0.05,0.76) 
  
IPF death  4 / 65 6.2  3 / 53 3.8 0.551 0.59  
(0.10,3.37) 
  
Medicine 
increase 
 18/58 31.0  9 /51 17.7 0.08 0.39 
(0.14,1.12) 
  
Medicine 
decrease 
 4 / 51 7.8  6 /50 12.0 0.610 1.42 
(0.37,5.56) 
  
Oxygen 
increase 
 10 / 55 18.2  1 / 50 2.0 0.019 0.05 
(0.00,0.61) 
  
Oxygen 
decrease 
 0 /51   0 /50  - - - - 
6 minute 
walk 
desaturati
on 
 27 / 31 87.1  15 / 19 79.0 0.446 0.55 (0.12,2.54) 0.644 0.64 
(0.10,4.15) 
Table 4.8 Results of per-protocol analysis  
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Also there was a signif icant (p=0.02) reduction in deaths with co -
tr imoxazole treatment (3/53) compared to placebo (14/65) with a hazard 
ratio of 0.21 (0.06,0.78) (P=0.02). A Kaplan -Meier p lot of the t ime unti l  
death is given in F igure 4.7.  
 
 
Figure 4.7 Kaplan-Meier estimate of survival function for the per-protocol population.  
 
In the placebo group 13% (2/15) of those who withdrew died within 1 
month of withdrawing, in the intervention group 6% (2/36) of those who 
withdrew d ied with in 1 month.   
 
Sensit iv ity analyses  
The f indings were the same as in the full analys is. Fo r patients with  
honeycombing, UIP or l ikely to have UIP on biopsy using Fell’s  algorithm 
there was a signif icant (p=0.024) reduction in deaths with co -tr imoxazole  
(2/46) compared to placebo (12/62) with a hazard ratio of 0.17 
(0.04,0.79)). The results of analys is using radiological rev iew data 
remained signif icant too (p=0.032) with a reduction in deaths with co -
tr imoxazole (2/42) compared to placebo (11/58) with a hazard ratio of 0.18 
(0.04,0.86) (Table 4.9).  
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 Placebo Co-trimoxazole Unadjusted Adjusted for baseline 
Outcome N Mean Sd N Mean Sd p-
value 
95 CI% p-
value 
95% CI 
FVC 
(millilitres) 
[primary 
analysis] 
51 -
183.73 
279.90 48 -
175.21 
359.30 0.864 11.09 (-
115.47,137.64) 
0.985 1.23 (-
125.92,128.37) 
FVC 
(millilitres) 
[Fell 
criteria] 
50 -
184.80 
282.64 42 -
185.24 
365.68 0.992 -0.65 (-
132.18,130.87) 
0.865 -11.47 (-
144.15,121.21) 
FVC 
(millilitres) 
[radiology 
review] 
47 -
173.19  
279.65 38 -
218.16 
351.31 0.552 -39.69 (-
170.48,91.09) 
0.329 -65.72 (-
197.62,66.17) 
Deaths 
[primary 
analysis] 
 14/65 21.54  3/53 5.66 0.02 0.21 
(0.06,0.78) 
  
Deaths 
[Fell 
criteria] 
 12/62 19.35  2/46 4.35 0.024 0.17 
(0.04,0.79) 
  
Deaths 
[radiology 
review] 
 11/58 18.97  2/42 4.76 0.032 0.18 
(0.04,0.86) 
  
Table 4.9 Sensitivity analysis of FVC (change from baseline) between the original sample 
and the subsamples in the PP analysis.  
 
Subgroup analysis  
Patients receiv ing immunosuppressive treatment at entry into the study 
were more likely to d ie if  they were in the control group in both the ITT 
( immunosuppression 17/53 no immunosuppression 2/33) and PP 
( immunosuppression 12/35 no immunosuppression 2/30) analyses.  
However baseline immunosuppressive therapy did not have an effect on 
mortal ity over 12 months in the intervention group: ITT 
( immunosuppression 11/54 no immunosuppression 7/40) and PP 
( immunosuppression 3/28 no immunosuppression 0/25).  
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Comparison of baseline characterist ics of intent ion to treat and per 
protocol populat ion 
 
Comparing the baseline data for those who have valid FVC measurements 
at v is it  5 with those who do not (Table 4.10) reveals s ignif icant d iffe rences 
in terms of FEV1, FVC and DLCO.  
 
Outcome Valid visit 5 results No valid visit 5 results 95% CI p-value 
 Mean Sd Mean Sd   
FEV1 
absolute 
2.00 0.65 1.68 0.49 0.32 
(0.13,0.51) 
0.0010 
FEV1 percent 75.38 20.62 68.44 18.51 6.94 
(0.66,13.22) 
0.0304 
FVC absolute 2.47 0.84 2.09 0.67 0.38 
(0.13,0.62) 
0.0032 
FVC percent 72.92 21.20 66.07 20.71 6.85 
(0.24,13.47) 
0.0424 
TLC absolute 4.08 1.49 3.76 1.10 0.32  
(-0.18,0.82) 
0.2025 
TLC percent 65.30  20.85 60.96 15.21 4.34 (-
2.59,11.27) 
0.2180 
DLCO 
absolute 
3.52 1.78 2.79 1.54 0.73 
(0.10,1.36) 
0.0225 
DLCO 
percent 
39.00 11.33 33.54 11.29 5.46 
(1.33,9.60) 
0.0100 
Table 4.10 Differences in baseline lung measurements between those with valid visit 5 
data and those without 
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Change in FVC and DLCO over 12 months  
22 (40%) patients in placebo arm had equal to or greater than 10% annual 
decline in absolute FVC; 29 (54%) patients demonstrated an annual 
change in FVC with in 10% decline and 10% improvement (Table 4.11).  
a) b) 
  
  
Figure 4.8 Change in Forced Vital capacity over 12 months in per protocol population in a) 
placebo arm and b) co-trimoxazole arm. Each symbol represents a different subject 
a) b) 
 
 
 
Figure 4.9 Change in Diffusion Capacity of carbon monoxide over 12 months in per 
protocol population in a) placebo arm and b) co-trimoxazole arm. Each symbol represents 
a different subject 
 
Baseline 
12 months 
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% change in absolute FVC  Placebo and co-trimoxazole 
arms 
(n=112) 
n (%) 
Placebo arm 
 
(n=54) 
n (%) 
≥ 10% decline 45 (40) 22 (40) 
10% decline/10% increase 58 (52) 29 (54) 
≥10 % increase 9 (8) 3 (6) 
Table 4.11 12 months change in FVC in TIPAC study patients 
 
4.3.2.3 Safety analysis 
Adverse events 
The safety results are based on every indiv idual who took at least one 
dose of the study drug. One patient receiv ing co -trimoxazole and 
azathoprine, developed severe transient neutropenia which required 
hospita l isation. Fo llowing th is event, al l  pat ients receiv ing azathioprine or 
mycophenolate mofeti l had 2 weekly monitor ing of their fu l l b lood count 
and two other patients (both receiv ing azathioprine and co-trimoxazole)  
were withdrawn because of neutropenia. There was a signif icant reduction 
in number of patients with one or more infection (41.3% versus 68.9%) 
with co-tr imoxazole t reatment compared to placebo (Table 4.12). Whereas 
no patient receiv ing co-trimoxazole developed cl in ic ian diagnosed 
pneumonia, e ight patients (9.3%) in the placebo group had one or more 
episodes of pneumonia. There were also signif icant differences between 
placebo and active treatment in terms of lower (38 (44.2%) versus 27 
(29.4%) patients) and upper (14 (16.3%) versus 6 (6.5%) patients)  
respiratory t ract infections (Tab le 4.13). An increase in the reporting of  
nausea (18.5% versus 7.0%) was seen in the co -tr imoxazole group (Table  
4.15). In the placebo group 12.5% (7/56) had an increase in creatin ine 
from their baseline by 10 mmol/ l,  compared to 59.3% (32/54) in the 
treatment group.  
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  Placebo Co-
trimoxazole 
Total Placebo Co-
trimoxazole   
Group Number 
of events 
Number of 
events 
  Number of 
individuals 
with 1 or 
more  
Number of 
individuals 
with 1 or 
more  
p-value 
Blood disorder 5 7 12 3 (3.5) 6 (6.5) 0.356 
Cardiac disorder 10 3 13 9 (10.5) 3 (3.3) 0.055 
Dental condition 1 2 3 1 (1.2) 2 (2.2) 1 
Ear disorder 1 0 1 1 (1.2) 0 (0.0) 0.483 
Eye disorder 3 7 10 3 (3.5) 5 (5.4) 0.722 
General 
disorders 16 22 38 14 (16.3) 17 (18.5) 0.699 
Gastrointestinal  37 78 115 21 (24.4) 41 (44.6) 0.005 
Immune system 
disorders 2 0 2 1 (1.2) 0 (0.0) 0.483 
Infection 125 68 193 59 (68.6) 38 (41.3) <0.001 
Injury 0 4 4 0 (0.0) 3 (3.3) 0.247 
Investigations 7 12 19 7 (8.1) 11 (12.0) 0.399 
Metabolic 
disorder 11 15 26 8 (9.3) 13 (14.1) 0.318 
Muscle and 
tissue disorder 15 13 28 11 (12.8) 12 (13.0) 0.96 
Neoplasia 4 1 5 4 (4.7) 1 (1.1) 0.199 
Nervous system 16 17 33 11 (12.8) 11 (12.0) 0.866 
None 21 24 45 21 (24.4) 16 (17.4) 0.248 
Phsychiatric 4 5 9 4 (4.7) 5 (5.4) 1 
Renal and 
urinary disorder 3 3 6 3 (3.5) 3 (3.3) 1 
Respiratory 55 48 103 39 (45.4) 35 (38.0) 0.323 
Reproductive 
and breast 2 0 2 2 (2.3) 0 (0.0) 0.232 
Skin disorder 5 16 21 4 (4.7) 14 (15.2) 0.019 
Surgical and 
medical 6 1 7 5 (5.8) 1 (1.1) 0.318 
Vascular 
disorders 7 9 16 7 (8.1) 9 (9.8) 0.702 
Table 4.12 Tabulation of adverse event by category. There was a significant reduction in number of 
patients with one or more infection, pneumonia, lower and upper respiratory tract infections in the 
co-trimoxazole group. There was an increase in the reporting of nausea and an increase in 
creatinine from their baseline by 10 mmol/l in the co-trimoxazole group.  
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  Placebo Co-
trimoxazole 
Total Placebo Co-
trimoxazole   
Group Number 
of events 
Number of 
events 
  Number of 
individuals 
with 1 or 
more  
Number of 
individuals 
with 1 or 
more  
p-value 
Candida infection 1 0 1 1 (1.2) 0 (0.0) 0.483 
Cellulitis 1 2 3 1 (1.2) 2 (2.2) 1 
Fungal infection 1 3 4 1 (1.2) 3 (3.3) 0.622 
Gastritis 0 1 1 0 (0.0) 1 (1.1) 1 
Gastroenteritis 3 3 6 3 (3.5) 3 (3.3) 1 
Infectious 
enteritis 
0 1 1 0 (0.0) 1 (1.1) 1 
Infectious gastritis 2 1 3 1 (1.2) 1 (1.1) 1 
Respiratory  
Upper respiratory 
tract infection 
17 6 23 14 (16.3) 6 (6.5) 0.039 
Low respiratory 
tract infection 
76 45 121 38 (44.2) 27 (29.4) 0.04 
Pneumonia 8 0 8 8 (9.3) 0 (0.0) 0.002 
Oral candidiasis 1 0 1 1 (1.2) 0 (0.0) 0.483 
Rhinitis 0 1 1 0 (0.0) 1 (1.1) 1 
Sepsis 1 0 1 1 (1.2) 0 (0.0) 0.483 
Sinusitis 1 0 1 1 (1.2) 0 (0.0) 0.483 
Skin varicella 
zoster 
2 1 3 2 (2.3) 1 (1.1) 0.61 
Urinary tract 
infection 
7 4 11 7 (8.1) 4 (4.4) 0.294 
Verruca 1 0 1 1 (1.2) 0 (0.0) 0.483 
Vulvovaginal 
candidia 
3 0 3 2 (2.3) 0 (0.0) 0.232 
Table 4.13 Preferred term for all infections 
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  Placebo Co-
trimoxazole 
Total Placebo Co-
trimoxazole   
Group Number 
of 
events 
Number of 
events 
  Number of 
individuals 
with 1 or 
more  
Number of 
individuals 
with 1 or 
more  
p-value 
Aspiration 
pneumonia 
1 0 1 1 (1.2) 0 (0.0) 0.483 
Bronchospasm 0 1 1 0 (0.0) 1 (1.1)  1 
Copd 0 3 3 0 (0.0) 1 (1.1) 1 
Cough 14 14 28 13 (15.1) 13 (14.1) 0.852 
Dyspnoea 14 17 31 12 (14.0) 15 (16.3) 0.662 
Epistaxis 2 2 4 2 (2.3) 2 (2.2) 1 
Increased 
expectoration 
1 0 1 1 (1.2) 0 (0.0) 0.483 
IPF 2 0 2 2 (2.3) 0 (0.0) 0.232 
IPF exacerbation 
3 2 4 2 (2.3) 2 (2.2) 1 
IPF progression 
5 2 7 5 (5.8) 2 (2.2) 0.265 
Nasal congestion 
1 0 1 1 (1.2) 0 (0.0) 0.483 
Pleural effusion 1 0 1 1 (1.2) 0 (0.0) 0.483 
Respiratory failure 
7 5 12 7 (8.1) 4 (4.4) 0.359 
Respiratory failure 
on exercise 
4 2 6 4 (4.7) 2 (2.2) 0.431 
Table 4.14 Preferred terms for respiratory adverse events 
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  Placebo Co-
trimoxazole 
Total Placebo Co-
trimoxazole   
Group Number 
of 
events 
Number of 
events 
  Number of 
individuals 
with 1 or more  
Number of 
individuals 
with 1 or more  
p-value 
Abdominal 
discomfort 
3 3 6 3 (3.5) 3 (3.3) 1 
Abdominal pain 1 8 9 1 (1.2) 5 (5.4) 0.212 
Anorectal 
disorder 
1 0 1 1 (1.2) 0 (0.0) 0.483 
Bloating 0 1 1 0 (0.0) 1 (1.1) 1 
Constipation 5 7 12 5 (5.8) 7 (7.6) 0.633 
Diarrhoea 6 12 18 4 (4.7) 10 (10.9) 0.124 
Dry mouth 0 2 2 0 (0.0) 2 (2.2) 0.498 
Dyspepsia 5 2 7 4 (4.7) 2 (2.2) 0.431 
Epigastric 
discomfort 
1 0 1 1 (1.2)  0 (0.0 0.483 
Flatulence 0 2 2 0 (0.0) 2 (2.2) 0.498 
Gastrointestinal  
upset 
2 1 3 2 (2.3) 1 (1.1) 0.61 
Glossitis 0 4 4 0 (0.0) 4 (4.4) 0.122 
Mouth ulceration 1 0 1 1 (1.2) 0 (0.0) 0.483 
Nausea 6 21 27 6 (7.0) 17 (18.5) 0.022 
Soft bowel 
motions 
1 0 1 1 (1.2) 0 (0.0) 0.483 
Stomatitis 2 2 4 2 (2.3) 2 (2.2) 1 
Strangulated 
inguinal 
0 1 1 0 (0.0) 1 (1.1) 1 
Tongue coating 0 1 1 0 (0.0) 1 (1.1) 1 
Tongue 
discoloration 
0 2 2 0 (0.0) 2 (2.2) 0.498 
Vomiting 3 9 12 2 (2.3) 6 (6.5) 0.28 
Table 4.15 Preferred term for all gastrointestinal adverse events 
 
Serious adverse events  
There was a total number of 93 serious adverse events (SAE) defined as 
deaths, events requiring hospital isat ion, l ife - threatening or medically 
s ignif icant; 61% (57) were respiratory in orig in with gastrointestinal and 
general medical (6.5% each) as well as cardiac (5.4%) being next most 
frequent organ localisat ion (Tab le 4.16).  
137 
 
                           Total           93      100.00
                                                                     
                       infection            1        1.08      100.00
                      Urological            1        1.08       98.92
Respiratory AND GASTROINTESTINAL            1        1.08       97.85
                     Respiratory           57       61.29       96.77
                     Orthopaedic            3        3.23       35.48
                   Ophthalmology            1        1.08       32.26
                       Neurology            1        1.08       31.18
                       Neoplasia            2        2.15       30.11
     Infection of unknown source            1        1.08       27.96
                     Haematology            3        3.23       26.88
                 General medical            6        6.45       23.66
                Gastrointestinal            6        6.45       17.20
                             ENT            2        2.15       10.75
     Dermatology and Respiratory            1        1.08        8.60
                     Dermatology            1        1.08        7.53
         Cardiac and Respiratory            1        1.08        6.45
                         Cardiac            5        5.38        5.38
                                                                     
     Organ System Classification        Freq.     Percent        Cum.
 
Table 4.16 SAE including deaths by organ (Intention to treat analysis) 
 
 
Two analyses of SAE were performed –  analys is of a l l SAE and analysis of  
those due to a respiratory cause for both intent ion to treat and per protocol 
populat ion. 
 
Intention to treat population  
 
All SAE  
The number of indiv iduals with al l SAE including death is given in Table 
4.17. After adjusting for medication status at baseline (a strati fy ing factor) 
the odds ratio was 0.64 (0.34,0.1.18) in favour of the intervention group. 
There was a total of 51 SAE events in the control group, an average of 
0.59 events per indiv idual compared with 42 in the intervention group an 
average of 0.44 event per indiv idual.  From a Poisson regression model this  
was not s ignif icant (p=0.145).  
 Intention to treat analysis  
 Placebo Co-trimoxazole Total 
Patients without  SAE, n 52 70 122 
Patients with any SAE, n 34 25 59 
Total  86 95 181 
Table 4.17 All SAE including death by group (Intention to treat analysis) 
 
Respiratory SAE 
The number of indiv iduals with any respiratory SAE includ ing death is 
given in Table 4.18. After adjusting for medication status at baseline (a 
stratify ing factor) the odds ra tio  was 0.49 (0.24,1.04) in favour of the 
intervention group. There was a total of 32 SAE events in the control 
group, an average of 0.37 events per ind iv idual compared with 25 in the 
intervention group an average of 0.26 event per indiv idual. From a Poiss on 
regression model th is was not s ignif icant (p=0.171).  
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 Intention to treat analysis  
 Placebo Co-trimoxazole Total 
Patients without  respiratory SAE, 
n 
63 80 143 
Patients with respiratory SAE, n 23 15 38 
Total  86 95 181 
Table 4.18 Any respiratory SAE including death by group (Intention to treat analysis) 
 
Per protocol population  
All SAE  
The number of indiv iduals with al l SAE including death is given in Table 
4.19. After adjusting for medication status at baseline (a strati fy ing factor) 
the odds ratio was 0.29 (0.12,0.71) in favour of the intervention group. 
There was a total of 41 SAE events in the control group, an average of 
0.63 events per indiv idual compared with 19 in the intervention group an 
average of 0.36 event per indiv idual.  From a Poisson  regression model this  
was signif icant (p=0.035).  
 Per protocol analysis  
 Placebo Co-trimoxazole Total 
Patients without  SAE, n 39 44 83 
Patients with any SAE, n 26 9 35 
Total  65 53 118 
Table 4.19 Any SAE including death by group (per protocol analysis) 
 
Respiratory SAE 
The number of indiv iduals with any respiratory SAE or death is given in 
Table 4.20. After adjusting for medication status at baseline (a strat ify ing  
factor) the odds ratio was 0.25 (0.09,0.75) in favour of the intervention 
group. There was a total of 26 SAE events in the control group, an average 
of 0.40 events per indiv idual compared with 9 in the intervention group an 
average of 0.17 event per indiv idual.  From a Poisson regression model this  
was signif icant (p=0.021).  
 Per protocol analysis  
 Placebo Co-trimoxazole Total 
Patients without  respiratory SAE, 
n 
47 48 95 
Patients with respiratory SAE, n 18 5 23 
Total  65 53 118 
Table 4.20 Any respiratory SAE or death by group (per protocol analysis) 
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Cause of death  
Cause of death o f patients in per protocol population is shown in  table  
4.21. All 17 deaths were due to a respiratory cause with 7 (40%) result ing  
from gradual progression of IPF itself and 5 fol lowing pneumonia (al l in  
placebo arm), with 80% of non -IPF related deaths exh ibit ing signs of 
gradual rather than acute progression of underly ing IPF.  
 
 
 
Placebo 
(n=14) 
Co-trimoxazole 
(n=3) 
Mean age, years 72.8 74 
Respiratory related# 14 (100%) 3 (100%) 
IPF related 
Non-IPF related 
Pneumonia 
LRTI 
Aspiration pneumonia 
Cardiorespiratory failure* 
Multiorgan failure∞  
Metastatic lung cancer 
5 (36%) 
9 (64%) 
5 (36%) 
1 (7%) 
1 (7%) 
1 (7%) 
1 (7%) 
0 
2 (67%) 
1 (33%) 
0 
0 
0 
0 
0 
1 (33%) 
 
# Death was defined as respiratory related if resulted from respiratory failure, acute exacerbation or 
progression of IPF, pneumonia or respiratory tract infection,   pulmonary embolism, lung cancer, 
pneumothorax or pulmonary embolism  
*Due to IPF and ischaemic heart disease. ∞ Due to IPF, LRTI and perforated Meckel's 
diverticulum  
Table 4.21 Cause of death in per protocol populat ion  
 
 
4.3.2.4 Cost-effectiveness and cost-utility analysis  
The results of resource use quant it ies and summary costs by sector are 
displayed in Tab le 4.23 and Table 4.24 respectively. The results of cost 
effectiveness and cost uti l ity analyses are in Table 4.26 and Table 4.27 
respectively.  
In al l analyses, 95% confidence intervals did not exclude zero. Point 
estimate results, adjusted for baseline and with missing data imputed 
showed a higher cost and worse change in FVC for the treatment group 
compared with p lacebo.  However, overall  health gain was higher in the 
treatment group: the incremental cost per QALY gained was estimated at 
between £2,530 in favour of co-tr imoxazole and £16,636 in favour of 
placebo, depending on perspective and ITT/PP population: given a typ i cal 
threshold of £30,000 per QALY, co -tr imoxazole is cost-effective in the ITT 
analyses and PP analysis from the perspective of the NHS, the incremental 
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cost-effectiveness ratios  (ICER) is higher (is less cost effective) when 
societal costs are included ra ther than just NHS costs There is between 
46.9% and 89.8% probabil i ty that the ICER is below £30,000 (Figure 4. 10).  
 
Economic evaluation additional details 
 
NHS costs Social services 
costs 
Out of pocket 
expenditure 
Lost productivity 
Prescribed medications 
(including study 
medication) 
Primary care  
Secondary care 
Tertiary care & allied 
health professionals 
Social care Travel 
Other OOP 
Patient time off 
work  
Carer time off work 
Informal caring time 
 
 
Table 4.21 Cost categories and subcategories within each 
 
 
Cost item Unit cost Source 
Cost OP appt for PF £132.00 Ref Costs 2008-09,[193] Respiratory medicine consultant led FU 
attendance, non-admitted f2f.  Appendix NSRC4, worksheet 
TPCTCLFUSFF code 340 
Cost OP appt for other £126.00 PSSRU 2009,[194] P93, weighted average of all adult OP attendances 
(follow-up face-to-face attendance) 
Cost Daycase appt for 
PF 
£669.00 Ref Costs 2008-09,[193] daycase HRG data.  HRG DZ19B: Other 
respiratory diagnoses with CC.  Appendix NSRC4, worksheet TPCTDC 
code DZ19B 
Cost Daycase appt for 
other 
£638.00 PSSRU 2009,[194] P93, weighted average of all stays 
Cost IP admission for 
PF 
£1,425.00 Ref Costs 2008-09,[193] elective IP data.  HRG DZ19B: Other respiratory 
diagnoses with CC.  Appendix NSRC4, worksheet TPCTEI code DZ19B 
Cost IP admission for 
Other 
£2,626.00 PSSRU 2009,[194]  P93, weighted average of all elective IP stays 
Cost per day, IP 
Admission 
£335.00 Ref Costs 2008-09,[193] elective IP excess bed day data.  HRG DZ19B: 
Other respiratory diagnoses with CC.  Appendix NSRC4, worksheet 
TPCTEIXS code DZ19B 
Cost of A&E 
attendance 
£93.00 PSSRU 2009,[194]  A&E services not leading to admitted.  P93. 
Hourly wage £11.03 ONS,[195] Annual Survey of Hours and Earnings (ASHE) 2009, Table 
1.5a: Hourly pay Gross.   
Cost GP surgery 
consultation 
£35.00 PSSRU 2009,[194]  P121, per surgery consultation 11.7mins with qual 
costs and direct care staff costs 
Cost GP home visit £117.00 PSSRU 2009,[194]  P121, per home visit 23.4mins in qualification and 
direct care staff costs 
Cost GP phone 
consultation 
£21.00 PSSRU 2009,[194]  P121, per telecon 7.1mins inc qualification and direct 
care staff costs 
Cost nurse surgery 
consultation 
£11.00 PSSRU 2009,[194]  P118, per consultation inc qualifications 
Cost nurse home visit £20.00 PSSRU 2009,[194]  P118, per home visit inc qualifications 
Cost nurse phone 
consultation 
£11.00 Assumed same as surgery consultation 
Cost health visitor 
surgery consultation 
£27.33 PSSRU 2009,[194]  P115, per hr clinic contact inc qualifications * 20/60 
(length of contact - assumed same as for home visit) 
Cost health visitor 
home visit 
£41.00 PSSRU 2009,[194]  P115, per home visit inc qualifications 
Cost health visitor 
phone consultation 
£27.33 Assumed same as surgery consultation 
Cost physio surgery £17.00 PSSRU 2009,[194]  P105, per clinic visit inc qualifications 
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consultation 
Cost physio home visit £48.00 PSSRU 2009,[194]  P105, per home visit inc qualifications 
Cost physio phone 
consultation 
£17.00 Assumed same as surgery consultation 
Cost OT surgery 
consultation 
£41.33 PSSRU 2009,[194]  P130, per hour client contact * 40mins (length of visit 
- assumed same for clinic visit) 
Cost OT home visit £43.00 PSSRU 2009,[194]  P130, per home visit inc qualifications 
Cost OT phone 
consultation 
£41.33 Assumed same as surgery consultation 
Cost Other AHP 
surgery consultation 
£17.00 Assumed same as physiotherapist 
Cost Other AHP  home 
visit 
£48.00 Assumed same as physiotherapist 
Cost Other AHP  
phone consultation 
£17.00 Assumed same as physiotherapist 
Cost carer home visit £18.00 PSSRU 2009,[194]  P129, per hour face to face weekday contact 
Cost social worker 
office visit 
£39.00 PSSRU 2009,[194]  P126, per hour of client related work. 
Cost social worker 
home visit 
£130.00 Assumed same proportionate increase as GP home/surgery visit (= £39 * 
117/35) 
Cost social worker 
phone call 
£23.40 Assumed same proportionate decrease as GP phone/surgery visit (= £39 
* 21/35) 
Cost cleaner home 
visit 
£18.00 Assumed same as carer home visit 
Cost car transport to 
hospital 
£2.40 assumed 6 miles x 40p per mile  
Cost car transport to 
GP surgery 
£1.20 assumes half distance to hospital 
Cost child care per 
hour 
£5.00 child or other dependent care cost per hour during hospital or GP visit 
 
Table 4.22 Cost and the source of the cost information for each unit of inpatient and 
outpatient medical activity as well as social worker and occupational therapist activity due 
to pulmonary fibrosis (PF) and non-pulmonary fibrosis (other) related issues  
 
 
 
Variable 
N 
(intervention, 
control) 
Intervention 
mean (SD) 
Control 
mean (SD) Increment 
Primary care     
GP Surgery visits due to PF (64, 72) 1.13 (1.65) 1.44 (2.23)  
due to other (64, 72) 2.16 (2.58) 2.44 (3.24)  
Total (64, 72) 3.28 (3.08) 3.89 (3.83) -0.608 
GP home visits due to PF (64, 72) 0.13 (0.55) 0.18 (0.66)  
due to other (64, 72) 0.23 (1.09) 0.1 (0.38)  
Total (64, 72) 0.36 (1.2) 0.28 (0.83) 0.082 
GP phone calls due to PF (64, 72) 0.19 (0.56) 0.24 (0.66)  
due to other (64, 72) 0.13 (0.63) 0.1 (0.34)  
Total (64, 72) 0.31 (0.89) 0.33 (0.87) -0.021 
Nurse surgery visits due to PF (64, 72) 0.14 (0.5) 0.24 (0.66)  
due to other (64, 72) 3.36 (4.77) 2.99 (3.71)  
Total (64, 72) 3.5 (4.71) 3.22 (3.7) 0.278 
Nurse home visits due to PF (64, 72) 0.83 (3.78) 0.08 (0.6)  
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due to other (64, 72) 0.86 (4.78) 0.43 (2.19)  
Total (64, 72) 1.69 (5.98) 0.51 (2.62) 1.174 
Nurse phone calls due to PF (64, 72) 0.02 (0.13) 0.04 (0.26)  
due to other (64, 72) 0.03 (0.25) 0.13 (0.95)  
Total (64, 72) 0.05 (0.28) 0.17 (1.09) -0.12 
     
Secondary care     
OP appts due to PF (64, 72) 2 (4.49) 1 (1.36)  
due to other (64, 72) 0.89 (1.45) 0.99 (1.63)  
Total (64, 72) 2.89 (4.91) 1.99 (2.13) 0.905 
Daycase appts due to PF (64, 72) 0.09 (0.34) 0.03 (0.17)  
due to other (64, 72) 0.11 (0.44) 0.17 (0.41)  
Total (64, 72) 0.2 (0.54) 0.19 (0.46) 0.009 
IP admissions due to PF (64, 72) 0.19 (0.75) 0.19 (0.46)  
due to other (64, 72) 0.08 (0.32) 0.1 (0.3)  
Total (64, 72) 0.27 (0.84) 0.29 (0.59) -0.026 
A&E attendances due to PF (64, 72) 0.13 (0.58) 0.14 (0.42)  
due to other (64, 72) 0.02 (0.13) 0.03 (0.17)  
Total (64, 72) 0.14 (0.61) 0.17 (0.47) -0.026 
     
Other health professional     
Health visitor office visits due 
to PF (64, 72) 0.05 (0.28) 0.01 (0.12)  
due to other (64, 72) 0.03 (0.18) 0 (0)  
Total (64, 72) 0.08 (0.37) 0.01 (0.12) 0.064 
Health visitor home visits due 
to PF (64, 72) 0.25 (1.39) 0.06 (0.23)  
due to other (64, 72) 0.02 (0.13) 0 (0)  
Total (64, 72) 0.27 (1.39) 0.06 (0.23) 0.21 
Health visitor phone calls due 
to PF (64, 72) 0.03 (0.25) 0.03 (0.24)  
due to other (64, 72) 0 (0) 0 (0)  
Total (64, 72) 0.03 (0.25) 0.03 (0.24) 0.003 
Physiotherapist office visits 
due to PF (64, 72) 0.06 (0.3) 0.13 (0.5)  
due to other (64, 72) 0.02 (0.13) 0.18 (1.42)  
Total (64, 72) 0.08 (0.32) 0.31 (1.49) -0.227 
Physiotherapist home visits 
due to PF (64, 72) 0.06 (0.39) 0.06 (0.37)  
due to other (64, 72) 0 (0) 0.04 (0.35)  
Total (64, 72) 0.06 (0.39) 0.1 (0.51) -0.035 
Physiotherapist phone calls 
due to PF (64, 72) 0.02 (0.13) 0 (0)  
due to other (64, 72) 0 (0) 0 (0)  
Total (64, 72) 0.02 (0.13) 0 (0) 0.016 
OT office visits due to PF (64, 72) 0.16 (1.01) 0 (0)  
due to other (64, 72) 0 (0) 0.03 (0.17)  
Total (64, 72) 0.16 (1.01) 0.03 (0.17) 0.128 
OT home visits due to PF (64, 72) 0.03 (0.18) 0.06 (0.37)  
due to other (64, 72) 0.16 (0.91) 0.28 (1.4)  
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Total (64, 72) 0.19 (0.92) 0.33 (1.43) -0.146 
OT phone calls due to PF (64, 72) 0 (0) 0 (0)  
due to other (64, 72) 0.02 (0.13) 0.01 (0.12)  
Total (64, 72) 0.02 (0.13) 0.01 (0.12) 0.002 
Other health prof. office visits 
due to PF (64, 72) 0.25 (0.87) 0.18 (0.81)  
due to other (64, 72) 0.2 (0.82) 0.19 (0.68)  
Total (64, 72) 0.45 (1.19) 0.38 (1.23) 0.078 
Other health prof. home visits 
due to PF (64, 72) 0.25 (0.99) 0.14 (0.45)  
due to other (64, 72) 0.02 (0.13) 0.01 (0.12)  
Total (64, 72) 0.27 (1) 0.15 (0.46) 0.113 
Other health prof. phone calls 
due to PF (64, 72) 0.11 (0.51) 0 (0)  
due to other (64, 72) 0 (0) 0.06 (0.47)  
Total (64, 72) 0.11 (0.51) 0.06 (0.47) 0.054 
Pulmonary rehabilitation 
sessions (64, 72) 0.92 (3.14) 0.47 (1.8) 0.45 
     
Social Services     
Social services office visit due 
to PF (64, 72) 0 (0) 0.03 (0.17)  
due to other (64, 72) 0 (0) 0 (0)  
Total (64, 72) 0 (0) 0.03 (0.17) -0.028 
Social services home visit due 
to PF (64, 72) 0.34 (2.51) 0 (0)  
due to other (64, 72) 0 (0) 0 (0)  
Total (64, 72) 0.34 (2.51) 0 (0) 0.344 
Social services phone call due 
to PF (64, 72) 0 (0) 0.03 (0.24)  
due to other (64, 72) 0 (0) 0.01 (0.12)  
Total (64, 72) 0 (0) 0.04 (0.26) -0.042 
Carer home visit due to PF (64, 72) 1.22 (7.23) 0 (0)  
due to other (64, 72) 0.52 (4) 0 (0)  
Total (64, 72) 1.73 (9.56) 0 (0) 1.734 
Cleaner home visit due to PF (64, 72) 0 (0) 0 (0)  
due to other (64, 72) 0.03 (0.25) 0.01 (0.12)  
Total (64, 72) 0.03 (0.25) 0.01 (0.12) 0.017 
 
Table 4.23 Resource use quantities 
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N 
(intervention, 
control) 
Intervention Control Increment SE 
Study drug 
(64, 72) 
186.58 
(68.83) 0 (0) 186.581 
 
Prescription 
medicines (excl. 
study drug) (63, 71) 
1469.59 
(1737.04) 
1642.99 
(1964.97) -173.402 
 
Primary care 
(64, 72) 
236.22 
(256.2) 
223.17 
(183.73) 13.052 
 
Secondary care 
(64, 72) 
1004.31 
(1793.56) 
961.51 
(1195.68) 42.799 
 
Other health 
professionals (64, 72) 
71.62 
(155.55) 52.01 (96.85) 19.61 
 
Social services 
(64, 72) 
285.47 
(1002.14) 
85.07 
(415.58) 200.397 
 
Patient Out of 
Pocket Costs (57, 68) 
274.86 
(826.66) 
226.22 
(711.77) 48.64 
 
Indirect Costs 
(54, 62) 
12531.47 
(19061.81) 
10472.06 
(18008.26) 2059.41 
 
NHS 
(63, 71) 
2988.3 
(2760.56) 
2896.3 
(2495.15) 92  454 
Societal (NHS + 
social services + 
patient OOP + 
indirect) (51, 57) 
14321.36 
(17462.04) 
14724.29 
(20183.74) -403 3652 
 
Table 4.24 Summary costs by sector 
Results are mean (SD) 
  
       Unadjusted Imputed, adjusted for baseline  
FVC 
 N  Cost   dFVC  Inc £ Inc 
dFVC 
ICER Inc £ Inc 
dFVC 
ICER 
Analysis Co-
Trim 
Placebo Co-Trim Placebo Co-
Trim 
Placebo (95%CI) (95%CI)  (95%CI) (95%CI)  
ITT 
NHS 
51 55 £3,400 £3,121 -
0.170 
-0.199 £279 
(-£763, 
£1328) 
0.029 
(-0.091, 
0.150) 
£9,634 £295 
(-£483, 
£1067) 
0.001 
(-0.095, 
0.094) 
£239,047 
ITT 
Societal 
41 45 £16,321 £15,872 -
0.207 
-0.199 £449 
(-£8094, 
£8928) 
-0.008 
(-0.147, 
0.127) 
[Placebo 
dominant] 
£1,145 
(-
£4854, 
£6849) 
0.001 
(-0.094, 
0.099) 
£928,564 
PP NHS 48 50 £3,421 £3,194 -
0.175 
-0.174 £226 
(-£892, 
£1346) 
-0.001 
(-0.130, 
0.126) 
[Placebo 
dominant] 
£256  
(-£481, 
£1039) 
-0.022  
(-0.138, 
0.089) 
[Placebo 
dominant] 
PP 
Societal 
39 41 £16,620 £17,003 -
0.212 
-0.170 -£383 
(-£9390, 
£8576) 
-0.042 
(-0.185, 
0.093) 
£9,156 £366 
(-
£5618, 
£6135) 
0.005 
(-0.095, 
0.106) 
£76,966 
Table 4.25 Cost effectiveness 
Co-Trim: Co-trimoxazole; ITT: Intention to treat; PP: Per Protocol; NHS: NHS cost perspective; Societal: Societal cost perspective; FVC: change in 
FVC; Inc: Incremental; ICER: Incremental Cost Effectiveness Ratio 
 
 
  
 
 
 
 
Figure 4.10 Cost-effectiveness acceptability curves 
ITT=intention to treat analysis. PP=per protocol analysis. The cost-effectiveness 
acceptability curve is the probability that the incremental cost-effectiveness ratios (ICERs) 
is below a given willingness to pay for a quality adjusted life year (i.e. the probability that 
co-trimoxazole is cost-effective given a threshold of X). There is between 46.9% and 
89.8%probability that the ICER is below £30,000. 
  
 
       Unadjusted Imputed, adjusted for baseline utility and cost 
 N  Cost   QALYs  Inc £ Inc QALYS ICER P(CE|£3
0k) 
Inc £ Inc 
QALYS 
ICER P(CE|£30k
) 
Analysis Co-Trim Placebo Co-Trim Placebo Co-Trim Placebo (95%CI) (95%CI)   (95%CI) (95%CI)   
ITT 
NHS 
61 64 £2,989 £2,918 0.571 0.539 £71  
(-£848, £991) 
0.032 
(-0.062, 
0.127) 
£2,244 70.52% £136 
(-£628, 
£915) 
0.045 
(-0.028, 
0.116) 
£3,002 84.78% 
ITT 
Societal 
51 53 £14,321 £15,131 0.590 0.539 -£810 
(-£8412, 
£6491) 
0.051 
(-0.055, 
0.157) 
[Active 
dominant] 
69.68% £115 
(-£5024 
£4726) 
0.045 
(-0.029, 
0.115) 
£2,530 67.76% 
PP NHS 58 61 £2,999 £2,922 0.571 0.527 -£77 
(-£895, £1051) 
0.045 
(-0.053, 
0.140) 
£1,724 77.80% £149 
(-£674, 
£884) 
0.054 
(-0.024, 
0.121) 
£2,743 89.80% 
PP 
Societal 
41 38 £14477 £16,307 0.584 0.527 -£1830 
(-£9797, 
£5741) 
0.057 
(-0.052, 
0.167) 
[Active 
dominant] 
78.08% -£246  
(-£5326, 
£4511) 
 
-0.015 
(-0.103, 
0.063) 
£16,636 
[favour 
placebo] 
46.92% 
Table 4.26 Cost utility 
Co-Trim: Co-trimoxazole; ITT: Intention to treat; PP: Per Protocol; NHS: NHS cost perspective; Societal: Societal cost perspective; Inc: 
Incremental; ICER: Incremental Cost Effectiveness Ratio; P(CE|£30k): Probability that the ICER is below £30,000 per QALY gained. 
  
 
4.4 Discussion 
TIPAC is a large randomised, double -b l ind placebo-controlled c l in ical t r ia l 
that assessed the eff icacy and safety of co -tr imoxazole in a dose of 960 
mg twice a day prescribed for 12 months in patients with f ib rot ic id iopathic 
interst it ia l pneumonia. S imilar to a number of recent interventio nal tr ia ls  
using novel or exist ing drugs with anti -f ibrot ic, ant i-oxidant,  anti-
prol iferat ive, and anti- inf lammatory properties [97-99, 104, 105, 109] this  
study did not demonstrate an effect on a primary endpoint but led to a 
reduction in mortality over 12 months associated with a reduction in a rate 
of infect ions.  
 
4.4.1 The effect on lung function 
A range of tr ia ls assessed the eff icacy of treatment by measuring changes 
in phys iolog ical parameters [96, 99, 101-104, 109]. Three other tr ia ls used 
change in v ita l capacity and forced v ital capacity absolute value as a 
primary end-point [96, 102, 109] wh ile two other used change in FVC % 
predicted as a primary end-point [103, 104]. Overall of a l l  the recent tr ia ls  
using physiologica l measures as primary endpoint s ign if icant dif ferences 
were demonstrated for two drugs only –  n-acetylcysteine and pirfenidone 
[96, 102, 103].  
Assessment of changes of FVC over the study period demonstrated  that 
both patient groups experienced decline in this parameter (196 ml decline 
in p lacebo group and 182 ml decline in co -trimoxazole group). This rate of 
decline is consistent with a s lowly progressive course of the disease and is 
comparable with mean annual rate of decline in FVC shown in other 
c l in ical tr ia ls ranging from 130 ml to 200 ml (Figure 4.10). [196].  
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Figure 4.10 Decline in FVC in idiopathic pulmonary fibrosis (IPF). Shown are the mean 
rates of decline in FVC observed in the placebo arms of clinical trials of patients with IPF. 
The FVC declines approximately 150-200 ml/year in patients with IPF. Data are from the 
placebo arms of the following clinical trials: 1 Pirfenidone[101], 2 Imatinib[105],3  
Interferon-γ-1b[97], 4 Pirfenidone[102], 5 Co-trimoxazole (current thesis), 6 N-
acetylcysteine (NAC)[96], 7 Etanercept[104], 8 Bosentan[99], 9 BIBF 1120[109]. Adapted 
from Ley et al[196]. 
 
 
In this study, there were no signif icant differences in other physiological 
measures including DLCO, TLC and 6 minute walk distance and 
desaturation of >4% in both ITT and PP analyses.  
 
Why was there no difference in FVC? 
Potential reasons for a study not to have an effect on the FVC include: 
inappropriate choice of the primary endpoint, inadequate durat ion of 
treatment, inadequate sample size  to detect s ignif icant difference, the dr ug 
not being effective, the drug being effective but only in a subgroup of 
patients.  
I  considered the f irst three reasons not to be a case in this study. It has 
been suggested that FVC may be the most appropriate s ingle prognostic 
parameter, given its ease of measurement, reproducibi l i ty, and abil i ty to  
predict prognosis at baseline and over t ime with even marginal changes 
(5-10% decline over 6 months) being associated with a higher risk of 
mortal ity[196, 197]. It  has also been demonstrated that of all physio log ical 
parameters change in FVC over 6 -12 months is not only associated with  
surv ival [23, 62, 63] but is more predict ive of prognosis and outcome than 
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the majority of baseline characterist ics including histopathologic  
diagnosis [23]. FVC has been used and estimated to be an appropriate 
outcome measure in c lin ical t r ia ls [198]. Also, taking into account the 
results of the pi lot study which showed signif icant improvement in FVC as 
its secondary endpoint , it  was relevant to use change in FVC as the 
primary endpoint in th is larger study.  
The value of 200ml for the mean difference in FVC from baseline was used 
to power the study since this represented the minimum change required for 
a favourable or unfavourable response to treatment as proposed in t he 
ATS/ERS International Consensus statement from 1999 which was the 
most up to date document at the t ime of the study protocol approval 
(2007). Assuming a residual Standard Dev iation of 400ml (from data from 
ISOLDE and TRISTAN study courtesy of J. Anderson, GSK, Greenford), 
then with 63 patients in each group this study had an 80% power to detect 
a mean difference of 200ml at a s ignif icance level of p = 0.05. The total 
patient sample was higher (181) to allow for drop outs and 111 patients  
completed 12 months of treatment nearing the required number; with this  
number of patients complet ing the study the power was 74%.  
For a drug to have an effect on lung function tests in IPF it should be able 
to affect the underly ing pathogenic process. Changes in lung function 
should not be a result of other concomitant condit ions for example 
infect ion and emphysema. Since changes in FVC reflect either progression 
or stabil i ty of the disease and co -trimoxazole did not show any 
preservation in this parameter (or any other lung function parameters) it  is  
more l ikely that i t  does not have a disease modify ing action.  
The reasons for a discrepancy in the results of th is study and the pilot  
study regarding changes in FVC are not c lear. Baseline characterist ics in 
both studies were similar in terms of the mean age, gender distr ibut ion and 
the number of patients on prednisolone at recruitment. Seven patients out 
of 20 in the p i lot study had a sib l ing with IIP which makes it  possible that 
the spectrum of the disease was somewhat di fferent to defin ite/probable 
UIP or f ibrot ic NSIP. These patients also had milder disease as ev idenced 
by DLCO of 59% predicted in p lacebo and 51% predicted in active group 
as opposed to 39 and 36% in the TIPAC study respectively. The authors of 
the pilot study admit dif f iculty in interpreting of the lung function results in 
the bl inded part of the study (the f irst 3 months) due to the change in lung 
function equipment and a wide t ime range of baseline PFT measurement 
from 0 to 8 months (due to demand on th e serv ice from three other 
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hospita ls). Nevertheless the out of study measurements in the fol lowing 9 
months (when patients continued taking co -trimoxazole as an open label 
treatment) demonstrated a sustained effect on FVC in the active group. At 
the same t ime there was no effect on FVC for the placebo arm patients  
during this open labelled phase.  
Our patient population had a slower progression of disease - <5% decline 
in FVC over 1 year versus 11% seen by Varney el al [188], indicative of 
s lowly progressive disease and this may account for the lack of effect with  
co-trimoxazole treatment,.  
Subgroup analysis in pat ients with mild/moderate disease showed no 
signif icant dif ference in the rate of decline of FVC over 12 months 
(p=0.816 in the ITT analys is and 0.378 in the PP analys is). Though DLCO 
% predicted at a given t ime point is more reflective of the severity of the 
disease and more predictive of outcome a  FVC % predicted with a cut off 
of 60% was used to discriminate severe (≤60% predicted) from 
mild/moderate (≥60% predicted) as this was the measure assessed in al l  
patients unlike DLCO (measured in 150 out of 181).  
 
4.4.2 Survival  
This study has shown that although co -trimoxazole treatment has no effect 
on pulmonary function in pat ients with f ibrot ic id iopath ic intersti t ia l 
pneumonia, th is treatment, when subject to a per protocol analys is  had a 
signif icant reduction in al l -cause mortal i ty over 12 months. The difference 
between the f ind ings of the intention -to-treat  and per-protocol analyses 
may be due to improved surv ival in those adhering to treatment as we 
would not expect any effects of co -trimoxazole to be exhib ited fol lowing 
cessation of th is treatment. Alternatively, i t  could be due to an increased 
mortal i ty in those withdrawing from the drug because of s ide effects or the  
higher withdrawal rate  in the act ive group could be a marker of the disease 
severity. However, the reduction in mortal ity was not due to 
disproportionate withdrawal of pat ients in  the treatment arm immediate ly  
prior to death as only 4 pat ients (2 from each group) withdrew from the 
study with in 1 month of death.  
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IPF has a variable course in indiv idual patients [70], however several 
studies performed using the current c lassif icat ion of IIP [6] have reported a 
median surv ival between 2 and 4 years from the t ime of diagnosis and a 5 
year surv ival between 20 and 40%[10, 12, 17, 63].  
Few studies have reported the effects of a pharmacological intervention on 
surv ival in IPF. Raghu et al [97] showed no difference in death or disease 
progression with interferon gamma,   though a post-hoc exploratory 
analysis suggested a surv ival benefit  in  patients with milder disease with  
FVC of greater than 62% (12% died in placebo arm vs. 4% in treatment 
arm). Nevertheless in a meta -analysis with a larger study[98] of patients 
with mild  to moderate disease, no effect on mortal ity was observed (hazard 
ratio 0.88)[199]. Kubo et al[106] demonstrated a signif icant increase in 
surv ival with anticoagulation (hazard ratio 0.34) in 56 prednisolone -treated 
patients with IPF. However, the open labelled nature of th is study resulted 
in greater healthcare contact with active treatment due to coagulat ion  
monitor ing and 20% of the active treatment g roup withdrew consent at the 
start of the study because of concerns about the treatment or monitoring.  
In our study, we have shown a reduction in al l -cause mortali ty over 12 
months (hazard ratio 0.21) from 18 in the placebo group to 3 in the co-
tr imoxazole group. Of note, the death rate returns to that of the placebo 
group when co-trimoxazole is discontinued. 
The mortal ity rate in recently performed high quality interventional studies 
varied from under 10% in studies using pir fenidone [101], bosentan (BUILD-
1)[99], etanercept[104] and acetylcyste ine [96] ( in the latter deaths were 
reported for PP population only) to around 13 -16% in studies using 
imatin ib[105] and interferon-gamma[97, 98] and up to as high as 45% in a  
study using warfar in [106]. The total number of deaths by the end of th is 
study was higher than in the majority of tr ia ls - th irty-seven (20%) pat ients 
died (19 (22%) in placebo group and 18 (19%) in co -trimoxazole  group 
(p=0.379)). Possible exp lanations for th is could be that patients were older 
with mean age of 71 years and had moderate to  severe disease as 
opposed to a mean age of 62 -65 years and mild to moderate disease in the 
majority of recent tr ia ls.  Recent commercial ly sponsored cl in ica l tr ia ls  
recruited predominantly inc ident cases while  a h igh number of TIPAC study 
patients were prevalent cases with only 25% patients being diagnosed in 
12 months prior to recruitment.  
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4.4.3 Anti-infective role  
Our study demonstrated a signif icant reduction in the rate of upper and 
lower respiratory t ract infections in  the treatment group and the occurrence 
of pneumonia in the placebo group only.   
I t  has been postulated that infectious agents may perpetuate the 
pathogenesis of IPF and may increase the risk of an  acute exacerbation. It 
is  possible that chronic inf lammatory stimulus in a genetically susceptible  
host disrupts the normal healing response thus making the lung highly 
susceptib le to a separate in jurious tr igger [200]. Much more is known 
about the role of v iruses than bacteria , but the information on both remains 
l imited.  
Some v iruses exist as an antigenic stimula nt in the epithelia l ce l ls of the 
lung in an actively replicat ing and potential ly in jurio us phase for an entire  
l i fet ime.  Viruses such as Epstein -Barr v irus, infect most people at some 
point in their l ife and that’s where the different ia l host responses m ay 
modify the pathogenesis [200], as only a small proportion of exposed 
people wil l  develop the disease. A number of v iruses have been associated 
with IPF inc luding hepatit is  C,  adenov irus, cytomegalov irus but the 
strongest association was found with the gammaherpesv irus Epstein -Barr  
v irus. Given that hepatit is  C v irus (HCV) is not known to replicate in the 
lung, i t  is  not c lear if  the association with HCV is pathogenic in IPF or if  i t  
ind icates that IPF patients develop HCV cross -reactive antibodies. Kuwano 
et al d id not f ind correlat ion between adenov irus infection and IPF but 
showed that the incidence of the adenov irus gene product E1A was 
considerably h igher in patients treated with corticosteroids (67%) 
compared to the untreated group(10%)[201]. E1A has been shown to  
upregulate the production of the profibrot ic mediator TGF-ß and to induce 
lung epithelia l cel ls to express mesenchymal markers [202]. Human 
cytomegalov irus  DNA (HCMV), a widespread opportunistic pathogen, was 
found in higher levels in IPF t issue compared to control samples [203] and  
HCMV IgG and complement f ixat ion t itres were found to be elevated in the 
serum of IPF patients compared to controls [204]. The mechanism of the 
association between HCMV and IPF is not c lear. An association between 
Epstein-Barr v irus infection and IPF was f irst established in 1984 by 
Vergnon et al [205] who ident if ied ra ised levels of immunoglobulins A and 
G against EBV antigens in 13 patients with IPF in contrast to normal levels 
in 12 patients with ILD of known cause. Stewart et al [206] confirmed by 
immunohistochemistry and polymerase chain reaction that EBV is present 
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in the lung t issue of patients with IPF in s ignif i cantly higher number of 
cases (48%) than in control subjects (14%). Tang et al  extended the 
hypothesis to see if there is an association between IPF and herpesv iruses 
and confirmed the presence of one or more of four herpesv iruses (EBV, 
HCMV, HHV-7 and HHV-8) in  32 of 33 patients with IPF against 9 [207]of 
25 control subjects. Vira l infection is often complicated by a s econdary 
bacterial infect ion which might be responsible for the in it iat ing or  
maintain ing inf lammatory and/or f ibrotic process in IPF.  
There is a very l imited data on the role of fungal and bacterial infect ion in  
IPF. Shimizu et al. demonstrated a high prevalence of Pneumocystis  
j irovecii  colonisat ion (23.3%) among a group of 25 patients with IPF and 
19 patients with collagen vascular disease , treated with  oral 
cort icosteroids which is  a s ignif icant r isk factor for colonisation  (p<0.05) 
(P. j irovecii DNA was detected in sputum samples) [207]. Chlamidophila  
pneumoniae (C. pneumoniae) is a frequent causative agent for 
exacerbations of asthma and COPD, Tomioka et al. [208] conducted a 
prospective observational study over 5 years to evaluate its role in the 
pathogenesis of exacerbations of IPF. Though the ev idence of prev ious 
exposure to C. pneumonia is high with 18 out of 27 patients hav ing 
posit ive C. pneumonia IgG index, there was no ev idence of acute infection 
at the t ime of the exacerbation as ev idenced by the change in IgA and IgG 
index in paired sera.  
The only study evaluating bacteria l co lon isat ion in IPF, wh ich was 
undertaken as a disease control group for comparison with patie nts with  
Wegener granulomatosis,  demonstrated that a s ignif icant number of IPF 
patients cultured pathogenic bacteria from their broncho -alveolar lavage 
f lu id - 36% (8/22) compared to none (0/8%) of the controls. None of these 
patients were immunosuppressed or had ev idence of infe ct ion in the 
preceding 4 weeks. These included Haemophilus inf luenza and 
parainfluenzae (2 cases each), Streptococcus pneumonia, Moraxella  
catarrhalis, Pseudomonas Aeruginosa and Proteus mirabil is  (1 case each ).  
There were no cases of Staphylococcus aureus which was a dominating 
agent (40%) in patients with Wegener granulomatosis. The authors 
postulated that unrecognised airway colonisat ion may contribute to the 
presence of cellu lar neutrophil ic  in f lammation in the vasculit is  group[209].  
Whilst acute exacerbation (defined as an acute worsening for wh ich an 
identif iable cause eg pneumothorax, pu lmonary embolism, pneumonia and 
heart fa i lure cannot be identif ied) is reported to be the leading cause of 
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acute deterioration  in IPF[210], infect ions were reported to be often 
present in a number of studies with an acute exacerbations [56, 210, 211]. 
Huie et al in their study of 27 patients with acute deterioration of f ibrotic 
lung disease (13 IPF patients) identif ied an infective agent in a third of 
cases[211]. So did Kim in a study of  acute exacerbations in 147 pat ients 
with b iopsy proven IPF, among 23 patients with an acute worsening 7 had 
to be excluded as infection could not be completely exc luded[56]. 
Unrecognised infection may be the cause of exacerbation in many more 
cases particular ly as the cl in ica l and radiologica l features of both infection  
and non-infectious exacerbations may be indist inguishable [212]. Infection 
is the most important differentia l d iagnosis in patients with an acute 
exacerbation especial ly those immunocompromised, as shown by Song et 
al. Opportunistic infections comprised 57.1% of the documented organisms 
and usually developed in those pat ients treated with steroids regardless of 
other cytotoxic agent ued. Opportunist ic infect ions included PCP (17%), 
CMV (sing le organism in 42% and as a co -infection in fur ther 17%), 
candida, inf luenza v irus, aspergil los is and M. tuberculosis in 8% 
each[210].  
Another study of an Egyptian IPF population assessed the spectrum of 
bacteria involved in prev iously untreated infective exacerbations of IPF . 
Although the study did not have a control arm) [213], it  showed that 80% of 
25 patients with an infective exacerbation of IPF had posit ive sputum 
culture, with the majority of cases showing growth of Pneumococci and 
Staphylococci (16/20 patients). The remaining patients grew gram negative 
bacteria, 28% of cases had co-infection with fungi and one case was 
posit ive for acid fast bacil l i  ( the data is in abstract form only).  
W ith mortal ity rates from IPF increasing progressive pulmonary f ibrosis 
i tself  is  reported to be an underly ing cause of death in approximately 60% 
of cases in epidemiological and autopsy studies [28, 214] and up to 71% of 
cases of the placebo group from the Interferon gamma clin ical study [97].  
An analysis of cause of death in a number of recent c l in ical tr ia ls showed 
that 77% of patients died from respiratory causes , including progression of 
IPF, acute exacerbation, acute lung injury, pneumonia, and cor 
pulmonale[98, 104, 105, 196, 215]. Respiratory infect ions were found to 
lead to death in 6.5-14% cases in a number of observational studies [124, 
216, 217], and pneumonia was specif ied as a cause of death in 2.4 ± 0.5% 
in an epidemiologica l study [28], and in 5-23.3% of cases in autopsy 
studies [214, 218].  
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Respiratory tract infect ions including pneumonia were reported to be the 
cause of death in a large proport ion of patients from four c l in ical tr ia ls  
(Table 4.27) and though the results are diff icu lt to compare , due to 
different analyses being and small number of patients , the average number 
of patients with respiratory tract  infections appears to be higher than that 
reported in the epidemiolog ical study[28].   
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 Interferon-gamma 
(ITT) 
 
IFIGENIA  
(NAC) 
(PP) 
Etanercept 
(ITT) 
 
INSPIRE 
(Interferon-
gamma)  
(ITT) 
TIPAC 
(Co-trimoxazole) 
(ITT) 
Duration of 
treatment 
58 weeks 12 months 48 weeks 96 weeks 12 months  
 Active Placebo active placebo active placebo active placebo active placebo 
Total 
number of 
deaths 
16 
(10%) 
28 
(17%) 
p=0.08 
7  
(9%) 
8  
(11%) 
p<0.69 
4 
(9%) 
2 
(5%) 
p=0.41) 
93 
(17%) 
39 
(14%) 
p=0.346 
18  
(19%) 
19 
(22%) 
p=0.379 
Respiratory 
deaths 
 
81% 
 
82% 
6  
(86%) 
6  
(75%) 
3  
(75%) 
2 
(100%) 
75 
(81%) 
32 
(81%) 
16 
(89%) 
19 
(100%) 
RTI 3 
(19%) 
3  
(11%) 
3 
(43%) 
1 
(13%) 
      
Pneumonia     1  
(25%) 
1  
(50%) 
  4 
(22%) 
7 
(37%) 
 
Table 4.27 Respiratory system infections reported as the cause of death in 4 clinical trials 
and this  trial. ITT – intention to treat analysis, PP – per protocol analysis, RTI – 
respiratory tract infection. 
 
Respiratory tract infections are also reported as adverse events in a large 
proportion of patients in  c l in ica l t r ia ls (Tab le 4.28). A lthough the results 
cannot be compared directly due to difference in defin it ions of respiratory 
tract infections with some studies inc luding pneumonia and some not, it  is  
c lear that a large proportion of patients (from 33 to 68%) experience a 
respiratory system related infective event with in 48 weeks minimum to 96 
weeks maximum observation period and in one study pneumonia was 
reported to be the most commonly occurring form of serious adverse 
event[98]. None of the study drugs have prev iously been reported to have 
an effect on respiratory tract infections.  
 
 Interferon-gamma IFIGENIA  
(NAC) 
Etanercept 
 
INSPIRE 
(Interferon-
gamma) 
TIPAC 
(Co-trimoxazole) 
Duration of 
treatment 
58 weeks 12 months 48 weeks 96 weeks 12 months  
Active/place
bo 
Active Placebo active placebo active placebo active placebo active placebo 
RTI  
68% 
 
56% 
20* 
(25%) 
24* 
(32%) 
15 
(33%) 
13 
(32%) 
  27∞ 
(29%) 
38∞ 
(44%) 
Bronchitis     10 
(22%) 
11 
(27%) 
    
Pneumonia 15% 8%       0 8 (9%) 
Admission 
with RTI 
16% 10%         
SAE       32 
(6%) 
13 (5%)   
Table 4.28 Respiratory tract infections reported as adverse events in safety analysis in 4 
clinical trials and current trial. *including LRTI, pneumonia, bronchitis; ∞ LRTI 
 
 
The data from this study suggests that the surv ival benefit of co -
tr imoxazole is more l ikely due to its anti - infect ive activ ity despite a lack of 
data on pneumocystis j irovecii and bacteria l colon isation. Th is is probably 
not unexpected considering co-tr imoxazole is a sulphonamide with  
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bacteriostatic activ ity. Co-tr imoxazole exerts i ts antimicrobia l effect by 
inh ibit ing synthesis of tetrahydrofol ic acid, the metabolica l ly act ive form of 
fo l ic acid with the result ing inh ib it ion of thymid ine synthesi s; 
sulphamethoxazole acts primari ly through inh ibit ing synthesis of 
dihydrofol ic acid, wh ile tr imethopr im acts as a competit ive inhibitor of 
dihydrofolate reductase, the f inal enzyme in the pathway to tetrahydrofol ic  
acid[219]. Co-tr imoxazole is a broad spectrum antimicrobial agent, in v itro  
i t  is  active against a wide range of organisms including gram -posit ive 
(Staphylococcus species (includ ing invasive methic i l l in -resistant 
Staphylococcus aureus infections), Streptococcus species (including 
Streptococcus pneumoniae), Corynebacterium diphther) and gram -negative 
aerobic (Neisseria gonorrhoeae, Escherichia coli,  Shige lla species, 
Salmonella, Proteus, Enterobacter, Klebsie l la , Yers in ia, Vibr io cholerae,  
Haemophilus inf luenza) bacteria, Chlamydia, Nocardia (actinomycetes),  
some mycobacteria and protozoa and many anaerobic bacteria [220]. 
Pseudomonas aeruginosa, Treponema species. , Mycoplasma pneumonia, 
Mycobacterium tuberculosis are resistant to co -trimoxazole. Tak ing into 
account a spectrum of colonis ing bacteria in non -immunocompromised 
patients with IPF[209] and of bacteria associated with exacerbation of 
IPF[210, 213] it  is  possible that co-tr imoxazole treats bacteria l colon isation 
and prevents or prov ides early treatment of acute infection for some types 
of microorganisms. Since over half  of patients were on immunosuppressive 
treatment at recruitment it  is  possible that co-tr imoxazole acts by 
preventing steroid- induced infections.   
 
4.4.4 Other antibiotics in pulmonary fibrosis 
The effects of two other antib iot ics were  assessed in murine models of 
bleomycine induced pulmonary f ibrosis and of one of them in a small 
c l in ical study. Azithromycin s ignif icantly reduced fibrot ic lesions (spindle  
cell prol i ferat ion and collagen I deposit ion) as well as restrict ive lung 
function pattern after 35 days of treatment with changes found in 
neutrophils and macrophages (innate immunity) and TH2, TH17 and Treg 
cytokines (adaptive immunity) [221]. Doxycycline was also shown to have 
an inhib itory effec t in mice with bleomycine induced pulmonary f ibrosis in  
two studies. Its use led to a reduction in secretion and activ ity of  
collagenase type IV and in hydroxyproline level associated with a decrease 
in the extensiveness of the f ibrot ic lesions, th ickness of the alveolar septa 
and accumulation of nucleated cells on image analysis [222] as well as to a  
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reduction of production of collagen type I, connective t issue growth factor 
(CTGF), TGF-beta 1 and to inhib it ion of mRNA expression of matrix 
metalloproteinases 2 and 9, CTGF, collagen type I in alveolar epithelia l 
cel ls but not in normal lung f ibroblasts [223]. The latter  effects were 
assessed in a prospective open label study which showed that in 6  
patients taking doxycycline for 24 weeks the BALF levels of MMP3 and 9 
as well as of t issue inhibitor of metalloproteinase -1 and VEGF were 
reduced nearer to the normal level shown in 6 healthy control subjects; 
these changes were associated with s ignif icant improvement in tota l score  
of SGRQ and such clin ical parameters as 6MWD, FVC which was not 
s ignif icant[224].  
On the grounds of animal studies it was proposed that doxycycline through 
the inhib it ion of alveolar epithelia l cel ls production of MMP and growth 
factors which are involved in remodell ing and degradation of extracellu lar  
matrix, and azithromycin through the modulation of both innate and 
adaptive immunity might play an antif ibrot ic ro le in IPF. At present there is 
no suff ic ient ev idence to suggest that these effects would translate into  
c l in ical practice with the effect on markers of disease activ ity and/or 
mortal ity.  
As far as we are aware there is no l iterature on use of other antib io t ics in 
experimental models of PF or in c l in ical sett ings.  
 
4.4.5 Serious adverse events 
In our study, respiratory events were the most frequent cause (61%) of 
SAE (Chapter 4, Table 4.16) which is s imilar to prev iously reported 
interventional studies.[98, 100] studies prev iously. In tota l 33% of  study 
patients, including 26% of patients receiv ing co-tr imoxazole experienced at 
least one SAE (Chapter 4, Table 4.17). The latter is s imilar to the number 
of SAEs reported in the active arms of c l in ical tr ia ls using etanercept [104] 
and BIBF[109] (26-27%)  but is lower than the tr ia ls evaluat ing  
bosentan[100] and interferon-gamma[98] (32-39%) as well as in the 
observational study of rapid deteriorat ions where 35% of pat ients 
sustained admissions [210]. In the intent ion to treat analys is the total  
number of patients experiencing at least one SAE (Chapter 4, Table  4.17) 
and the average number of events per person were lower in the active 
group but this was not  statist ica l ly s ignif icant. Similar ly amongst  patients 
adhering to treatment both of these outcomes as well as the number of 
patients with respiratory SAE and an average number of respiratory events 
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per person were signif icantly lower in the co-trimoxazole arm compared to 
the placebo arm (Chapter 4, Table 4.19 and Table 4.20). None of the 
prev ious interventional tr ia ls have reported a signif icant dif ference in the 
total number of SAEs or in a number of respiratory related SAEs in favour 
of the treatment arm.  
 
4.4.6 Acute exacerbations 
The natural history of IPF is variable with a 5-year surv ival of  only 20-
30%[11, 20] is unpredictable at the t ime of diagnosis [16]. The major ity of  
patients show slow progression over a number of years, some remain 
stable and other have an accelerated decline [16]. Recent observations 
have also suggested that acute respiratory worsening can occur in a small 
minority of patients with IPF annually  rang ing from 5-10%[16, 99, 101, 
225], to 19%[210] with some patients experiencing mult ip le episodes  of 
acute exacerbations[210]. Episodes of acute worsening can occur at any 
point in the course of IPF in patients with both stable and slowly 
progressive disease which may expla in the fact that patients with  more 
stable disease (i.e. those showing a < 10% change in FVC over 6 -12 
months after diagnosis) in spite of  hav ing a better surv ival st i l l  continue to 
die albe it at a lower rate [23, 63]. In one study the onset of acute 
exacerbations was not related to the degree of pre -exist ing lung function 
impairment[56] wh ilst in another study the r isk was higher in pat ients with  
more severe disease[210]. Mortal ity associated with an acute exacerbation  
of IPF is up to 75%[226] and in pat ients requir ing mechanical venti la t ion it  
is  as high as 90%[210].  As has been prospectively recorded in published 
cl in ical tr ia ls, 30% of a l l deaths is the result of an acute exacerbation[196]. 
The aetiology of acute exacerbation is unknown but many patients present 
with fever, f lu- l ike symptoms and neutrophil ic  bronchoalveolar lavage 
(BAL) suggesting an unrecognised infective aetiology[227]. 
The effect of co-tr imoxazole on acute exacerbations is not known.  In this  
study 7 deaths in per protocol population were attr ibutable to IPF in the 
absence of identif iable cause (infection, he art fa i lure, pu lmonary embolism 
or pulmonary hypertension). All of  these  were preceded by a gradual (over 
months) decline in lung function associated with a gradual deteriorat ion of  
symptoms rather than had features consistent with an acute exacerbat ion.   
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4.4.7 Immuno-modulatory and disease modifying action 
Oxidative stress , from the release of reactive oxygen species , is thought to 
be a mechanism of epithelia l in jury in IPF[228]. Repetit ive in jury to the 
alveolar epithe lium and endothelia l in jury causes chemokines and growth 
factors release which in turn drives recruitment of f ibroblasts and 
endothelia l ce l ls wh ich leads to collagen -matrix remodell ing with l i t t le  
ev idence of inf lammation. There is ev idence of inflammatory cell  
recruitment with inf i l trat ion of lymphocytes, plasma cells  and histiocytes 
associated with type II  pneumocyte  hyperplasia[6]. I t  is  thought that free 
radicals are involved in f ibrogenesis and the activation of inf lammatory 
cells , which leads to the production of reactive oxygen species. A  strong 
expression of nitrotyrosine (a byproduct of protein nit rat ion caused by a 
potent oxidant peroxin itrate) and nitr ic oxide synthase is found in 
macrophages, neutrophils and the alveolar epithelium in the lungs of 
patients with early to moderate stage of IPF compared to normal control 
subjects [229]. 
Potential immunomodulatory propert ies of co -trimoxazole have been poorly 
studied. Roberts et al[230] have demonstrated that sulfamethoxazole  
interferes with the production of oxygen derived free radicals by activated 
neutrophils. Co-tr imoxazole has been shown to suppress tumour necrosis 
factor (TNF)α secretion from stimulated peripheral blood mononuclear 
cells [231]. Other researchers suggest that the hydroxylamine metabolite of 
sulfamethoxazole causes a shift  towards a TH1 response from a TH2 
response with inhib it ion  of the production of TNFα, inter leukin (IL) -2 and 
IL4 without inhib it ing interferon (IFN) secretion[232]. Co-tr imoxazole may 
therefore reverse the shift from TH1 to pro-f ibrotic TH2 cytokine seen in 
patients with IPF[233].  
Co-trimoxazole has been shown to reduce the rate of relapse in patients 
with granulomatosis with  polyarter it is  (formerly Wegner’s 
granulomatosis) [234, 235], relapsing polychondrit is [236] and to have 
benefic ial effects in rheumatoid arthrit is [237]. The response to co-
tr imoxazole granulmatosis polyarterit is  is greater if  tr eatment is started in  
the in it ia l phase of the disease [238] and is not related to nasal d isease or 
infect ion[235]. 
Though the tr igger in it iat ing the deve lopment of f ibrosis in IPF is not 
known it has been suggested that the disease has a mult ip le pathway 
mechanism of pathogenesis (Figure below 4.11, [239] and that the balance 
of abnormalit ies in each of the key pathways may vary between affected 
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ind iv iduals which would expla in the range of c lin ical, radio logical and 
pathological phenotypes observed in IPF [239]. As a result tak ing into  
account pathogenic complexity of the process the need for mult imodality 
therapy to target mult ip le f ibrosis pathways s imultaneously ha s been 
proposed[239, 240] and supported by the committee of the jo int IPF 
guidelines group[16], th is has been echoed by the approach used in the 
treatment of many cancers. If the mult ip le pathways hypothesis suggested 
is correct it  is  possible that co -tr imoxazole may play a role in  one of these 
pathways as an adjunct to other therapies as an antibiot ic treat ing subtle 
subclin ica l infect ion or colonisation or hav ing a prophylactic effect against 
infect ive exacerbations or even possible ant ioxidant effect.  
From the data presented here suggests that co-trimoxazole is unlikely to  
have a relevant effect on the progression of IPF , but may have a 
considerable effect on surv ival, probably due to anti - infective propert ies.  
 
 
Figure 4.11 A model for pathogenesis of IPF[239] 
 
 
4.4.8 Quality of life 
 
Taking into account that the major ity of exist ing therapies do not improve 
surv ival in IPF, improvement in symptoms and  quality of l i fe is important 
from a patient’s perspective.  
The TIPAC study showed that patients had signif icant deterioration in their  
SGRQ total score at recruitment (59 in p lacebo and 57 in active group) and 
that the use of co-trimoxazole led to a s ignif icant improvement in the 
symptom domain of SGRQ in both ITT and per protocol analyses.  
The degree of impairment of the total SGRQ score at baseline was 
compatible with a moderate degree of impairment demonstrated in other 
c l in ical tr ia ls ranging from 41 -46 in tr ia ls using interferon-gamma, 
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etanercept and bosentan [97, 99, 104] to 50-55 demonstrated in tr ia l using 
NAC, s ildenafi l and a pilot study using co -trimoxazole[96, 109, 188]. Of 
studies using SGRQ as a tool of HRQL assessment on ly two other studies 
demonstrated a statist ical ly s ign if icant difference between the two groups 
in favour of active drug: a study using a new tyrosine kinase inhibito r BIBF 
1120 in a group taking a dose of 100mg twice a day and a group taking a 
dose of 150mg twice a day in patients with mild to moderate IPF [109], and 
in a study using si ldenafi l  in patients with advanced IPF [132]. It  is  not  
unexpected that the majority of  tr ia ls did not demonstrate s ignif icant 
changes in quality of l i fe scores as the instrument has to be sensit ive to 
detect a treatment effect  and there has to be a treatment  effect which has 
not been the case with most of recently examined drugs.   
In our study the magnitude of change in SGRQ symptoms score was what 
has been considered to be signif icant by the majority of investigators (4 
and above). Since there was no difference in any PFT parameters it  is  
unlikely that it  was a d isease modify ing activ ity of co -tr imoxazole that led  
to the improvement in symptoms and thus scores. An anti - infect ive activ ity 
is a possible  mechanism of action of co -tr imoxazole but it  is  not c lear at 
th is stage if an improvement in cough, sputum and breathlessness was due 
to treatment of subtle infect ions, treatment of lower airway co lonisation or  
prevention of infect ions.  
It has been debated whether SGRQ is a rel iab le and valid instrument in  the 
assessment of HRQL in IPF.  An instrument is re l iab le if  i t  measures 
something in a reproducible way; valid ity refers to whether an instrument 
truly measures what it  intends to measure and whether its scores convey 
important information about particular attr ibutes of the people who produ ce 
them [74]. There is no reference standard for the psychological construct 
HRQL therefore clin ica l parameters are used as a point of reference; i t  is  
not expected that that there would be a high correlation as this wo uld  
suggest that the instrument is unable to prov ide unique information and is 
therefore not required; it  is  nevertheless expected that the correlations 
would be in direction and of magnitude that make sense in terms of a 
concept of HRQL[74]. Valid ity is population-specif ic ( instrument is valid for 
performing a role in a particular type of population) and use -specif ic  
( instrument is valid for performing a particular purpose in population) [74]. 
While SGRQ was designed and validated for the use in patients with  
COPD[241], it  has subsequently been validated for the use in IPF [81, 83, 
242]. At the same time use of non-disease specif ic measures for 
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assessment of HRQL may not capture some effects of IPF on patients’  
l ives or can cover areas that are not relevant to IPF. Due to physiolog ical 
differences between COPD and IPF some symptoms do not usually occur 
in IPF pat ients (unless there is co -exist ing obstructive airways d isease) 
therefore questions about wheezing, attacks of disease and pr oductive 
cough become irre levant.  
On the other hand patients in both prev ious studies that assessed IPF 
patients’ perspectives felt that SGRQ did not adequately capture their  
disease experience. Compared with twelve primary conceptual categories 
(the domains of IPF-related quality of  l ife)  identif ied by Swigr is  et al  
(symptoms, IPF therapy, s leep, exhaustion, forethought, employment and 
f inances, dependence, family, sexual re lat ionship, social part ic ipat ion and 
le isure activ it ies, mental and spiri tual we ll -being, mortali ty) 5 areas were 
not covered by the questionnaire: s leep, dependence, family, sexual 
relat ions, and mortali ty [76].  Exclusion of these items means that the 
questionnaire is not able to ref lect changes in al l  aspects of QOL.  
To address these issues Yorke et al  went through the stages of reducing 
and refin ing the orig inal questionnaire, developing a new scoring scheme, 
assessing cross-sectional and longitudina l valid ity arr ived to create  SGRQ-
I fo l lowed by examining internal consistency rel iab il i ty for each domain of  
the SGRQ-I and for comparison purposes for each domain of the or igina l 
SGRQ[243]. Rasch analysis and psychometric testing confirmed that the 
SGRQ-I has acceptable measurement properties; the construct valid ity was 
supported by mult ip le s ignif icant correlat ions between component scores 
and FVC% predicted, DLCO% predicted, 6MWD, BDI, SF -36. Prospective 
studies are required to assess the responsiveness of the new instrument 
and to determine the minimum important difference [243]. 
A change in SGRQ score of four units was shown to be consistent with  
c l in ically s ign if icant change in patients with COPD based upon expert 
opinion and anchor based approach [244]. One recent study determined 
that grand means of minimum important difference (MID) est imates for 
SGRQ domains were 5 for the activ ity domain, 7 for the impact domain and 
8 for the symptoms domain. Possib le exp lanations for th is d i fference are 
f irst ly the dif ference in physiology of the diseases (COPD and IPF) and 
irre levance of some of the questions when applied to the IPF populat ion  
(wheeze, chest attacks); secondly a small number of study patients who 
had signif icant change in their physio logical parameters over 6 months 
(47% had a change in FVC of >7% and only 35% had a change in DLCO of 
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>15%), third ly only pat ients with mild to moderate disease were included 
into the study therefore not the ful l spectrum of disease severity was 
represented. These MID estimates wil l  need to be reassessed in future 
studies before they are recommended for regular applicat ion.  
On the grounds of the results of the f irst assessment of the longitudinal 
performance of SGRQ its use has been recommended in  studies unti l  IPF-
specif ic instrument is developed and tested [83]. The f irst two versions of 
such instrument have been developed. ATAQ-IPF (A Tool to Assess 
Quality of  l ife in IPF) is based on patients’ perspectives and is composed 
of 74 items compris ing 13 domains [245]. The questionnaire valid ity is 
supported by the pattern of correlat ion with psychologic variables known to 
be important in IPF as well as s ignif icant dif ferences in its scores between 
patients using and not using supplemental oxygen. Simple summation 
scoring is used to derive indiv idual domain scores as well as a total score. 
King’s Brief ILD questionnaire (K -BILD) was generated from patient  
interv iews, l i terature rev iew and mult i-d iscip l inary team meeting and 
comprises 15 items that generate an overall and three health domain QOL 
scores (physiolog ical, breath lessness and activ it ies, and physica l 
symptoms)[246]. Rasch analys is was used for construction of both 
questionnaires, Future studies wil l  build on the  valid ity o f both 
questionnaires.  
 
4.4.9 Cost effectiveness  
There are very few data on the costs of interst it ia l lung disease or the 
cost-effectiveness of treatments. Researchers have investigated the 
economics of diagnostic assessments. When comparing VA TS biopsy with 
l imited thoracotomy (LT) in homogeneous patient populat ions with IPF 
operating t ime, number of specimens obtained, chest tube output, day of 
chest tube removal, and amount of analgesics did not differ; at the same 
t ime operating room cost and anesthesia-related costs for VATS was 
signif icant ly greater than that for LT[247]. Only procedure-related costs 
were assessed in that study and it  is  not c lear if  the results of biopsy were 
equally conclusive for both procedures. Another study compared the use of 
CA 15-3 as a v iable alternative to KL-6 for ILDs with and without f ibrosis; 
the use and costs of CA 15-3 and KL-6 were found to be equally sensit ive 
and specif ic in terms of different ia t ing between ILDs with and without 
f ibrosis; at the same time the wide availab il i ty, ease of use, and cost 
effectiveness, made CA 15-3 a suitable alternat ive for KL-6 as a possible  
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marker for pulmonary f ibrosis [248]. A pharmacogenetic cost -effectiveness 
analysis of  Th iopurine methyltransferase (TPMT) testing before 
commencement of azathioprine,  NAC, and steroids found that TPMT 
testing (a genotypic assay developed to help to identify  those at risk of 
leucopenia with azathioprine and therefore to limit the toxic ity) was the 
most costly but the most effective strategy compared to commencement of 
tr ip le therapy without prior TPMT testing, and conservative therapy, 
consisting of only supportive measures.  This study is an example of 
decis ion modell ing and does not involve real patients. The therapeutic 
choices and treatment outcomes were modelled based on clin ical p ractice 
and TPMT act iv ity (normal, intermediate and low)  after a survey of expert  
panel of pulmonologists special is ing in t reatment of ILD to prov ide 
estimates of therapies and complications. Available (at the t ime) data on 
the prevalence of types of TPMT activ ity from population based studies 
was used as base case values.  Costs are expressed in dollars and cost of 
medications as well as in and outpatient events and disease progression 
similar ly to our study was obtained from the relevant US online group 
codes sources. The marginal cost-effectiveness of the TPMT testing 
strategy was $49,156 per QALY gained versus conservative treatment  
wh ich is be low the societal $50,000 wil l ingness to pay threshold; compared 
with tr ip le therapy without pr ior testing, the TPMT test ing strategy cost 
only $29,662 per QALY gained [249].  Both the co-tr imoxazole study and 
the study of Hagaman et al [249]  demonstrate the value of the low cost 
intervention and as shown in the  TPMT model though as many as 313 
patients would need to undergo TPMT test ing to prevent one admission 
due to leucopenia the relat ively low cost of the test al lows cos t recovery 
by admission prevention.  The health-economics part of the co-tr imoxazole  
study and the study of Hagaman et al [249] can not be compared directly 
due to different design and outcome measures used. At the same time as 
opposed to large dataset modell ing used in Hagaman’s study ,  the co-
tr imoxazole study used prospective data collect ion over 12 months based 
on the use of a detai led questionnaire amid an element of  recall  b ias.  
The only data relating to IPF treatment are in abstract form and show 
r is ing healthcare costs using database of medical and pharmacy cla ims 
from private health plans in the USA and that 70% of mean annual tota l 
health-care costs were due to hospital isat ion, were increasing with age 
and were signif icant ly higher in those who died at the end of the  annual 
fo l low up[250]. Ours is the f irst study to examine the cost -effectiveness of 
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a treatment for IPF from a healthcare prov ider and from a s ocietal 
prospective. We have shown that co -tr imoxazole may increase mean costs, 
but may also increase QALYs. The point estimate extra cost per QALY 
gained is of borderl ine cost -effectiveness compared with the threshold  
commonly adopted in the UK NHS (£21,3 91 vs. £20,000 - £30,000 per 
QALY gained[251]). The lower ICER in the per protocol analyses is 
consistent with a dose-response effect.  However this is not the case when 
considering cost per ml change in the primary outcome. The explanation 
for th is is that the primary outcome (change in FVC) does not take 
mortal ity into account, whilst QALYs do by definit ion. Two studies in  
patients with  COPD of s imilar age group (mean age 64 years) assessed 
cost-effectiveness of treatment with new agents. Analyt ic modell ing  study 
using Markov model in patients with moderate to severe COPD evaluated 
cost-effectiveness of indacaterol, a novel inhaled once -daily long-acting 
beta2agonist, compared to exist ing inhaled monotherapies (t iotrop ium and 
salmeterol) [252]; it  showed that indacaterol was dominant (lower total  
costs and better outcomes) against other two therapies and had an ICER 
of 28,300 per QALY. In patients with severe COPD (mean FEV1 41% 
predicted) a cost-effectiveness analysis was performed alon gside 
randomised double-bl ind p lacebo-controlled study of the effect of one -year 
treatment with rof lumilast, an oral once daily phosphodiesterase IV 
inh ibitor[253]; incremental costs were related to the differences in the 
number of moderate to severe exacerbations and the net proportion of  
patients with at least 4 unit improvement in tota l SGRQ score. The result  
of th is mult inat ional study showed that annual COPD -related costs were 
high in roflumilast group compared to placebo from b oth societal and HNS 
prospective; treatment with rof lumilast was cost sav ing in patients with  
very severe COPD due to a statist ical ly s ignif icant reduction in a number 
of exacerbations; in a subgroup of patients with high health -care uti l isation 
a 19% reduction in exacerbation rate was observed which translated into 
an ICER of 804 per exacerbation avoided.  
The example of these two COPD studies and the TIPAC confirms that that 
health economic analysis concerns itse lf not on ly the inputs (costs) but 
outcomes too and that wh ile the treatment could be overall more cost ly the  
effect of sav ing due to reduction of exacerbations of the disease/infections 
and related hospital admissions and usage primary healthcare serv ices 
could not be disregarded. Interestingly ec onomic evaluation of different 
disease groups might demonstrate that different sectors attract higher 
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costs. For example in asthma where patients are younger with the majority 
being employed the costs associated with the loss of productiv ity are  l ike ly  
to be higher compared to disease of older age l ike COPD and IPF with the 
majority being ret ired where this aspect is more relevant to family  
members who would be caring after their  re lat ive during the disease 
exacerbation. Disease of older age also encounter higher costs in terms of 
social care including care attendant serv ice and meals -on-wheels,  
occupational therapy including home and walking adaptations l ike walking 
sticks and wheel chairs, t ravel to hospital.  
.  
 
4.4.10 Limitations 
 
HRCT rev iew 
This study was conducted prior to publicat ion of the recent guidelines for 
diagnosis and management of IPF [113]. Patients were entered into the 
study based on clin ical and HRCT f indings and few patients (16%) had 
histolog ical confirmation of their d isease, which reflects current c lin ical 
practice (with many patients being elderly and hav ing contraindications for 
a surgical lung biopsy), and is s imilar to other c lin ical tr ia ls [101, 106]. A 
radio logical rev iew was undertaken in a b l inded fashion by two respiratory 
radio logists in pat ients who did not undergo lung biopsy (132 of 153 (86%) 
of HRCT scans were ava ilable) . 10% were felt by radio logist to have NSIP. 
Amongst patients with IPF 43 pat ients (28%) had a confident diagnosis 
(scans showed all features of IPF including honeycombing) and 74 pat ients 
(48%) had a probable diagnosis ( in the absence of honeycombing). For the 
latter group an algorithm described by Fell et a l. was used to predict a 
histolog ical d iagnosis of IPF. The algor ithm showed that when using age at 
a cut-off of 70 years as a sole predictor in patients with even modest 
amount of f ibrosis a pos it ive predict ive value of the diagnosis of IPF is 
95%[165]. A probabil i ty of IPF score combining age with the HRCT 
interst it ia l score was calculated for 89 patients without honeycomb change 
on HRCT and showed that it  was equal or greater than 0.6 in 83 (93%) 
patients. Th is cut-off of 0.6 is associated with a posit ive predictive value 
and specif ic ity for  the d iagnosis of IPF of 100%. Both our sensit iv ity 
analyses of patients with a confident diagnosis of IPF (biopsy,  
characterist ic radio logica l features or c l in ic -rad io logical features using Fell 
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criter ia)  showed the same degree of mortality benefit  with co -tr imoxazole.  
The weakness of the radiolog ical rev iew is that it  was retrospective.  
 
Treatment with cort icosteroids  
BTS ILD guidelines from 2008 [14] as well as the current IPF guidelines 
from 2011[113] recommend against the routine use of immunosuppression. 
59% of study patients were treated with immunosuppressive therapy either 
in a form of prednisolone alone or in combination with azath iopr ine or 
mycophenolate mofeti l at recru itment. This ref lected current practice at the 
t ime of the study and may be also partia l ly expla ined by the fact that o nly 
25% of cases were prevalent, which means that the majority of pat ients 
were diagnosed and treated according to the IPF guidelines from 2000 [5] 
wh ich did recommend the use of immunosuppression. Interestingly the BTS 
national interst it ia l lung disease survey with data collected during late  
2010 and early 2011 showed that around a half of responders from a total 
of 120 continued to use prednisolone (55%) and azathioprine (49%) for the 
treatment of IPF[254]. 
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NSIP 
We included a small proportion (6%) of patients with NSIP and some of 
these (4% of total study population) were not biopsy proven. This was a 
real l ife study where some patients were not suitable for a lung biopsy and 
where an overall c l in ica l d iagnosis was used rather than radiological 
diagnosis alone. Patients with nonbiopsy proven NSIP had a mean DLCO 
of 36% predicted and there is an ev idence that NSIP patie nts with  
advanced disease have an outcome similar to pat ients with IPF [23].  
 
Absence of microbio logical analys is  
It was not a part of study assessment to conduct microbiological 
evaluation of al l  cases for the presence/absence of pneumocysti s or  
bacterial colonisat ion at recruitment or of all subsequent cases with  
respiratory tract infections therefore it is  not known if co -tr imoxazole had 
an antipneumocystis effect or acted as a broad spectrum antib iot ic. It  is  
also not known if another antibiot ic (for example from a group of 
macrolides) wou ld have a simila r effect on the rate of infections and 
surv ival.  
 
Absence of DLCO measurements in some patients  
Prov is ion of DLCO measurements was not an obligatory requirement for  
the study. There was a number of reasons for th is: DLCO was not a 
primary endpoint and it is  known that some patients with s ignif icant 
functional impairment are not able to produce valid DLCO measurements . 
Hence it was considered that the absence of DLCO should not prevent 
patients with otherwise suitab le disease from partic ipat ing in the study.   
Some sites did not have access to the necessary equipment. Nevertheless 
83% of patients had DLCO measurement at recruitment and 84% of those 
who completed 12 months of treatment and were included in per protocol 
analyses.  
 
Variable PFT equipment 
The study partic ipants were recruited f rom 28 sites. Local pulmonary 
function equipment was used at each site. Stat ic lung volumes were 
measured with the use of body plet ismography (103 patients) or helium 
dilut ion (69 patients) and two sites (12 patients) used nitrogen washout in  
addit ion to body plet ismography. Vita lograph was used in a small number 
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of patients (9 patients). All PFT laboratories use ATS guidelines for the 
measurement of PFT and 6  MWT but it  is  possible that there were inter -
s ite d iscrepancies. Nevertheless since for the duration of the study each 
patient had all measurements performed on the same equipment hence 
there should not have been inconsistency in the technique and inter-
patient results.  
I t  was ensured that al l patients who had a LRTI would have PFT performed 
at least 4 weeks after the resolution of symptoms.  
 
Quality of  questionnaires and other missing data  
Each patient v is it a long with c l in ical and functional assessment involved 
complet ing a number of questionnaires – four at recruitment (SGRQ, 
EQ5D, socioeconomic status questionnaire, cost questionnaire - baseline),  
three at 6 and 12 months v is it (SGRQ, cost questionnaire – fo l low-up and 
EQ5D), and two at 6 weeks and 9 mon ths v is it (EQ5D and cost 
questionnaire– fo l low-up). Lack of regular check of adequacy of  
questionnaire completion led to incomplete data in some patients for al l  
four questionnaires at recruitment. Th is was indentif ied a few months into 
recruitment and the attempts were made to ensure that all questionnaires 
were completed adequately at  each v is it .  Some patients found it onerous 
to f i l l in four questionnaires at recruitment which was another reason for 
prov iding either no entries or incomplete entries. In a small proportion of 
patients information for a Background Questionnaire (wh ich is a part of 
socio-economical analys is and includes education, l iv ing arrangements, 
employment, wellfare benefits) was obtained retrospectively. A lso patients 
who reported adverse events dur ing their last study v is it or in whom 
missing data in their f inal v is it  c l in ical questionnaires was identif ied were 
contacted for the purpose of accurate data collect ion and to follow up 
adverse events. An approval of the Ethics committee was obtained for 
these out of study contacts.  Some patients took a decis ion to withdraw 
from the study prematurely outs ide clin ic v is it.  Ideally a l l  these patients 
should have had a withdrawal v is it organised within a short period of t ime 
after stopping taking  the study drug with measurements taken as at exit  
v is it.  Nevertheless this did not happen on some occasions either because 
the study team was not informed of premature discontinuation of the study 
drug or because adequate arrangements for withdrawal v is it  were not 
made or because patient refused to attend.  
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Missing data was dealt with by performing a sensit iv ity analysis conducted 
by mult ip le imputations from an imputation model (by using l inear 
interpolat ion, in other words replacing the missing values wit h the results 
derived from non-missing adjacent values) which contained randomizat ion 
group and all outcome measures; however if  40% or more of the data were 
missing the variable was not imputed or used in the imputation model. The 
imputation model chosen was a mult ivariate normal d istr ibut ion [190], wh ich 
has been shown to be robust against departures from mult ivariate normal 
distr ibut ion. Due to the small number of deaths, deaths or changes in 
medication were not imputed. Addit ionally, due to the small number of 
availab le data it  was decided it was not appropriate to impute the six 
minute walk data. A total of 5 imputed data sets were created and the 
results were averaged over these 5 datasets using Rubin’s equations. No 
safety or per-protocol data were imputed.  
 
W ithdrawal rate  
30 patients (34.9%) in placebo arm and 41 patients (43.2%) in co -
tr imoxazole arm withdrew pr ior to prespecif ied end of treatment at 12 
months. Excluding deaths, the withdrawal rate due to adverse events/ 
adverse reactions or withdrawal of  consent was 17.4% in placebo arm and 
38.9% in co-trimoxazole arm –  while the rate of withdrawal of consent was 
similar in both groups (8 (9.3%) and 9 (9.5%) patients respectively) ,  
patients in active arm had a higher r isk of adverse event/reactions leading 
to withdrawal (28 patients (29.5%) as opposed  to 8 (9.3%) in p lacebo arm).  
There are a number of factors that may inf luence the withdrawal rate  in an 
interventional study inc luding duration of the study, patients’  
characterist ics (severity of the  disease studied, age at recruitment, 
comorbidit ies), s ide effect profi le  of the study drug. In IPF tr ia ls disease 
progression, acute exacerbation and lung transplantation may lead to 
patient withdrawal too. When it comes to drug related adverse reactions it  
could be a patient decis ion to discontinue treatmen t if  it  affects their  
quality of l ife or an investigator decis ion if patient’s safety is  being 
compromised. Interestingly disease progression itself could be a reason 
for withdrawal of consent by a patient as one might feel it  harder to 
continue attending t ime and effort consuming v is its or become frustrated if  
the hopes of disease stabil isat ion while in the study are not met. Some 
practical aspects l ike travel d istance and frequency of study v is its,  support 
in terms of travel means and costs could also inf luence a patient decis ion 
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whether to take up or continue in the study. Rate of total treatment 
withdrawal (exc lud ing deaths) in  the treatment arms o f recent tr ia ls varies  
between 18-26% in tr ia ls using bosentan, NAC, etanercept and interferon 
gamma[96, 98, 100, 104] and 30-37% in tr ia ls using imatinib and 
pirfen idone (higher dose group) [102, 105]. W ithdrawal rate due to adverse 
events was around 14-15% in the majority of these tr ia ls with an exception 
of the tr ia l using imatinib where it was 22%. Possible explanations for a 
higher rate of withdrawals due to adverse events may be that an older 
populat ion with more  severe disease recruited into this study. Also a large 
proportion of withdrawals were early withdrawals due to drug related 
adverse reactions, predominantly gastrointestinal (8 patients (8.4%)), rash 
(3 patients (3.2%), and neutropenia (3 patients (3.2%))  which is probably 
not unexpected taking into account the side effects profi le of co -
tr imoxazole. All cases of rash leading to withdrawal were mild in severity,  
were not associated with b l ister  formation or  mucosal involvement and 
were self terminating with in 3-5 days after drug withdrawal.  The 
occurrence of nausea as the most  frequent cause for drug related 
treatment withdrawal was higher than in the study using pirfenidone (where 
it was 1%)[103] but lower than in the study using BIBF1120 in a dose of 
150 mg twice a day (where it  was 16.5%). At the same time withdrawal rate  
(exclud ing deaths) in placebo arm was lower (17.4%) than in some tr ia ls –  
25% in tr ia ls using imatinib [105] and BIBF[109] though patients in those 
tr ia ls were younger. The majority of recent studies in patients of s imilar  
age (mean age 62-64 years) with COPD which do not included true 
placebo arm but rather compare treatme nt effects of different drugs 
demonstrate that the withdrawal rate is also high particular ly in studies of 
more than six months duration and ranges between 20 and 40% [255, 256]. 
A recent Cochrane rev iew concluded that due to a high withdrawal rate  
(35-42%) coupled with a high proportion of missing outcome data the 
eff icacy and safety of combined treatment with inhaled corticosteroid and 
long acting beta-2 agonists as well as with t iotropium remained 
uncertain[255]. The rate of consent withdrawal in COPD studies is s imilar  
to our study while the rate of adverse events is only marginally lower (20 -
23%)[257]. High withdrawal rate in patients of s imilar age and different 
underly ing problems might suggest that age related comorbidit ies and 
perception of disease stabil ity might play a role.  
Over the course of the study three patients receiv ing co -trimoxazole and 
azathioprine developed transient neutropenia, wh ich resolved in a l l  cases 
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fo l lowing discontinuation of co -tr imoxazole. In the f irst case neutropenia 
was severe (aneutrophil ia ) and required hospital isat ion and t reatment with  
granulocyte-macrophage colony-stimulat ing growth factor. The neutrophil 
count returned to normal with 7 days. Although co-trimoxazole is known to 
cause pancytopenia due to its mode of action ( inhib it ing synthesis of 
tetrahydrofol ic acid, the metabolical ly active form of fo lic acid) th is s ide 
effect was unexpected to see any of i ts forms considering it was ensured 
that al l patients had normal blood folate level at recruitment and were 
receiv ing supplemental fo l ic acid in a standard dose of 5 mg  a day.  
Interestingly Medic ines and Healthcare products Regulatory Agency 
(MHRA) which was contacted after the f irst case of neutropenia stated 
there had been no prev ious reports of cytopenia in patients treated with a  
combination of co-tr imoxazole and azathiopr ine. Following th is, a l l patients  
receiv ing azathioprine or mycophenolate mofeti l had 2 -weekly monitor ing 
of their  fu l l b lood count and two further cases were withdrawn as a result  
of mild rather than severe neutropenia.  
Attempts were made to obtain  the data on primary endpoint (FVC) on all  
patients who withdrew prematurely and remained alive at 12 months after 
recruitment; th is was possible in 4 patients in placebo arm and 9 in active 
arm bringing up the total number of patients assessed for eff icac y to 60 
and 63 respectively (see consort diagram).  
 
Dif ference in baseline characterist ics in patients in PP and ITT analyses  
The results of per protocol population are potential ly biased. Comparing 
the baseline lung function data for those who have valid  FVC 
measurements at 12 months v is it with those who do not reveals s ignif icant 
differences in terms of FEV1, FVC and DLCO (Chapter 4, Table 4.10). Th is  
implies that the results of the per protocol analys is are not generalisable  
to the populat ion from which  the orig inal sample was drawn.  
 
How to improve 
In an ideal study of pat ients with  IPF a long with using appropriate 
endpoints one would want to enrol pat ients with  a l l  d isease severity 
groups, optimise recruitment, reduce withdrawal rate and compare 
treatment effects with a true p lacebo arm. In retrospect it  is  c lear that IPF 
studies should be arranged on a national level as recruitment at a regional 
level even in as large region as  large as East Anglia can be a limit ing 
factor. Although the overall IPF population in the study sites was sizable  
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(582 patients), it  is  necessary to take into account that 14% declined 
partic ipation and further 24% had stable disease. Recruitment of patients  
with stable d isease in to a study that uses change in a functional 
parameter as a primary endpoint would make it d iff icult to detect a 
difference over t ime. It would have been ideal to inc lude a true placebo 
arm to enable a definit ive assessment o f the effects of co-tr imoxazole. I t 
would have been ideal to have radiolog ical rev iew in advance of 
randomisation to ensure a selection of correct patient group. Optimising 
data collect ion by using a checklist for each v is it and ensuring 
completeness of questionnaires from the start of the study are required. In 
a study using antibiot ics i t  would be useful to determine the 
microbiologica l prof i le  of pat ients at recruitment in terms of PCP 
colonisation as well as obtain ev idence of infective agent causing 
respiratory t ract infect ion/pneumonia during the course of the study. 
Prospective assessment of causes of deteriorat ion to establish the effect 
on acute exacerbations would be required.  
 
Strengths 
This was a real l i fe study among patients from distr ict general hospitals  
populat ion predominantly. It  a l lowed patients with any severity of I PF to 
partic ipate and reflects the range of disease that is seen in c l in ical 
practice. TIPAC was a relatively large study with a total of 181 pat ients 
randomised similar to stud ies using NAC[96], bosentan[99] (BUILD-1) and 
a larger scale than some other [101, 104]. It  was pragmatic and is the only 
one in IPF that incorporated health -economics analysis. It  is  the only non -
pharmaceutically funded study in  IPF and its total budget was relative ly 
small. An integrated database was used for data collect ion and analys is  
wh ich could be used for other tr ia ls. Statist ical analys is plan was produced 
in advance of recruitment and there was a good adherence to protocol 
without change in primary or secondary endpoints after its approval.  
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Chapter 5  
 
Study 3 
Are alveolar nitric oxide and plasma VEGF markers of 
disease severity and progression in patients  
with idiopathic pulmonary fibrosis? 
5.1 Introduction  
IPF is a progressive chronic ILD of unknown cause associated with 
histopathologic pattern of UIP. Although the median surv ival in IPF is  poor, 
there is considerable variabil i ty in d isease progression with  only a  
proportion of pat ients showing ev idence of decline at 6 and 12 months 
from diagnosis. F laherty et  al [63] showed that whilst  32% of pat ients with  
IPF had a 10% decline in FVC at 6 mon ths and 54% had a similar decline 
at 12 months, 68% and 31% remained with in 10% or had a 10% 
improvement in their FVC at 6 and 12 months respectively. Even with this 
enormous variabil ity, the best method to assess disease progression and 
hence to predict outcome is serial pulmonary function over a 6 to 12 month 
period. Biomarkers, biochemical tests which predict prognosis or response 
to treatment, are required to help  identify those patients with a good or 
poor outlook. Two potentia l b iomarkers are exhaled nitr ic oxide or vascular 
endothelia l growth factor (VEGF).  
Current concept of pathogenesis of IPF suggests that repetit ive in jury to  
alveolar   epithelium and endothelia l in jury causes chemokines and growth 
factors release which in turn drives recruitment of f ibroblasts and 
endothelia l ce l ls wh ich leads to collagen -matrix remodell ing with l i t t le  
ev idence of inf lammation. Nevertheless there is ev idence of inflammatory 
cell involvement with an alveolar septal inf i l trate of lymphocytes, plasma 
cells, and hist iocytes associated with type I I pneumocytes hyperplasia [5].  
This is in l ine with a mult ip le pathways hypothesis of pathogenesis of IPF 
with ev idence of activation  of oxidant-antioxidant cascades[239].  I t  is  
thought that free radicals are involved in the role of f ibrogenesis of human 
lungs in ILD and the activation of inflammatory cells leads to the 
production of reactive oxygen species: a strong expression of nitrotyro sine 
(a byproduct of protein nit rat ion caused by a potent oxidant peroxynitrate)  
and nitr ic oxide synthase is seen in macrophages, neutrophils and alveolar 
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epithelium of lungs of patients with ear ly to intermediate stage of IPF 
compared to normal control subjects[229].  
NO is a gaseous signall ing molecule and can act as a bronchial and 
vascular smooth muscle d i lator [258]. It  was f irst  detected in 1991 in the 
exhaled breath in rabbits, gu inea pigs and humans [259]. NO is produced 
by constitut ive NO synthases (cNOS) (endothelia l  NOS and neuronal 
NOS) in the physio logical state; during inf lammation inducible NO 
synthase (iNOS) is  produced in h igher quantit ies leading to secretion of 
large amounts of NO[260].  This secretion takes place in airway ep ithelia l 
cel ls, a irway and circulatory endothelia l ce l ls and traff ick ing inf lammatory 
cells in both large and peripheral a irways and alveoli [261]. Fraction of 
exhaled NO (FeNO) is easily measured, these measurements are simple  
and highly reproducible [262]. It  is  known that FeNO concentrat ion is  
inversely re lated to the exhalat ion f low which is a result of  a reduction of  
the contact t ime of the airst ream with a surface serv ing as a source of NO. 
It is  also known that the eliminat ion rate of NO (product of FeNO and flow) 
is a  posit ive function of exhalat ion  f low which is consistent with the source 
of NO from a region of the lung that changes volume during exhalation.  
Both of these observations imply that an exhaled NO has two orig ins: 
alveolar or ig in and bronchial or ig in [261]. These princip les were used as a 
basis for creating a two-compartment model of NO exchange consistin g of  
airway and alveolar compartment reported by Tsoukias et al in 1998 [263], 
Fig 5.1 
 
Figure 5.1 Schematic of 2-compartment model used to describe nitric oxide (NO) 
exchange dynamics. Exhaled NO concentration (CENO) is the sum of 2 contributions, the 
alveolar region and the airway region, which depends on 3 flow-independent parameters: 
maximum total volumetric flux of NO from the airway wall (J'awNO, pl/s), diffusing capacity 
of NO in the airways (DawNO, pl·s-1·ppb-1), and steady-state alveolar concentration 
(CaNO, ppb). JawNO, total flux (pl/s) of NO between the tissue and gas phase in the 
airway and is an inverse function of the exhalation flow rate (VE); CNO, concentration of 
NO in the gas phase within the airway compartment[167].  
178 
 
 
When FeNO is measured at two or more f low rates (VE, ml/s)  there is a  
l inear re lat ionship between VE and the el iminat ion rate of NO VNO (a  
product of FeNO and measurement f low rate).   The way to determine 
J’awNO and CaNO is to extrapolate the a plot of  VNO against the 
exhalat ion f low back to the Y-axis (where f low is zero) to determineJ’awNO 
and to calculate the slope of the plot to determine the CaNO(“slope -
intercept” method) (F ig 5.2).  C lin ical usefulness of differentiat ing between 
CaNO and JawNO is that its change is able to prov ide information about 
the site of inf lammation (alveolar or bronchial).   
 
 
Figure 5.2  “Slope-intercept” method for estimation of alveolar concentration and 
bronchial flux of nitric oxide[167] 
Exhaled NO in healthy subjects is independent of age and lung function 
and there is no ev idence of diurnal  variat ion; at the same time there is a  
number of factors that can affect NO levels: intravenous, inhaled or 
digested L-arginine, env ironmental factors such as NO ozone, and chlor ine  
dioxide; smoking and alcohol consumption reduce the levels of exhaled 
NO[264]. There is  no complete agreement on the effect of gender (some 
large studies with more than 500 partic ipants reported an associat ion  
between female gender and lower eNO levels) and physical exercise[265].  
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Reference values for CaNO have been published by a number of research 
groups but it  is  emphasized that the choice of f low rates and algorithms for 
calculat ing the alveolar NO would result in d ifferent alveolar NO 
values[265].  
Prev ious studies of patients with asthma show that FeNO measurements at 
a s ingle expiratory f low rate of 50 ml/ l may be an important adjunct to 
diagnosis and management in selected cases [261], that inhaled steroids 
reduce the levels of exhaled NO in the asthmatic airways, that these levels 
correlate we ll with the d isease activ ity in a form of sputum eosinophil ia   
and that  they could well be used successfully to guide t itrat ion of  the dose 
of inhaled steroids [266]. Recent ATS guidelines on interpretat ion of 
exhaled NO levels recommend the use of FeNO in d iagnosing eosinophil ic  
inf lammation, monitor ing disease activ ity and predicting steroid  
responsiveness in asthma[267].  I t  was also shown that mult ip le exhalat ion 
f low FeNO d ifferent iates between bronchial and alveolar inf lammation in  
COPD and asthma and that CaNO is increased in COPD patients and its  
levels depend upon the severity of the disease as assessed by GOLD 
criter ia.  [268].  
A number of studies have investigated the role of  exhaled NO in pat ients 
with ILD inc luding systemic sclerosis with and without i ts complications in 
a form of interst it ia l lung disease and/or pulmonary hypertension [269-273], 
in pat ients with asbestosis [274], eosinophil ic  pneumonia [275] and stage 
1-4 sarcodosis [260, 276]. Some of these studies looked at alveolar rather 
than total exhaled NO.  At the same time there is a paucity of research 
investigat ing the role of  NO in pat ients with id iopathic pu lmonary f ib rosis. 
To date three studies involved measuring exhaled NO in patients with IPF: 
one assessed if  tota l eNO levels could be used for monitoring of  d isease 
activ ity[277], one other assessed if mult ip le exhalat ion f low NO levels 
would help to ident ify the level of inf lammation (alveolar or bronchial) in  
patients with a lveolit is  ( inc luding IPF) and would correlate with the severity 
of the disease[258], and one more  used IPF patients as a control group in 
assessment of role of eNO in eosinophil ic  pneumonia [275]. 
Vascular endothelia l growth factor (VEGF) is know for its dual act ion –  i t  
promotes both neoangiogenesis and increased vascular permeabil i ty as  
well as epithe lia l pro l iferat ion and repair [278]. Vascular endothe lia l growth 
factor-A is a heparin bind ing glycoprotein; several other members of VEGF 
family have been cloned recently includ ing VEGF -B, -C and –D, 
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angiogenesis is mainly regulated by VEGF-A (subsequently called as 
VEGF in this thesis) and lymphogenesis by  VEGF-C and -D. Macrophages 
and type II pneumocytes are two major sources of VEGF in the lung with  
former known to be one of the main inf lammatory cells inf i l trat ing lung 
t issue in IPF[279, 280]. Increased production of VEGF in both epithelia l 
cel ls and f ibroblasts is induced by TGF-β which is one of the main 
cytokines implicated in pathogenesis of IPF [138]. VEGF in turn increases 
the expression of connective t issue disease growth factor which promotes 
prol iferat ion of f ibroblasts [281] and production of matrix 
metalloproteinases by muscular smooth muscle cells [282]. VEGF can be 
measured in blood (both serum and plasma), BAL flu id, sputum, bronchial 
epithelia l cel ls, a lveolar type II cel ls, alveolar macrophages and 
endothelia l ce l ls. Serum VEGF levels are higher compared to those 
measured in plasma reflecting ex v ivo platelet and leukocyte release 
during blood clott ing thus result ing in an increase of VEGF concentra tion  
by 2-7 fold; in healthy adult ep ithelia l l in ing f lu id VEGF level is 500 t imes 
higher than plasma levels [148]. Plasma concentrations of VEGF correlate  
with  HRCT thoracic scan f ibrosis scores[149]. In support of i ts ro le  in the 
development of pulmonary f ibrosis, a VEFG receptor antagonist attenuated 
bleomycin-induced lung f ibrosis in a murine model [150]. Although its  
concentration is h igher in patients with progressive disease (defined as 
those with a 10% change in FVC after 6 months) [149], the usefulness of 
VEGF as a surv ival ind icator has not been evaluated.  
The aims of the study were:  
To determine if  there is an associat ion between the disease severity (as 
assessed by DLco) of pat ients with  id iopathic pulmonary f ibrosis and 
alveolar NO or p lasma VEGF. 
To determine if a lveolar NO and/or plasma VEGF measured at baseline 
might help to  predict subsequent disease progression (defined as death or  
10% decline in FVC and/or 15% decline in DLCO) at 18 months. 
 
5.2 Methods 
The study was conducted in accordance with Goo d Clin ical Practice 
inc luding Research Ethics Committee (09/H0310/78) and all  part ic ipants 
gave wr itten informed consent.  
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Patients 
Patients were identif ied  from the respiratory c l in ic of  the Norfolk and 
Norwich Hospital and approached by the Chief Investigator (Dr Shulgina).  
Elig ib le patients had clin ically labelled diagnosis of id iopathic pulmonary 
f ibrosis with HRCT scan features compatib le with Usual Interstit ia l 
Pneumonia (UIP)[5]  and were able to prov ide informed consent. Histology 
was not required as an entry cr iter ion. Pat ients were greater than 40 years 
old; none had exacerbation of their d isease or respiratory tract infect ion or  
changes in their immunosuppression treatment with in 6 weeks of 
recruitment. None of the patients were taking co -tr imoxazole. Patients  
were exc luded from the study if  a secondary cause for pulmonary f ibrosis 
was identif ied, i f  they had a recognised signif icant co -exist ing respiratory 
disorder or if  they had a signif icant medical,  surgical or  psychiatr ic d isease 
that wou ld affect subject safety or inf luence the study outcome, i f  they had 
cl in ical ev idence of r ight heart fa i lure or were current smokers or females 
who were pregnant or were breast-feeding.  
 
Study design  
Patients attended the cl in ic  for a screening v is it  and baseline 
measurements including history, medical examination, and assessment of 
alveolar n it r ic oxide, and a venepuncture to collect per ipheral venous 
blood for plasma VEGF analys is, fo l lowing informed consent. All other data 
was obtained from the medical notes. Patients attended clin ic for v is it 2  
between four and eight months and v is it  3 between sixteen and twenty 
months after the screening v is it  for repeat pulmonary function tests. 
Disease progression was def ined as death or 10% decline in FVC and/or 
15% decline in DLCO at 18 months. 
Exhaled nitr ic oxide measurement 
Exhaled nitr ic oxide was measured using a NIOX n itr ic oxide analyzer at  
baseline v is it  (Aerocr ine, Chicago, I l l ino is USA), with an expiratory f low 
rate of 50ml/sec according to American Thoracic Society  guide lines (18).  
In addit ion, measurements were made at expiratory f low rates (VE) of 30, 
100 and 200 ml/sec. An attempt to obtain  three valid  FeNO measurements 
was undertaken at each of four f low rates for each patient. The mean of 
three separate measures of nitr ic oxide at each f low rate was used in the 
analysis. A model by Tsoukias and George was used to estimate CaNO and 
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JawNO[167, 263]. For each f low rate VE the eliminat ion rate of NO (VNO) 
was calculated as a function of VE (VNO = VE x FeNO). At a f low rate of ≥ 
50 ml/s th is re lat ionship is l inear and could be expressed as VNO = VE x 
FeNO = CaNO x VE + JawNO .  The analyser was calibrate d two weekly 
using a cyl inder of nitr ic oxide at concentration of 208ppb.  
Vascular endothelia l growth factor (VEGF) 
Five mil l i l i tres of  venous blood was drawn dur ing venepuncture into 
ethylene diamine tetra acetic acid  bott le, centr ifuged with in 1  hour of  
collection at 300g for 10 min . P lasma was separated and stored at -80°C 
freezer. All  samples were analysed simultaneously  after being kept in a  
freezer for  18-24 months. Level of  VEGF in p lasma was assessed using a  
commercial ly availab le validated Human V EGF-A Platinum Enzyme- l inked 
immunosorbent assay (ELISA) k it  (eBioscience, Bender MedSystems 
GmbH). The assay was performed by Dr D Sexton,  a Lecture in  
Immunology at the University of East Anglia A manufacturer ’s 
recommendation was used as guidance and ea ch sample, standard and 
control was assayed in duplicate.  Seven standard dilut ions ranging from 
1000 to 15.6 pg/ml were used. The absorbance was measured at 450 nm. A 
standard curve was prepared from seven human VEGF -A standard dilutions 
and sample concentration determined. The l imit of  detection of human 
VEGF-A defined as the analyte concentration result ing in an absorbance 
signif icant ly h igher than that of the di lu t ion medium (mean plus two 
standard dev iations) was determined to be 7.9 pg/ml (mean of 6 
independent assays). Intra -assay reproducibi l i ty was prev iously calculated 
in three exper iments and the coeff ic ient of variat ion was 6.2%. The 
calculated overall inter -assay coeff ic ient of variat ion was 4.3%. There was 
no cross reactiv ity detected for the assay, notably not with human VEGF-B, 
C, D and PfGF. According to a manufacture’s brochure an expected VEGF -
A level in plasma of healthy donors was estimated as mean 45.7 pg/ml.   
Stat ist ical analysis  
All stat ist ica l analys is was completed using statist ica l a nalys is using SPSS 
version 18 (Statist ical Package for the Social Sc iences). Because of non -
normally d istr ibuted data of exhaled nit r ic oxide measurements it  was 
transformed using natural log with subsequent back -transformation for the  
purpose of obtain ing  means and standard dev iations. A T test was 
undertaken to compare the differences between baseline demographic 
data, pulmonary function tests and exhaled nitr ic oxide measurements in  
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(1) pat ients with severe or mild/moderate IPF defined as DLCO < 40% and 
≥ 40% predicted respectively and (2) patients with or without a combined 
event defined as death, or a 10% decline in absolute FVC and/or 15% 
decline in absolute DLCO at 18 months after recruitment. Univariate  
correlat ion between alveolar NO as well as VEGF  and lung function 
parameters at baseline was examined using Spearman’s rank correlat ion 
coeff ic ient. Mult ip le l inear regression analysis was used to evaluate an 
abil ity of  a lveolar NO as well as VEGF to predict  (1)  a 10% decline in  
absolute FVC, (2) 15% decline in absolute DLCO, and (3) a combined 
event defined as death or a 10% decline in absolute FVC and/or 15% 
decline in absolute DLCO, at 18 months after recruitment. A two -sided p-
value <0.05 was considered statist ica l ly s ign if icant.  
5.3 Results 
A total 27 patients with IPF were recruited into the study. The mean age of 
patients was 73.1 ± 9.4 years and 23 (85%) were men. All  patients were 
non smokers. The majority (82%) were prevalent cases. Four (15%) 
patients had histopathological confirmation of d iag nosis and 13 (48%) 
patients had severe disease as ev idenced by DLCO of < 40% predicted. 
Six (22%) patients were receiv ing treatment with long term prednisolone, 
two of these in combination with  azathiopr ine. All  pat ients were able to  
perform the mult ip le  f low rate manoeuvre and 89% patients were able to  
produce three valid measurements for each of the f low rates. Two pat ients 
died, one was withdrawn from the study (fol lowing development of lung 
carcinoma) and two more were lost to fo l low up by 18 months aft er  
recruitment. 
5.3.1 Association between the disease severity and alveolar NO and 
plasma VEGF  
Baseline characterist ics  
13 patients had ev idence of severe disease. In two patients who did not  
have baseline DLCO measurements the disease severity was assess ed on 
the grounds of FVC percent predicted as severe if less than 60% and 
mild/moderate if  greater than 60% (both patients had mild/moderate 
disease based on this cut off).  Patient baseline characterist ics pending on 
disease severity are shown in Table 5.1 . At baseline patients with severe 
disease were older,  had higher MRC dyspnoea grade, longer disease 
duration and lower FVC.  
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Severe IPF 
(n=13) 
Mild/moderate IPF 
(n=14) 
Male, n 10 13 
Age, years 75.3 ± 9.7 71 ± 9.0 
Smoking history, n 
   Never smoker 
   Ex-smoker 
3 
10 
4 
10 
Clubbing, n 4 4 
Histopathological confirmation, n 2 2 
Emphysema 4 3 
Time from diagnosis, years 3.4 ± 2.3 2.3 ± 1.9 
MRC dyspnoea grade, mean 3.2 2.7 
FVC, % predicted 68.7 ± 11.2 74.2 + 22.7 
DLCO, % predicted 31.9 ± 5.7 56.2 +14.2 
Immunosuppressive therapy, n              
   Prednisolone  
   Azathioprine 
4 
2 
2 
0 
Use of oxygen, n 2 0 
Table 5.1 Baseline characteristics of patients with severe (DLCO < 40% predicted) and 
mild/moderate (DLCO ≥ 40% predicted) idiopathic pulmonary fibrosis. MRC: Medical 
Research Council, FVC: forced expiratory volume, ml: millilitres, DLCO: diffusing capacity 
of carbon monoxide.  
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Exhaled NO and its correlat ion with c l in ical parameters  
Patients with severe disease had lower FeNO50, JawNO and plasma VEGF 
but higher CaNO, the results were statist ical ly s ign if icant for FeNO and 
JawNO (Table 5.2).  
 
Severe IPF 
(n=13) 
Mild/moderate IPF 
(n=14) 
p 
FeNO 50, ppb 18.45 ± 2.38 27.34 ± 3.43 0.038 
CaNO, ppb 4.67 ± 0.74 3.27 ± 0.64 0.171 
JawNO, nl/sec 663.22± 137.36 1200.51± 166.92 0.023 
Plasma VEGF, pg/ml 103.86 ± 17.00 146.10 ± 17.06 0.095 
Table 5.2  Comparison of FeNO50, CaNO, JawNO and VEGF results between patients 
with severe and non-severe IPF. All data presented as mean and SD. FeNO: fraction of 
end tidal nitric oxide, CaNO: alveolar concentration of nitric oxide, JawNO: nitric oxide flux 
from the airway wall, VEGF: vascular endothelial growth factor. 
 
Correlat ion between exhaled NO and pulmonary function parameters at 
baseline are shown in Table 5.3  and Figure 5.3 . There was a signif icant 
negative correlation between plasma FeNO50 and TLC percent predicted (r 
= -0.482, p = 0.017).There was a sign if icant posit ive correlat ion between 
plasma VEGF concentration and FVC percent predicted (r = 0.393, p = 
0.047) and DLCO percent predicted (r  = 0.575, p = 0.003). There was also  
a s ignif icant posit ive correlation between alveolar conc entration of nit r ic 
oxide and Medical Research Council dyspnoea score and a negative 
correlat ion between bronchial f lux JawNO and FVC percent predicted and 
TLC percent predicted. 
  
SaO2 MRC 
FVC, 
%predicted  
TLC, 
% predicted    
DLCO, 
% 
predicted    
FeNO 50 Correlation Coefficient .221 -.028 -.361 -.482
*
 .162 
 
Sig. (2-tailed) .269 .892 .065 .017 .440 
CaNO Correlation Coefficient -.076 .394
*
 .061 .045 -.341 
 
Sig. (2-tailed) .707 .042 .761 .835 .096 
JawNO Correlation Coefficient .179 -.015 -.417
*
 -.555
**
 .220 
 
Sig. (2-tailed) .371 .942 .030 .005 .291 
Plasma  
Correlation Coefficient 
.013 .037 .393
*
 .291 .575
**
 
 VEGF Sig. (2-tailed) 
.950 .856 .047 .178 .003 
**. Correlation is significant at the 0.01 level (2-tailed)  
*. Correlation is significant at the 0.05 level (2-tailed) 
Table 5.3 Correlation between exhaled NO and baseline lung function parameters  
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Figure 5.3 Relationship between (A) exhaled NO and TLC % predicted, (B) plasma VEGF 
and FVC % predicted and (C) plasma VEGF and DLCO % predicted at baseline 
A 
 
 
B 
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5.3.2 An association between alveolar NO and/or plasma VEGF and disease 
progression at 18 months  
Disease status at 18 months after recruitment was established in 26 
patients. One pat ient was lost to fol low up, was confirm ed to be al ive but 
did not have lung function measurements after the baseline v is it and is 
therefore not included in th is analysis;  in two more patients who did not  
have 18 months measurements (but were confirmed to be alive at that t ime 
point) the d isease status was assessed on the grounds of their  lung 
function results at  a 6  months fol low up v is it  using the same pre -defined 
lung function criter ia. Overall two patients died and further sixteen 
experienced a decline in the ir FVC and/or DLCO during 18 month s of 
fo l low up.  
Baseline characteristics 
Baseline characterist ics of patients with progressive and stable id iopathic 
pulmonary f ibros is are shown in Table 5.4. Patients with progressive 
disease were younger, had a signif icantly lower baseline FVC percent 
predicted (p = 0.008), TLC percent predicted (p = 0.025) and DLCO 
percent predicted (p = 0.005). Only patients with progressive disease were 
prescribed with immunosuppression and oxygen.  
 
Progressive 
disease 
(n=18) 
Stable disease 
(n=8) 
Male, n 14 8 
Age, years 71.8 ± 10.3 75.1 ± 7.3 
Smoking history, n 
   Never smoker 
   Ex-smoker 
4 
14 
3 
5 
Clubbing, n 5 2 
Histopathological confirmation, n 4 0 
Time from diagnosis, years 2.9 ± 1.9 2.7 ± 2.9 
MRC dyspnoea grade, mean 2.9 3.0 
FVC, % predicted 65.8 ± 14.2 85.5 + 19.9 
TLC, % predicted 64.0 ± 13.7 82.0 ± 21.2 
DLCO, % predicted 38.0 ± 12.1 57.9 +18.0 
Immunosuppressive therapy, n              
   Prednisolone  
   Azathioprine 
6 
2 
0 
0 
Use of oxygen, n 2 0 
Table 5.4 Baseline characteristics of patients with progressive and stable idiopathic 
pulmonary fibrosis.  
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Exhaled nitric oxide and plasma VEGF 
Comparison of exhaled nitr ic oxide results shows that there is no 
difference in any of n itr ic  oxide parameters between patients with and 
without progressive disease but patients who progressed had a 
signif icant ly lower VEGF levels compared to those who did not (Table 5.5, 
Figure 5.4).  
 
 
Disease progression 
(n=18) 
Stable disease 
(n=8) 
p 
FeNO 50, ppb 22.72± 2.86 21.62± 3.60 0.82 
CaNO, ppb 3.83± 0.64 3.53 ± 0.68 0.77 
JawNO, nl/sec 934.77± 141.87 800.95± 248.81 0.62 
Plasma VEGF, pg/ml 105.54± 11.21 159.68 ± 29.87 0.05 
 
Table 5.5 Comparison of FeNO50, CaNO, JawNO and VEGF results between patients with 
stable and progressive IPF. All data presented as mean and SD. FeNO: fraction of end 
tidal nitric oxide, CaNO: alveolar concentration of nitric oxide, JawNO: nitric oxide flux 
from the airway wall, VEGF: vascular endothelial growth factor. 
 
 
Figure 5.4 Comparison of plasma VEGF results between patients with progressive and 
stable IPF 
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Prediction power of exhaled nitric oxide and VEGF 
Mult ip le l inear regression model used to predict a r isk of 10% decline in  
FVC or 15% decline in DLCO or a combined event (either or both of the 
above or death at 18 months) was set to include the fo l lowing baseline 
parameters: MRC dyspnoea score, SaO2, FVC percent predicted, TLC 
percent predicted, DLCO percent predicted, FeNO, CaNO, JawNO, plasma 
VEGF. 
 The r isk of  10% decline in  absolute FVC at 18 months after recruitment 
was signif icantly and independently re lated to MRC dyspnoea score 
(regression coeff ic ient = 9.11; 95% confidence interval = 2.94, 15.29; p = 
0.007), DLCO percent predicted (regression coeff ic ient = 0.91;  95% 
confidence interval = 0.54, 1.27; p = < 0.001), JawNO (regression  
coeff ic ient = -0.02; 95% confidence interval = -0.02, -0.006; p = 0.004), 
and plasma concentration of VEGF (regression coeff ic ient = -0.01; 95% 
confidence interval = -0.17, -0.03; p = 0.01). The R and R square values 
for th is model were 0.83 and 0.69 respectively;  the result ing model 
s ignif icance value was 0.002. Using the model output the result ing FVC at 
18 months could be calculated using the fol lowing formula:  
FVC = -47.42 + (9.11xMRC) + (0.91xDLCO%predicted) –  (0.02xJawNO) –  
(-0.1xVEGF) 
The same model set at predict ing a 15% absolute decline in DLCO at 18 
months after recruitment showed that MRC dyspnoea score (regression 
coeff ic ient = 6.34; 95% confidence interval = 0.19, 12.5; p = 0.044) and 
alveolar concentration of nitr ic oxide (CaNO) (regression coeff ic ient = 
3.46; 95% confidence interval = 1.40, 5.51; p = 0.003) were signif icantly 
predictive of th is outcome. The R and R square values for th is model were 
0.82 and 0.68 respectively; the result ing model s ignif icance value was < 
0.001. Using the mode l output the result ing DLCO at 18 months could be 
calculated using the fol lowing formula:  
DLCO = -40.49 + (0.19xMRC) + (03.CaNO) 
Only baseline DLCO percent predicted (regression coeff ic ient = 0.02; 95% 
confidence interval = 0.005, 0.03; p = 0.006) remaine d in the model 
predicting an occurrence of a combined events of death or 10% decline in 
FVC and/or 15% decline in  DLCO at 18 months. The R and R square 
values for th is model were 0.58 and 0.33 respectively; the result ing model 
s ignif icance value was < 0.006. 
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5.4 Discussion 
This prospective study looking at the ro le of  exhaled n itr ic  oxide 
parameters and plasma vascular endothelia l growth factor in pat ients with 
id iopathic pulmonary f ibrosis  showed that alveolar nit r ic oxide 
concentration which is  a marker of a lveolar inf lammation has a strong 
predictive value for subsequent c lin ically s ignif icant decline in DLCO and 
that plasma VEGF level is s ignif icantly lower in pat ients with progressive 
disease, that it  corre lates posit ively with FVC and DLCO, and that i t  is  a  
strong predictive factor of a c l in ically s ignif icant FVC decline over t ime.  
A number of studies assessed the role of eNO in patients with interstit ia l 
lung disease (ILD) and found that i ts measurement might be useful in  
patients with systemic sclerosis both with and without ILD as well as in 
eosinophil ic  pneumonia and less useful in both active and inactive 
sarcoidosis. Moodley et a l [269],  demonstrated that alveolar NO was 
elevated in patients with scleroderma without ILD compared to those with 
ILD suggesting presence of subclin ical inf lammation ( confirmed by higher 
neutrophil and eosinophil count in broncho -alveolar lavage f lu id in  
scleroderma patients compared to healthy controls) before the cl in ical and 
radio logical ev idence of it  becomes apparent. Girgis  et al [270] 
demonstrated increased concentrations of a lveolar NO in sc leroderma 
patients with ILD with and without concomitant pulmonary hypertension.  I t  
had also been shown that in patients with scleroderma the levels of  
alveolar NO accurately ident ify patients with a h igh r isk of developing lung 
function deteriorat ion [273],  are related to the extent of ILD as ev idenced 
by the CT scan f ibrosis score and are inversely related to  the sever ity of  
ILD as ev idenced by diffusing capacity for carbon monoxide [271, 283].  
A recent study of patients with eosinophil ic  pneumonia  (EP) showed that 
CaNO levels in  these patients were signif icantly h igher than in patients  
with IPF and healthy controls, th is  was associated with a higher number of 
iNOS posit ive cells in BAL flu id (suggesting that more ntirosative stress 
occurs in EP compared to IPF), that CaNO levels had a signif icant 
correlat ions with VC, VC % predicted and peripheral blood eosinophil ia  
(prior  to  treatment with cort icosteroids) and that CaNO level a long with  
FeNO level was reduced by treatment with corticosteroids [275]. Alveolar 
NO has also been suggested for use as a noninvasive marker for 
assessment of severity of inf lammation in asbestosis [274]. 
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In a study of 42 patients with sarcoidosis no difference was found in FeNO, 
CaNO and JawNO compared to healthy controls; a lso  there was no 
difference in these measures between patients with active and inactive 
sarcoidosis though there was a signif icant negative correlat ion between 
CaNO and FVC % predicted and DLCO % predicted [276]. 
The data on role  of eNO in d iagnosis and management of IPF is l imit ed 
and does not allow drawing  any f irm conclusions. A study by Paredi et  
al[277] assessed total exhaled NO in 11 patients with f ibrosing alveolit is  in  
relat ion to  the d isease activ ity based on the cellu lar  content of broncho -
alveolar lavage f lu id and  the effect of treatment with oral cort icosteroids 
on its levels. It  showed that al l  patients ( irrespective of disease activ ity)  
had elevated total exhaled NO levels (11.2 ppb) compared to 13 
nonsmoking healthy subjects (6.9 ± 0.5 ppb, p<0.05) and this cor related 
well with d isease activ ity (as ind icated by any of the fo l lowing ce ll  count in  
BAL flu id: lymphocytes >14%, neutrophils >4%, eosinophils >3%);  patients  
treated with cort icosteroids had lower levels of NO than untreated patients  
(9.0 ± 1.0 ppb and 13.1 ± 1.0 ppb respectively,  p<0.05). Lehtimaki et al ’s 
study[258] of patients with alveolit is   suggested that there was an 
increased alveolar concentration of NO in these patients compared to 
healthy controls (4.1 ± 0.3 ppb  and 1.1 ± 0.1 ppb respectively) and that 
bronchial NO f lux was equal in both alveolit is  and healthy control groups 
suggesting inf lammatory process on alveolar rather than conducting 
airways level. A lveolar NO concentrat ion correlated negatively with DLCO 
percentage of predicted. It  has to be kept in  mind that pat ients enrolled in  
the f irst study were relat ively young (mean age 58 ±  12 years), had milder 
disease (DLCO 61 ± 7% predicted)  and were diagnosed prior to 
reconsideration of IPF diagnostic criter ia[5] with only 3 of 11 pat ients 
hav ing undergone lung biopsy therefore they might have represented a 
more heterogeneous disease group. A lso only tota l eNO was measured 
therefore it is  not possible to comment on the level of inf lammation in  
detai ls. In the second study alveolit is  group included patients with both IPF 
and hypersensit iv ity pneumonit is with no separate analys is made for each 
of condit ions. A study of Furukawa et al assessing the role of eNO in  
diagnosis and management of eosinophil ic  pneumonia enrolled 13 patients  
with mild/moderate IPF (mean DLCO 66.7%) as a control group and 
showed that there was no signif icant difference between FeNO and CaNO 
levels between patients with IPF and healthy controls and that JawNO 
levels were not different between all three groups [275]. Two other studies 
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are presented in an abstract form; one compared CaNO and JawNO levels 
between 12 patients with IPF (al l with c l in ica l -rad iolog ical d iagnosis), 
sarcoidosis and healthy controls and found that patients with IPF had a 
higher level of CaNO compared to two other groups and that JawNO was 
not different between all three groups [284]. Another study comparing 
combined pulmonary f ibrosis and emphysema with emphysema alone 
recruited 14 patients with IPF as a control group but the detai ls of  the IPF 
patients and their NO characterist ics are not available [285].  
This study is  the f irst  one assessing a discriminat ing ro le of exha led nitr ic  
oxide in d isease severity and disease progression in pat ients with IPF. 
CaNO was able to strongly (R square 0.69) predict a c l in ically s ignif icant 
decline in DLCO over subsequent 18 months which is a marker of disease 
progression and poor outcome. Elevated levels of alveolar NO in IPF 
reflect presence of an inf lammatory component in  addit ion to  an epithelia l  
in jury wh ich is considered to be the main pathogenic pathway in IPF [286]. 
The presence of inf lammation in IPF has been prev iously confirmed by an 
expression of inducible NOS in a lveolar epithe lium the intensity of which is  
related to h isto logic abnormalit ies found in b iopsy specimens of the lung of 
patients with IPF and is more pronounced in pat ients with  s igns of active 
inf lammation rather than with honeycombing [229].  
A signif icant difference in  FeNO and JawNO between patients with severe 
and non-severe IPF is unexpected and the reason for i t  is  not c lear.   
Raised levels of FeNO and JawNO would ref lect an inf lammation at the 
level of airways which would not be affected in IPF  alone. While s imilar  
number of patients were formally d iagnosed with emphysema in both 
groups it is  possible that a h igher number of patients had undiagnosed 
emphysema or asthma in non-severe group that would expla in a d iffe rence 
in markers of bronchial inf lammation.  
There is confl ict ing data on the ro le of VEGF in  pulmonary f ibrosis. Most of  
these data come from animal models and in human s VEGF levels have 
been studied predominantly in BAL flu id. Data from murine model suggests 
that high levels of VEGF can aggravate pulmonary f ibrosis  but a l lev iate 
pulmonary hypertension [140]. In contrary recent work by Stockman et al 
showed that that deletion of VEGF in myelo id cells (wh ich include 
macrophages) resulted in s ignif icantly reduced formation of b lood vessels 
wh ich was associated with aggrav ated f ibrot ic t issue damage with  
decrease in ep ithelia l cel l  surv ival and an increase in myof ibroblast 
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invasion; the authors concluded that the process of angiogenesis driven by 
myeloid cell-der ived VEGF was essential for prevention of 
f ibrosis [280].There is a suggestion that VEGF expression with in  
f ibroblastic foci may be reduced[146]. While BALF VEGF levels were 
reported to be depressed in IPF pa tients in  three studies [287-289] and not 
to be signif icant ly d ifferent compared to healthy controls or to correlate  
with baseline lung function in another study [290], the levels were 
signif icant ly higher in those patients who subsequently showed progressive 
disease or died than in those who did not suggesting that the elevated 
levels were of c l in ica l s ignif icance [290]. Serum[288, 289] as well as 
plasma[149] levels in pat ients with IPF were also reported as not being 
different from those in healthy volunteers. Longitudina l changes in VEGF  
and HRCT score were also found to be posit ively re lated [149].  
This study showed that baseline plasma VEGF levels were lower in  
patients with severe disease (though not reaching sta tist ica l s ignif icance) 
compared to those with milder disease and signif icant ly lower (p = 0.05) in  
patients with subsequent disease progression as opposed to those with 
stable disease. This is in contrast to prev ious f indings of Simler et al 
showing that pat ients with  subsequent disease progression had higher 
levels of baseline VEGF compared to non -progressors. Possible  
explanation for  th is d ifference may be that whilst  baseline d isease severity  
was similar in both study groups (mean DLCO percent predicted 40.8 in  
Simler et  a l study versus 43.6 in our study) our patients were o lder (mean 
age 73.1 years versus 60.4 years), had shorter disease duration (2.8 years 
versus 4.3 years) and a smaller  percent of them were on treatment for IPF 
inc luding immunosuppress ion (30 versus 44%). The effect of age, d isease 
duration and treatment on VEGF levels in IPF is  not known (a lthough there 
is a c l in ical observation suggesting that treatment with co -tr imoxazole may 
reduce the levels of VEGF compared to patients not treated  with co-
tr imoxazole[188]). It  is  possible that patients had different c l in ical 
phenotypes and that patients in S imler cohort had a more slow progression 
(considering longer disease duration) possibly with a smaller  number of 
exacerbations.  
To understand the reasons for reduction in p lasma VEGF level in pat ients  
with  progressive disease compared to stable  patients i t  wou ld be helpful to  
know the BAL flu id and alveolar l in ing VEGF level. There is an ev idence of 
a s ignif icant gradient in alveolar VEGF concentration from epithelia l 
broncho-alveolar surface f lu id to serum and of BALF VEGF levels declin ing 
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signif icant ly with age in healthy volunteers [288]. A phenomenon of a 
difference between BALF VEGF concentration (be ing low) and 
serum/plasma VEGF concentration (being high) as well as a correlat ion 
between BAL flu id VEGF concentration and DLCO have been demonstrated 
in the past[149, 288]. Low BALF VEGF levels could reflect damage to or 
apoptosis of alveolar epithelium with absent angiogenesis in the affected 
areas while higher plasma VEGF levels could ref lect a compensatory 
angiogenesis in a lternat ive areas of the lung [291]. Heterogeneity in  
vascular remodell ing  in IPF has been demonstrated with h igh vascular  
density in areas of low grade f ibrosis and lo w vascular density in the most 
extensively f ibrot ic  lesions [145]. An increased expression of VEGF in  
capil lary endothelia l cel ls and alveolar type II epithe lia l cel ls in highly 
vascularised alveolar septa in contrast to low expression of VEGF in  
f ibroblasts and leucocytes of f ibrot ic lesions has also been reported [145]. 
In this respect it  is  not possible to  compare radiolog ical or h istopathologic  
severity of the disease in terms of the extent of honeycombing and 
f ibroblastic foc i between our patients and patients recruited into Simler et  
al study. While i t  is  st i l l  not c lear i f  angiogenesis provokes f ibrogenesis or  
is a necessary mechanism to prevent excessive f ibrosis demonstrat ion of 
lower VEGF levels in pat ients w ith subsequent disease progression is in  
support of the recent f ind ings by Stockmann et al of a  drastic increase in 
miofibroblast invasion associated with ra ised levels of hypoxia - inducible 
factor expression in  a context of reduced VEGF expression due to m yelo id  
cell VEGF deletion in a model of f ibrosis in b leomycin treated mice [280]. 
A signif icant posit ive correlation between baseline levels of VEGF and 
baseline DLCO and FVC as well as a protective effect of higher baseline 
plasma VEGF levels on subsequent 18 months disease progression  was 
observed in th is study. Th is was contrary to the observation of Ando et a l 
who demonstrated that higher VEGF levels were highly predic t ive of 
disease severity defined as a high alveolar -arter ia l d ifference of oxygen 
value and that lower baseline VEGF level correlated with smaller monthly 
change in percent predicted v ita l capacity  in their study of 41 patients with  
IPF [289]. 
Of note DLCO percent predicted at baseline confirms the well  accepted 
fact of its prognostic s ignif icance [14] by predicting both FVC decline and a 
combined event of FVC decline and death over subsequent 18 month 
fol low up. 
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This study has a number of l imitations. First ly it  d id not inc lude healthy 
controls. It  is  possible to correlate our CaNO results with those shown in  
healthy controls in other studies of exhaled NO in asthma, COPD and other 
ILD the majority of which showed mean CaNO in a range of 1.1 –  3.4 ppb 
but ideally controls should be matched for age as recent data shows that 
FeNO50 and CaNO increase signif icantly with age greater than 60 years 
which could be a result of a decrease in the capil lary b lood volume with  
reduced NO diffusion [292]. Secondly a small group of patients was on 
immunosuppression treatment the effect of which on CaNO in IPF and 
VEGF levels is not known. Third ly HRCT data on extent and sever ity of  
f ibrosis as well as longitud inal CT data would  be helpfu l to fo l low up the 
value of baseline results of CaNO and VEGF. On the other hand CaNO and 
VEGF are both non-invasive markers of d isease activ ity the use of which is  
not associated with an addit ional dose of radiation.  
In conclusion CaNO and VEGF, both non -invasive markers, might 
complement the information obtained from three other c lin ically re levant 
investigat ions including HRCT, FVC and DLCO measurement. The 
usefulness of CaNO assessment as shown in this study is that a s ingle  
measurement at baseline may predict further disease behav iour.  The role  
of plasma VEGF in the assessment of baseline severity and subs equent 
behav iour of IPF requires further evaluation as the results of th is study are 
not in l ine with  published data. 
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Chapter 6 
Study 4 
Prognostic modelling in IPF 
6.1 Introduction 
Although overall prognosis of IPF is poor there is a s ignif icant variabil i ty in  
functional change over t ime ranging from improvement or minimal change 
in PFT over years to a s ignif icant decline leading to death over 6 -12 
months often preceded by an exacerbation/admission [215, 293]. A large 
number of indiv idual c l in ical parameters are associated with poor surv ival 
in IPF inc luding demographic, c l in ica l, phys iolog ic, rad io logic a nd 
pathologic markers. A range of investigators have looked at combining a 
few parameters into c l in ical prediction models. Clin ical pred ict ion models 
are statist ical models that combine clin ical f ind ings from history, physica l 
examination, and/or test resu lts to estimate the probabil ity of an outcome, 
usually a diagnosis or prognosis [196]. The success of the model depends 
on the careful selection of predictor variables that are reproducibly a nd 
commonly measured in current c lin ical pract ice, and on performance of 
external validat ion and cl in ica l impact analys is [196].  
Using the identif ied independent determinants of surv ival Kin g et al[61]  
developed a mathematical c l in ical-rad io logic-physio logic (CRP) scoring 
system for predict ion of surv ival t ime in pat ients with IPF. I t inc luded the 
fol lowing parameters: age, smoking history, c lubbing, extent of profusion 
of interst it ia l opacit ies and presence or absence of pulmonary 
hypertension on the chest radiograph, % predicted TLC and pO2 at the end 
of maximal exercise. The CRP scoring system was used in 238 pat ients 
with new d iagnosis of IPF. It was demonstrated that the CRP score 
correlated with the extent and severity of the important histopathologic  
features of IPF (f ibrosis, ce llu lar ity, granulat ion/connective t issue, and the 
total pathologic derangement). The degree of dyspnoea, presence of f inger 
c lubbing, the extent of profusion and honeycombing, ev idence of 
pulmonary hypertension on chest radiograph, the severi ty of impairment of 
lung volumes, spirometry, lung mechanics, DLCO and gas exchange while  
at rest and on exercise at baseline were al l s ignif icant predictors of 
surv ival (p<0.05) as demonstrated by the study of King et al. [61]. As a 
result a CRP model was derived that could be used in estimation of the 
surv ival t ime in a pat ient with IPF  
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As mentioned prev iously in IPF co -exist ing emphysema can contribute to 
the PFT abnormality and this  should be taken into account when 
quantify ing the disease severity as using PFT alone might be misleading.  
Therefore Wells et al. constructed a composi te physio logic index (CPI) 
against the morphologic severity of disease in order to calibrate the 
quantif icat ion of pulmonary f ibrosis using PFT in isolat ion [294]. The CPI 
was derived in 106 patients with  IPF and was tested on a further 106 
patients. The fol lowing formula was used: extent of disease on CT = 91.0 –  
(0.65 x percent predicted DLCO) - (0.53 x percent predicted FVC) + (0.34 x 
percent predicted FEV1). The study demonstrated that 1) CPI correlates 
with the extent of pu lmonary f ibrosis on CT more strongly (r  = 0.71) and is 
l inked to mortal ity more closely than indiv idual pulmonary function indices; 
2) the CPI accounts for existing emphysema; 3) in p atients without 
emphysema on CT the CPI reflected the extent of f ibrosis no better than 
DLCO levels [294]. 
Du Bois et al in a study of 1,099 patients with  definite HRCT or biopsy 
confirmed diagnosis of IPF used Cox proportional hazards model to derive 
an abbrev iated clin ica l model compris in g only 4 readily available  
predictors of mortal ity: age ≥ 70 years vs <60, HR 2.21 (95% CI 1.35 -
3.62), respiratory hospita l isations, HR 4.11 (95% CI 2.57 -6.58), % 
predicted FVC ≤ 50 vs ≥ 80, HR 5.79 (95% CI 2.55 -13.15), and 24 week 
change in % predicted FVC ≤ -10 vs > 5, HR 7.99 (95% CI 5.26 -12.14). As 
a result they developed a practical mortal i ty scor ing system (Table  
6.1)[295] which if  validated would  be useful in c l in ical practice for  patients 
with the d isease of any severity.  
 
Table 6.1  Mortality risk scoring system for patients with IPF[295]. 
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Mathematical c l in ical- radio logic-physiolog ic (CRP) scoring system 
developed by King et al could be used for prediction of surv ival wh ile  
composite physiolog ic index developed by Wells et a l could be used for the 
assessment of the extent of the disease in IPF patient with coexist ing  
emphysema. However these two models are confined to research only as  
they are large ly based on the inclusion of factors that are not widely 
accessible in the cl in ical practice [295]. At present there is a lack of 
l i terature on models that include readily availab le s imple cl in ical factors 
and there is no data available on whether patient education, income and 
l iv ing arrangements are important predictors of prognosis and sh ould be 
inc luded in outcome prediction models.  
The purpose of the study was to identify independent predictors of both 
mortal ity at 12 months and 5% and 10% decline in FVC over 6 and 12 
months the latter being a marker of poor prognosis in patients with IP F. It 
was also aimed at assessing if  patients’ social background and status 
affect the course of the disease.  
 
6.2 Methods 
Patients 
The source population included patients who partic ipated in the 
interventional study 2 (co -tr imoxazole in I IP). Considering  absence of 
effect of co-tr imoxazole on lung function and surv ival in intent ion to treat 
populat ion data of patients from both active and placebo groups were used 
(s imilar to patients choice in a study which developed simplif ied mortal it y 
r isk scoring system for IPF patients [295]). Patients who died between the 
date of recruitment and f inal v is it a t 12 months were inc luded.  
Parameters include into a model of predictors of outcome 
The fol lowing baseline characterist ics were incorporated in a model:   
age 
gender 
emphysema at recruitment 
t ime from diagnosis to recruitment 
surgical lung biopsy ( includes open lung biopsy, VATs vs no biopsy  
MRC dyspnoea grade 
FVC, percent predicted 
DLCO, percent predicted 
clubbing  
treatment with prednisolone 
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treatment with azathiopr ine 
treatment with oxygen (any - ambulatory, long term) 
SGRQ total score and domains score  
education, l iv ing arrangements (l ives alone or not), employment (working  
or not), weekly income, benefits, p r ivate insurance (available or not);  data 
obtained from background questionnaire  
 
The outcomes used in these models are defined as: 
1. Death within 12 months of the study start date; 
2. Absolute FVC decline of 5% by 6 months and by 12 months 
3. Absolute FVC decline of 10% by 6 months and by 12 months 
 
Statistical analysis 
Logistic regression analysis was used to identify independent predictors of 
al l-cause mortali ty as well as of 5% and 10% decline in FVC at 6 and 12 
months. Unadjusted risk of al l-cause mortal ity was estimated for patients 
stratif ied by each potential predictor separately. Continuous covar iates 
were split  into quart i les. Adjusted analysis was performed by using a 
forward–backward algorithm (forward selection with p robabil ity of entry of  
p=0.10 and then a back el iminat ion with probabil i ty threshold of p=0.10 
were used). The missing data were not imputed. An estimabil i ty problem 
with SGRQ scores and lung function results due to missing data was 
affecting the use of fo rward-backward algor ithm in modell ing predictors of 
FVC decline. Hence, the selection without SGRQ/PFT variables present 
was undertaken f irst, then it was checked if they signif icant ly improved the 
model.  
 
6.3 Results 
Baseline characterist ics  
All patients  (181) included into intention to treat analysis of  co -tr imoxazole  
study (study 2, Chapter 4) were included in a model of baseline predictors  
of death. Patients had a mean age of 71.6 ± 8.5 years, 72% were male,  
mean FVC% predicted was 70.7 ± 21.2% and DLCO% predicted was 37.5 ± 
11.5% (Table 4.4 in Chapter 4).  
Of these 138 and 113 patients had FVC measurements available at 6 and 
12 months after recruitment respectively and therefore were included in 
models of predictors of decline of FVC.  
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Predictors of  mortal i ty 
Thirty-seven (20%) patients had died by the end of the study. The 
univariate analys is showed that the fol lowing characterist ics were 
predictive of death: age (p=0.0064), MRC dyspnoea score (p=0.0082), 
prednisolone (p=0.049), SGRQ symptoms score (p=0.0376), SGRQ activ ity 
score (p=0.0093), SGRQ impact score (p=0.0009), SGRQ total score 
(p=0.0006), DLco percent predicted (0.0332). In the mult ivariate analys is  
SGRQ total score and treatment with prednisolone were statist ical ly 
s ignif icant predictors of a l l-cause mortal ity at 12 months (Table 6.2).   
     Univariate analysis Adjusted analysis 
Covariate Level Alive Dead Dead 
% 
OR (95% CI) p-
value 
OR (95% 
CI) 
p-
value 
Age, years       0.0064   
 46-65 45 4 8.2 1    
 66-72 35 14 28.6 4.5 (1.36,14.88) 0.014   
 73-78 38 6 13.6 1.78 (0.47,6.76) 0.4   
 79-96 26 13 33.3 5.63 (1.66,19.06) 0.006   
Gender         
 Female 41 9 18 1    
 Male 
103 28 21.4 
1.24 (0.54,2.85) 0.615 
 
  
Emphysema         
 No 131 35 21.1 1    
 Yes 
13 2 13.3 
0.58 (0.12,2.67) 0.481 
 
  
Time since 
diagnosis, days 
 
   
 0.2845   
 34-363 34 12 26.1 1    
 372-847 40 5 11.1 0.35 (0.11,1.11) 0.074   
 848-1624 35 10 22.2 0.81 (0.31,2.12) 0.667   
 1674-9721 35 10 22.2 0.81 (0.31,2.12) 0.667   
Surgical biopsy 
 
 
   
    
 No 121 31 20.4 1    
 Yes 
23 6 20.7 
1.02 (0.38,2.72) 0.971 
 
  
MRC      0.0082   
 2 27 2 6.9 1    
 3 59 11 15.7 2.52 (0.52,12.15) 0.25   
 4 47 15 24.2 4.31 (0.91,20.29) 0.065   
 5 
11 9 45 
11.05 
(2.05,59.56) 0.005 
  
Finger clubbing         
 No 93 20 17.7 1    
 Yes 51 17 25 1.55 (0.75,3.22) 0.24   
FVC group      0.0770   
 <50% 19 11 36.7 1    
 51%-65% 37 9 19.6 0.42 (0.15,1.19) 0.102   
 >65%-79% 38 10 20.8 0.45 (0.16,1.26) 0.129   
 >79% 50 7 12.3 0.24 (0.08,0.72) 0.01   
Table 6.2: Predictions model for death 
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DLCO group      0.0332   
 <35% 46 16 25.8 1    
 >35%-45% 46 4 8 0.25 (0.08,0.81) 0.020   
 >45% 32 5 13.5 0.45 (0.15,1.35) 0.154   
Prednisolone         
 No 65 10 13.3 1  1  
 Yes 
79 27 25.5 
2.22 (1,4.93) 0.049 
 
3.56 
(1.34,9.48) 
0.011 
Azathioprine         
 No 100 23 18.7 1    
 Yes 
40 14 25.9 
1.52 (0.71,3.25) 0.278 
 
  
Oxygen (any)         
 No 128 31 19.5 1    
 Yes 
16 6 27.3 
1.55 (0.56,4.28) 0.399 
 
  
SGRQ 
symptoms 
 
   
 0.0376   
 8.56-44.89 41 3 6.8 1    
 46.05-
60.44 32 11 25.6 4.7 (1.21,18.26) 0.026 
  
 60.45-
72.57 36 8 18.2 3.04 (0.75,12.32) 0.12 
  
 72.89-
90.09 31 12 27.9 5.29 (1.37,20.37) 0.015 
  
SGRQ activity      0.0093   
 21.96-
60.35 39 5 11.4 
1    
 60.47-
79.67 38 5 11.6 1.03 (0.27,3.83) 0.969 
  
 79.91-
92.51 53 17 24.3 2.5 (0.85,7.36) 0.096 
  
 92.76-100 9 8 47.1 6.93 (1.83,26.26) 0.004   
SGRQ impact      0.0009   
 0-30.02 39 3 7.1 1    
 30.13-
43.70 39 3 7.1 1 (0.19,5.26) 1 
  
 44.36-
61.11 29 13 31 5.83 (1.52,22.35) 0.01 
  
 61.23-100 29 13 31 5.83 (1.52,22.35) 0.01   
SGRQ total  
   
 0.0006  0.001
4 
 15.5-44.11 38 4 9.5 1    
 44.33-
58.28 39 2 4.9 0.49 (0.08,2.82) 0.422 
0.45 
(0.08,2.64) 0.377 
 58.41-
70.45 32 10 23.8 2.97 (0.85,10.38) 0.088 
2.78 
(0.78,9.91) 0.115 
 70.85-
96.39 
26 15 36.6 5.48 (1.63,18.39) 0.006 
6.48 
(1.86,22.66
) 0.003 
Table 6.2: Predictions model for death 
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Education      0.910   
 None/scho
ol 
certificate 84 18 17.6 
1    
 A-Levels. 
CSEs, 
GCSE 17 5 22.7 1.37 (0.45,4.2) 0.579 
  
 HND/Btech
\NVQ 16 3 15.8 0.88 (0.23,3.32) 0.844 
  
 Degree/Ph
D 22 6 21.4 1.27 (0.45,3.59) 0.648 
  
Living alone         
 No 141 35 19.9 1    
 Yes 
3 1 25 
1.34 (0.14,13.3) 0.801 
 
  
Paid 
employment 
 
   
    
 No 131 32 19.6 1    
 Yes 10 2 16.7 0.82 (0.17,3.92) 0.802   
Monthly 
household 
income 
 
   
 0.842   
 <199 27 6 18.2 1    
 200-299 21 5 19.2 1.07 (0.29,4) 0.918   
 300-399 22 4 15.4 0.82 (0.2,3.27) 0.776   
 400-499 19 5 20.8 1.18 (0.32,4.45) 0.802   
 500+ 21 8 27.6 1.71 (0.52,5.7) 0.38   
State pension         
 No 98 27 21.6 1    
 Yes 46 9 16.4 0.71 (0.31,1.63) 0.420   
Disability benefit         
 No 86 23 21.1 1    
 
Yes 58 13 18.3 
0.84 (0.39,1.79) 0.648 
 
  
Other benefit         
 No 107 29 21.3 1    
 
Yes 37 7 15.9 
0.7 (0.28,1.73) 0.437 
 
  
Private health 
insurance     
    
 No 131 30 18.6 1    
 
Yes 10 3 23.1 
1.31 (0.34,5.05) 0.695 
 
  
Table 6.2: Predictions model for death 
 
 
Predictors of FVC decline at 6 months  
There were no statist ical ly s ignif icant (at p=0.05 level) predictors of 5% 
decline at 6 months identif ied. However, there was mild ev idence of an 
effect of emphysema (p=0.063) (Table 6.3).  
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     Univariate Adjusted 
Covariate Level Did not 
decline 
5% FVC 
decline 
over 6 
months 
% of 
patient
s with 
decline 
OR (95% CI) p-value OR 
(95% 
CI) 
p-
val
ue 
Age       0.6609   
 46-65 21 20 48.8 1    
 66-72 18 21 53.8 1.23 (0.51,2.95) 0.651   
 73-78 21 14 40 0.7 (0.28,1.74) 0.444   
 79-96 13 10 43.5 0.81 (0.29,2.26) 0.684   
Gender         
 Female 20 18 47.4 1    
 Male 53 47 47 0.99 (0.47,2.08) 0.969   
Emphysema         
 No 64 63 49.6 1    
 Yes 9 2 18.2 0.23 (0.05,1.09) 0.063   
Time since 
diagnosis 
 
   
 0.4915   
 34-363 16 17 51.5 1    
 372-847 23 13 36.1 0.53 (0.2,1.39) 0.199   
 848-1624 18 18 50 0.94 (0.37,2.42) 0.9   
 1674-9721 16 17 51.5 1 (0.38,2.63) 1   
Surgical biopsy         
 No 59 54 47.8 1    
 Yes 14 11 44 0.86 (0.36,2.05) 0.731   
MRC      0.7883   
 2 15 10 40 1    
 3 27 29 51.8 1.61 (0.62,4.19) 0.328   
 4 25 21 45.7 1.26 (0.47,3.39) 0.647   
 5 6 5 45.5 1.25 (0.3,5.23) 0.76   
Finger clubbing         
 No 44 39 47 1    
 Yes 29 26 47.3 1.01 (0.51,2) 0.974   
FVC group      0.6799   
 <50% 10 8 44.4 1    
 51%-65% 18 22 55 1.53 (0.5,4.68) 0.458   
 >65%-79% 19 16 45.7 1.05 (0.34,3.3) 0.93   
 >79% 26 19 42.2 0.91 (0.3,2.75) 0.872   
DLCO group      0.5478   
 <35% 22 26 54.2 1    
 >35%-45% 23 17 42.5 0.63 (0.27,1.46) 0.277   
 >45% 16 16 50 0.85 (0.35,2.07) 0.715   
Prednisolone         
 No 35 24 40.7 1    
 Yes 38 41 51.9 1.57 (0.8,3.11) 0.192   
Azathioprine         
 No 49 48 49.5 1    
 Yes 22 15 40.5 0.7 (0.32,1.5) 0.355   
Oxygen (any)         
 No 68 54 44.3 1    
 Yes 5 11 68.8 2.77 (0.91,8.46) 0.073   
SGRQ symptoms      0.5608   
 8.56-44.89 20 14 41.2 1    
Table 6.3: FVC decline by 5% over 6 months 
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 46.05-60.44 15 18 54.5 1.71 (0.65,4.51) 0.275   
 60.45-72.57 22 16 42.1 1.04 (0.41,2.66) 0.936   
 72.89-90.09 15 17 53.1 1.62 (0.61,4.29) 0.332   
SGRQ activity      0.2752   
 21.96-60.35 18 18 50 1    
 60.47-79.67 20 13 39.4 0.65 (0.25,1.69) 0.377   
 79.91-92.51 30 26 46.4 0.87 (0.37,2) 0.738   
 92.76-100 3 8 72.7 2.67 (0.61,11.7) 0.194   
SGRQ impact      0.6418   
 0-30.02 18 14 43.8 1    
 30.13-43.70 18 19 51.4 1.36 (0.52,3.51) 0.529   
 44.36-61.11 19 13 40.6 0.88 (0.33,2.37) 0.8   
 61.23-100 14 17 54.8 1.56 (0.58,4.22) 0.38   
SGRQ total      0.4321   
 15.5-44.11 15 18 54.5 1    
 44.33-58.28 22 15 40.5 0.57 (0.22,1.47) 0.243   
 58.41-70.45 19 14 42.4 0.61 (0.23,1.62) 0.326   
 70.85-96.39 12 16 57.1 1.11 (0.4,3.07) 0.839   
Education         
 None/school 
certificate 39 40 50.6 
1    
 A-Levels. 
CSEs, GCSE 13 6 31.6 0.45 (0.16,1.3) 0.141 
  
 HND/Btech\N
VQ 8 8 50 0.98 (0.33,2.86) 0.963 
  
 Degree/PhD 10 11 52.4 1.07 (0.41,2.81) 0.887   
Living alone         
 No 73 65 47.1     
 Yes 0 0 0     
Paid 
employment 
 
   
    
 No 68 60 46.9 1    
 Yes 5 5 50 1.13 (0.31,4.11) 0.849   
Monthly household 
income 
 
   
 0.2140   
 <199 10 15 60 1    
 200-299 15 7 31.8 0.31 (0.09,1.04) 0.057   
 300-399 11 10 47.6 0.61 (0.19,1.96) 0.402   
 400-499 12 7 36.8 0.39 (0.11,1.33) 0.132   
 500+ 10 14 58.3 0.93 (0.3,2.92) 0.906   
State pension         
 No 52 47 47.5 1    
 Yes 21 18 46.2 0.95 (0.45,1.99) 0.889   
Disability 
benefit     
    
 No 45 40 47.1 1    
 Yes 28 25 47.2 1 (0.51,2) 0.99   
Other benefit         
 No 52 51 49.5 1    
 Yes 21 14 40 0.68 (0.31,1.48) 0.331   
Private health 
insurance     
    
 No 68 59 46.5 1    
 Yes 5 6 54.5 1.38 (0.4,4.76) 0.607   
Table 6.3 FVC decline by 5% over 6 months 
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Treatment with prednisolone (p=0.006) and oxygen therapy (p=0.055), 
receipt of benefit other than state pension or disabil i ty l iv ing al lowance 
(p=0.053) were predictors of 10% FVC decline at 6 months on univariate  
analysis.    The f inal model selected only the use of prednisolone. None for 
the SGRQ domains were signif icant (Tab le 6.4).  
 
     Univariate Adjusted 
Covariate Level Did 
not 
declin
e 
10% 
FVC 
decline 
over 6 
months 
% of 
patients 
with 
decline 
OR (95% CI) p-value OR 
(95
% 
CI) 
p-
valu
e 
Age       0.0640   
 46-65 34 7 17.1 1    
 66-72 
24 15 38.5 
3.04 
(1.07,8.57) 0.036 
  
 73-78 
30 5 14.3 
0.81 
(0.23,2.82) 0.74 
  
 79-96 17 6 26.1 1.71 (0.5,5.9) 0.393   
Gender         
 Female 30 8 21.1 1    
 Male 
75 25 25 
1.25 
(0.51,3.08) 
0.628   
Emphysema         
 No 95 32 25.2 1    
 Yes 
10 1 9.1 
0.3 (0.04,2.41) 0.256 
 
  
Time since 
diagnosis 
 
   
 0.2758   
 34-363 25 8 24.2 1    
 372-847 31 5 13.9 0.5 (0.15,1.73) 0.277   
 848-1624 
24 12 33.3 
1.56 
(0.54,4.49) 0.407 
  
 1674-9721 25 8 24.2 1 (0.32,3.08) 1   
Surgical biopsy 
 
 
   
    
 No 83 30 26.5 1    
 Yes 
22 3 12 
0.38 
(0.11,1.35) 
0.134   
MRC      0.6498   
 2 20 5 20 1    
 3 
44 12 21.4 
1.09 
(0.34,3.51) 0.884 
  
 4 32 14 30.4 1.75 (0.55,5.6) 0.346   
 5 
9 2 18.2 
0.89 
(0.14,5.48) 0.899 
  
Finger clubbing         
 No 67 16 19.3 1    
Table 6.4: FVC decline by 10% over 6 months 
 
 
 
206 
 
FVC group      0.9864   
 <50% 14 4 22.2 1    
 
51%-65% 31 9 22.5 
1.02 
(0.27,3.87) 0.981 
  
 
>65%-79% 26 9 25.7 
1.21 
(0.32,4.65) 0.78 
  
 
>79% 34 11 24.4 
1.13 
(0.31,4.17) 0.852 
  
DLCO group      0.9552   
 <35% 36 12 25 1    
 
>35%-45% 31 9 22.5 
0.87 
(0.32,2.34) 0.784 
  
 >45% 24 8 25 1 (0.36,2.81) 1   
 Yes 
38 17 30.9 
1.87 
(0.85,4.13) 
0.119   
Prednisolone         
 No 52 7 11.9 1    
 Yes 
53 26 32.9 
3.64 
(1.46,9.13) 
0.006   
Azathioprine         
 No 73 24 24.7 1    
 Yes 
29 8 21.6 
0.84 
(0.34,2.08) 
0.705   
Oxygen (any)         
 No 96 26 21.3 1    
 Yes 
9 7 43.8 
2.87 
(0.98,8.44) 
 
0.055 
 
  
SGRQ symptoms      0.5029   
 8.56-44.89 25 9 26.5 1    
 46.05-60.44 23 10 30.3 1.21 (0.42,3.5) 0.728   
 60.45-72.57 
32 6 15.8 
0.52 
(0.16,1.66) 0.27 
  
 72.89-90.09 24 8 25 0.93 (0.31,2.8) 0.891   
SGRQ activity      0.3696   
 21.96-60.35 28 8 22.2 1    
 60.47-79.67 
27 6 18.2 
0.78 
(0.24,2.54) 0.677 
  
 79.91-92.51 
42 14 25 
1.17 
(0.43,3.14) 0.761 
  
 92.76-100 
6 5 45.5 
2.92 
(0.7,12.11) 0.14 
  
SGRQ impact      0.3145   
 0-30.02 28 4 12.5 1    
 30.13-43.70 
27 10 27 
2.59 
(0.72,9.27) 0.143 
  
 44.36-61.11 
23 9 28.1 
2.74 
(0.75,10.06) 0.129 
  
 61.23-100 
22 9 29 
2.86 
(0.78,10.54) 0.114 
  
SGRQ total      0.6428   
 15.5-44.11 26 7 21.2 1    
 44.33-58.28 30 7 18.9 0.87 (0.27,2.8) 0.811   
Table 6.4: FVC decline by 10% over 6 months 
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 58.41-70.45 
23 10 30.3 
1.61 
(0.53,4.93) 0.4   
 70.85-96.39 
20 8 28.6 
1.49 
(0.46,4.79) 0.507   
Education      0.1629   
 None/school 
certificate 57 22 27.8 
1    
 A-Levels. 
CSEs, GCSE 17 2 10.5 0.3 (0.06,1.43) 0.132 
  
 HND/Btech\N
VQ 14 2 12.5 
0.37 
(0.08,1.76) 0.212 
  
 Degree/PhD 14 7 33.3 1.3 (0.46,3.64) 0.623   
Paid employment         
 No 98 30 23.4 1    
 Yes 7 3 30 1.4 (0.34,5.75) 0.641   
Monthly 
household 
income 
 
   
    
 <199 17 8 32 1    
 
200-299 18 4 18.2 
0.47 
(0.12,1.86) 0.283 
  
 
300-399 16 5 23.8 
0.66 
(0.18,2.46) 0.54 
  
 400-499 14 5 26.3 0.76 (0.2,2.85) 0.683   
 500+ 21 3 12.5 0.3 (0.07,1.32) 0.113   
State pension         
 No 77 22 22.2 1    
 Yes 28 11 28.2 1.38 (0.59,3.2) 0.459   
Disability benefit         
 No 66 19 22.4 1    
 
Yes 39 14 26.4 
1.25 
(0.56,2.76) 
0.587   
Other benefit         
 No 74 29 28.2 1    
 
Yes 31 4 11.4 
0.33 
(0.11,1.02) 
0.053   
Table 6.4: FVC decline by 10% over 6 months 
 
 
Predictors of FVC decline at 12 months  
Table 6.5 shows a univariate relat ionships between the covaria tes and a 
5% decline in FVC at 12 months. SGRQ symptoms score was signif icant; 
there was a suggestion of a trend in SGRQ total score. There was some 
ev idence for an effect with education (p=0.077) and paid employment 
(p=0.09). 
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     Univariate Adjusted 
Covariate Level Did not 
decline 
5% FVC 
decline 
over 12 
months 
% of 
patien
ts with 
declin
e 
OR (95% CI) p-
value 
OR (95% 
CI) 
p-
value 
Age       0.499   
 46-65 15 25 62.5 1    
 66-72 10 20 66.7 1.2 (0.44,3.24) 0.719   
 73-78 16 16 50 0.6 (0.23,1.54) 0.289   
 79-96 10 11 52.4 0.66 (0.23,1.92) 0.446   
Gender         
 Female 16 18 52.9 1    
 Male 35 54 60.7 1.37 (0.62,3.04) 0.437   
Emphysema         
 No 45 66 59.5 1    
 Yes 6 6 50 0.68 (0.21,2.25) 0.529   
Time since 
diagnosis 
 
   
 0.144   
 34-363 14 17 54.8 1    
 372-847 13 21 61.8 1.33 (0.49,3.58) 0.572   
 848-1624 7 20 74.1 2.35 (0.77,7.17) 0.132   
 1674-9721 17 14 45.2 0.68 (0.25,1.84) 0.447   
Surgical biopsy 
 
 
   
    
 No 44 59 57.3 1    
 Yes 7 13 65 1.38 (0.51,3.76) 0.523   
MRC      0.233   
 2 9 15 62.5 1    
 3 21 29 58 0.83 (0.31,2.25) 0.712   
 4 15 26 63.4 1.04 (0.37,2.95) 0.941   
 5 6 2 25 0.2 (0.03,1.21) 0.08   
Finger clubbing         
 No 36 46 56.1 1    
 Yes 15 26 63.4 1.36 (0.63,2.93) 0.438   
FVC group      0.123   
 <50% 7 9 56.3 1    
 51%-65% 7 23 76.7 2.56 (0.7,9.38) 0.157   
 >65%-79% 16 18 52.9 0.88 (0.26,2.89) 0.827   
 >79% 21 22 51.2 0.81 (0.26,2.59) 0.728   
DLCO group      0.710   
 <35% 15 25 62.5 1    
 >35%-45% 15 24 61.5 0.96 (0.39,2.38) 0.93   
 >45% 14 16 53.3 0.69 (0.26,1.79) 0.442   
Prednisolone         
 No 25 33 56.9 1    
 Yes 26 39 60 1.14 (0.55,2.33) 0.727   
Azathioprine         
 No 34 51 60 1    
 Yes 15 19 55.9 0.84 (0.38,1.89) 0.680   
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Oxygen (any)         
 No 46 63 57.8 1    
 Yes 
5 9 64.3 
1.31 (0.41,4.18) 
 
0.644   
SGRQ 
symptoms 
 
   
 0.013  0.017 
 8.56-44.89 14 22 61.1 1    
 46.05-60.44 
10 18 64.3 1.15 (0.41,3.19) 0.795 
1.05 
(0.36,3.03) 0.935 
 60.45-72.57 
20 12 37.5 0.38 (0.14,1.02) 0.054 
0.32 
(0.11,0.87) 0.026 
 72.89-90.09 
5 19 79.2 2.42 (0.73,7.96) 0.146 
2.08 
(0.62,6.93) 0.234 
SGRQ activity      0.716   
 21.96-60.35 13 21 61.8 1    
 60.47-79.67 11 21 65.6 1.18 (0.43,3.23) 0.745   
 79.91-92.51 22 25 53.2 0.7 (0.29,1.73) 0.443   
 92.76-100 3 4 57.1 0.83 (0.16,4.29) 0.82   
SGRQ impact      0.591   
 0-30.02 10 22 68.8 1    
 30.13-43.70 15 19 55.9 0.58 (0.21,1.58) 0.283   
 44.36-61.11 12 16 57.1 0.61 (0.21,1.75) 0.353   
 61.23-100 11 12 52.2 0.5 (0.16,1.5) 0.215   
SGRQ total      0.626   
 15.5-44.11 11 22 66.7 1    
 44.33-58.28 13 21 61.8 0.81 (0.3,2.2) 0.676   
 58.41-70.45 13 16 55.2 0.62 (0.22,1.72) 0.355   
 70.85-96.39 10 10 50 0.5 (0.16,1.56) 0.232   
Education      0.077   
 None/school 
certificate 25 47 65.3 
1    
 A-Levels. 
CSEs, 
GCSE 7 7 50 0.53 (0.17,1.69) 0.284 
  
 HND/Btech\
NVQ 5 10 66.7 1.06 (0.33,3.46) 0.918 
  
 Degree/PhD 12 6 33.3 0.27 (0.09,0.79) 0.018   
Live alone         
 No 50 71 58.7 1    
 Yes 1 1 50 0.7 (0.04,11.53) 0.806   
Paid work         
 No 49 63 56.3 1  1  
 Yes 
1 8 88.9 
6.22 
(0.75,51.43) 
0.090 7.62 
(0.84,68.74) 
 
0.07 
 
Monthly 
household 
income 
 
   
 0.899   
 <199 10 12 54.5 1    
 200-299 8 12 60 1.25 (0.37,4.26) 0.721   
 300-399 7 11 61.1 1.31 (0.37,4.64) 0.676   
 400-499 7 6 46.2 0.71 (0.18,2.83) 0.632   
 500+ 8 13 61.9 1.35 (0.4,4.57) 0.625   
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State pension         
 No 36 48 57.1 1    
 Yes 15 24 61.5 1.2 (0.55,2.61) 0.645   
Disability 
benefit     
    
 No 30 44 59.5 1    
 Yes 21 28 57.1 0.91 (0.44,1.89) 0.799   
Other benefit         
 No 35 55 61.1 1    
 Yes 16 17 51.5 0.68 (0.3,1.51) 0.340   
Private health 
insurance     
    
 No 45 67 59.8 1    
 Yes 5 4 44.4 0.54 (0.14,2.11) 0.373   
Table 6.5: FVC decline by 5% over 12 months 
 
There were no statist ica l ly s ignif icant predictors of a 10% decline in FVC 
at 12 months identif ied on the univariate analys is (Table 6.6).  
     Univariate Adjusted 
Covariate Level Did not 
decline 
10% 
FVC 
decline 
over 12 
months 
% of 
patients 
with 
decline 
OR (95% CI) p-
value 
OR 
(95% 
CI) 
p-
value 
Age       0.252   
 46-65 22 18 45 1    
 66-72 14 16 53.3 1.4 (0.54,3.61) 0.491   
 73-78 
21 11 34.4 
0.64 
(0.25,1.67) 0.362 
  
 79-96 
15 6 28.6 
0.49 
(0.16,1.52) 0.216 
  
Gender         
 Female 22 12 35.3 1    
 Male 
50 39 43.8 
1.43 
(0.63,3.24) 
0.392   
Emphysema         
 No 63 48 43.2 1    
 Yes 9 3 25 0.44 (0.11,1.7) 0.233   
Time since 
diagnosis 
 
   
 0.103   
 34-363 18 13 41.9 1    
 372-847 
15 19 55.9 
1.75 
(0.66,4.69) 0.263 
  
 848-1624 
16 11 40.7 
0.95 
(0.33,2.71) 0.927 
  
 1674-9721 
23 8 25.8 
0.48 
(0.16,1.41) 0.183 
  
Surgical biopsy         
 No 61 42 40.8 1    
 Yes 
11 9 45 
1.19 
(0.45,3.12) 
0.726   
MRC         
 2 11 13 54.2 1    
Table 6.6: FVC decline by 10% over 12 months 
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 3 
31 19 38 
0.52 
(0.19,1.39) 0.192 
  
 4 
23 18 43.9 
0.66 
(0.24,1.82) 0.425 
  
 5 
7 1 12.5 
0.12 
(0.01,1.14) 0.065 
  
Finger clubbing         
 No 50 32 39 1    
 Yes 
22 19 46.3 
1.35 
(0.63,2.88) 
0.438   
FVC group      0.323   
 <50% 8 8 50 1    
 51%-65% 15 15 50 1 (0.3,3.37) 1   
 
>65%-79% 24 10 29.4 
0.42 
(0.12,1.42) 0.162 
  
 
>79% 25 18 41.9 
0.72 
(0.23,2.28) 0.576 
  
DLCO group      0.977   
 <35% 23 17 42.5 1    
 >35%-45% 23 16 41 0.94 (0.38,2.3) 0.894   
 >45% 18 12 40 0.9 (0.34,2.36) 0.834   
Prednisolone         
 No 35 23 39.7 1    
 Yes 
37 28 43.1 
1.15 
(0.56,2.36) 
0.701   
Azathioprine         
 No 49 36 42.4 1    
 Yes 21 13 38.2 0.84 (0.37,1.9) 0.680   
Oxygen (any)         
 No 64 45 41.3 1    
 Yes 
8 6 42.9 
1.07 
(0.35,3.29) 
0.910   
SGRQ 
symptoms 
 
   
 0.656   
 8.56-44.89 21 15 41.7 1    
 46.05-60.44 
15 13 46.4 
1.21 
(0.45,3.28) 0.703 
  
 60.45-72.57 
21 11 34.4 
0.73 
(0.27,1.96) 0.537 
  
 72.89-90.09 12 12 50 1.4 (0.5,3.96) 0.526   
SGRQ activity      0.762   
 21.96-60.35 17 17 50 1    
 60.47-79.67 
19 13 40.6 
0.68 
(0.26,1.81) 0.445 
  
 79.91-92.51 
29 18 38.3 
0.62 
(0.25,1.52) 0.295 
  
 92.76-100 
4 3 42.9 
0.75 
(0.15,3.87) 0.731 
  
SGRQ impact      0.843   
 0-30.02 17 15 46.9 1    
 30.13-43.70 20 14 41.2 0.79 (0.3,2.1) 0.641   
 44.36-61.11 
16 12 42.9 
0.85 
(0.31,2.36) 0.755 
  
 61.23-100 15 8 34.8 0.6 (0.2,1.82) 0.371   
Table 6.6: FVC decline by 10% over 12 months 
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SGRQ total      0.745   
 15.5-44.11 17 16 48.5 1    
 44.33-58.28 
19 15 44.1 
0.84 
(0.32,2.19) 0.72   
 58.41-70.45 
18 11 37.9 
0.65 
(0.24,1.79) 0.404   
 70.85-96.39 13 7 35 0.57 (0.18,1.8) 0.339   
Education      0.723   
 None/school 
certificate 39 33 45.8 
1    
 A-Levels. CSEs, 
GCSE 9 5 35.7 0.66 (0.2,2.15) 0.487 
  
 HND/Btech\NVQ 
8 7 46.7 
1.03 
(0.34,3.15) 0.953 
  
 Degree/PhD 12 6 33.3 0.59 (0.2,1.75) 0.342   
Living alone         
 No 70 51 42.1 1    
 Yes 2 0 0 -    
Paid 
employment 
 
   
    
 No 67 45 40.2 1    
 Yes 
3 6 66.7 
2.98 
(0.71,12.52) 
 
0.137   
Monthly 
household 
income 
 
   
 0.733   
 <199 15 7 31.8 1    
 200-299 12 8 40 1.43 (0.4,5.07) 0.581   
 
300-399 10 8 44.4 
1.71 
(0.47,6.24) 0.414 
  
 
400-499 8 5 38.5 
1.34 
(0.32,5.61) 0.689 
  
 
500+ 10 11 52.4 
2.36 
(0.68,8.15) 0.175 
  
State pension         
 No 50 34 40.5 1    
 
Yes 22 17 43.6 
1.14 
(0.53,2.45) 
0.744   
Disability 
benefit     
    
 No 40 34 45.9 1    
 Yes 32 17 34.7 0.63 (0.3,1.32) 0.216   
Other benefit         
 No 50 40 44.4 1    
 
Yes 22 11 33.3 
0.63 
(0.27,1.44) 
0.270   
Private health 
insurance     
    
 No 65 47 42 1    
 
Yes 5 4 44.4 
1.11 
(0.28,4.34) 
0.885   
Table 6.6: FVC decline by 10% over 12 months 
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6.4 Discussion 
 
Although overall prognosis of IPF is poor there is a s ignif icant variabil i ty in  
functional change over t ime ranging from improvement or minimal change 
in PFT over years to a s ignif icant decline leading to death over 6 -12 
months often preceded by an exacerbation/admission [215, 293]. A number 
of indiv idual c l in ical, radio logical, pathological parameter s and biomarkers 
obtained both at baseline and over t ime have been associat ed with poor 
prognosis in IPF. C lin ical predict ion models have been prev iously 
produced in an attempt to combine these parameters/predictors in order to 
accurately predict prognosis  and help to decide on treatment. However two 
of these models and scoring systems (clin ica l -rad iolog ic-physio logic (CRP) 
scoring system and composite physio logic index (CPI)) are confined to 
research only as they are largely based on the inclusion of facto rs that are 
not wide ly accessible in the clin ical practice [295]. The most recently 
published abbrev iated predict ion model and based on it scoring system 
inc lude readily available parameters and could be easily used in c l in ical 
practice to assess 1 year risk of mortal ity [295]. Th is scoring system could 
be applied to patients with  the disease of any severity but at present it  
requires validation before it  is  recommended for a routine use.  
 
The results of th is study show that treatment with prednisolone at baseline 
was predictive of both death at 12 months and a 10% decline in FVC at 6 
months but not at 12 months. Both SGRQ symptoms domain score and 
being in pa id employment were predictive of 5% FVC decline at 12 months 
while SGRQ total score at baseline was predictive of death at 12 months.  
There were no baseline predictors of 5% FVC decline at 6 months and 10% 
FVC decline at 12 months identif ied.  
  
10% decline in FVC at 6 and 12 months was chosen as an outcome 
measure as it has a prognostic s ignif icance. A number of studies 
demonstrated that th is change during th is t ime scale is h ighly predic t ive of 
death[62, 65] and that it  is  more predictive of prognosis than most baseline 
character ist ics includ ing histopathologic diagnosis [196]. Though as a 
result ≥10% FVC change has been considered clin ically s ign if icant,  recent 
data suggest that even marginal decline in FVC of 5% at 6 months is 
associated with more than two-fold increase in the risk of death over 
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subsequent 12 months [295]. This magnitude of change has prev iously 
been considered to be with in normal l imits. Since the prospective follow up 
was l imited to 12 months it seemed to be reasonable to use changes in 
FVC as a surrogate marker of mortal ity.  
 
Baseline characterist ics used in this modell ing were chosen based on its 
practical ity and availabil i ty during routine cl in ica l consultation (with an 
exception of SGRQ which is normally not a part of a standard evaluati on of 
patients with ILD). Change in DLCO % predicted over t ime was not 
inc luded in modell ing as it  is  not readily available in c l in ical pract ice (only  
62% of patients who had FVC measurements at 12 months after 
recruitment had DLCO measurements done also) and is known to possess 
signif icant variabil i ty.  
 
Though consistent with prev ious research age, MRC dyspnoea score, 
DLCO percent predicted, SGRQ scores, and the use of prednisolone were 
predictive of death on univariate analysis it  was unexpected to see th at 
only the lat ter two markers were included into a f ina l model of predictors of 
death. At the same time this might mean that longitudina l data reflect ing 
disease behav iour over a period of t ime is at least equally i f  not more 
relevant than cl in ica l predic tors obtained at a s ingle t ime point. The result 
of the study of du Bois et al [295] aimed at identify ing indiv idual r isk factors 
of mortal ity for IPF patients is in l ine with this showing that four out of 
seven cl in ica l factors s ignif icant ly predictive of all cause mortal ity were of 
longitud inal nature (history of respiratory hospital isat ion, 24 -week change   
in FVC percent predicted, DLCO percent predicted and HRQL ( SGRQ) 
(alongside age, FVC percent predicted and DLCO percent predicted).  
 
An important observation adding to a recently accumulating data about the 
effect of steroid treatment on the course of IPF is the fact that the use of 
prednisolone at baseline appears to be a signif icant predictor  of both 10% 
decline in FVC at 6 months and death at 12 months. This means that 
patients receiv ing treatment with corticosteroids not only continue to 
progress but are at a higher risk of death than those who do not, more 
l ike ly due to associated side effects, on the f irst place possibly increased 
r isk of infect ions. It is  l ike ly that  patients with severe disease or rapid ly 
declin ing condit ion were more often treated with cort icosteroid therapy 
than patients with mild or stab le disease. Corticosteroid therapy could 
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therefore be a marker of increasing disease severity and of increasing 
l ike l ihood of death. However corticosteroid therapy was predictive of death 
even in the adjusted analys is wh ich was corrected for age and availa ble  
makers of severity (namely FVC) but the decis ion to when to inst igate 
corticosteroid therapy is complex and involves more aspects than we can 
inc lude in the predict ion model. Of the patients inc luded in co -trimoxazole  
study 60% were receiv ing corticosteroids at recruitment. Only 25% of 
recruited patients were incident cases which means that the majority of  
cort icosteroid treated patients had been on this treatment for over 12 
months by the t ime of recruitment. This is part icular ly re levant in a v iew of 
the BTS national intersti t ia l lung disease survey with data collected during 
late 2010 and early 2011 demonstrating that around 50% of chest 
physic ians (from a total of 120) continued to use prednisolone for the 
treatment of IPF[254] which means that th is treatment continued to be a 
routine practice at least unti l  very recent past. Though a recent 
recommendation of BTS and ERS [296] is not to commence newly 
diagnosed patients on immunosuppression and to consider withdrawal of  
cort icosteroids in patients who have been commenced on it previously 
there wil l  be a large proportion of patients in who th eir attending physic ian 
would fee l re luctant to withdraw this long term medication either due to 
potential withdrawal r isks (adrenal insuff ic iency) or anecdotal r isk of  
exacerbation of underly ing IPF fol lowing the withdrawal of cort icosteroids .  
 
Treatment with immunosuppression has recently been demonstrated to 
increase mortal ity in two major studies - a retrospective study assessing 
predictors of mortal ity in IPF and in an interventional study assessing the 
effects of N-acetylcyste ine. As shown by du Bois  et a l t reatment with  
prednisolone in any dose as well as with azath iopr ine was associated with  
increased risk of death in univaria te analysis of 1099 patients with a wide 
severity spectrum disease [295]. At the same time the inter im safety 
analysis from the three arm PANTHER-IPF study assessing the eff icacy of 
N-acetylcysteine compared to placebo and a combination of Prednisone, 
Azathiopr ine, and N-acetylcysteine reported that treatment with  
immunosuppression (the latter arm) was associated with increased 
mortal ity compared to placebo (11% versus 1%) as well as higher 
frequency of hospital izat ions (29% versus 8%), serious adverse events 
(31% versus 9%) and showed no di fference in lung function test [297]. As a 
result recruitment into the tr ip le therapy arm has been discontinued. It is  
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possible that those patients died from infections. In this respect the 
treatment effect in co-tr imoxazole study (Chapter 4) was signif icantly 
related to those receiv ing immunosuppressive therapy.  
 
Populat ion based studies have looked at the impact of race and ethnic ity 
on surv ival in IPF and showed that non -Hispanic black and Hispanic 
patients with IPF have worse surv ival than white pat ients after l is t ing for a  
lung transplant both in a s ingle and a mult icentre (94 centres in the US) 
studies[27, 298] .  Though some ILD disease registers’ data form along with  
basic socio-demographic information (gender, age, smoking history)  
contain more extended information for example on years of education [299] 
none of the epidemiological or interventional studies reported on the ro le 
of social factors such as education, employment and family arrangements 
in surv ival in IPF. Only one study in i ts or ig ina l abstract report  
demonstrated that in a cohort of long term lung transplant surv ivors 
(among who 11% patients had an underly ing diagnosis of IPF) both 
bi latera l lung transplant and HLA matching as well as higher education 
may portend improved surv ival [300] (this data was not included in the 
f inal fu l l  text  paper[116]). 
 
This study is the f irst one to determine the role of educati on, l iv ing 
arrangements, employment, and welfare benefit in the prognosis of IPF.  It  
showed that patients with degree with or without a PhD are less l ikely to  
exhib it a 5% decline in their FVC over 12 months while those with a school 
cert if icate alone without the subsequent education were more likely to  
decline over this t ime period. It is  possib le that patients with a higher 
education are more v igi lant to infections and are more open to addit ional 
treatments such as pulmonary rehabil itat ion (even though s o far pulmonary 
rehabil i tat ion was shown to improve only functional exercise capacity in  
IPF as measured by 6 minute walk distance [120]). At the same time being 
in paid employment increased the risk of a 5% decline in FVC over 12 
months. This may ref lect the fact that patients in pa id employment who a re 
more l ikely to be younger than those who do not work have a more severe 
disease and therefore progress quicker.  
 
Alongside a lack of use of longitudinal predictors of deteriorat ion in IPF 
mentioned prev iously th is study has a number of other l imitat ion s. First, i t  
had a l imited duration of fo l low up of 12 months. At the same time we 
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ensured that the status of patients who withdrew from the co -trimoxazole  
study prematurely was established at a 12 months t ime point and for those 
who remained alive al l attempts were maid to obtain their lung function 
data. Second, the study included a relat ively small group of patients wh ich 
could partly exp la in why the f inal models were including only a  small 
number of parameters. Third, large proportions of patients were older and 
had severe disease therefore whether the results wou ld be applicable to 
those younger with less severe disease is not c lear. Fo urth, radiological 
parameters (CT fibrosis score) were not included in the baseline 
characterist ics of the model.  
 
In conclusion, th is study prov ides further ev idence that treatment with  
prednisolone is predictive of a sign if icant decline in FVC and death in 
patients with IPF over a limited period  of observation of 6 -12 months and 
suggests that commencement of long term co rticosteroids should be 
avoided in this condit ion.  
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Chapter 7 
Overal l discussion 
 
7.1 Diagnostic accuracy 
As shown by audit and radiolog ical rev iew of TIPAC study there is a  
degree of variabil ity in diagnosing IPF. Only 10 out of 108 cases involved 
in the audit project had confidently excluded identif iab le cause for the ILD. 
Particular ly weak areas included evaluation of prev ious and current 
hobbies, prev ious medical history,  medication exposure and family history.  
While occupational history enquir ies we re made in 75% of patients this 
was incomplete in most of cases. Similar ly wh ile 66% of patients had 
serological connective t issue disease screen performed most of them did  
not have an evaluation of symptoms undertaken.  
In both the audit (93.5%) and the TIPAC study (84%) the major ity of  
diagnosis of IPF was made without histology. Th is leads one to the next  
question of the accuracy and rel iabil ity of diagnostic assessment of UIP 
HRCT pattern. In the TIPAC study in the absence of surgical lung biopsy  
IPF was diagnosed by an investigator based on clin ica l -rad iolog ical data  
with rad io logical evaluation having been performed by a study s ite 
radio logist at the t ime of patient’s diagnosis. Where available the same 
(87% of cases) diagnostic scans were subsequently used in the 
retrospective  radiologica l rev iew that was undertaken by two specia l ist  
respiratory rad iolog ists using published criteria [164]. Interest ingly 7  
patients who were assigned the diagnosis of NSIP by the loca l 
investigator/radio logist  were fe lt  to  have a UIP HRCT pattern (3 typ ical and 
4 probable) by the study radiologist. Simila r ly 15 patients who were 
assigned the diagnosis of UIP by the local investigator/radio logist were felt  
to have NSIP by the study radiologist (study radiolog ists  were bl inded to 
patients’ c l in ica l diagnosis). Th is had an implication on deciding which 
patients would be included in the sensit iv ity analysis for defin ite/probable 
diagnosis of IPF (biopsy, defin ite /probable UIP on HRCT) with the latter  
patients being excluded from it.  At the same time when following an 
algor ithm to predict a biopsy confirmation of IPF described by Fell et 
al[165] the HRCT scans of 15 patients who were diagnosed by study 
radio logists as NSIP  were also scored according to the degree of 
interst it ia l changes, only 4 scans scored as intermediate probabil ity of IPF 
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and the remaining 11 were consistent with a high probabil i ty diagnosis of 
IPF.  
This d iversity of approaches and re -classif icat ion using different criter ia  
reflects that even in the presence of detai led guidelines there is no full  
consistency in diagnostic approach and it is  sti l l cha llenging to establish a 
correct diagnosis in some cases.  
 
7.2 Poor survival and longitudinal changes in lung function  
Twelve months follow up in the TIPAC study confirmed the prev ious data 
that older patients with more advanced disease have a high mortal i ty rate - 
20% of patients died over this observation period. Though median surv ival 
in IPF is reported to be no greater than 3 years some patients l ive longer 
and some do not exhibit  ev idence of functional decline  for prolonged 
period of t ime. Flaherty et a l [13] was the f irst to demonstrate that 
although overall  surv ival in IPF is  poor , a large proportion of pat ients (up 
to a third in the study by Flaherty et al) had stable disease over 12 months 
of observation. The analys is of lung function trends of TIPAC stu dy 
patients over 12 months showed  that 40% of patients have ≥10% decline in  
FVC whilst 50% had changes that in rout ine cl in ica l practice would be 
considered as ev idence of non -progressive disease. The latter results  
were similar  in the group includ ing both treatment arms and in the group 
inc luding placebo arm patients only and was in l ine with the prev ious 
observation of Flaherty (Chapter 4, Tab le 4.11).  
 
7.3 Predictors of outcome  
Considering a diversity of  behav iour of IPF it would be valuable for both 
patients and attending physic ians to have a way of predict ing at d iagnosis  
how the disease would behave over t ime. This requires biomarkers as 
ind iv idual predictors of surv ival as well as for use in  c l in ical predict ion  
models that combine a number of parameters. Indiv idual predictors include 
cl in ical, rad iolog ical, physio logical, pathological , and biomarker 
predictors [196]. Changes in some of these parameters  over t ime 
(physio logical and radiolog ical)  could be particu lar ly helpfu l in ident ify ing 
patients with progressive disease. Th is thesis reported two prospective 
studies looking at the role of c lin ical -physio logica l parameters as well as 
two b iomarkers in predicting d isease behav iour in  patients with id iopathic 
pulmonary f ibrosis. It  was shown that alveolar nitr ic oxide concentrat ion 
has a strong predict ive value for subsequent c l in ically s ignif icant decline 
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in DLCO and that plasma VEGF level is a strong predictive factor of a 
c l in ically s ignif icant FVC decline over t ime. It was also demonstrated that 
treatment with prednisolone at baseline was predict ive of both death at 12 
months and a 10% decline in FVC at 6 months and that SGRQ total score 
at baseline was predict ive of death at 12 months.  
There is accumulating prospective ev idence that indiv idual p hys io logical 
markers are responsive measures of disease status [68, 301]. FVC is a  
rel iab le and valid parameter for assessing disease status in patients with  
IPF and even a small change of 5 -10% over t ime (24 weeks) is highly 
predictive of mortali ty at 1 year [197, 301]. At the same time the 
signif icance of 2-6% magnitude of change in FVC percent predicted as a 
minimal c l in ically important difference [301] would be dif f icult  to interpret in  
iso lat ion due to the test variabil i ty. Therefore changes in indiv idua l 
parameter should be used in conjunction with other markers of the disease 
progression which may be done with in the frames of  a prediction model.   
Indeed, du Bois [295] has suggested a mortal ity scoring model that 
inc ludes age, history of respiratory hospital isat ions, %predicted FVC, and 
24 week change in % predicted FVC .  
 
7.4 Future studies arising from this thesis  
Many questions have arisen from the results of th is thesis. The effect of 
co-tr imoxazole on surv ival was unexpected and taking into account the 
associated reduction in infect ions it would be interesting to know whether 
any antibiot ic would have such an effect and whether this is re lated to  the 
treatment with steroids or not. To answer such question a new study would  
need to recruit ideally treatment naive patients and  to use two treatment 
arms, one using co-tr imoxazole and one using another antibiot ic c lass.  It  
would also be important to know if co -tr imoxazole treats colonisation or 
prov ides early treatment for acute infections . To answer this quest ion a 
study with thorough assessment of microbiologica l prof i le at recruitment 
and during any infective episode would be required. Such study may be 
challenging to conduct as ideally microbiologica l specimens would need to 
be obtained using broncho-alveolar f lu id. A lternatively co -tr imoxazole may 
have a non-antibiot ic role and mechanistic studies would be required to 
investigate this. Co-tr imoxazole reduced a number of admissions to 
hospita l due to any reason and due to a respiratory causes; it  would be 
interest ing to see if the drug affects the rate of acute exacerbations in 
wh ich case a precise defin it ion of exacerbation would need to be given in 
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the protocol. The posit ion ing of co-tr imoxazole therapy is not c lear: should 
al l patients receive co-trimoxazole  at diagnosis or should it  be reserved for 
patients who have had an exacerbation  or recurrent respiratory tract 
infect ions? A role of longitudina l changes  in CaNO and VEGF in predict ing  
prognosis of IPF is not known.  Given the ease of measuring exhaled nitr ic  
oxide th is parameter could be included with in a predict ion model however 
a larger long-term prospective mortal i ty study would be required.  
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fibrosis with the addition of co-trimoxazole) 
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Appendix 2  
Medicines and Healthcare products Regulatory Agency approval letter of study 2 (Treating 
idiopathic pulmonary fibrosis with the addition of co-trimoxazole) 
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Appendix 3 
STUDY PROTOCOL (version 13) 
 
TREATING INTERSTITIAL PNEUMONIA WITH THE ADDITION OF CO-TRIMOXAZOLE 
(TIPAC) STUDY 
 
Full title 
The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial 
pneumonia 
Investigators 
 
Andrew M Wilson  - Clinical Senior Lecturer 
Orion Twentyman  - Consultant Physician 
Tony Davison – Consultant Physician 
Veronica Varney – Consultant Physician 
Allan Clark – Medical Statistician 
John Curtin – Consultant Radiologist 
Ed Wilson – Health Economist 
 
1) BACKGROUND AND RATIONALE 
Idiopathic interstitial pneumonia, a type of diffuse parenchymal lung disease, consists of conditions of 
unknown aetiology that result in fibrosis, with or without inflammation, of the lung parenchyma. Clinically it 
is recognised as idiopathic pulmonary fibrosis (IPF), also called cryptogenic fibrosis alveolit is. Recent 
epidemiological data suggest that the incidence is 6.8-16.3/100,000(1). The median survival from diagnosis 
of is only 2.9 years(2). During this time individuals become increasingly dyspnoeic such that simple 
activities of daily living become difficult even with continuous oxygen therapy, and the disease often ends 
with a distressing death from respiratory failure. There is no cure, no treatment has been proven to be 
effective and the mortality rate in the UK is increasing(2). There is therefore a considerable unmet need. 
 
Corticosteroids are the most widely used treatment for IPF, and are recommended in current guidelines(3). 
However a Cochrane review failed to demonstrate any advantage of this form of therapy(4). Recent review 
articles consistently state that there is no clear evidence that corticosteroids are beneficial(5;6). Given the 
significant adverse effects of corticosteroids; azathioprine or cyclosporin are prescribed concomitantly as 
steroid sparing agents. These immunotherapies given alone or in combination with corticosteroids also have 
adverse effects with no clear survival advantage(7;8). More recently newer therapies have been evaluated 
including interferon--1b, n-acetylcysteine and pirfenidone. These have shown modest beneficial effects, the 
clinical significance of which is unknown(9;10).  
  
Co-trimoxazole is an antibiotic that has been available for more than 20 years. It is the first-line treatment for 
pneumocystis carini pneumonia and is also used long–term as prophylaxis against this infection. It is often 
used in the management of Wegner’s granulomatosis – which may involve the lung parenchyma – and has 
been shown to reduce the incidence of relapse in this condition(11). Co-trimoxazole has also been shown to 
have beneficial effects in rheumatoid arthritis(12). In a small randomised, double blind, study of 20 patients 
with idiopathic pulmonary fibrosis, randomised to receive co-trimoxazole or placebo, there were clinically 
and statistically significant improvements in FVC, shuttle walking distance and symptom scores after 3 
months of active therapy(13). The improvements in the treatment group were maintained at one year, and 
similar improvements were seen when the original placebo group were crossed over to an open extension 
treatment period and received therapy with co-trimoxazole. Given the lack of efficacy of standard therapies 
and modest improvement with newer expensive therapies, validation of a trial that showed remarkable 
improvements with an inexpensive, well tolerated therapy is required. 
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We will assess the effects of co-trimoxazole by measuring forced vital capacity. Forced 
vital capacity (FVC) is a standard breathing test that is performed routinely as part of 
clinical care and is therefore appropriate for this type of multicentre study. Furthermore, 
FVC correlates closely with health related quality of life and breathlessness scores in 
patients with idiopathic pulmonary fibrosis(14) and change in FVC is the best predictor of 
survival(15).  
 
Secondary outcomes will include the six minute walk test and St Georges Respiratory 
Questionnaire. The six minute walk is a reproducible procedure that has been shown to 
relate to full cardiopulmonary exercise testing in patients with pulmonary fibrosis(16) and 
that the change oxygen saturation during the six minute walk is a good predictor of 
survial(17;18). The St Georges Respiratory Questionnaire is a tool for assessing health 
related quality of life that has been validated for use with patients with idiopathic 
interstitial pneumonitis(19). It is a responsive tool that has three domains: symptoms, 
activity, and impacts (on daily life)(20). 
 
2) OBJECTIVE 
The primary objective is to compare the efficacy and safety of 12 months therapy with co-
trimoxazole 960 mg twice daily to placebo in a double-blind placebo-controlled study of 
patients with fibrotic idiopathic interstitial pneumonia.  The secondary objective is to 
estimate the incremental cost effectiveness of co-trimoxazole plus standard care compared 
with standard care alone. 
 
3) ENDPOINTS 
3.1 The primary endpoint of the study will be change in forced vital capacity after 12 
months of study drug.  
 
3.2 Secondary outcomes will be  
1. change in MRC breathlessness score. 
2. change in total lung capacity. 
3. change in total lung diffusing capacity of carbon monoxide. 
4. change in St Georges Respiratory Questionnaire. 
5. change in 6 minute walking distance and desaturation. 
6. change in EuroQol (EQ-5D) score. 
 
3.2 Other endpoints will be 
1. all cause mortality and mortality due to IPF. 
2. the requirement for escalation of therapy. This includes commencement of prednisolone or 
azathioprine (in patients who had not been on immunossupression prior to recruitment) or increase 
or decrease in the dose of prednisolone or azathioprine (in those who had been on 
immunosuppression prior to recruitment), addition of other treatments including acetylcystein and 
the commencement of oxygen therapy. 
3. the number of  hospitalisations. 
 
3.3 Safety endpoints will be 
1. Blood haematology and biochemistry. 
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2. Drug related adverse events. 
 
4) DESIGN  
This will be a 12 month double-blind placebo-controlled, randomised multicentre study of oral co-
trimoxazole when added to standard care in 200 patients (100 in each arm) with fibrotic idiopathic interstitial 
pneumonia. Patients will attend for a screening visit to ensure that inclusion and exclusion criteria are met 
and obtain consent. The screening visit will be within 6 weeks of commencing therapy. Baseline 
measurements will be made as detailed below and repeated at 6 weeks, 6, 9 and 12 months following 
randomisation. Randomisation will be performed centrally with stratification for baseline therapy. The study 
centres will be responsible for identification and recruitment of subjects including obtaining written informed 
consent. Investigations will be performed as part of routine clinic appointments. An intention to treat analysis 
will be performed at the conclusion of the study. There will be an interim safety analysis after 50% of 
patients have completed 6 months of therapy.  
 
All patients participating in the TIPAC study shall receive their supply of study medication following 
documentation of any side effects and other adverse events, clinical assessment and confirmation of the 
patient’s consent to continue in the study. This assessment may be undertaken by the local principal 
investigator or a designee. Following receipt of a signed study drug prescription, the pharmacist shall 
dispense the medication to the participant directly or to the research team, who will dispense the medication 
to the participant. Wherever possible, the study drug prescription shall be signed, and the study medication 
shall be dispensed from the pharmacy on the day of patient’s study visit. On some occasions this is not 
possible and the prescription may be signed in advance of the study visit. The research team shall document, 
in the study workbook, the amount of study drug supplied, and by whom 
 
5) STUDY POPULATION  
 
 SAMPLE SIZE 
 
A sample size of 63 subject in each arm will have an 80% power to detect a mean difference of 200ml in 
forced vital capacity at a significance level of p = 0.05, assuming a standard deviation of 400 ml. In order to 
accommodate a withdrawal rate of 37% we will recruit 200 patients into the study.  
 
INCLUSION CRITERIA 
 
1. Male or female, aged greater than 40 years. 
2. Female subjects must be of non-childbearing potential, defined as follows: 
 postmenopausal females who have had at least 12 months of spontaneous amenorrhea or 6 months 
of spontaneous amenorrhoea with serum FSH>40mIU/ml. 
 females who have had a hysterectomy or bilateral oophorectomy for at least 6 weeks. 
3. Able to provide informed consent.  
4. A clinical labelled diagnosis of fibrotic idiopathic interstitial pneumonia with HRCT scan features 
compatible with Usual Interstitial Pneumonia (UIP) or Fibrotic Non-specific Interstitial Pneumonia 
(NSIP). The following criteria adapted from the ATS/ERS consensus statement will be used for the 
diagnosis the clinical manifestation of UIP (idiopathic pulmonary fibrosis): 
 Major Criteria (All present) 
o Exclusion of other known causes of interstitial lung disease, such as drug toxicities, 
environmental exposures, and collagen vascular diseases 
o Abnormal pulmonary function studies that include evidence of restriction with or without 
impaired gas exchange 
o Bibasal reticular abnormalities with minimal ground glass opacities on HRCT 
 Minor criteria (two out of three features) 
o Insidious onset of otherwise unexplained dyspnoea on exertion 
o Duration of illness 3 months 
o Bibasal inspiratory crackles (dry or ‘‘Velcro-’’ type in quality) 
Patients with clinical diagnosis of non-specific interstitial pneumonia will be entered if fibrotic features 
are predominant on HRCT. Histology will not be required as an entry criterion however histology from 
lung biopsy or autopsy will be reviewed if available. 
 
241 
 
5. Patients may have had initial treatment of prednisolone +/- azathioprine, as indicated and described 
in the current BTS guidelines, without a significant response to immunosuppressive therapy that 
would make the physician doubt the diagnosis of fibrotic idiopathic interstitial pneumonia.  
6. Patients should be on stable treatment regimen for at least 6 weeks. Patients may be on no 
immunosuppressive medication or may be receiving immunosuppressive medication in the form 
of oral prednisolone up to a dose of 20mg per day +/- azathioprine. Patients receiving higher 
doses of up to 0.5mg/kg may be enrolled in exceptional circumstances after discussion with the 
principal investigator. 
7. Those patients who are not on immunosuppressive therapy and have not had steroid treatment in the 
past due to concern of potential adverse effects or for other reasons, but who have a significant 
deterioration in their lung function, as determined by the attending physician and investigator 
would be invited to participate in the study.  
8. Patients may be receiving treatment with n-acetylcysteine or other anti-oxidants. 
9. MRC dyspnoea score of 2. 
10. A normal serum folate and B12 (to ensure no bone marrow or neurological adverse effects occur 
with folate therapy to B12 deficient individuals) is required at screening. 
11. Subjects have a 12 lead ECG recording that does not demonstrate any clinically important 
abnormality that, in the opinion of the investigator, would make the subject unsuitable for 
participation in the study. 
 
5.3 EXCLUSION CRITERIA 
 
1. A secondary cause for pulmonary fibrosis including a diagnosis of asbestosis, drug 
induced pulmonary fibrosis, collagen vascular disease or other secondary 
pulmonary fibrosis. 
2. A recognised significant co-existing respiratory disorder.  
.  
3. A respiratory tract infection within the last 2 months.  
4. Overt and persistent heart failure, a myocardial infarction within 12months, 
ischaemic heart disease requiring more than one regular therapy or a clinically 
significant uncontrolled arrhythmia (including Mobitz type II or third degree heart 
block). 
5. Significant medical, surgical or psychiatric disease that in the opinion of the 
patients’ attending physician would affect subject safety or influence the study 
outcome.   
6. Women who are pregnant or are breast-feeding.  
7. Patients receiving immunosuppressant medication (with the exception of 
prednisolone and azathioprine according to guidelines).   
8. Co-trimoxazole allergy or intolerance and patients receiving medication known to 
interact with co-trimoxazole.  
9. Untreated folate or B12 deficiency.  
10. Glucose-6-phosphate dehydrogenase deficiency as measured at screening (in males 
only). 
11. Receipt of an investigational drug or biological agent within the 4 weeks prior to 
entry in to this study.   
12. Patients with evidence of drug or alcohol misuse. 
 
6.1 STUDY ASSESSMENTS 
At screening, assessment will be made for glucose-6-phosphate deficiency and will be performed unless 
previously documented. An ECG will be taken unless performed within the last 6 months. A brief 
questionnaire will be administered to assess baseline health and social care resource utilisation and costs. An 
additional questionnaire will assess baseline socioeconomic status. 
 
The following will be performed at screening and 6 weeks, 6 months 9 months and 12 months after 
randomisation: 
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1. Spirometry – this will be performed according to American Thoracic Society criteria and 
represented as absolute values(21). 
2. MRC Breathlessness score. 
3. Full blood count, Urea and Electrolytes and Liver function tests (this is unlikely to be additional 
to standard care). 
4. The EuroQol EQ-5D (a 1 page self administered questionnaire) 
5. A health and social care resource utilisation and costs questionnaire (3 pages). 
 
The following will be performed at screening and 6 months and 12 months after randomisation: 
6. Six minute walking test as described previously with assessment of desaturation during the test 
and distance walked(22) – in a subgroup of patients only. 
7. St George’s Respiratory Questionnaire (SGRQ). This patient completed questionnaire has been 
previously validated in idiopathic pulmonary fibrosis(19). 
8. Total lung diffusing capacity of carbon monoxide (DLCO). 
9. Static lung volumes including total lung capacity (TLC) by body plethysmography or helium 
dilution. 
10. Blood will be stored for vascular endothelial growth and KL-6 in a subgroup of patients only. 
 
For the duration of the study an assessment will be made of 
11. all cause mortality and mortality due to IPF. 
12. the requirement for escalation of therapy. This includes an increase or decrease in the dose of 
prednisolone or azathioprine, addition of other treatments including acetylcystine and the 
commencement of oxygen therapy. 
13. adverse events. 
14. hospitalisations.  
 
The 6 week assessment will be undertaken between 4 and 8 weeks and the 6 month assessment will be 
conducted between 5 and 7 months, the 9 month assessment will be between 8 and 10 months and the 12 
month assessment between 11-13 months to permit study visits to coincide with routine medical follow-up. 
 
 
6.2 SAFETY 
6.2.1 Laboratory values 
Screening for glucose-6-phosphate deficiency will be performed (as described in 6.1 above) 
Full blood count, Urea and Electrolytes and Liver function tests will be measured at screening, at 6 weeks, 6 
months, 9 months and at 12 months of therapy (as described in 6.1 above). 
Patients on Azathioprine or  Mycophenolate Mofetil will require additional monitoring of full blood count on 
two weekly basis due to potential risk of neutropenia. Patients on Mycophanolate Mofetil will have their 
Urea and Electrolytes and Liver function tests checked two weeks after recruitment. 
Details of adverse events will be collected (as describe in 6.1 above). 
Additional investigations will be requested as deemed appropriate by the investigator on an individual patient 
basis 
 
6.2.2 Pregnancy 
6.2.2.1  Action to be taken if pregnancy occurs 
Female subjects with the potential to become pregnant will be excluded from entry into the study.  
 
6.2.2.2 Action to be taken if pregnancy occurs in a female partner of a male study subject 
The investigator will attempt to collect pregnancy information on any female partner of a male study subject 
who becomes pregnant while participating in this study. The investigator will record pregnancy information 
and submit it to the principle investigator within 2 weeks of learning of the partner’s pregnancy. The partner 
will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and 
child will be forwarded to the principle investigator. Generally, follow-up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any premature termination of the pregnancy will be reported.  
 
7. LIFESTYLE CHANGE 
There will be no lifestyle changes required 
 
8. INVESTIGATIONAL PRODUCT 
Patients will be randomised to receive either of the following treatments for 12 months: 
 
1) Co-trimoxazole (non-proprietary) 960mg twice daily as 2 tablets of 480mg twice daily.  
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Or  
 
2) Placebo tablets (manufactured from pharmacy at Guy’s and St Thomas’s Hospital – to be identical to co-
trimoxazole 480mg) 2 tablets twice daily 
 
Plus 
 
Folic acid (non-proprietary) 5mg once daily 
 
9. CONCOMITANT MEDICATION 
Permitted Therapy 
1. Patients may be receiving oral prednisolone at a stable dose (up to 20 mg per day) for 6 weeks prior 
to the start of the study. Patients receiving prednisolone will continue this dose unless clinically 
indicated. Any change in prednisolone dose will be recorded 
 
2. Some patients will also be receiving azathioprine (1-3 mg/kg/day). They will continue this dose 
unless clinically indicated. Any change in azathiorpine dose will be recorded. 
 
3. Acetylcysteine or other anti-oxidant therapy 
Non-permitted therapy on entry 
1. Cyclophosphamide 
2. Methotrexate 
3. D-penicillamine 
4. Colchicine 
5. Gamma-interferon 
Concurrent therapy requiring caution or increased monitoring 
1. Digoxin 
2. Warfarin 
3. Phenytoin 
4. Sulphonylureas 
5. Procainamide hydrochloride 
 
10 WITHDRAWAL 
Patients will be withdrawn for any of the following reasons 
 
1. Patient choice.   
2. Intolerance to study drugs.  
3. Co-trimoxazole related haematological disease (e.g. blood dyscrasia, thrombocytopaenia).  
 
11. ADVERSE EVENTS ANDADVERSE REACTIONS  
The local investigator at the study site is responsible for the detection and documentation of events meeting 
the criteria and definition of adverse events or adverse reactions including reporting to the sponsor.  
 
11.1.1 "adverse event" (AE) means any untoward medical occurrence in a subject to whom a medicinal 
product has been administered, including occurrences which are not necessarily caused by or related to that 
product. 
 
11.1.2 "adverse reaction" (AR) means any untoward and unintended response in a subject to an 
investigational medicinal product, which is related to any dose administered to that subject. 
11.1.3 “serious adverse event” (SAE) or “serious adverse reaction” (SAR) or “unexpected serious adverse 
reaction” means an adverse event/reaction that fulfils at least one of the following criteria:  
A) Results in death 
B) Is life-threatening 
NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused 
death, if it were more severe 
C) Requires hospitalisation or prolongation of existing hospitalisation  
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NOTE: In general, hospitalization signifies that the subject has been detained (usually involving at least an 
overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been 
appropriate at the GP clinic or out-patient setting. Complications that occur during hospitalization are AEs. If 
a complication prolongs hospitalization or fulfils any other serious criteria, the event is serious. When in 
doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not 
considered an AE. 
D) Results in persistent or significant disability or incapacity or 
NOTE: The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. This definition is not intended to include experiences of relatively minor medical significance such 
as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained 
ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption. 
E) Consists of a congenital anomaly or birth defect 
 
Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other 
situations, such as important medical events that may not be immediately life-threatening or result in death or 
hospitalization but may jeopardize the subject or may require medical or surgical intervention to prevent one 
of the other outcomes listed in the above definition. These should also be considered serious. Examples of 
such events are invasive or malignant cancers, intensive treatment in an emergency department or at home 
for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or 
development of drug dependency or drug abuse. 
 
11.1.4 “unexpected adverse reaction” means any adverse reaction, the nature or severity of which is not 
consistent with the applicable product information (e.g. investigator’s brochure for an unapproved 
investigational product, or summary of product characteristics [SMPC] for an authorised product). 
 
11.1.5 Severity: The term “severe” is used to describe the intensity of a specific event. This is not the same 
as “serious” which is based on patient/event outcome, or action criteria. 
 
11.1.6 “Suspected Serious Adverse Reaction (SSAR)” 
Means an adverse reaction that is classed in nature as serious and which is consistent with the information 
about the medicinal product in question set out 
 
(a) In the case of a licensed product, in the summary of product characteristics (SMPC) for that product 
(b) In the case of any other investigational medicinal product, in the Investigator’s brochure (IB) 
relating to the trial in question.  
 
11.1.7 “Suspected Unexpected Serious Adverse Reaction (SUSAR)” 
means an adverse reaction that is classed in nature as serious and which is not consistent with the information 
about the medicinal product in question set out 
 
(a) In the case of a licensed product, in the summary of product characteristics (SMPC) for that product 
(b) In the case of any other investigational medicinal product, in the Investigator’s brochure (IB) 
relating to the trial in question. 
 
11.2.1. Clinical Laboratory Abnormalities and Other Abnormal Assessments  
Abnormal laboratory findings (e.g., clinical chemistry, haematology, urinalysis) or other abnormal 
assessments (e.g., ECGs, and vital signs) that are judged by the investigator as clinically significant will be 
recorded as AEs or ARs if they meet the definition’s above. Clinically significant abnormal laboratory 
findings or other abnormal assessments that are detected during the study or are present at baseline and 
significantly worsen following the start of the study will be reported as AEs or ARs. However, clinically 
significant abnormal laboratory findings or other abnormal assessments that are associated with the disease 
being studied, unless judged by the investigator as more severe than expected for the subject’s condition, or 
that are present or detected at the start of the study and do not worsen, will not be reported as AEs or ARs. 
The investigator will exercise his or her medical and scientific judgment in deciding whether an abnormal 
laboratory finding or other abnormal assessment is clinically significant.   
 
11.3. Time Period, and Frequency of Detecting AEs and ARs 
From the time a subject consents to participate in the study until he or she has completed the study (including 
any follow-up period), all SAEs assessed as related to study participation (e.g., protocol-mandated 
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procedures, invasive tests, or change in existing therapy) will be reported promptly to the principle 
investigator. 
 
11.4. Reporting of Adverse events  
In compliance with Article 16 of the European Directive 2001/20/EC, the investigator will report all SAEs 
promptly to the sponsor (Ms Sue Steel, RBS, UEA, Norwich Fax 01603 591550) within 24 hours of being 
identified. The immediate report will be followed by detailed written reports. The immediate and follow-up 
reports will identify subjects by unique code numbers assigned to the latter. The investigator will report AE’s 
to the sponsor within 3 months. For reported deaths of a subject, the investigator shall supply the sponsor and 
the Ethics Committee with any additional information requested. The sponsor shall keep detailed records of 
all adverse events which are reported to him by the investigators. These records shall be submitted to the 
Medicines and Healthcare Products Regulatory Agency, UK if they so request. 
 
11.5 Reporting of Serious adverse reactions 
11.5.1 In compliance with Article 17 of the European Directive 2001/20/EC, the sponsor (Ms Sue Steel, 
RBS, UEA, Norwich) shall ensure that all relevant information about SUSARs that are fatal or life-
threatening is recorded and reported as soon as possible to the Medicines and Healthcare products Regulation 
Agency (MHRA), the Data Monitoring and Ethical Committee (DMEC) and to the Ethics Committee, and in 
any case no later than seven days after knowledge by the sponsor of such a case, and that relevant follow-up 
information is subsequently communicated within an additional eight days. 
 
11.5.2 All other suspected serious unexpected adverse reactions shall be reported to MHRA, DMEC and 
Ethics Committee concerned as soon as possible but within a maximum of fifteen days of first knowledge by 
the sponsor (Ms Sue Steel, RBS, UEA, Norwich). 
 
11.5.3 The sponsor shall also inform all investigators. 
 
11.5.4 Once a year throughout the clinical trial, the sponsor (Ms Sue Steel, RBS, UEA, Norwich) shall 
provide the MHRA, DMEC and the Ethics Committee with a listing of all suspected serious adverse 
reactions which have occurred over this period and a report of the subjects' safety. 
 
12 STATISTICAL ANALYSIS 
There will be central randomisation with stratification for baseline treatment at entry into the study. The 
primary endpoint will be the change in Forced Vital Capacity (ml) from baseline to 12 months of therapy.  
Assuming a residual SD of 400ml (from data from ISOLDE and TRISTAN study courtesy of J. Anderson, 
GSK, Greenford), then with 63 patients in each group this study has an 80% power to detect a mean 
difference of 200ml at a significance level of p = 0.05. The value of 200ml for the mean difference in FVC 
from baseline was used to power the study since this represents the minimum change required for a 
favourable or unfavourable response to treatment as proposed in the ATS/ERS International Consensus 
statement (1999). The study will be analysed on an intention to treat base. A mixed-effect model with centre 
and centre-by-treatment included as random effects with outcomes FVC, FEV1, FV6, 6 min walking 
distance, change in oxygen saturation during 6 minute walk, MRC, Borg dyspnoea and SGRQ scores, steroid 
dose, total lung diffusion capacity of carbon monoxide and total lung volume. This assumes the baseline 
values are similar for both groups, if they are not a suitable adjustment will be used. This also assumes that 
the residuals will be normally distributed, if this is not the case then a suitable transformation will be used. 
An adjustment may also be used if a the correlation between baseline and the final value is high The number 
of patients with abnormal renal function, liver function or full blood count or the number of patients with a 
significant escalation in therapy, adverse event or hospitalisation in each group and the number of deaths in 
each group will be compared using a chi squared test. 
 
A cost-effectiveness and cost-utility analysis will be performed to determine the costs and outcomes (point 
improvement in FVC and QALYs gained) of treating a patient with or without co-trimoxazole, measured 
from the viewpoints of both the health service and society. Health service costs will be taken as drug costs, 
hospital costs and GP practice costs.  The societal analysis will include NHS costs plus costs arising from 
social care providers, patient out of pocket costs and informal carer time.   
 
Quality Adjust Life Years (QALYs) will be calculated by converting the EQ-5D questionnaire results into 
utilities using UK health state valuations(23), then measuring the resulting area under the curve. 
 
A point estimate of the Incremental Cost Effectiveness Ratio (ICER) will be calculated and confidence 
intervals around differences in cost and outcome generated using a non-parametric bootstrap approach.  The 
results will be presented as a cost-effectiveness acceptability curve.  
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13 STUDY CONDUCT CONSIDERATIONS 
13.1 Regulatory considerations 
 
The study will also be conducted in accordance with "good clinical practice" (GCP), all applicable subject 
privacy requirements, and, the guiding principles of the Declaration of Helsinki. This includes, but is not 
limited to, the following: 
• MREC review and favourable opinion/approval to conduct the study and of any 
subsequent relevant amended documents 
• Subject informed consent 
• Investigator reporting requirements 
 
Written informed consent will be obtained for each subject before he or she can 
participate in the study. 
 
13.2. Quality Control (Study Monitoring) 
 
This study will be managed by the East Anglia Thoracic Society (EATS) clinical fellow. The EATS fellow 
will have training in Good Clinical Practice. Prior to enrolment of a site, the EATS fellow will contact the 
site prior to the start of the study to review with the site staff the protocol, study requirements, and their 
responsibilities to satisfy regulatory and ethical requirements. When reviewing data collection procedures, 
the discussion will also include identification, agreement and documentation of data items for which the CRF 
will serve as the source document. 
 
A monitoring committee will be formed and will monitor the study consistent with the demands of the study 
and site activity to verify that the: 
• All outcomes and resource use data are authentic, accurate, and complete. 
• Safety and rights of subjects are being protected. 
• Study is conducted in accordance with the currently approved protocol and any other study agreements, 
GCP, and all applicable regulatory requirements. 
 
13.3 An independent trial steering committee will be formed. It will be comprised of an Independent 
Chairman (no direct trial involvement), two additional independent expert members, Chief Investigator and a 
patient/lay representative 
 
13.4 A data monitoring and ethical committee will comprise a statistician and a researcher with special 
interest in interstitial lung disease. This committee will monitor the serious adverse events and mortality.  
 
13.5 Contacting patients after the end of their participation in the study  
 
For the purpose of accurate data collection and follow up of adverse events and reactions reported by the 
patients at the last visit of the study, patients might need to be contacted after their last study visit. It will be 
aimed at doing this as soon as possible when it is identified that some questionnaire questions are not filled in 
or in terms that are felt by the attending team to be relevant when a follow up of AE/AR is required. Patients 
will be contacted either over the phone or in writing. The status of a patient will be checked with hospital 
Patient Administration System (PAS) first to ensure that families of deceased patients are not disturbed. 
247 
 
Time and events table 
 
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 
 0 6 weeks 6 months 9 months 1 year 
Consent X     
History & Examination X X X X X 
Drug dispensed X X X X  
Adverse events X X X X X 
Concomitant medication X X X X X 
Spirometry X X X X X 
MRC score X X X X X 
FBC, U&E, LFT X X X X X 
6 Min Walk X  X  X 
SGRQ X  X  X 
DLCO X  X  X 
TLC X  X  X 
KL-6 X  X  X 
EQ-5D X X X X X 
Socioeconomic status 
questionnaire 
X     
Cost questionnaire - 
baseline 
X     
Cost questionnaire – 
follow-up 
 X X X X 
 
Bold  indicates measurements that will be performed in all subjects. Other measurements are will be 
performed in a subgroup of patients. 
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Appendix 4  
 
LOCAL HOSPITAL HEADED PAPER TO BE USED 
 
 
PATIENT INFORMATION SHEET 
PART 1 
 
1. Study title: 
The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial 
pneumonia   TIPAC Study 
 
2.  Invitation paragraph 
We are inviting you to participate in a research study being conducted by Chief Investigator, Dr 
Andrew Wilson, and his colleagues. Before you make your decision it is important for you to 
understand why the research is being done and what it would involve for you if you took part. 
Your participation in this study is entirely voluntary. If you decide not to take part, or want to 
withdraw at any stage without giving a reason, you can do so without this affecting the standard of 
care that you receive. 
Please take time to read this information and discuss it with your GP or relatives or friends. 
 Part 1 of this information sheet tells you the purpose of the study and what would happen if 
you took part, 
 Part 2 gives more detailed information about how the study will be conducted. 
 
3. What is the purpose of the study? 
The purpose of this study is to investigate whether the use of an antibiotic (called co-trimoxazole) 
improves the breathing function of patients with pulmonary fibrosis . 
 
4. Why have I been chosen? 
You have been chosen because you have a lung condition called pulmonary fibrosis (also called 
idiopathic interstitial pneumonia). If you agree to participate, you will be one of 180 patients from 
England and Wales who are helping with this study.  
 
5. Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information sheet, which we 
will then give to you. We will then ask you to sign a consent form to show that you have agreed to 
take part. You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
6. What will happen to me if I take part? 
When we don’t know which way of treating patients is best we need to compare the new way of 
treating you with the old way. The best way to do this is to put people into groups and give each 
group different treatment. The results are then compared to see if one is better. To try to make sure 
the groups of people are the same to start with, each patient is put into a group by chance 
(randomly). This is like tossing a coin to decide which group you will be in. You will have an equal 
chance of getting the co-trimoxazole treatment or the placebo. A placebo is a ‘dummy treatment’ 
that looks like the genuine medicine but contains no active ingredient. 
 
7. What do I have to do? 
 
PLEASE READ APPENDIX 1 – INFORMATION ABOUT CO-TRIMOXAZOLE 
 
You will be invited to attend for a screening visit at the clinic. At the visit you will have some 
breathing tests done, a test to see how far you can walk in 6 minutes, a blood sample will be taken 
and you will be asked some questions about your breathing. The breathing tests will be the same 
ones that you usually have when you attend the Respiratory Clinic ie no additional breathing tests 
will be necessary. They will include a forced breathing test when you have to breathe hard and a 
gentle breathing test – you may need to enter a Perspex box for this test. The questionnaires are 
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standard questionnaires and will not take long to complete. During the 6 minute walking test you 
will have to walk as fast and as far as you can. During this test we will measure the oxygen in your 
blood by clipping a peg on your finger. You will also have a heart wave tracing done. You will be 
given a short questionnaire to complete that asks questions about your employment etc and about 
your contact with the NHS - doctors, nurses, hospital, etc 
 
There is a rare condition, that only effects males, which causes their red blood cells (oxygen 
carrying cells in the blood) to break up if they are exposed to certain medications including co-
trimoxazole. We therefore are required to take a blood test from all male patients who are 
interested in helping with the study to check that they do not have this condition before they take 
the study medication. If you are a man then we will need to take an additional blood test during the 
screening visit. If you are shown to be positive for this condition then we will refer you to a 
specialist haematologist for further information/advice. 
 
You will then be allocated to either receive the active drug or the dummy drug, which you will need 
to take in the morning and at night. You will also be prescribed with a vitamin called Folic acid 
which you will need to take in the morning which will help to protect your bone marrow (which 
produces blood cells) from potential rare risk of affecting the number of certain blood cells. You will 
then be followed up in the clinic in the normal way. After six weeks, 6 months and 9 months of 
taking the study drug you will be asked to return to the clinic for a blood test, a breathing test and to 
complete a short questionnaire. After twelve months of taking the study drug you will be invited 
back to the clinic to repeat the tests that were done at the beginning of the study. 
 
You will need stop taking the study medication and contact your hospital consultant or family doctor 
immediately if you experience: 
 Sudden wheeziness or difficulty in breathing  
 Swelling of the eyelids, face or lips  
 Blisters with a skin rash 
8. What is the drug being tested? 
Co-trimoxazole is an antibiotic that is used routinely to treat and prevent certain types of respiratory 
infections. 
 
9. What are the alternatives for treatment? 
You will already either be receiving optimal (best possible) treatment for your condition or not be on 
any treatment but be followed up by your Consultant to ensure early signs of deterioration are 
picked up and acted on so  the study drug will be in addition to your usual medication (if you are 
taking any). You will not be excluded from taking any recommended treatment for your condition. 
 
10. What are the possible disadvantages and risks of taking part? 
You may not get the active treatment and may receive the dummy treatment.  
The active drug (co-trimoxazole) sometimes causes unwanted effects in some people. We have 
classified these into common, less common and very rare to give you an idea of the chances of an 
unwanted effect occurring. However all side effects are listed in the patient information sheet which 
comes with the tablets. 
 
Common:   Nausea, Diarrhoea, Headache, Rash 
Less common:  Thrush, Vomiting 
Very Rare  Sore mouth, Lack of appetite,   
Problems with liver, pancreas, lungs, intestine or kidneys, 
Depression, fits, nerve problems, dizziness, ringing in ears 
Blood cell and chemical abnormalities or a serious skin rash 
 
If you experience any unwanted side-effect, either those mentioned above or not, you should 
contact your hospital consultant or family doctor.  
 
It is likely that you will require increased monitoring of your blood clotting tests if you are receiving 
warfarin. 
 
There is an increased risk of a problem with your blood cells, liver and kidney tests if you take co-
trimoxazole and azathioprine or mycophenolate mofetil together. Although this risk is low the 
effects may be severe and therefore we will increase the monitoring of your blood count from every 
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four weeks (required for azathioprine or mycophenolate treatment when given alone) to every two 
weeks. You will also have an additional liver and kidney test two weeks after starting a study drug. 
 
It may be necessary for you to attend the hospital on visits in addition to your clinic visit. If you are 
required to make an additional visit, we will reimburse your traveling expenses at a rate of 22p/mile 
if traveling by car or bus/train/taxi fares against receipts if using public transport 
 
11. What are the possible benefits of taking part? 
It cannot be guaranteed that the active drug will improve your breathing and ability to exercise, 
although we think that it might. 
  
12. What happens when the research study stops? 
Co-trimoxazole is not currently used to treat patients with pulmonary fibrosis however if we find out 
that you have been taking co-trimoxazole and that you have had a noticeable benefit from it your 
doctor may be in a position to prescribe it for you. If you are taking the dummy tablet and the 
results of this study are very encouraging your doctor may prescribe it for you. If the results are 
disappointing then you would continue with your usual treatment. 
 
13. What if something goes wrong? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. (Further detailed information in Part 2). 
 
14. Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. The details 
are included in Part 2. 
 
 
 
15. Contact details 
If you have any queries about your participation in this study, please contact one of the following.  
 Dr…………….., 
 Consultant Respiratory Physician,  Tel: …………………………….… 
  
Dr Ludmila Shulgina  
Study co-ordinator     Tel………………………………… 
 
If the information in Part 1 has interested you and you would consider participating please read the 
additional information in Part 2 before making a decision 
 
PART 2  
 
16. What if new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, your 
research doctor will tell you and discuss whether you should continue in the study. If you decide not 
to carry on, your research doctor will make arrangements for your care to continue. If you decide to 
continue in the study he may ask you to sign an updated consent form. 
 
17. What will happen if I don’t want to carry on with the study? 
If you decide at some point that you no longer wish to take part in the study, you may withdraw at 
any time. You may decide that you no longer want to take the study medication, but we would still 
ask that you return for your follow-up visits at 6 and 12 months after starting treatment, but you are 
not obliged to do so. 
If you withdraw from the study, we will destroy all your identifiable samples, but we will need to use the 
data collected up to your withdrawal. 
 
18. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions. If you remain unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. Details can be obtained from 
your hospital. 
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If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed during the research due to someone’s negligence then you may 
have grounds for legal action for compensation against your hospital, but you may have to pay your 
legal costs. The normal NHS complaints mechanisms will still be available to you.  
 
19. Will my taking part in this study be kept confidential? 
Your data will be collected by your hospital consultant or members of clinical staff at your hospital 
and by members of the research team. It will be used to assess whether you have had any benefit 
or side effects with the study medication. All information that is collected about you during the 
course of this study will be kept strictly confidential, and any information about you which leaves 
the hospital will have your name and address removed so that you cannot be recognised. 
Representatives of the sponsor or the Trust R&D department will have access to identifiable data 
to ensure the study is being corrected properly. This anonymised information will be accessible to 
the research team and may also be looked at by representatives of regulatory authorities and by 
authorized people to check that the study is being carried out correctly. All will have a duty of 
confidentiality to you as a research participant. It will be stored securely and Dr Wilson will be the 
custodian. It will be kept for your 15 years after which it will be disposed of securely. Use of your 
data will be in compliance with the Data Protection Act. 
 
With your permission, your GP will be informed of your participation in this study. 
 
20. What will happen to the results of the research study? 
This study should be completed by the end of 2010 when a report will be completed and we will 
also publish our findings in research journals. You will not be named or identified in any way in any 
report of the study. If you would like information about the results of the study please contact the 
Principal Investigator named below. 
 
21. Who is organising and funding the research? 
This research study is being organised and conducted by Dr Andrew Wilson and is sponsored by 
The University of East Anglia. The study is supported by a grant from the East Anglian Thoracic 
Society and the Research for Patient Benefit programme. The study co-ordinator will be Dr Ludmila 
Shulgina. Dr Shulgina will be working on this study as part of an educational qualification. Your 
Doctor is not being paid for including you in this study. 
 
22. Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by the Cambridgeshire 4 
Research Ethics Committee. 
 
23. Contact for further information 
If you have any queries about your participation in this study, please 
contact one of the investigators (contact details below). 
 
Principal Investigator: 
 
 
Co-investigator: 
  
 
Dr Ludmila Shulgina 
Study co-ordinator 
Tel……………………………… 
Thank you for considering taking part in this study! 
If you decide to participate you will be asked to sign a consent form and given a copy of this information 
sheet and consent form to keep. 
APPENDIX 4.1 
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INFORMATION ABOUT CO-TRIMOXAZOLE – adapted from datasheet 
 Please read this leaflet carefully before you start to take your medicine.  
 It gives you important information about your medicine.  
 If you want to know more, or you are not sure about anything, ask your 
pharmacist or doctor.  
 Keep the leaflet until you have finished the medicine.  
What's in co-trimoxazole 
One of the active ingredients in this medicine is Sulfamethoxazole. 
This is the new name for Sulphamethoxazole. 
The ingredient itself has not changed. 
ABOUT YOUR MEDICINE 
Before taking your medicine 
Do not take Co-trimoxazole tablets if you: 
 are sensitive to any of the ingredients in the product  
 have severe liver damage or are jaundiced (yellowing of the skin and whites of 
the eyes)  
 have any blood disorder. If you keep getting infections or nosebleeds or notice 
any unusual bruising tell your doctor  
 have the metabolic disease porphyria  
 have severe kidney damage or disease  
 are giving the tablets to children under 6 years as they are not suitable. Co-
trimoxazole must not be given to new born babies under 6 weeks of age.  
Check with your doctor or pharmacist before taking Co-trimoxazole tablets if you: 
 have a history of severe allergic reactions or bronchial asthma  
 have been told you have a reduced amount of the enzyme glucose 6 phosphate 
dehydrogenase. You may react badly when you eat certain types of foods such 
as fava beans  
 have a protein disorder called phenylketonuria  
 have Group A beta-haemolytic streptococcia (a bacterial infection)  
 are elderly as you may suffer with more side effects.  
Check with your doctor or pharmacist if you are taking any of the following: 
 ace inhibitors used to treat high blood pressure (e.g. captopril, lisinopril)  
 anaesthetics such as prilocaine  
 antiarrhythmics used to treat some heart conditions such as procainamide, 
amiodarone, dofetilide  
 antibiotics such as rifampicin, dapsone, methenamine  
 anticoagulants drugs used to prevent your blood clotting (eg warfarin)  
 sulphonylureas used to treat diabetes  
 phenytoin used to treat epilepsy  
 pyrimethamine used to treat malaria  
 antivirals such as lamivudine, zidovudine, zalcitabine  
 amantidine used to treat parkinsonism or some viral infections  
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 clozapine used to treat mental health problems  
 cytotoxic drugs such as methotrexate, azathioprine, mercaptopurine (used to 
treat some cancers, severe psoriasis or severe rheumatoid arthritis)  
 cardiac glycosides (used to treat heart conditions e.g. digoxin)  
 diuretics such as bendroflumethiazide or hydrochlorothiazide  
 ciclosporin used to prevent rejection after transplantation  
 potassium aminobenzoate  
 any other medicines that you have bought without a prescription.  
Driving and using machines: 
Co-trimoxazole tablets may make you feel drowsy or dizzy, see things that are not 
there, cause ringing in the ears or sleeplessness. Make sure you are not affected 
before you drive or operate machinery. 
 You MUST STOP taking the tablets immediately and contact your doctor if you 
experience sudden wheeziness, breathlessness; swelling of the eyelids, face or 
lips; or  blisters and a skin rash. 
If you see another doctor or go into hospital, let them know what medicines you are 
taking because Co-trimoxazole tablets may effect some medical tests. Please tell them 
that you are participating in a clinical study under the supervision of …………………………. 
phone number…………………… 
TAKING YOUR MEDICINE 
Swallow the tablets preferably with food or a drink at the same times each day. This 
medicine should be taken for as long as your doctor tells you to, it may be dangerous 
to stop without their advice. 
If you (or someone else) swallow a lot of the tablets at the same time, or if you think 
a child has swallowed any of the tablets, contact your nearest hospital casualty unit or 
tell your doctor immediately. Please tell them that you are participating in a clinical 
study under the supervision of …………………………. phone number…………………… 
If you forget to take a dose, take one as soon as you remember, unless it is nearly 
time to take the next one. Never take two doses together. Take the remaining doses 
at the correct time. DO NOT take two doses at the same time. 
If you are worried ask your pharmacist or hospital consultant or family doctor for 
advice. 
TAKING YOUR MEDICINE 
This medicine sometimes causes unwanted effects in some people. These effects may 
include skin rashes, these can be serious. If you get a skin rash you must stop taking 
the tablets and consult your doctor immediately. These skin rashes may be itchy, red 
or your skin may become sensitive to light.  
Effects on the blood: co-trimoxazole can alter the number and type of certain blood 
cells. If you get increased bruising, nose bleeds, sore throats or infections you should 
consult your doctor. 
Allergic reactions: these can be serious, if you notice any symptoms such as swelling, 
difficulty breathing or fever tell your doctor. Other allergic reactions can include 
inflamed heart or blood vessels, fever and systemic lupus erythematosus (SLE 
characterised by skin rash, hair loss, difficulty breathing and joint pains). 
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Aseptic meningitis can occur in some patients. This may show as a combination of 
symptoms such as headache, fever, stiff neck, tiredness, feeling ill and your eyes 
become very sensitive to bright light. If you experience any of these symptoms seek 
medical attention immediately. 
Effects on the nervous system: headaches which may be severe, depression, 
dizziness, giddiness, hallucinations (seeing things that are not there), fits, lack of co-
ordination, numbness of fingers or toes, drowsiness, fatigue, sleeplessness and 
increase pressure in the skull. Consult your doctor if any of these effects are severe or 
prolonged. 
Effects on the stomach: feeling or being sick, diarrhoea, loss of appetite and sore 
tongue or mouth and rarely colitis.  
Effects on the liver: rare but serious effects can include jaundice, changes in liver 
function and liver damage or an inflamed pancreas. If you notice yellowing of your 
skin or eyes, get severe diarrhoea or severe abdominal pain you should consult your 
doctor immediately. 
Other effects: cough, difficult or painful breathing, sensitivity to light, vertigo, ringing 
in the ears, overgrowth of some fungal organisms, kidney damage, crystal in the urine 
and changes in body chemicals (especially potassium and sodium) can also occur. If 
you have difficulties passing water, pain or blood in your urine, or difficulties breathing 
tell your doctor. 
If you are concerned about any of these effects or get any other unusual effects, tell 
your doctor or pharmacist immediately. 
STORING YOUR MEDICINE 
Do not use the tablets after the end of the expiry month shown on the product 
packaging.  
 Keep the tablets stored below 25°C in a dry place and protected from light  
 Do not transfer them to another container.  
 Keep CO-TRIMOXAZOLE out of the reach and sight of children in a secure 
place.  
 Remember that this medicine is for you only. Never give it to anyone else. It 
may harm them, even if their symptoms are the same as yours.  
 Return all unused medicines to your pharmacist for safe disposal.  
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Appendix 5 
 
LOCAL HOSPITAL HEADED PAPER TO BE USED 
 
 
 
 
 
 
PATIENT CONSENT FORM 
Patient Identification Number for this trial: 
 
Title of Project:     
 
Treating Interstitial Pneumonia with the Addition of Co-
trimoxazole (TIPAC) Study 
. 
Name of Researcher:    Dr Andrew M Wilson 
        Please initial box 
1. I confirm that I have read and understand the information sheet dated ............................ 
 (version ............) for the above study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,  
 without giving any reason, without my medical care or legal rights being affected. 
3 I give permission for my General Practitioner to be informed about my participation  
in the study           
4. I understand that sections of any of my medical notes may be looked at by responsible 
 individuals  from regulatory authorities where it is relevant to my taking part 
 in research.  I give permission   
 for these individuals to have access to my records.       
5. I agree for my data to be stored securely in an anonymised form     
6. I agree to undergo screening for glucose-6-phosphate deficiency (males only)   
7. I agree to take part in the above study.        
 
 
________________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
 
 
                1 for patient;  1 for researcher;  1 to be kept with hospital notes Version 3 13 August 2007 
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Appendix 6 
ILD PROFORMA  
 
Patient’s name______________________________________________________ 
 
Demographics 
 
DOB________________ 
Age_________________ 
Race: Caucasian    African Descent   
            Mediterranean    
Other____________(specify) 
Weight______(kg)  Height______(cm) 
Gender: F   M  
  
 Respiratory hazard 
Inorganic: Organic: 
 1. Asbestos: 
 Construction worker 
 Shipyard worker 
 Power station construction 
 Maintenance worker 
 Naval boiler man 
 Garage worker (brake lining) 
 Joiner 
 Electrician 
 Carpenter 
2. Coal  mining 
3. Metal exposure 
4. Sandblasting  
5. Talc 
6. Aluminium oxide 
7. Wood work 
8. Other  
1. Birds (describe, length of 
exposure)  
2. Farmers lung 
3. Sugar cane 
4. Coffee 
5. Tobacco (tobacco growers 
lung) 
6. Fishmeal (fishmeal worker’s 
lung) 
7. Mushroom 
8. Maple bark stripper 
9. Malt 
10. Tea grower 
11. Cheese 
12. Wine 
13. Other  
 
 
Smoking history 
Never smoked      
Ex-smoker            
Current smoker    
 
Pack-years ________ 
Year started________ Year finished_______ 
 
 
Occupational history (see respiratory hazard box above) 
 
Employer Job type, activities  Occupational hazard 
 
Respiratory 
protection  
Respiratory 
symptoms at the 
time 
     
     
     
     
     
     
     
 
Domestic/environmental exposure  
(See respiratory hazard box above, including exposure to domestic mould and humidifiers) 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
Spouse 
employment_______________________________________________________________ 
______________________________________________________________________________ 
 
Hobbies:  
Birds Yes    No   
age of exposure____________duration of exposure____________birds indoors/outdoors 
respiratory symptoms at the time Yes    No   
Isocyanates, age and length of exposure 
Other (see respiratory hazard box above)______________________________________________________________ 
 
Family history of ILD_____ ______________________________________________________ 
Family history of CTD___________________________________________________________ 
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Medical history other than possible ILD 
Diagnosis Details  
Previous malignancy Tx with Radiotherapy +/-Chemotherapy  
Connective tissue disease  
Inflammatory bowel disease  
Cardiac disorders  
Other  
 
Drug history 
Drug Dose and duration of Tx Respiratory symptoms 
at the time of drug use 
Nitrofurantoin   
Disease modifying antirheumatic drugs( 
Sulphasalazine, MTX, Gold, Penicillamine, 
Leflunomide, Etanercept) 
  
Cardiovascular (Amiodarone, ACEI, Statin)   
Chemotherapeutic agents (bleomycine, 
Cyclophosphamide) 
  
Ilicit drugs (heroin, methadone, talc)   
Miscellaneous (oxygen, radiation, aspirin, interferons)   
Over the counter/herbal medicines   
 
Clinical symptoms/examination at Diagnosis 
Respiratory symptoms (list): Connective tissue disease symptoms: 
 
 Ocular symptoms  
Sicca symptoms 
Oral ulcers 
Alopecia 
Recurrent fevers 
Weight loss 
Photosensitivity  
Raynaud’s phenomenon  
Skin thickening 
Rash 
Teleangiectasia 
Arthralgia 
Myalgia 
Proximal muscle weakness 
Dysphagea/acid reflux 
 
Cyanosis              Yes  No  
Finger clubbing     Yes  No  
SaO2_______(%) on_______l/min 
 
Auscultation of the chest    
Wheeze  Crepitations  Other(specify)______ 
Auscultation of precordium _________________ 
Hepatomegaly      Yes  No  
Peripheral oedema Yes  No  
 
MRC dyspnoea grade:    ____________ (use table for guidance) 
 
Autoantibodies  
RhF, result____________  
ANA_____negative   positive    Titre______________ 
In patient with raised ANA titre is Lupus Anticoagulant Positive  Negative    
In patient with raised ANA titre are Anticardiolipin Antibodies Positive  Negative    
Anti-double stranded DNA (dsDNA) Antibodies:  Negative   Positive    Titre_____ 
ENA Negative   Positive     
  Anti-SSA (Ro) Antibodies Negative   Positive     
Anti-SSB (La) Antibodies Negative   Positive     
Anti-Sm Antibodies Negative   Positive     
Anti-RNP Antibodies Negative   Positive     
Anti-Scl-70 Antibodies Negative   Positive     
Anti-Jo 1 Antibodies Negative   Positive     
Cryoglobulins checked Yes    No   
ESR_______  CRP_______     Avian Precipitins  Positive  Negative   Framers Lung precipitins Positive  Negative    
 
Lung function tests  
 
6 Minute Walk at diagnosis 
 
Distance________(metres) Max SaO2_______% Min SaO2________  
HRCT requested Yes  No   
 
 
Grad
e 
Degree of Breathlessness Related to 
Activities 
1 Not troubled by breathlessness 
except on strenuous exercise 
2 Short of breath when hurrying or 
walking up a slight hill 
3 Walks slower than contemporaries on 
level ground because of 
breathlessness or has to stop for 
breath when walking at own pace 
4 Stops for breath after walking about 
100 meters or after a few minutes on 
level ground 
5 Too breathless to leave the house or 
breathless when dressing or 
undressing 
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Appendix 7 
Study protocol (version 4) 
 
Are alveolar nitric oxide and plasma VEGF markers of disease 
severity and progression in patients with idiopathic pulmonary 
fibrosis 
 
 
Authors 
 
Andrew M Wilson 
Ludmila Shulgina 
Helen Parfrey 
 
 
1 Introduction  
 
Interstitial lung diseases (ILD) are a group of lung disorders which may be acute or chronic and can 
involve varying degrees of pulmonary inflammation and fibrosis(1)  The commonest ILD of all is 
Idiopathic Pulmonary Fibrosis (IPF) with Usual Interstitial Pneumonia (UIP)  histology pattern and 
Idiopathic Nonspecific Interstitial Pneumonia (NSIP). The prognosis is usually poor (median 
survival of 2-3 years)(2). Patients usually die from gradually progressive disease, some have 
rapidly fatal course due to acute exacerbation(3). Previously much of the research into ILD had 
been hampered as there was no uniform international diagnostic criteria or classification of 
disease.  However, the American Thoracic Society and European respiratory society (ATS/ERS)(1) 
have now published a guideline and  joint international consensus statement.  The guidelines 
define IPF as a ‘’progressive chronic ILD of unknown cause associated with histopathologic pattern 
of UIP’’(4) .   
 
Although the median survival is poor, there is considerable variability in disease progression with 
only a proportion of patients showing evidence of decline at 6 and 12 months from diagnosis. 
Flaherty et al (5) showed that whilst 32% of patients with IPF had a 10% decline in FVC at 6 
months and 54% had a similar decline at 12 months, 68% and 31% remained within 10% or had a 
10% improvement in their FVC at 6 and 12 months respectively. Even with this enormous 
variability, the best method to assess disease progression and hence to predict outcome is serial 
pulmonary function over a 6 to 12 month period. Biomarkers, biochemical tests which predict 
prognosis or response to treatment, are required to help identify those patients with a good or poor 
outlook. Two potential biomarerks are exhaled nitric oxide or vascular endothelial growth factor 
(VEGF). 
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Current concept of pathogenesis of IPF suggests that repetitive injury to alveolar   epithelium and  
endothelial injury causes chemokines and growth factors release which in turn drives recruitment of 
fibroblasts and endothelial cells which leads to collagen-matrix remodelling with little evidence of 
inflammation. Nevertheless there is evidence of inflammatory cell involvement with an alveolar 
septal infiltrate of lymphocytes, plasma cells, and histiocytes associated withtype II pneumocytes 
hyperplasia (ATS/ERS consensus Classification). It is thought that free radicals are involved in the 
role of fibrogenesis of human lungs in ILD and the activation of inflammatory cells leads to the 
production of reactive oxygen species: a strong expression of nitrotyrosine (a byproduct of protein 
nitration caused by a potent oxidant peroxinitrate) and nitric oxide synthase is seen in 
macrophages, neutrophils and alveolar epithelium of lungs of patients with early to intermediate 
stage of IPF compared to normal control subjects(6).  
NO is a gaseous signalling molecule and can act as a bronchial and vascular smooth muscle 
dilator(7).  NO is produced by constitutive NO synthases (cNOS) in the physiological state and 
during inflammation inducible NO synthase (iNOS) is produced in higher quantities(8).  Previous 
studies of patients with asthma show that inhaled steroids reduce the levels of exhaled NO in the 
asthmatic airways, that these levels correlate well with the disease activity in a form of sputum 
eosinophilia  and that  they could well be used successfully to guide titration of the dose of inhaled 
steroids(9).   
 
Although a number of studies have investigated the role of exhaled NO in patients with systemic 
sclerosis with and without its complications in a form of interstitial lung disease and/or pulmonary 
hypertension, in patients with asbestosis(10) and stage 1-4 sarcodosis(8); there is a paucity of 
research investigating the role of NO in patients with idiopathic pulmonary fibrosis. Some of this 
studies looked at alveolar rather than total exhaled NO.  Modley et al(11), demonstrated that 
alveolar NO was elevated in patients with scleroderma without ILD compared to those with ILD 
suggesting presence of subclinical inflammation (confirmed by higher neutrophil and eosinophil 
count in broncho-alveolar lavage fluid in Scleroderma patients compared to healthy controls) before 
the clinical and radiological evidence of it becomes apparent. Girgis et al(2) demonstrated 
increased concentrations of alveolar NO in Scleroderma patients with ILD with and without 
concomitant pulmonary hypertension.  It had also been shown that in patients with scleroderma the 
levels of alveolar NO are related to the extent of ILD as evidenced by the CT scan fibrosis score 
and inversely related to the severity of ILD as evidenced by diffusing capacity for carbon 
monoxide(12;13). Alveolar NO has been suggested for use as a noninvasive marker for 
assessment of severity of inflammation in asbestosis(10). 
A study by Paredi et al(14) showed that patients with fibrosing alveolitis had elevated total exhaled 
NO levels and this correlated well with activity in broncho-alveolar lavage fluid (as indicated by any 
of the following: lymphocytes >14%, neutrophils >4%, eosinophils >3%); patients treated with 
corticosteroids had lower levels of NO than untreated patients. Lehtimaki et al’s(7) study of patients 
with IPF suggests that there was an increased alveolar concentration of NO in patients with IPF 
and that it correlated negatively with DLco percentage of predicted which is a marker of disease 
severity. 
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Vascular endothelial growth factor (VEGF) is a potent mediator of vascular regulation in 
angiogenesis and vascular permeability(15). Plasma concentrations of VEGF correlate with HRCT 
thoracic scan fibrosis scores(16). In support of its role in the development of pulmonary fibrosis, a 
VEFG receptor antagonist attenuated bleomycin-induced lung fibrosis in a murine model(17). 
Although its concentration is higher in patients with progressive disease (defined as those with a 
10% change in FVC after 6 months), the usefulness of VEGF as a survival indicator has not been 
evaluated. 
 
2 Objectives 
Is there an association between the disease severity (as assessed by DLco) of patients with 
idiopathic  pulmonary fibrosis and alveolar NO or plasma VEGF? 
Is there an association between alveolar NO and/or plasma VEGF and disease progression (as 
measured by % change in FVC) at 6 and 18 months? 
 
3 Methods  
3.1 Study design 
This is a prospective observational study to evaluate the concentration of small airways nitric oxide 
and levels of vascular endothelial growth factor in 30 patients with idiopathic pulmonary fibrosis and 
relate this to pulmonary function measures of disease severity and progression. Participants will be 
identified from clinical notes of patients with ILD attending the respiratory out patients department 
at the Norfolk and Norwich University Hospital NHS Trust (NNUH) and will be approached by their 
attending physician. Patients will attend the clinic for a screening visit and baseline measurements 
including history, medical examination, and assessment of alveolar nitric oxide, and a 
venepuncture to collect blood for VEGF analysis, following informed consent. All other data will be 
obtained from the medical notes. Patients will attend clinic for visit 2 which will take place  between 
four and eight months and visit 3 which will take place between sixteen and twenty months after the 
screening visit for repeat pulmonary function tests, repeat NO measurements and blood collection 
for VEGF levels(4 months time span for each follow up visit will be given to permit study visits to 
coincide with routine medical review).  General Practitioners (GP) responsible for patients care will 
be informed of the patients participation in the study by the means of GP letter. 
 
Clinical Assessment 
A full medical history and examination will be undertaken. Details of age, gender, diagnosis, length 
of diagnosis, time of onset of illness (first noticed breathlessness), main symptom (e.g. 
breathlessness, cough), treatments, environmental exposure to known aetiological factors, drug 
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history, key examination findings, autoantibody screen including rheumatoid factor will be obtained. 
A blood sample will be taken and plasma stored for subsequent analysis of VEGF. 
 
Review of Medical Notes 
A review of the medical notes will be completed to ensure they meet the entry criteria.  Details of 
previous pulmonary function tests, from time of diagnosis, including spirometry and gas transfer will 
be obtained from the clinic notes or pulmonary function laboratory database.  
 
Exhaled Nitric Oxide 
This will be measured using a NIOX nitric oxide analyzer at visit 1 and 2 (Aerocrine, Chicago, 
Illinois USA), with an expiratory flow rate of 50ml/sec according to American Thoracic Society  
guidelines (18). The mean of three separate measures of nitric oxide will be used in the analysis. In 
addition, measurements will be made at expiratory flow rates of 30, 100 and 200 ml/sec. The 
analyser will be calibrated daily using a cylinder of nitric oxide at concentration of 208ppb. At visit 3 
nitric oxide will be measured using a NIOX mino rather than NIOX machine as the NIOX machine is 
no longer serviced and is not safe for patient use as of March 2011. Niox mino is the a calibration 
and maintenance free device with built in control that displays measurement results from correctly 
performed procedures only, it measures nitric oxide with an expiratory rate of 50ml/sec according 
to American Thoracic Society  guidelines (18). 
 
Vascular endothelial growth factor (VEGF) 
Levels of VEGF in plasma will be assessed using a commercially available validated VEGF ELISA 
kit. 
 
Assessment of disease severity 
This will be based on assessment of impairment of  diffusing capacity for carbon monoxide (DLco) 
as a well recognised marker of disease severity (levels below 40% of predicted value reflect severe 
disease). This will be performed, as required for routine clinical assessment, at the same time as 
the measurement of exhaled nitric oxide and VGEF 
 
Assessment of disease progression.  
This is based on percentage change in Forced Vital Capacity (FVC) within 6 to 18 months of follow 
up. All patients with pulmonary fibrosis undergo routine pulmonary function assessment (forced 
vital capacity and gas transfer) at least annually. Details of pulmonary function will be obtained 
from the respiratory department pulmonary function database. Date and cause of death will be 
obtained from medical records. 
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3.2 Sample size estimation 
 
This study is a pilot study and the results from the study could potentially provide information for a 
future study which will enable a power calculation.  Thirty patients should be sufficient to gain 
sufficient data for this study. 
 
3.3 Patient Recruitment  
3.3.1 Inclusion criteria  
1. male or female: aged greater than 40 years 
2. able to provide informed consent 
3. Clinically labelled diagnosis of fibrotic idiopathic pulmonary fibrosis with HRCT 
scan features compatible with Usual Interstitial Pneumonia (UIP) or Fibrotic 
Non-specific Interstitial Pneumonia (NSIP) according to current guidelines(19)  
 
3.3.2 Exclusion criteria   
1. A secondary cause for pulmonary fibrosis including a diagnosis of asbestosis, 
drug induced pulmonary fibrosis, collagen vascular disease or other secondary 
pulmonary fibrosis. 
2. A recognised significant co-existing respiratory disorder.  
3. A respiratory tract infection within the last 2 months.  
4. Significant medical, surgical or psychiatric disease that in the opinion of the 
patients' attending physician would affect subject safety or influence the study 
outcome.   
5. Women who are pregnant or are breast-feeding as pregnancy itself might alter 
levels of VEGF(20)  
6. Patients with clinical evidence of right heart failure 
7. Current smokers 
 
4 Ethics 
Research governance and ethical committee approval will be obtained before commencement of 
the study.  Written informed consent will be obtained from all participants involved in the study 
(appendix 2).  Patients will be given a unique identification number and no-patient identifiable 
information will be available.  All data will be stored at the NNUH which will be password protected 
and only accessible by student, supervisor and a study co-ordinator.  The study will be conducted 
at the NNUH and no patient identifiable data will leave the NNUH site.  The investigations are not 
onerous but do require the patient to blow at a predetermined flow.  Some patients may become 
light headed during the procedure and they will be given time to recover. Patients might have a 
bruise at a venepuncture site. 
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5  Data analysis and statistical analysis:  
 
Alveolar NO will be calculated using a linear interpolation of the NO versus flow curve as described 
by George et al(21). Linear regression analysis (using Pearson correlation coefficient or 
Spearman’s rank correlation coefficient) will be used to evaluate relationship between alveolar 
NO/VEGF and (1) gas transfer corrected for alveolar volume and (2) 6 and 12 months decline in 
FVC in the preceding year and (3) a decline in FVC in the forthcoming 6 months and 18 months.  
 
A T test or distribution-free tests will be undertaken to compare the differences between patients 
with or without a decline in FVC greater or less than 10% from previous records.  Multivariate 
analysis will be used to investigate the contributing  role of previous smoking, age and gender. All 
statistical analysis will be completed using statistical analysis using SPSS (Statistical Package for 
the Social Sciences). 
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Appendix 8 
 
PATIENT INFORMATION SHEET 
 
Study title:  
Are alveolar nitric oxide and plasma VEGF  markers of disease severity and lung function 
decline in patients with idiopathic pulmonary fibrosis  
 
You are being invited to take part in this research study, but before you decide to do this it is 
important to understand why the research is being done and what you will be required to do.  
Please read the information provided carefully and if necessary discuss it with others.  If there is 
any aspect which appears unclear please do not hesitate to ask for more information.  Please feel 
free to take time in deciding whether you wish to participate in the study.  
 
Thank you for reading this. 
 
What is the purpose of the study? 
 
The purpose of the study is to find out how the amount of a gas that patients with pulmonary 
fibrosis breathe out and a level of certain blood test (marker called Vascular Endothelial Growth 
Factor, VEGF) compares to patients’ breathing tests. We know that the breathing tests of some 
patients with interstitial lung diseases deteriorate quicker than others.  We want to know whether 
the gas breathed out and a level of blood test can be used to tell which patients will have a quicker 
deterioration than others. 
Why have I been chosen? 
 
You have been chosen because you have a lung condition called pulmonary fibrosis.  Thirty 
patients are required for the study and all these patients must comply with several study entry 
criteria.  These include details of your medical history and surgery you have had in the past  and 
certain examination findings (if you want to know these then we can provide this information).   
Do I have to take part? 
 
No, you are not under any obligation to take part.  It is completely up to you whether or not you 
take part and if you do decide to take part you will be given this information sheet to keep along 
with a consent form that will need signing.  If you decide to take part you are still free to withdraw 
from the study at any time and without giving reason.  If you do decide to withdraw from this study 
this will not affect your future treatment at the respiratory department. 
 
 
What will happen to me if I take part? 
 
If you enter the study you will be asked to come into the lung function laboratory at the Norfolk and 
Norwich University Hospital NHS Trust.  Here we will assess your breathing tests as you do when 
you have your outpatient clinic appointments. The test will be slightly different than normal as you 
will be asked to exhale into the tube at five different flow rates (at visit 1 and 2 only) and at one flow 
rate at visit 3 so that we can measure the level of the gas we are investigating- nitric oxide.   
 
Before this happens you will have some baseline assessments.  These will be: 
o Confirming your consent to take part by signing the consent form 
o Confirming that you meet all the criteria for the study. 
o Collection of information relating to you, your medical history and your lung disease 
o Collection of information relating to all the medications you are taking. 
 
We will also take a small sample of blood from you approximately equivalent to a table spoonful 
which will be analysed for the study. 
After an initial assessment you will be invited for the second clinic assessment which will take place 
between four and eight months and then for the third clinic assessment which will take place 
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between sixteen and twenty months after your first visit to perform the lung function test. You might 
spend approximately 1 hour at the department for your first visit and half an hour for the second 
and third one. We will analyse the results following your initial assessment and then after your 
second and your final visit. 
We would like to ensure the female patients are not pregnant as pregnancy itself might alter levels 
of VEGF therefore if you are a woman we will ask you to confirm in a consent from that you are not 
pregnant and are not planning to become pregnant during the period of the study. If you do 
become pregnant during the study you will be withdrawn from the study but the information 
collected until then will be used for analysis. 
 
What is being tested? 
 
The study is looking to see whether there is an association with pulmonary fibrosis and the exhaled 
gas and levels of blood test; and whether the gas and a level of blood test are  indicators of how 
severe the disease is.   
 
What are the possible disadvantages and risks of taking part? 
 
The trial is not intended to cause pain or harm but you may feel tired, breathless or light headed 
after the test.  There are no major disadvantages or risks from taking part in the study.   It will be a 
similar feeling to when you have your yearly lung function test. Taking a blood sample might leave 
you with a small bruise.                              
 
What are the possible benefits of taking part? 
 
There are no direct benefits to you but it is hoped that the study will provide insight and 
understanding about this group of diseases as there is a lack of information on how and why these 
diseases progress the way they do.  We hope the information will be useful for future studies into 
this field.  It will also give you more information with regards to your condition and this may help 
you understand the condition better. 
 
 
What happens when the research study stops? 
 
Once the research is conducted some results will be presented as a part of a student’s medical 
degree as a part of their assessment and subsequently as a part of postgraduate degree of a 
medical doctor and if the results prove beneficial will be adapted to be published in a journal that 
will be read by other healthcare professionals. 
 
Once you have completed the study your doctor will continue to manage your interstitial lung 
disease in the usual way. 
 
What if something goes wrong? 
 
All efforts will be made to prevent injury from participation in the trial, your right to legal action in the 
event of an injury will not be affected by consenting to the participate in the study.  Your right at law 
to claim compensation for injury where you can prove negligence is not affected.  Copies of these 
guidelines are available on request.      
 
 
Will my taking part in this study be kept confidential? 
 
All information collected will be made anonymous (your personal data such as name and date of 
birth will not be used) and you will be given a unique identification number (for example the first 
patient entering the study will be allocated number 1, the second – number 2 etc) at the start.  Data 
will only be available to those who are involved in the study and stored securely.      
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With your permission, your GP will be informed of your participation in this study. 
 
What will happen to the results of the research study? 
 
The data collected will be analysed and a report will be written on the findings of the study which 
will be read by University of East Anglia medical school assessors.  If the results prove beneficial 
there will be potential to submit results to a journal for publication for wider access to other 
healthcare professionals, you will not be identified in these publications.  
 
Should you decide to withdraw from the study at any time, the information collected on you up to 
that point will be used in the results of the study. 
 
Who is organising and funding the research? 
The Norfolk and Norwich University Hospital NHS Trust (NNUH) Respiratory department will fund 
the study. 
Who has reviewed the study? 
The study protocol has been reviewed by the Norfolk and Norwich University Hospitals NHS 
Foundation Trust, and the Norfolk Research Ethics Committee. 
Contact for further information 
If you would like to discuss this information in more detail or want further information please 
contact: 
 
Dr Andrew M Wilson 
Senior Clinical Lecturer in Respiratory Health 
Biomedicine Group 
School of Medicine, Health Policy and Practice 
University of East Anglia 
Norwich UK NR4 7TJ 
Tel  01603 591257 
Fax  01603 591750 
 
Dr Ludmila Shulgina  
Research Fellow 
School of Medicine, Health Policy and Practice 
University of East Anglia 
Norwich UK NR4 7TJ 
Tel: 07985494105 
Email: Ludmila.shulgina@nhs.net 
 
  
 
If you decide to take part in this study you will be given a copy of information sheet and a signed 
consent form to keep. 
 
Thank you for taking the time to read this information leaflet. 
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Appendix 9 
 
 PATIENT CONSENT FORM 
 
Patient Trial Identification Number: 
 
Protocol Title: 
  
Is alveolar nitric oxide a marker of disease severity and lung   function decline 
 in patients with interstitial lung disease 
 
Name of Researcher:  Dr Andrew Wilson 
                                                 Please initial box 
 
I confirm that I have read and understood the information sheet dated …………….. 
(version…….) for the above study and have had the opportunity to ask questions. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time,  
without giving any reason, without my medical care or legal rights being affected. 
 
I understand that sections of any of my medical notes may be looked at by responsible  
individuals from the study monitors where it is relevant to my taking part in research.  
 I give permission for these individuals to have access to my records. 
 
I give permission for my blood samples to be stored in anonymized form at the Norfolk  
and Norwich Hospital for further analysis. 
 
I give permission for my General Practitioner to be informed about my participation     
in the study  
 
I agree for my data to be stored securely in an anonymised form. 
 
 
I confirm that I am not pregnant, am not planning to become pregnant during the period  
of the trial, and that if I become pregnant I will notify you and be withdrawn from the trial. 
 
I agree to participate as a part of the above study. 
 
 
 
 
Name of Patient   
                              Signature 
 Date 
 
 
Name of Person Taking Consent                       Signature    Date 
    
 
Researcher   
                               Signature 
 Date  
  
3 copies, 1 for patient, 1 for researcher and 1 to kept with hospital notes 
 
 
 
 
 
 
 
 
 
 
 
 
 
